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Cortisol	  and	  cortisone	  are	  steroid	  hormones	  naturally	  produced	  in	  the	  adrenal	  cortex.	  Since	  their	  
discovery	   in	   the	   1940s,	   the	   recognition	   of	   their	   anti-­‐inflammatory	   properties	   has	   led	   to	   the	  
development	  of	  synthetic	  glucocorticoid	  analogues,	  which	  exert	  even	  higher	  anti-­‐inflammatory	  
activities	   i.e.	   betamethasone,	   dexamethasone,	   methylprednisolone	   and	   prednisolone,	   with	  
prednisone	  as	  prodrug	   [1].	  Besides	   their	  anti-­‐inflammatory	  properties,	   these	  drugs	  also	   induce	  
body	   weight	   gain	   in	   production	   animals.	   Since	   the	   early	   1950s	   they	   became	   very	   popular	   as	  
growth-­‐promoting	  agents	  in	  livestock	  [2].	  	  
1.1. Origin	  and	  chemical	  configuration	  
1.1.1.	  Natural	  glucocorticoids	  
Cortisol	   is	   the	   main	   natural	   glucocorticoid	   and	   its	   circulating	   level	   is	   maintained	   by	   the	  
hypothalamus-­‐pituitary-­‐adrenocortical	   (HPA)	   axis	   (Figure	   1.1.A).	   Small-­‐bodied	   neurons	   in	   the	  
paraventricular	   nucleus	   of	   the	   hypothalamus	   secrete	   the	   neuropeptide	   corticotropin-­‐releasing	  
hormone	   (CRH)	   that	   leads	   to	   the	   release	  of	  preformed	  adrenocorticotropic	  hormone	   (ACTH	  or	  
corticotropine)	   in	   the	  neighbouring	   anterior	   pituitary	   gland.	  ACTH	  enhances	   the	   conversion	  of	  
cholesterol	  to	  cortisol,	  mainly	  by	  cytochrome	  P450	  enzymes	  in	  the	  adrenal	  gland.	  The	  series	  of	  
hydroxylation	   steps	   required	   to	   form	  cortisol	   take	  place	   in	   the	  zona	   fasciculata	   of	   the	  adrenal	  
cortex,	  which	  defines	  the	  outer	  layer	  of	  the	  gland	  (Figure	  1.1.B).	  Afterwards,	  cortisol	  diffuses	  out	  
of	   the	   cells	   into	   the	   plasma	   where	   most	   of	   the	   circulating	   cortisol	   is	   bound	   to	   proteins.	  
Approximately	   90%	   is	   transported	   by	   the	   corticosteroid-­‐binding	   globulin,	   also	   known	   as	  
transcortin.	  An	  additional	  7%	  is	  bound	  to	  albumin	  and	  only	  3%	  to	  4%	  of	  the	  circulating	  cortisol	  is	  
free.	  Only	  the	  unbound	  fraction	  can	  pass	  through	  the	  cell	  membranes	  and	  bind	  to	  intracellular	  




Figure	   1.1.	   The	   hypothalamic-­‐pituitary-­‐adrenocortical	   axis	   and	   its	   negative	   feedback	   circuit	   enables	   to	  
provide	  a	  continuous	  and	  equilibrated	  release	  of	  glucocorticoids	  (A)	  (after	  Eisenberger	  and	  Cole,	  2012)	  [4].	  
Schematic	   summary	   of	   the	   biosynthesis	   of	   the	   adrenal	   steroids,	   the	  mineralocorticoid	   aldosterone,	   the	  
glucocorticoid	   cortisol	   and	   the	   sex	   hormone	   testosterone	   from	   cholesterol	  with	   the	   help	   of	   cholesterol	  
desmolase	   (CYP11A1),	   17α-­‐hydroxylase	   (CYP17A1),	   17,20-­‐lyase	   (CYP17A1),	   3β-­‐hydroxysteroid	  
dehydrogenase,	   21-­‐hydroxylase	   (CYP21A2),	   11β-­‐hydroxylase	   (CYP11B1),	   18-­‐hydroxylase	   (CYP11B2),	   17β-­‐
hydroxysteroid	  dehydrogenase	  (B)	  (after	  Ortsäter	  et	  al.,	  2012)	  [5].	  CRH:	  corticotropin-­‐releasing	  hormone;	  
ACTH:	   adrenocorticotropic	   hormone;	   DHEA:	   dehydroepiandrosteron;	   Δ4-­‐ADD:	   1,4-­‐androstadiene-­‐3,17-­‐
dione.	  
To	  maintain	   the	   circulating	   glucocorticoid	   levels,	   CRH	   is	   secreted	   with	   a	   frequency	   of	   two	   or	  
three	  secretory	  episodes	  per	  hour	  in	  a	  circadian,	  pulsatile	  manner,	  with	  greater	  pulse	  amplitudes	  
in	   the	  early	  morning.	  This	  can	  be	  modulated	  by	  changes	   in	   light	   intensities,	   feeding	  schedules,	  
activity	  and	  stress	  [6][7].	  Secreted	  cortisol	  has	  a	  negative	  feedback	  at	  multiple	  levels	  of	  the	  HPA	  
axis.	   Stress	   such	   as	   injury,	   infection,	   cold,	   pain	   and	   fear	   can	   override	   the	   normal	   negative	  
feedback	  control	  mechanisms,	  leading	  to	  increased	  plasma	  concentrations	  of	  cortisol	  [8][9].	  
Cortisol	   is	   partially	   converted	   into	   cortisone	   by	   the	   11β-­‐hydroxysteroid	   dehydrogenase	   type	   2	  
(11β-­‐HSD)	  enzyme.	  The	  glucocorticoid	  activity	  of	  this	  metabolite	  is	  however	  much	  lower,	  hence	  
one	  sometimes	  refers	  to	  it	  as	  the	  hormonal	  inactive	  metabolite	  of	  cortisol	  [5].	  In	  time	  of	  stress,	  





predominantly	   as	   an	   11-­‐oxo-­‐reductase	   [10].	   Unlike	   cortisol,	   cortisone	   only	   occurs	   in	   unbound	  
form	  in	  the	  plasma	  [11].	  
The	  natural	  glucocorticoid,	  cortisol,	  has	  a	  double	  bond	  in	  the	  4,5	  position	  and	  a	  3-­‐keto	  group	  on	  
ring	   A,	   an	   11β-­‐hydroxyl	   group	   on	   ring	   C,	   17α-­‐hydroxyl	   group	   on	   ring	   D	   and	   a	   20-­‐keto	   group	  
(Figure	  1.2.).	  	  
	  
Figure	   1.2.	   The	   important	   structural	   sites,	   which	   determine	   the	   activity	   of	   a	   glucocorticoid	   base,	   are	  
shown	  on	  the	  structure	  of	  cortisol,	  together	  with	  structures	  of	  common	  glucocorticoids	  used	  in	  veterinary	  
medicine	  (after	  Brunton	  et	  al.,	  2006)	  [3].	  	  
1.1.2.	  Synthetic	  glucocorticoids	  
Chemical	  modifications	  of	  the	  cortisol	  molecule	  have	  generated	  a	  range	  of	  synthetic	  analogues,	  
which	   react	   more	   specifically	   and	   exert	   a	   more	   potent	   glucocorticoid	   activity	   with	   different	  
pharmacokinetic	  and	  pharmacodynamic	  properties.	   For	  example,	   introduction	  of	  an	  additional	  
double	  bond	  in	  the	  1,2-­‐position	  of	  ring	  A,	  results	  in	  the	  formation	  of	  prednisolone	  or	  prednisone	  
(Figure	  1.2).	  This	  double	  bond	  in	  combination	  with	  9α-­‐fluoro	  derivatives	  results	  in	  the	  formation	  
of	   dexamethasone,	   betamethasone	   and	   triamcinolone.	   Besides,	   other	   substitutions	   such	   as	   a	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6α-­‐methyl	  group,	  may	  as	  well	  influence	  the	  glucocorticoid	  receptor	  sensitivity.	  Steroids	  with	  an	  
11-­‐keto	  substituent,	  i.e.	  cortisone	  and	  prednisone,	  must	  be	  enzymatically	  reduced	  in	  the	  liver	  by	  
11β-­‐HSD	  type	  1	  to	  the	  corresponding	  11β-­‐hydroxyl	  group,	  before	  they	  are	  biologically	  active	  [3].	  
Hydrocortisone	  is	  chemically	  identical	  to	  cortisol,	  but	  is	  used	  to	  distinguish	  drug	  administration	  
from	  endogenous	  production	  [12].	  
1.2. Metabolism	  and	  excretion	  
Glucocorticoids	  are	   inactivated	  and	   removed	   from	   the	  circulation	  by	   the	   liver	  or	   intestine	   in	  a	  
two-­‐step	   process	   where	   a	   sequential	   addition	   of	   oxygen	   or	   hydrogen	   atoms	   (phase	   I	  
metabolism)	  is	  followed	  by	  the	  conjugation	  to	  more	  polar	  glucuronides	  and	  sulphates	  (phase	  II	  
metabolism)	  in	  order	  to	  be	  excreted	  via	  urine	  or	  faeces	  [13].	  
1.2.1. Phase	  I	  metabolism	  
Endogenous	   cortisol	   has	   a	   short	   half-­‐life	   and	   is	   converted	   into	   cortisone	   or	   is	   inactivated	   by	  
reduction	  of	  the	  4,5	  double	  bond	  in	  the	  A-­‐ring.	  This	  can	  occur	  hepatically	  or	  extrahepatically	  (i.e.	  
kidney).	   Reduction	  of	   the	  3-­‐ketone	   substituent	   to	   the	  3-­‐hydroxyl	   derivative	  only	  occurs	   in	   the	  
liver	  (Figure	  1.3.)	  [14].	  	  
	  
Figure	   1.3.	   The	   principal	   biotransformation	   of	   cortisol	   and	   cortisone	   performed	   by	   cytochrome	   P450	  





In	   addition,	   a	   side-­‐chain	   cleavage	   was	   found	   for	   cortisol,	   which	   resulted	   in	   the	   formation	   of	  
11,17-­‐dioxoandrostane,	  which	  is	  a	  typical	  faecal	  glucocorticoid	  metabolite	  [15].	  Cortisone	  can	  be	  
metabolized	  in	  an	  identical	  fashion	  to	  cortisol.	  Both	  cortisol	  and	  cortisone	  are	  excreted	  in	  urine,	  
whereby	  a	  certain	  fraction	  retains	  its	  initial	  structural	  configuration	  [16].	  	  
Synthetic	   glucocorticoids	   can	   also	   be	   partially	   biotransformed	   before	   excretion.	   The	  
biotransformation	   of	   prednisolone	   to	   20α-­‐	   and	   20β-­‐dihydroprednisolone,	   and	   6β-­‐
hydroxyprednisolone	  relies	  more	  on	  the	  oxidative	  metabolism	  than	  the	  reductive	  one	  [18][19].	  
The	   urinary	   excretion	   profiles	   of	   methylprednisolone	   treated	   animals,	   revealed	   15	   phase	   I	  
metabolites	   [20].	   Several	  metabolites	  were	   also	   determined	   for	   dexamethasone	   in	   urine	   (e.g.	  
17-­‐oxodexamethasone,	  20-­‐dihydrodexamethasone,	  6-­‐hydroxydexamethasone)	  [21].	  	  
1.2.2. Phase	  II	  metabolism	  
In	  humans,	  most	  of	  these	  A-­‐ring-­‐reduced	  steroids	  are	  conjugated	  through	  the	  3-­‐hydroxyl	  group	  
with	  a	  sulphate	  or	  glucuronide	  through	  enzymatic	  reactions	  that	  take	  place	  in	  the	  liver,	  and	  to	  a	  
lesser	  extent	  in	  the	  kidney.	  The	  resultant	  glucuronides	  (95%)	  and	  sulphate	  esters	  (4%)	  are	  water-­‐
soluble	   and	   are	   the	   predominant	   excreted	   metabolites	   in	   urine.	   Only	   1%	   was	   reported	   as	  
unconjugated	  [22].	  Neither	  biliary	  nor	  faecal	  excretion	  is	  of	  quantitative	  importance	  in	  humans	  
[3].	   This	   is	   in	   strong	   contrast	   with	   cattle,	   where	   the	   relative	   proportion	   of	   unconjugated	  
glucocorticoids	  in	  urine	  are	  the	  most	  abundant	  (Table	  1.1.).	  	  
Table	  1.1.	  Relative	  proportions	  (%)	  of	  free,	  glucuronide	  and	  sulphate	  forms	  for	  cortisol,	  tetrahydrocortisol	  




1.2.3. Urinary	  and	  faecal	  excretion	  
Plasma	  is	  filtered	  in	  the	  glomerular	  endothelium	  of	  the	  kidney,	  where	  water	  and	  electrolytes	  are	  
passively	   and	   actively	   reabsorbed	   into	   the	   circulation.	   However,	   polar	   compounds,	   including	  
conjugated	  glucocorticoids,	  cannot	  diffuse	  back	   into	  the	  circulation	  and	  are	  excreted	  via	  urine.	  
This	   is	   the	  predominating	  excretory	  route	   for	  glucocorticoids,	  but	  high	   interspecies	  differences	  
	   Cortisol	   Tetrahydrocortisol	   Dexamethasone	  
Unconjugated	   91	  -­‐	  98%	   35	  -­‐	  59%	   72	  -­‐	  96%	  
Glucuronide	   0.0	  -­‐	  0.4%	   37	  -­‐	  61%	   1.0	  -­‐	  10%	  
Sulphate	   1.0	  -­‐	  8.0%	   2.0	  -­‐	  3.0%	   3.0	  -­‐	  17%	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were	  found.	  In	  sheep,	  72%	  of	  the	  glucocorticoids	  are	  excreted	  in	  urine,	  while	  in	  horses	  and	  pigs	  
59%	  and	  93%,	  respectively	  [24].	  
Besides,	  conjugated	  glucocorticoids	  i.e.	  glucuronides	  are	  excreted	  via	  the	  bile	  into	  the	  gut.	  Once	  
in	   the	   intestine,	  microbial	   flora	  under	   anaerobic	   conditions,	   can	  deconjugate	   a	   fraction	  of	   the	  
glucocorticoids,	  which	  makes	  reabsorption	   in	   the	  circulation	  possible	  [25].	  This	   is	   the	  so	  called	  
enterohepatic	   circulation.	   The	   part	   that	   stays	   in	   the	   gut	   is	   excreted	   in	   the	   faeces.	   In	   farm	  
animals,	  cortisol	  excretion	  via	  faeces	  is	  28%	  in	  sheep,	  41%	  in	  horses	  and	  only	  7%	  in	  pigs	  [26].	  
1.3. Function	  in	  the	  body	  
Glucocorticoids	   exert	   a	   dual	   role	   in	   the	   body,	   which	   is	   translated	   into	   metabolic	   and	  
immunological	   responses.	   As	   such	   glucocorticoids	   participate	   in	   the	   control	   of	   whole	   body	  
homeostasis	  and	  the	  organism’s	  response	  to	  stress.	  
Glucocorticoids	  are	  responsible	  for	  modulating	  the	  carbohydrate	  metabolism	  via	  mobilization	  of	  
glucose	   towards	   the	   systemic	   circulation	   by	   stimulating	   the	   action	   of	   other	   hyperglycemic	  
hormones	   for	   glycogen	  breakdown	   (e.g.	   glucagon,	   catecholamines	   and	  growth	  hormone).	   This	  
results	   in	   the	   release	   of	   glucose	   from	   the	   hepatocytes.	   Besides,	   glucocorticoids	   inhibit	   the	  
uptake	  and	  utilization	  of	  glucose	  in	  skeletal	  muscle	  and	  adipose	  tissue	  by	  interfering	  with	  insulin	  
signalling	  [5].	  Additionally,	  glucocorticoids	  induce	  gluconeogenesis	  by	  promoting	  muscle	  atrophy	  
via	  reduction	  of	  protein	  synthesis	  and	  degradation	  of	  protein	  into	  amino	  acids.	  An	  increased	  rate	  
of	  protein	  metabolism	  leads	  to	  an	  increased	  urinary	  nitrogen	  excretion	  and	  the	  induction	  of	  urea	  
cycle	   enzymes	   [27].	   Glucocorticoids	   also	   enhance	   gluconeogenesis,	   through	   the	   increased	  
breakdown	   of	   triglycerides	   in	   adipose	   tissues,	   which	   provide	   energy	   and	   substrates	   for	  






Figure	  1.4.	  Influence	  of	  glucocorticoids	  on	  carbohydrate	  metabolism	  (A),	  in	  detail	  (B).	  
In	  addition	  to	  their	  metabolic	  effects,	  glucocorticoids	  also	  have	  strong	  immunosuppressive,	  anti-­‐
inflammatory	   and	   anti-­‐allergic	   properties.	   In	   response	   to	   injury	  or	   infection,	   the	   inflammatory	  
response	   is	  a	  primary	  defence	  mechanism	   to	   restore	  homeostasis.	   Inflammation	   is	   initiated	  at	  
the	   site	   of	   injury	   by	   resident	   mast	   cells	   and	   macrophages,	   which	   release	   pro-­‐inflammatory	  
mediators	  including	  cytokines	  (e.g.	  tumour	  necrosis	  factor-­‐alpha,	  Interleukin-­‐1).	  These	  cause	  the	  
typical	   inflammatory	   reaction	   including	   vasodilation,	   increased	   capillary	  permeability	   (humoral	  
response)	  and	   leukocyte	  emigration	   into	   injured	  tissues	  (cellular	  response).	  Different	  cell	   types	  
are	   rapidly	   attracted	   to	   the	   inflamed	   site	   e.g.	   granulocytes.	   Antigen	   presenting	   cells	   will	   bind	  
foreign	  antigens	  and	  present	  them	  in	  the	  lymph	  nodes	  where	  they	  instruct	  the	  adaptive	  immune	  
response.	   Glucocorticoids	   inhibit	   many	   of	   these	   initial	   events	   such	   as	   the	   inhibition	   of	   the	  
vasodilation	   and	   the	   increased	   vascular	   permeability.	   In	   addition,	   they	   decrease	   leukocyte	  
emigration	   into	   inflamed	   sites	   [28].	   The	   anti-­‐inflammatory	   and	   immunosuppressive	   actions	   of	  
glucocorticoids	   are	   exerted	   through	   down-­‐regulation	   of	   the	   expression	   of	   pro-­‐inflammatory	  
cytokines,	  chemokines,	  etc.	  [29][30].	  Additionally,	  apoptosis	  of	  macrophages,	  dendritic	  cells	  and	  
T	  cells,	  is	  promoted,	  which	  leads	  to	  an	  inhibition	  of	  immune	  responses	  [31].	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Although	   the	  use	  of	  glucocorticoids	  does	  not	  address	   the	  underlying	  cause	  of	   the	  disease,	   the	  
major	  pharmacological	  use	  of	  glucocorticoids	  is	  their	  anti-­‐inflammatory	  and	  immunosuppressive	  
action.	  Depending	  on	  the	  chemical	  modification,	  derivatives	  with	  more	  selective	  glucocorticoid	  
activity,	   greater	   potencies	   and	   longer	   pharmacological	   activity	   were	   synthesized	   (Table	   1.2.)	  
[32].	  Prednisolone	   is	  widely	  used,	  particularly	   for	   its	  effectiveness	   in	  the	  treatment	  of	  mastitis,	  
this	   in	   combination	   with	   antimicrobial	   drugs	   [33].	   Dexamethasone	   is	   much	   more	   potent	   and	  
presents	   even	   longer	   pharmacological	   activity	   than	   prednisolone	   and	   6α-­‐methylprednisolone.	  
Given	  its	  high	  potency,	  long-­‐term	  treatment	  with	  dexamethasone	  is	  associated	  with	  severe	  HPA	  
axis	  suppression.	  Therefore,	  it	  is	  generally	  reserved	  for	  short-­‐term	  use	  in	  acute	  conditions	  [34].	  
Table	  1.2.	  Relative	  potencies	  of	  natural	  and	  synthetic	  glucocorticoids	  [32].	  






Short-­‐acting	   	   	   	  
Cortisol	   1	   8-­‐12	   +	  
Cortisone	   0.8	   8-­‐12	   +	  
Intermediate-­‐acting	   	   	   	  
Prednisone	   4	   12-­‐36	   +	  
Prednisolone	   4	   12-­‐36	   +	  
6α-­‐Methylprednisolone	   5	   12-­‐36	   +	  
Triamcinolone	   5	   12-­‐36	   ++	  
Long-­‐acting	   	   	   	  
Betamethasone	   25	   36-­‐72	   +++	  
Dexamethasone	   25	   36-­‐72	   +++	  
a	  HPA	  axis	  suppression	  equals	  the	  anti-­‐inflammatory	  potency	  in	  most	  cases.	  
Besides	   their	  broad	   therapeutic	  use,	   glucocorticoids	   induce	   side	  effects	  on	   several	   tissues	  and	  
organs	   depending	   on	   the	   dose	   and	   duration	   of	   use	   (Figure	   1.5.).	   Moreover,	   glucocorticoids	  
inhibit	   the	   pituitary	   growth	   hormone,	   gonadotropin	   and	   thyrotropin	   secretion	   and	   make	   the	  
target	   tissues	  of	   sex	   steroids	   and	  growth	   factors	   resistant	   to	   these	  hormones	   [3].	  A	  hormonal	  
disorder	  caused	  by	  prolonged	  exposure	  of	  body	  tissues	  to	  high	  levels	  of	  cortisol	  is	  the	  Cushing’s	  






Figure	   1.5.	   Some	   typical	   side	   effects	   resulting	   from	   long-­‐term	   glucocorticoid	   treatment	   in	   cattle	   (after	  
Barth,	  2006;	  Lui	  et	  al.,	  2013)	  [34][36].	  	  
Although	   large	   doses	   of	   synthetic	   glucocorticoids	   reduce	   growth	   rates	   and	   lead	   to	   muscle	  
atrophy,	  they	  have	  found	  a	  place	  among	  growth-­‐promoting	  additives	  in	  meat	  producing	  animals.	  
Originally	  glucocorticoids	  were	  often	  combined	  with	  β-­‐agonists	  and/or	  anabolic	  steroids	  in	  order	  
to	  prevent	   receptor	   down-­‐regulation	   and	   tolerance	   in	   the	   animal	   or	   to	   affect	  meat	   quality	   by	  
increasing	  water	   content	   [37].	  However,	   recently	   low	  dosage	  administration	  of	  glucocorticoids	  
has	   gained	   popularity.	   This	   has	   no	   therapeutic	   purpose	   but	   results	   in	   improved	   feed	   intake,	  
increased	  live	  weight	  gain,	  reduced	  feed	  conversion	  ratio,	  reduced	  nitrogen	  retention,	  increased	  
water	   retention	   and	   fat	   content	   [37][38][39].	   As	   for	   dexamethasone	   (0.4	   -­‐	   0.7	   mg/day)	   and	  
prednisolone	   (15	   -­‐	   30	  mg/day),	   growth-­‐promoting	   effects	   have	   been	   demonstrated	   after	   oral	  
administration	   during	  more	   than	   30	   days	   [40].	   After	   illicit	   treatment,	   appropriate	   withdrawal	  
periods	   are	   rarely	   applied,	   which	   means	   that	   potential	   harmful	   residues	   may	   be	   present	   in	  




In	  order	  to	  protect	  consumers	  against	  exposure	  to	  specific	  substances	  present	  in	  animal	  derived	  
food	   products,	   the	   therapeutic	   use	   of	   synthetic	   glucocorticoids	   in	   livestock	   has	   been	   strictly	  
regulated	   in	   the	   European	   Union.	   Certain	   withdrawal	   periods	   have	   to	   be	   respected	   between	  
treatment	   and	   slaughtering.	   To	   this	   purpose,	   the	   EU	  has	   introduced	  Maximum	  Residue	   Limits	  
(MRLs)	   for	   betamethasone,	   dexamethasone,	   methylprednisolone	   and	   prednisolone	   in	   various	  
edible	   tissues	  of	  animal	  origin	   [41]	   (Table	  1.3.).	  This	   is	   the	  maximum	  concentration	  of	   residue,	  
resulting	   from	   therapeutic	   use,	   which	   is	   legally	   permitted	   in	   animal	   derived	   food	   products.	  
Obviously,	   the	   use	   of	   synthetic	   glucocorticoids	   for	   the	   sole	   purpose	   of	   increasing	   the	   body	  
weight	  of	  bovines	  is	  prohibited	  in	  the	  European	  Union.	  
Table	  1.3.	  Pharmacologically	  active	  substances	  and	  their	  maximum	  residue	  limits	  (MRLs)	  [41][42].	  
Compound	   Animal	  species	   MRLs	   Target	  tissues	  
Betamethasone	   Bovine	   0.75	  µg	  kg-­‐1	   Muscle	  
	   	   2.0	  µg	  kg-­‐1	   Liver	  
	   	   0.75	  µg	  kg-­‐1	   Kidney	  
	   	   0.3	  µg	  kg-­‐1	   Milk	  
	   Porcine	   0.75	  µg	  kg-­‐1	   Muscle	  
	   	   2.0	  µg	  kg-­‐1	   Liver	  
	   	   0.75	  µg	  kg-­‐1	   Kidney	  
Dexamethasone	   Bovine,	  caprine,	  porcine,	  	   0.75	  µg	  kg-­‐1	   Muscle	  
	   Equidae	   2.0	  µg	  kg-­‐1	   Liver	  
	   	   0.75	  µg	  kg-­‐1	   Kidney	  
	   Bovine,	  caprine	   0.3	  µg	  kg-­‐1	   Milk	  
Methylprednisolone*	   Bovine	   10	  µg	  kg-­‐1	   Muscle	  
	   	   10	  µg	  kg-­‐1	   Fat	  
	   	   10	  µg	  kg-­‐1	   Liver	  
	   	   10	  µg	  kg-­‐1	   Kidney	  
Prednisolone	   Bovine	   4.0	  µg	  kg-­‐1	   Muscle	  
	   	   4.0	  µg	  kg-­‐1	   Fat	  
	   	   10	  µg	  kg-­‐1	   Liver	  
	   	   10	  µg	  kg-­‐1	   Kidney	  
	   	   6.0	  µg	  kg-­‐1	   Milk	  
	   Equidae	   4.0	  µg	  kg-­‐1	   Muscle	  
	   	   8.0	  µg	  kg-­‐1	   Fat	  
	   	   6.0	  µg	  kg-­‐1	   Liver	  
	   	   15	  µg	  kg-­‐1	   Kidney	  
*	  Not	  for	  use	  in	  animals	  from	  which	  milk	  is	  produced	  for	  human	  consumption.	  
The	  measures	   to	  monitor	   the	   residue	   control	   plan	   of	   glucocorticoids	   in	   livestock	   and	   derived	  





substances	  (group	  A	  and	  B)	  are	  included,	  based	  on	  Commission	  Regulation	  No.	  37/2010	  [41].	  In	  
Italy	   and	   the	   Netherlands,	   glucocorticoids	   are	   classified	   as	   group	   A	   substances,	   comprising	  
substances	   with	   hormonal	   effects,	   beta	   agonists	   and	   veterinary	   medicines	   that	   have	   been	  
banned	   (Table	   2	   of	   Council	   Regulation	   No	   37/2010)[41].	   The	   other	   member	   states,	   including	  
Belgium,	   regard	   them	   as	   group	   B	   substances,	   which	   holds	   the	   category	   of	   other	  
pharmacologically	  active	  substances.	  To	  monitor	  the	  misuse	  and/or	  abuse	  of	  veterinary	  drugs	  in	  
live	   animals	   and	   animal	   products,	   member	   states	   must	   draft	   and	   implement	   each	   year	   a	  
National	   Residue	   Plan	   [43].	   The	   analytical	   methods	   used	   for	   this	   control	   plan,	   must	   be	   in	  
compliance	  with	  the	  criteria	  of	  Commission	  Decision	  2002/657/EC	  [44].	  
In	   light	   of	   these	   national	   control	   plans,	   monitoring	   unauthorized	   administration	   of	  
glucocorticoids	   in	   urine	   samples	   is	   of	   critical	   importance.	   Recently,	   the	   European	   Commission	  
reported	   in	   the	   Commission	   Staff	   Working	   Document	   ‘Implementation	   of	   national	   residue	  
monitoring	   plans	   in	   the	  member	   states’	   (2009	   -­‐	   2012),	  when	   focussing	   on	   glucocorticoids,	   an	  
increasing	   occurrence	   of	   prednisolone	   residues	   (3.12	   -­‐	   179.72	   μg	   L-­‐1)	   in	   bovine	   urine	   samples	  
without	  any	  direct	  evidence	  for	  unauthorized	  administration	  (Table	  1.4.).	  	  
Table	  1.4.	  Prevalence	  of	  non-­‐compliant	  prednisolone	  bovine	  urine	  samples	  during	  the	  implementation	  of	  
national	   residue	  monitoring	   plans	   in	   the	  member	   states	   [45][46][47][48].	   In	   the	   Netherlands	   and	   Italy,	  
corticosteroids	  are	  classed	  as	  group	  A3	  substances,	  whereas	  other	  member	  states	  classify	  them	  as	  B2f.	  









2012	   A3	   4	   3036	   IT	   0.10	  
	   B2f	   3	   411	   BE	   0.73	  
	   B2f	   3	   418	   FR	   0.72	  
	   B2f	   1	   18	   RO	   5.55	  
2011	   A3	   7	   3336	   IT	   0.20	  
	   B2f	   1	   498	   BE	   0.30	  
2010	   A3	   2	   3590	   IT	   0.06	  
	   B2f	   3	   275	   BE	   1.10	  
	   B2f	   1	   424	   FR	   0.24	  
2009	   A3	   3	   2939	   IT	   0.10	  
	   B2f	   1	   2410	   BE	   0.04	  
	   B2f	   5	   206	   ES	   2.43	  




These	   findings,	   in	   essence	   originating	   from	   the	   increased	   sensitivity	   of	   analytical	   detection	  
methods,	  have	  raised	  many	  questions.	  Several	  hypotheses	  concerning	  the	  origin	  of	  this	  low	  level	  
prednisolone,	   have	   been	   suggested,	   i.e.	   prednisolone	   could	   be	   generated	   by	   physiologic	  
metabolic	  processes	  under	  influence	  of	  stress,	  resulting	  in	  higher	  cortisol	  levels	  (during	  transport	  
and	  slaughtering)	  [49][50][51]	  or	  by	  faecal	  microbial	  contamination	  of	  urine	  [52].	  A	  well-­‐known	  
example	  of	  such	  a	  process	  is	  the	  microbial	  transformation	  of	  testosterone	  to	  β-­‐boldenone	  by	  a	  
Δ1-­‐steroid-­‐dehydrogenase	   (Δ1-­‐SDH)	   [53][54].	   Just	   like	   the	   anabolic	   androgenic	   steroid	  
testosterone,	  cortisol	  and	  cortisone	  enclose	  a	  3-­‐oxo-­‐4-­‐ene	  structure,	  which	  is	  possibly	  the	  target	  
of	   Δ1-­‐SDH	   for	   the	   1,2-­‐dehydrogenation.	   This	   reaction	   could	   result	   in	   the	   formation	   of	  
prednisolone	  and	  prednisone,	  respectively	  (Figure	  1.6.)	  [55].	  
	  
Figure	  1.6.	  The	  microbial	  conversion	  of	  steroids	  of	  testosterone	  to	  β-­‐boldenone	  (A)	  and	  possibly	  of	  cortisol	  
to	  prednisolone	  (B)	  and	  cortisone	  to	  prednisone	  (C)	  by	  Δ1-­‐SDH	  (after	  Bredehöft	  et	  al.,	  2012)	  [51].	  
Recent	   in	   vitro	   incubation	   experiments	   of	   cortisol	   with	   bovine	   S9	   liver	   enzymes	   showed	   a	  





To	   account	   for	   potential	   other	   origins	   than	   unauthorized	   treatment,	   the	   European	   Union	  
Reference	   Laboratories	   suggested	  a	   threshold	   level	   for	  prednisolone	   in	  bovine	  urine	  based	  on	  
the	  following	  calculation:	  the	  average	  prednisolone	  concentration	  of	  100	  urine	  samples	  +	  three	  
times	   the	   standard	   deviation	   [56].	   Based	   on	   the	   results	   in	   literature,	   a	   threshold	   level	   for	  
prednisolone	  of	  5	  μg	  L-­‐1	  was	  proposed	  [57][58][59].	  	  
2. Analysis	  of	  glucocorticoids	  in	  urine	  and	  faeces	  
In	  order	  to	  provide	  the	  consumer	  residue	  free	  food	  products	  of	  animal	  origin,	  proper	  analytical	  
approaches	  for	  detecting	  glucocorticoid	  residues	  in	  edible	  or	  biological	  matrices	  are	  a	  necessity	  
[43].	  However,	   this	   is	   seen	  as	  an	  analytical	  challenge.	  After	  all,	  glucocorticoid	   residues	  may	  be	  
present	   at	   very	   low	   concentrations	   disguised	   in	   a	   background	   of	   abundant	   primary	   and	  
secondary	   metabolites	   [23].	   Besides,	   chromatographic	   separation	   of	   these	   compounds	   is	   not	  
straightforward	   due	   to	   their	   similar	   chemical	   configurations	   and	   chromatographic	   behavior	  
[60][61].	  As	  a	  consequence,	   the	  comprehensive	  analysis	  of	  glucocorticoids	  entails	   the	  use	  of	  a	  
highly	   efficient	   extraction	   procedure	   and	   an	   analytical	   platform	   that	   is	   both	   sensitive	   and	  
selective.	  	  
2.1. Sample	  preparation	  
Prior	   to	   the	   analysis,	   extensive	   clean-­‐up	   steps	   have	   been	   employed	   in	   the	   majority	   of	   the	  
reported	   analytical	   strategies	   to	   enable	   determination	   of	   glucocorticoids	   in	   urine	   and	   faeces.	  
This	  is	  an	  absolute	  requirement	  for	  eliminating	  interfering	  substances,	  enriching	  glucocorticoids	  
and	   performing	   solvent	   switching	   to	   the	   desired	   solvent	   conditions	   used	   for	   detection.	   This	  
should	  all	  happen	  preferably	  without	  causing	  unwanted	  chemical	  degradation	  of	  metabolites.	  	  
Sample	   preparation	   procedures	   often	   start	   with	   hydrolysis	   of	   the	   present	   conjugated	  
glucocorticoids	   by	   enzymatic	   or,	   to	   a	   lesser	   extent,	   chemical	   approaches	   (using	   acids	   like	  
hydrochloric	  or	  sulphuric	  acid).	  Bacterial	  (Escherichia	  coli)	  and	  mollusc	  (Helix	  pomatia)	  enzymatic	  
sources	   are	   most	   commonly	   used	   for	   this	   purpose.	   The	   bacterial	   sources	   only	   contain	   β-­‐
glucuronidase	   activity	   to	   cleave	   the	   glucuronide	   conjugates,	   whereas	   the	   mollusc	   sources	  
contain	   both	   β-­‐glucuronidase	   and	   sulfatase	   activities	   [62][63].	   However,	   it	   was	   shown	   that	  
deconjugation	   is	   dispensable,	   as	   prednisolone	   and	   cortisone	   are	   almost	   exclusively	   present	   in	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bovine	  urine	  and	  faeces	  in	  their	  free	  form	  [23].	  Moreover,	  the	  deconjugation	  process	  itself	  can	  
negatively	   influence	   the	   accuracy	   of	   analyte	   measurement	   by	   inducing	   unwanted	  
transformations	  i.e.	  androstenedione	  to	  testosterone	  [64][65][66][67].	  
Extraction	  of	  glucocorticoids	  can	  be	  performed	  by	   liquid-­‐liquid	  extraction	   in	  which	  compounds	  
are	   secluded	   on	   the	   basis	   of	   their	   relative	   solubility	   in	   two	   different	   immiscible	   liquids	   [68].	  
Therefore	  various	  organic	  solvents	  including	  diethylether,	  tert-­‐butyl-­‐methyl	  ether,	  ethyl	  acetate,	  
methanol	  and	  hexane	  are	  used	  [35][69][70][71][72].	  This	  extraction	   is	  usually	  repeated	  several	  
times	  to	   improve	  the	  efficiency	  [74].	  Depending	  on	  the	  complexity	  of	   the	  matrix,	   the	  obtained	  
extract	  may	  be	  evaporated	  to	  dryness	  under	  a	  gentle	  stream	  of	  nitrogen	  [40]	  or	  further	  purified	  
by	  solid-­‐phase	  extraction	  [60].	  This	   is	  a	  sample	  clean-­‐up	  technique	  in	  which	  glucocorticoids	  are	  
trapped	  on	  a	  solid-­‐phase	  extraction	  column,	  in	  function	  of	  their	  physical	  and	  chemical	  properties	  
while	   the	   interfering	   compounds	   are	   eluted	   or	   vice	   versa.	   The	   main	   separation	   modes	   (and	  
sorbents)	   include	   anion-­‐exchange	   (Sephadex,	   Ammonium)	   [23][75][76],	   reverse-­‐phase	   (C18,	  
Oasis	  HLB,	  Strata-­‐X)	  [77][78][79]	  and	  mixed	  mode	  (Oasis	  MAX)	  [60]	  cartridges.	  
A	  particular	  type	  of	  extraction	  that	  has	  been	  applied	  for	  glucocorticoids	  as	  well	  is	  the	  QuEChERS	  
procedure,	  which	   stands	   for	  Quick,	   Easy,	   Cheap,	   Effective,	   Rugged	   and	   Safe	   [80].	   This	   type	   of	  
extraction	  involves	  initial	  single-­‐phase	  extraction	  of	  samples	  with	  acetonitrile,	  followed	  by	  liquid-­‐
liquid	   partitioning	   under	   the	   influence	   of	   anhydrous	   MgSO4.	   Removal	   of	   residual	   water	   and	  
clean-­‐up	  are	  performed	  simultaneously	  by	  using	  a	  rapid	  procedure	  called	  dispersive	  solid-­‐phase	  
extraction,	   in	  which	  anhydrous	  MgSO4	  and	  a	   sorbent	   (e.g.	   primary	   secondary	   amine)	   removes	  
water	  and	  polar	  compounds	  [81].	  
2.2. Analytical	  detection	  approaches	  	  
For	   the	   detection	   of	   glucocorticoids	   different	   analytical	   methods	   exist,	   e.g.	   immunoassay,	  
chromatography	  coupled	   to	  different	   types	  of	  detectors	   relying	  on	  ultraviolet,	   fluorescence	  or	  
mass	   spectrometry	   [82].	   For	   accurate	   quantification	   however,	   the	  most	   applied	   technology	   is	  
mass	   spectrometric	   detection	   hyphenated	   to	   a	   separation	   technique.	   First	   the	   mass	  
spectrometer	   was	   coupled	   to	   gas	   chromatography.	   But	   more	   recently,	   due	   to	   advances	   in	  





ionization,	   it	   is	  possible	  to	  couple	  a	  mass	  spectrometer	  to	  liquid	  chromatography	  systems	  [83].	  
In	  this	  regard,	  the	  key	  concept	  of	  each	  technology	  is	  given.	  
2.2.1. Immunoassays	  
Enzyme	  immunoassays	  (EIA)	  and	  radioimmunoassays	  (RIA)	  are	  based	  on	  an	  antibody	  that	  binds	  
a	   specific	   compound.	   In	   response	   to	   binding,	   a	   measurable	   signal	   is	   produced	   due	   to	   an	  
enzymatic	  reaction	  (EIA)	  or	  radioactive	  isotopes	  bound	  at	  the	  antibody	  (RIA).	  These	  methods	  are	  
considered	  as	  easy	  and	  accessible	   screening	  methods,	  enabling	   the	  detection	  of	   several	   faecal	  
glucocorticoid	  metabolites	   e.g.	   11,17-­‐dioxoandrostanes,	   cortisol-­‐3-­‐(carboxymethyl)oxime,	   11β-­‐
hydroxyetiocholanolone	  [84][85][86]	  or	  free	  cortisol	  in	  urine	  [87].	  
These	   methodologies	   can	   be	   highly	   sensitive	   but	   are	   susceptible	   to	   cross-­‐reactivity	   of	   the	  
specific	   antibody	   with	   other	   structurally	   related	   endogenous	   and	   exogenous	   steroids.	   It	   has	  
been	  demonstrated	   that	  RIA,	  especially	   those	  based	  on	  direct	   assays,	  often	  overestimate	   true	  
steroid	  values	  [88][89].	  Another	  limitation	  of	  the	  RIA	  techniques	  is	  the	  impossibility	  of	  using	  an	  
internal	  standard	  to	  monitor	  the	  recovery	  during	  extraction.	  Comparison	  between	  RIA,	  EIA	  and	  
chromatographic	  methods	  clearly	   indicates	   the	  superiority	  of	  chromatographic-­‐based	  methods	  
towards	  quantification	  [87].	  	  
2.2.2. Chromatographic	  separation	  coupled	  to	  mass	  spectrometric	  detection	  
Chromatography	   separates	   a	   mixture	   into	   its	   components	   by	   interaction	   between	   two	  
immiscible	   phases,	   of	   which	   the	  mobile	   phase	  moves	   along	   the	   stationary	   phase.	   Due	   to	   the	  
similar	   chemical	   configuration	   and	   chromatographic	   behaviour	   of	   glucocorticoids,	  
chromatographic	   separation	   is	   not	   straightforward.	  Different	   types	   of	   chromatography	   can	   be	  
conducted	   for	   this	   purpose,	   however	   in	   this	   dissertation	   only	   the	   differentiation	   between	   gas	  
and	  liquid	  chromatography	  will	  be	  discussed.	  	  
2.2.2.1. Gas	  chromatography	  
During	  the	  1990s,	  gas	  chromatography	  coupled	  to	  mass	  spectrometry	  was	  considered	  the	  gold	  
standard	  for	  steroid	  quantitation	  [90].	  It	  is	  a	  sensitive,	  robust	  and	  therefore	  a	  suitable	  technique	  
for	  the	  detection	  of	  these	  hormones,	  despite	  the	  lengthy	  sample	  preparation	  and	  the	  need	  for	  
derivatization.	  Silylation,	  acylation	  or	  oxime/silylation	  are	  derivatization	  procedures	  enabled	  to	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reduce	  the	  analyte	  polarity	  and	  thermal	  instability	  [91][92][93].	  Nowadays,	  several	  laboratories	  
still	  measure	  steroid	  concentration	  by	  GC-­‐methods	  [94][95].	  
2.2.2.2. Liquid	  chromatography	  
In	  the	  mid	  1990s,	  high-­‐performance	  liquid	  chromatography	  (HPLC)	  has	  emerged	  as	  an	  effective	  
alternative	  for	  the	  analysis	  of	  glucocorticoids	  [60][96].	  It	  does	  present	  some	  limitations	  in	  terms	  
of	   run	   time	  and	  chromatographic	   resolution.	  This	   limitation	  can	  be	  circumvented	  by	  means	  of	  
ultra	   high-­‐performance	   liquid	   chromatography	   (UHPLC)	   that	   enables	   faster	   separation	   of	  
compounds	  in	  comparison	  to	  traditional	  LC,	  due	  to	  the	  use	  of	  columns	  with	  sub	  2	  μm	  particles.	  
UHPLC	   provides	   improved	   speed	   of	   analysis,	   a	   better	   resolution,	   increased	   sensitivity	   and	  
reduction	  of	  matrix	  effects	  [97].	  	  
To	  effectuate	  glucocorticoid	  separation,	  reversed	  phase	  (U)HPLC	  using	  silica	  based	  C18	  material	  	  
is	   most	   intensively	   used	   [77][78][98].	   With	   regard	   to	   the	   mobile	   phase,	   solvents	   are	   mostly	  
modifications	   of	   acetonitrile	   or	   methanol	   (Table	   1.5.).	   A	   small	   percentage	   of	   formic	   acid	   or	  
ammonium	   acetate	   is	   usually	   added	   to	   obtain	   the	   desired	   retention	   and	   improve	   compound	  
separation	   [60][79][80].	   Once	   the	   analytes	   have	   been	   separated	   over	   time,	   the	   liquid	   phase	  
needs	  to	  be	  evaporated	  and	  ionised	  by	  a	  proper	  interface	  system.	  
Table	   1.5.	   Selected	   confirmatory	   methods	   for	   detecting	   glucocorticoids	   in	   biological	   fluids	   using	  
chromatographic	  separation	  followed	  by	  mass	  spectrometric	  detection	  [83].	  
Matrix	   Column;	  mobile	  phase;	  flow	  rate	   Detection	  mode	   Ref.	  
Urine	   BEH	  C18	  column	  (2.1	  mm×50	  mm,	  1.7	  μm);	  	  
0.1%	  formic	  acid	  in	  H2O/0.1%	  formic	  acid	  in	  ACN,	  at	  0.35	  mL/min	  
ESI	  positive	   [70]	  
Plasma	   Pursuit	  C-­‐18	  column	  (2.0	  mm×150	  mm,	  5	  μm);	  








BEH	  C-­‐18	  column	  (2.1	  mm×50	  mm,	  1.7	  μm);	  
2	  mM	  ammonium	  acetate	  in	  water	  with	  0.1%	  formic	  acid/2	  mM	  





Urine	   Halo	  C-­‐18	  column	  (2.1	  mm×150	  mm,	  2.7	  μm	  and	  2.1	  mm×100	  mm,	  
2.7	  μm);	  




Urine	   Zorbax	  C-­‐18	  column	  (2.1	  mm×50	  mm,	  1.8	  μm);	  




Urine	   Inertsil	  ODS-­‐3	  C18	  column	  (50	  mm×4.6	  mm,	  3	  μm);	  




Urine	   Synergi	  C18	  (250	  mmx4.6.	  mm,	  4	  μm);	  








2.2.2.3 Interface	  systems	  
Various	   atmospheric	   pressure	   ionization	   (API)	   systems	   in	   both	   the	   positive	   and	   negative	   ion	  
modes	   e.g.	   electrospray	   ionization	   (ESI)	   and	   atmospheric	   pressure	   chemical	   ionization	   (APCI),	  
enable	   ionization	   of	   glucocorticoids.	   Haneef	   et	   al.	   (2013)	   [83]	   presented	   an	   overview	   of	   the	  
ionization	  techniques	  used	  for	  detecting	  glucocorticoids	  in	  biological	  fluids	  (Table	  1.5.).	  	  
ESI	   is	   a	   soft	   ionization	   technique	   that	   generates	   gas	   phase	   ions	   from	   a	   typical	   liquid-­‐phase	  
(Figure	  1.7.A).	  After	  passing	  the	  capillary	  needle	  on	  which	  a	  strong	  electrostatic	  field	  is	  applied,	  
the	   LC	   eluent	   is	   nebulized	   into	   a	   chamber	   at	   atmospheric	   pressure.	   The	   heated	   drying	   gas	  
evaporates	   the	   solvent	   into	   droplets,	   which	   results	   in	   increasing	   charge	   concentration	   in	   the	  
droplets.	   Eventually,	   the	   repulsive	   force	   between	   ions	   with	   the	   same	   charges	   exceeds	   the	  
cohesive	   forces	   and	   non-­‐fragmented	   ions	   are	   ejected	   into	   the	   gas	   phase.	   These	   ions	   are	  
attracted	   to	  and	   thus	  proceed	   to	   the	  mass	  analyser.	  The	  heated	  electrospray	   ionization	   (HESI)	  
interface	   has	   increased	   capacity	   for	   mobile	   phase	   desolvation,	   due	   to	   thermal	   desolvation	  
assistance	  in	  the	  capillary	  needle	  [103].	  
	  
Figure	  1.7.	  Schematic	  of	  electrospray	  ionisation	  (A)	  and	  chemical	  ionisation	  (after	  Thermo	  Fisher	  Scientific,	  
2012).	  
APCI	   in	   positive	   and	   negative	   mode	   was	   proven	   to	   be	   suitable	   for	   the	   ionisation	   of	  
corticosteroids	   in	  urine	  [90]	   (Figure	  1.7.B).	  With	  APCI,	   the	  analyte	  solution	   is	   introduced	   into	  a	  
pneumatic	  nebulizer	  and	  desolvated	  in	  a	  heated	  quartz	  tube	  before	  interacting	  with	  the	  corona	  
discharge	   creating	   ions.	   The	   LC	   eluent	   is	   sprayed	   through	   a	   heated	   (>	   250	   °C)	   vaporizer	   at	  
atmospheric	   pressure	   that	   vaporizes	   the	   liquid.	   The	   resulting	   gas	  phase	   solvent	  molecules	   are	  
subsequently	  ionised	  by	  electrons	  discharged	  from	  a	  corona	  needle	  and	  transfer	  their	  charge	  to	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the	   analyte	   molecules	   through	   chemical	   reactions.	   Positive	   ions	   are	   formed	   through	   proton	  
transfer,	  while	  negative	  ions	  are	  formed	  through	  electron	  transfer	  or	  proton	  loss	  [103].	  
2.2.2.4 Mass	  spectrometry	  	  
One	  of	  the	  most	  applied	  mass	  spectrometric	  techniques	  in	  hormone	  and	  veterinary	  drug	  residue	  
analysis,	   is	   quadrupole	   tandem	   mass	   spectrometry	   (QqQ-­‐MS/MS).	   This	   type	   of	   instrument	  
achieves	  high	  sensitivity,	  selectivity	  and	  reproducibility	  through	  the	  selected	  reaction-­‐monitoring	  
(SRM)	  mode	  [23][78][98].	  Nevertheless,	  this	  technology	  presents	   limitations	  with	  regard	  to	  the	  
limited	   number	   of	   compounds	   that	   can	   be	   analysed	   in	   one	   run	   and	   only	   in	   advance	   defined	  
analytes	  can	  be	  detected	  since	  there	  is	  no	  possibility	  of	  retrospective	  data	  analysis.	  Because	  of	  
these	   limitations,	   there	   is	  currently	  a	   trend	  towards	   full-­‐scan	  approaches	  using	  high-­‐resolution	  
mass	  spectrometry	  (HRMS)	  [80].	  Within	  this	  context,	  Fourier	  Transform	  Ion	  Cyclotron	  Resonance	  
(FT-­‐ICR),	  Time	  of	  Flight	  (ToF),	  and	  Fourier	  Transform	  Orbitrap	  have	  emerged	  as	  key	  technologies	  
[104].	  	  
These	  instruments	  are	  characterised	  by	  high	  mass	  resolution,	  which	  is	  the	  ability	  to	  distinguish	  
between	  narrow	  mass	  spectral	  peaks.	  This	  parameter	  can	  be	  interpreted	  in	  two	  ways.	  In	  case	  of	  
the	  valley-­‐based	  definition,	  mass	   resolution	   is	   the	   ratio	  between	   the	  mass	  of	   the	   second	  peak	  
and	  the	  mass	  difference	  between	  peaks.	  Alternatively,	  mass	  resolution	  may	  also	  be	  determined	  
based	   on	   an	   isolated	   peak	   whereby	   the	  mass	   difference	   now	   relates	   to	   the	   peak	   width	   at	   a	  
specified	  peak	  height.	  This	  peak	  width	  based	  approach	  is	  usually	  applied	  at	  peak	  half	  maximum	  
(full	  width	  at	  half	  maximum,	  FWHM).	  Besides	  high	  resolution,	  these	  instruments	  provide	  a	  full-­‐
scan	  mass	  spectrum	  of	  theoretically	  all	  analytes	  that	  were	  introduced	  into	  and	  ionized	  by	  the	  ion	  
source	   [105][106].	   This	   makes	   retrospective	   evaluation	   of	   acquired	   data	   for	   non-­‐“a	   priori”	  
selected	   compounds	   possible	   by	   reconstructing	   any	   desired	   ion	   chromatogram	   [107].	   In	  
addition,	  these	  mass	  analyzers	  provide	  high	  mass	  accuracy,	  which	  is	  indicative	  for	  the	  difference	  
between	   the	   theoretical	  and	  measured	  m/z-­‐vale	  and	  expressed	   in	  millimass	  units	   (mmu)	  or	   in	  
parts	  per	  million	  (ppm)	  [108].	  
The	  best	  results	  in	  terms	  of	  accuracy	  (<	  1.5	  ppm)	  and	  mass	  resolving	  power	  (up	  to	  1,000,000)	  are	  
achieved	  with	  FR-­‐ICR	  instruments.	  However,	  these	  instruments	  request	  a	  time-­‐consuming	  signal	  





comparison	   to	   Orbitrap	   and	   ToF	   based	   instruments	   [109].	   ToF	   analyzers	   present	   a	   mass	  
resolution	   up	   to	   60,000	   FWHM	   and	   mass	   accuracy	   below	   2	   ppm	   but	   cover	   only	   a	   limited	  
dynamic	   range	  over	  which	  accurate	  measurements	  of	  mass	   can	  be	  made	   [96].	   The	   latter	   is	   in	  
contrast	  with	  Orbitrap	  mass	  analyzers.	  Besides,	  these	  obtain	  a	  mass	  accuracy	  of	  <	  3	  ppm	  and	  a	  
resolution	  up	  to	  240,000	  FWHM.	  Its	  full-­‐scan	  speed	  (10	  Hz)	  allows	  fast,	  reproducible	  and	  reliable	  
analytical	  results	  [104][110].	  	  
The	  operating	  principle	  of	   the	  Orbitrap	  system	   is	  mainly	   founded	  on	   its	  ability	   to	   trap	   ions	   (C-­‐
trap)	   and	   allow	   them	   to	   start	   spinning	   around	   a	   central	   electrode	   (Figure	   1.8.).	   The	   C-­‐trap,	   a	  
curves	   radio	   frequency-­‐only	   quadrupole	   ion	   trap,	   injects	   a	   compact	   package	   of	   ions	   into	   the	  
orbitrap	  mass	  analyser.	  As	  an	  ion	  packet	  enters,	  the	  electric	  field	  is	  switched	  on	  and	  attracts	  the	  
ions	   to	   the	   central	   electrode.	   If	   the	   ions	   are	   sufficiently	   fast,	   they	   will	   not	   plunge	   onto	   the	  
electrode	  but	  rotate	  around	  the	  central	  axis	  while	  performing	  axial	  oscillation.	  The	  frequency	  of	  
this	  oscillation	  is	  proportional	  to	  the	  mass-­‐over-­‐charge	  (m/z)	  ratio	  and	  is	  detected	  and	  processed	  
by	   fast	   Fourier	   transform	   to	   obtain	   a	   spectrum.	   Structural	   information	   can	   be	   generated	   in	   a	  
non-­‐selective	   manner	   (all	   ions	   fragmentation)	   by	   using	   a	   High	   Energy	   Collisional	   Dissociation	  
(HCD)	  cell	  without	  precursor	  ion	  selection	  [111][112].	  	  
	  
Figure	   1.8.	   Schematic	   representation	   of	   a	   bench-­‐top	   ExactiveTM	   Orbitrap	   mass	   spectrometer	   and	   the	  
orbitrap	  mass	  analyser	  element.	  
The	   newest	   innovation	   in	   LC-­‐MS/MS	   techniques	   are	   the	   so	   called	   hybrid	  mass	   spectrometers.	  
These	  combine	  the	  full-­‐scan	  HRMS	  with	  a	  linear	  ion	  trap	  or	  a	  quadrupole	  mass	  filter	  to	  acquire	  
structural	  information	  in	  a	  selective	  manner	  [104][113].	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The	   emergence	   of	   hybrid	   MS,	   including	   LTQ-­‐Orbitrap,	   Q-­‐Exactive	   and	   Q-­‐ToF	   systems,	   has	  
promoted	   the	   development	   of	   automated	   data	   acquisition	   in	   the	  MS/MS	  mode	   to	   maximise	  
throughput	   capabilities	   and	   the	   information	   obtained	   from	   a	   single	   analytical	   run	  
[114][115][116]	   such	   as	   data-­‐dependent	   acquisition	   (DDA)	   and	   data-­‐independent	   acquisition	  
(DIA)	  [117].	  In	  DDA	  MS/MS	  spectra	  are	  acquired	  if	  selected	  criteria	  (e.g.	  threshold,	  charge	  of	  the	  
detected	   compound	   and	   dynamic	   exclusion	   list)	   are	  met	   in	   a	   survey	   scan,	   which	   is	   generally	  
based	  on	  a	   full-­‐scan	   to	  ensure	   that	   the	  process	   is	   non-­‐discriminative	   [118].	   This	   approach	  has	  
enabled	   the	   systematic	   selection	   and	   fragmentation	   of	   the	   base	   peak	   ion	   of	   the	   full-­‐scan	  
spectrum	   for	   the	   acquisition	   of	   specific	   MS/MS	   spectra.	   The	   same	   approach	   can	   then	   be	  
extended	  to	  the	  second	  and	  third	  most	  abundant	  ions,	  although	  this	  is	  limited	  by	  the	  duty	  cycle	  
that	   is	   necessary	   to	   acquire	   the	  MS/MS	   dependent	   scan	   [119].	   Unlike	  DDA,	   DIA	   is	   not	   biased	  
towards	  the	  detection	  of	  the	  most	  abundant	  ions	  in	  a	  full-­‐scan	  spectrum	  because	  it	  does	  not	  use	  
a	   selection	   step	   prior	   to	   fragmentation.	   For	   this	   purpose,	   any	  m/z	   contained	   in	   a	   range	   of	  
interest	   is	   fragmented	   either	   by	   simultaneously	   broadbanding	   all	   ions	   (entering	   the	   MS	   at	   a	  
single	  chromatographic	   time	  point)	   (MSE	  and	  AIF,	  all	   ion	   fragmentation)	  or	  by	  multiplexing	  the	  
full	  m/z	   range	   into	   smaller	  m/z	   isolated	   windows.	   Both	   MSX-­‐DIA,	   multiplexed	   MS/MS	   data-­‐
independent	   acquisition	   and	   SWATH,	   Sequential	   Window	   Acquisition	   of	   all	   Theoretical	   mass	  
spectra,	  are	  based	  on	  the	  fragmentation	  of	  all	  ions	  by	  dividing	  the	  m/z	  window	  into	  smaller	  mass	  
ranges	   [117][120].	   Although	   this	   approach	   results	   in	   more	   complex	   datasets,	   multiple	  
advantages	   have	   been	   achieved	   with	   these	   strategies,	   including	   comprehensive	  
qualitative/quantitative	   enquiries	   of	   samples	   with	   high	   specificity	   and	   the	   possibility	   of	  
retrospectively	  mining	  data	  because	  all	  m/z	  are	  fragmented	  within	  the	  LC	  time	  frame	  [121].	  	  
3. Discriminating	   endogenous	   from	   exogenous	   prednisolone:	  
metabolomics	  
The	  analytical	  methods	  used	  for	  monitoring	  the	  misuse	  and/or	  abuse	  of	  veterinary	  drugs	  in	  food	  
producing	  animals,	   are	   generally	   targeted-­‐oriented	  procedures	   [122].	  An	   inherent	   limitation	   is	  
the	   inability	   to	  detect	   residues	   such	  as	  novel	  unauthorized	  administered	  growth	  promoters	  or	  





well-­‐known	  example	  of	   the	   latter	   is	   the	   relatively	   recent	  discovered	  endogenous	   formation	  of	  
boldenone	  [123][124].	  More	  recently,	  a	  higher	  frequency	  of	  prednisolone	  levels	  in	  bovine	  urine	  
has	  been	  noticed,	  which	  could	  not	  be	  directly	  related	  to	  fraudulent	  use	  of	  prednisolone.	  As	  such,	  
questions	   have	   risen	   about	   the	   origin	   of	   this	   compound.	   Due	   to	   the	   similar	   endogenous	   and	  
exogenous	   urinary	   concentrations	   of	   prednisolone,	   at	   present,	   no	   decisive	   strategy	   has	   been	  
established	  to	  discriminate	  between	  endogenous	  and	  exogenous	  prednisolone	  (Table	  1.6.).	  This	  
makes	  it	  necessary	  to	  consider	  novel	  analytical	  strategies.	  
Table	  1.6.	  Overview	  of	  the	  reported	  urinary	  prednisolone	  concentrations	  upon	  exogenous	  administration	  
and	  following	  endogenous	  detection.	  	  
	   Administration/	  





Exogenous	  administration	   	   	   	  
Cannizzo	  et	  al.	  (2011)	  [40]	   Prednisolone	   15	  mg/day	  PO	  
during	  30	  days	  
0.67	   0.51	  -­‐	  0.68	  
	   Prednisolone	   30	  mg/day	  PO	  
during	  35	  days	  
0.67	   0.27	  -­‐	  1.18	  
Nebbia	  et	  al.	  (2014)	  [33]	   Prednisolone	  
acetate	  
2	  x	  0.4	  -­‐	  0.5	  mg/kg	  
in	  48h	  
0.05	   40	  -­‐	  72	  
Endogenous	  detection	   	   	   	  
Pompa	  et	  al.	  (2011)	  [49]	   ACTH	  treatment	   2	  x	  2	  mg	  in	  24h	  IM	   0.05	   0.69	  -­‐	  4.08	  
Ferranti	  et	  al.	  (2011)	  [125]	   Control	  group	   N/A	   0.40	   0.50	  -­‐	  0.70	  
	   Slaughterhouse	   N/A	   0.40	   0.40	  -­‐	  1.50	  
Vincenti	  et	  al.	  (2011)	  [51]	   Farm	   N/A	   0.70	   Not	  detected	  
Ferranti	  et	  al.	  (2013)	  [50]	   Control	  group	   N/A	   0.30	   0.60	  -­‐	  0.80	  
	   Slaughterhouse	   N/A	   0.30	   0.70	  -­‐	  6.20	  
Bertocchi	  et	  al.	  (2013)	  [126]	  	   Farm	   N/A	   0.40	   1.06	  ±	  0.65	  
	   Slaughterhouse	   N/A	   0.40	   0.84	  ±	  0.45	  
de	  Rijke	  et	  al.	  (2014)	  [56]	   Farm	   N/A	   0.20	   0.11	  -­‐	  0.90	  
	   Slaughterhouse	   N/A	   0.20	   0.11	  -­‐	  2.04	  
N/A:	  Not	  applicable	   	   	   	   	  
A	   prominent	   trend	   in	   analytical	   detection	   methods	   is	   the	   shift	   from	   targeted	   oriented	  
approaches	  towards	  accurate	  mass	  full-­‐scan	  HRMS	  [106],	  allowing	  the	  detection	  of	  non-­‐a	  priori	  
selected	  compounds.	  This	  shift	  allows	  differentiating	  exogenous	  and	  endogenous	  compounds	  on	  
another	  level,	  i.e.	  comparing	  complete	  urinary	  metabolite	  profiles.	  	  
Urinary	   steroid	   profiles	   provide	   quantitative	   information	   on	   the	   steroid	   biosynthetic	   and	  
catabolic	   pathways	   and	   can	   be	   essential	   for	   identification	   of	   inborn	   errors	   or	   other	   disorders	  
with	   altered	   steroid	   secretion	   [127].	   Besides,	   administration	   of	   steroid	   hormones	   may	   alter	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endogenous	  steroids	  profiles	  as	  well	  as	   related	  metabolite	   levels	   in	  urine	  as	  a	  consequence	  of	  
direct	  or	  indirect	  biological	  response.	  In	  this	  regard,	  strategies	  based	  on	  the	  detection	  of	  changes	  
in	   the	   metabolome	   are	   promising	   approaches	   in	   human	   antidoping	   control	   [20][128]	   or	   to	  
highlight	  growth-­‐promoting	  practices	  for	  animal	  fattening	  purposes	  [94][129][130][131].	  	  
An	   important	   factor	   before	   relying	   on	   a	  metabolomics	   approach	   is	   the	   availability	   of	   a	   suited	  
matrix,	  i.e.	  a	  matrix	  that	  contains	  a	  large	  range	  of	  potential	  interesting	  metabolites	  and	  reflects	  
the	  current	  metabolic	  state	  of	  the	  host	  [129].	  In	  this	  context	  urine	  is	  the	  matrix	  of	  choice,	  since	  it	  
fulfils	  these	  conditions	  and	  can	  be	  easily,	  non-­‐invasively,	  obtained.	  	  
3.1. Metabolomics	  
Metabolomics	  is	  defined	  as	  the	  qualitative	  and	  quantitative	  analysis	  of	  small	  metabolites	  (<	  1500	  
Da)	   in	   a	   specific	   biological	   system	   at	   a	   certain	   time	   point,	   under	   specific	   conditions	   [132].	   It	  
facilitates	   identification	   of	   patterns	   or	   biomarkers	   correlated	   to	   prednisolone	   administration	  
[133].	  It	  is	  useful	  whenever	  an	  assessment	  of	  changes	  in	  metabolite	  levels	  is	  important.	  
3.2. General	  strategy	  for	  metabolomics	  analysis	  
Within	   the	   metabolomics,	   two	   major	   approaches	   can	   be	   discerned:	   metabolite	   profiling	   and	  
metabolite	   fingerprinting.	   These	   strategies	   differ	   in	   many	   aspects	   including	   the	   level	   of	  
quantitation,	   complexity	   of	   sample	   preparation,	   experimental	   accuracy	   and	   precision	   and	  
number	  of	  metabolites	  detected.	  	  
Metabolite	  profiling	  is	  the	  oldest	  and	  most	  established	  approach	  and	  is	  considered	  the	  precursor	  
of	  metabolomics	   [134].	   It	   is	   the	   analysis	   of	   a	   group	   of	   known	  metabolites	   either	   related	   to	   a	  
specific	   metabolic	   pathway	   or	   a	   class	   of	   compounds	   e.g.	   steroids	   [135].	   These	   methods	   are	  
developed	  with	  the	  application	  of	  authentic	  chemical	  standards,	  offer	  medium	  throughput	  and	  a	  
semi-­‐quantitative	  output	  [94].	  The	  process	  of	  the	  acquired	  data	  can	  start	  immediately	  following	  
data	  analysis,	  since	  the	  chemical	  identity	  of	  the	  metabolites	  is	  known	  [136]	  	  
Metabolic	  fingerprinting	  does	  not	  attempt	  to	  identify	  or	  precisely	  quantify	  all	  metabolites	  in	  the	  
analysed	   sample.	   Rather,	   it	   considers	   a	   total	   fingerprint,	   as	   a	   unique	   pattern	   reflecting	   the	  
metabolic	   activity	   at	   that	   time	   in	   e.g.	   a	   urine	   sample.	   Pattern	   recognition	   tools	   are	   used	   to	  





for	   each	   pattern	   [137].	   Metabolic	   fingerprinting	   is	   most	   useful	   in	   biomarker	   discovery	   and	  
diagnostics	  [138].	  	  
After	  a	  biomarker	  is	  uncovered,	  targeted	  analysis	  may	  be	  performed	  to	  focus	  on	  the	  quantitative	  
analysis	   of	   a	   predefined	   number	   of	   known	   metabolites	   related	   to	   an	   uncovered	   metabolic	  
pathway	   or	   class	   of	   compounds.	   For	   this,	   a	   specific	   metabolite	   extraction,	   separation	   and	  
detection	  will	  be	  developed	  and	  optimized	  in	  order	  to	  achieve	  very	  low	  limits	  of	  detection	  and	  
high	   throughput	   [139].	   The	   chemical	   identification	   and	   structural	   elucidation	   of	   the	   newly	  
discovered	  compounds	   is	   a	   labour-­‐intensive	   step	   that	   follows	  data	  acquisition	  and	  must	  occur	  
before	  biological	   interpretation	   is	  possible.	  The	  major	   limitation	  of	  the	  targeted	  analysis	  of	  the	  
newly	   defined	   metabolites,	   is	   that	   it	   requires	   the	   compounds	   available	   in	   purified	   standards	  
[137].	  	  
3.3. General	  workflow	  for	  metabolomic	  analysis	  
The	  workflow	   that	   has	   been	   created	   for	   untargeted	  metabolomic	   studies	   consists	   of	  multiple	  
steps	  (Figure	  1.9.).	  	  
Figure	  1.9.	  Typical	  workflow	  for	  untargeted	  metabolomic	  studies	  including	  research	  planning,	  bioanalysis,	  
chemometrics	  and	  biochemistry.	  
CHAPTER	  I	  
26	  
The	   comprehensive	   investigation	   of	   the	   metabolome	   is	   being	   hampered	   by	   its	   enormous	  
complexity	   and	   dynamics.	   In	   order	   to	   extract	   the	   maximum	   amount	   of	   information,	   secure	  
planning	  of	  the	  experimental	  design	  is	  mandatory	  for	  the	  success	  of	  these	  types	  of	  investigations	  
[140].	   Therefore	   it	   is	   important	   to	   consider	   and	   carefully	   plan	   sample	   collection,	   storage	   and	  
stability	   of	   the	  matrix	   and	   compounds,	   intra-­‐individual	   variation	  due	   to	   environmental	   factors	  
such	  as	  diurnal	  variation	  and	  stress,	  inter-­‐individual	  variations	  due	  to	  genetic	  factors	  etc.	  [141].	  
In	  metabolomics,	  sample	  preparation	  may	  have	  a	  major	  impact	  on	  the	  obtained	  results.	  The	  goal	  
is	   extracting	   as	   many	   metabolites	   as	   possible	   without	   causing	   chemical	   degradation	   while	  
reducing	   the	  matrix	   effects	   and	   ion	   suppression.	   The	  main	   steps	   in	  most	   sample	   preparation	  
procedures	  include	  metabolite	  extraction	  with	  an	  appropriate	  solvent,	  and	  a	  procedure	  to	  enrich	  
the	  metabolite	  content	   in	  order	   to	  achieve	  sensitive	  detection	   limits	   [135][142].	  For	  metabolic	  
fingerprinting,	  a	  sample	  preparation	  procedure	   isn’t	  expected	  to	  be	  highly	  selective	  but	  has	  to	  
extract	  a	  broad	  range	  of	  compound	  classes	  in	  a	  robust	  and	  reproducible	  manner	  [130].	  	  
Two	   analytical	   platforms	   are	   by	   far	   the	   most	   used	   for	   data	   acquisition	   within	   metabolomic	  
analysis:	  mass	  spectrometry	  and	  1H	  nuclear	  magnetic	  resonance	  (NMR)	  spectroscopy.	  The	  great	  
potential	  of	  NMR	  lies	  in	  its	  non-­‐discriminatory,	  non-­‐destructive	  nature,	  while	  it	  provides	  unique	  
structural	   information.	   Although	  NMR	   requires	   limited	   sample	   preparation,	   it	   will	   only	   detect	  
medium	  to	  high	  abundant	  metabolites	  [143][144].	  MS-­‐based	  approaches	  currently	  yield	  higher	  
sensitivity	  than	  NMR	  when	  analysing	  minimal	  amounts	  of	  complex	  mixtures	  [145].	  In	  particular	  
the	   use	   of	   high	   and	   ultra	   high-­‐resolution	   mass	   spectrometry	   greatly	   improves	   analytical	  
performance	   and	   offers	   the	   best	   combination	   of	   selectivity	   and	   sensitivity.	   Mass	   analyzers	  
working	  in	  tandem	  or	  hybrid	  configuration	  can	  aid	  metabolite	  identification	  by	  acquiring	  highly	  
resolved	  and	  accurate	  MS/MS	  spectra	  [110][146].	  
During	  data	  mining,	  the	  acquired	  metabolomics	  data	  is	  converted	  into	  valuable	  and	  meaningful	  
information	  in	  successive	  steps.	  Data	  pre-­‐processing	  constitutes	  the	  initial	  step	  in	  data	  handling	  
and	   its	  goal	   is	   to	  extract	  all	   the	   relevant	   information	   from	  the	   raw	  data	  and	  summarize	   them.	  
This	   procedure	   includes	   steps	   such	   as	   noise	   filtering,	   data	   binning,	   peak	   detection	   and	  
chromatographic	  alignment	  [130].	  Data	  pre-­‐treatment	  e.g.	  normalization,	  scaling,	  etc.	  is	  used	  to	  





metabolomics	   data.	   Statistical	  modelling	   can	   highlight	   and	   identify	   underlying	   similarities	   and	  
differences	  in	  huge	  data	  sets	  and	  seek	  fingerprints	  or	  patterns	  that	  allow	  sample	  discrimination	  
or	  biomarker	  discovery	  [147][148].	  	  
Currently,	  the	  process	  of	  metabolite	  identification	  in	  untargeted	  metabolomic	  studies	  is	  seen	  as	  
the	  bottleneck	   in	  deriving	  biological	  knowledge	  from	  metabolomic	  studies.	  Nevertheless,	  mass	  
spectrometry	   can	   provide	   a	   wealth	   of	   structural	   information	   e.g.	  m/z-­‐ratios,	   relative	   isotope	  
abundance	   and	   fragmentation	   patterns.	   The	   comparison	   of	   this	   experimental	   data	   to	   mass	  
spectral	   libraries	  can	  provide	  reliable	  information	  (Table	  1.7.)	  [132][149]	  but	  it	   is	  unrealistic	  for	  
all	   metabolites	   to	   be	   incorporated	   into	   mass	   spectral	   libraries.	   Even	   when	   these	   data	   are	  
available,	   the	   transferability	   of	   libraries	   between	   instruments	  must	   be	   considered	   [136][150].	  
Besides,	  the	  lack	  of	  suitable	  reference	  standards	  to	  be	  purchased	  makes	  that	  the	  identification	  
can’t	  be	  performed	  at	  the	  highest	  level	  [138][151].	  	  
Table	  1.7.	  Overview	  of	  available	  web-­‐resources	  useful	  in	  metabolomics	  research	  [150][152].	  	  
Database	   Type	   Link	  
Comprehensive	  Metabolomic	  Databases	   	  
HMDB	   Human	  Metabolome	  Database	   http://www.hmdb.ca	  
BiGG	   Biochemical	  Genetic	  and	  Genomic	  knowledge	  base	  of	  large	  scale	  
metabolic	  reconstructions	  
http://bigg.ucsd.edu	  













Database	  containing	  detailed	  information	  about	  molecule	  





Bovine	  Metabolome	  Database	   http://www.cowmetdb.ca/cgi-­‐
bin/browse.cgi	  
Metabolic	  Pathway	  Databases	   	  
KEGG	   Kyoto	  Encyclopedia	  of	  Genes	  and	  Genomes	   http://www.genome.jp/kegg	  
MetaCyc	   Metabolic	  pathway	  database	   http://metacyc.org	  
HumanCyc	   Bioinformatics	  database	  that	  describes	  the	  human	  metabolic	  
pathways	  and	  the	  human	  genome	  
http://humancyc.org	  
Compound	  or	  Compound-­‐Specific	  Databases	   	  
PubChem	   Freely	  available	  database	  of	  chemical	  structures	  of	  small	  organic	  





Chemical	  Entities	  of	  Biological	  Interest	   http://www.ebi.ac.uk/chebi/	  
ChemSpider	   Aggregated	  database	  of	  organic	  molecules	  containing	  more	  than	   http://www.chemspider.com	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20	  million	  compounds	  from	  many	  different	  providers	  
IIMDB	  
	  
In	  Vivo/In	  Silico	  Metabolites	  Database	   http://metabolomics.pharm.uco
nn.edu/iimdb/	  
Drug	  Databases	   	  
DrugBank	   Blended	  bioinformatics	  and	  cheminformatics	  resource	  that	  
combines	  detailed	  drug	  data	  with	  comprehensive	  drug	  target	  
information	  
http://www.drugbank.ca	  
TTD	   Therapeutic	  Target	  Database	   http://xin.cz3.nus.edu.sg/group/
ttd/ttd.asp	  
STITCH	   Search	  tool	  for	  interactions	  of	  chemicals	   http://stitch.embl.de	  
SuperTarget	   Database	  that	  contains	  a	  core	  dataset	  of	  about	  7300	  drug-­‐target	  
relations	  of	  which	  4900	  interactions	  have	  been	  subjected	  to	  a	  




Spectral	  Databases	   	  
BMRB	  
	  
Biological	  Magnetic	  Resonance	  Databank	   http://www.bmrb.wisc.edu/met
abolomics/	  
MMCD	   Madison	  Metabolomics	  Consortium	  Database	   http://mmcd.nmrfam.wisc.edu	  
MassBank	   A	  mass	  spectral	  database	  of	  experimentally	  acquired	  high	  





Provides	  public	  access	  to	  custom	  GC/MS	  libraries	  which	  are	  stored	  
as	  Mass	  Spectral	  (MS)	  and	  Retention	  Time	  Index	  (RI)	  Libraries	  
(MSRI)	  
http://gmd.mpimp-­‐golm.mpg.de	  




Contains	  GC/MS	  data	  (spectra	  and	  retention	  indices)	  collected	  by	  





Birmingham	  Metabolite	  Library	  Nuclear	  Magnetic	  Resonance	   http://www.bml-­‐nmr.org	  
mzCloud	   Collection	  of	  high	  resolution/accurate	  mass	  spectral	  trees	  using	  a	  
new	  third	  generation	  spectra	  correlation	  algorithm	  
https://www.mzcloud.org	  
Besides	  the	  web-­‐based	  databases,	  other	  tools	  allow	  reduction	  of	  the	  metabolite	  search	  space	  to	  
a	  single	  or	  small	  number	  of	  metabolites	  to	  achieve	  putative	  annotation.	  This	  includes	  collation	  of	  
data	   for	   unidentified	   metabolites	   (e.g.	   accurate	   measurements	   of	   m/z,	   fragmentation	   mass	  
spectra	   related	   to	   chemical	   structure,	   the	   application	   of	   chemical	   and	   biological	   knowledge,	  
experimental	   isotope-­‐based	   studies)	   and	   the	   development	   of	   in	   silico	   tools	   to	   predict	   mass	  
spectral	  and	  chromatographic	  properties	  [136][153].	  
It	   is	  necessary	  to	  validate	  the	  performance	  and	  usefulness	  of	  biomarkers.	  Hereby,	  a	  distinction	  
should	   be	   made	   between	   analytical	   method	   validation	   and	   clinical	   qualification.	   Validation	   is	  
defined	   as	   the	   process	   of	   assessing	   the	   biomarker	   and	   its	   measurement	   performance	  
characteristics,	   and	   determining	   the	   range	   of	   conditions	   under	   which	   the	   biomarker	   will	   give	  
reproducible	   and	   accurate	   data	   [154][155][156].	  While	   clinical	   qualification	   is	   the	   evidentiary	  





4. Conceptual	  framework	  of	  this	  study	  
The	  European	  Commission	  reported	  more	  non-­‐compliant	  urine	  samples	  for	  prednisolone	  in	  the	  
past	   few	  years	   in	   their	  annual	  Commission	  Staff	  Working	  Document	  on	  the	   implementation	  of	  
the	  established	  national	  glucocorticoid	  monitoring	  plans	  in	  the	  different	  member	  states,	  without	  
any	  direct	  evidence	  of	  unauthorized	  use.	  These	  findings	  raised	  many	  questions	  about	  the	  origin	  
of	   this	  prednisolone.	  At	   the	  start	  of	   this	  PhD	  project,	  a	  mechanistically	  explanation	  or	  a	  direct	  
discrimination	  between	  endogenous	  and	  exogenous	  prednisolone	  had	  not	  yet	  been	  established.	  	  
In	   literature	   a	   few	   hypotheses	   had	   been	   put	   forward,	  which	  were	   further	   investigated	   in	   this	  
study.	   A	   first	   is	   the	   possible	   conversion	   of	   natural	   glucocorticoids	   into	   prednisolone	   during	  
inappropriate	  storage	  of	  the	  samples	  of	   interest.	  Therefore,	  this	  study	  aimed	  at	  deepening	  the	  
knowledge	   about	   the	   long-­‐term	   stability	   of	   natural	   and	   synthetic	   glucocorticoids	   in	   two	  
important	   matrices	   from	   a	   control	   perspective	   i.e.	   urine	   and	   faeces.	   To	   this	   end,	   analytical	  
methods	  for	  the	  accurate	  and	  specific	  determination	  of	  natural	  and	  synthetic	  glucocorticoids	  in	  
urine	  and	   faeces	  were	  developed	  and	  validated	  according	   to	  CD	  2002/657/EC	   [44]	   (Chapter	   II	  
and	  Chapter	  III).	  
A	  second	  hypothesis	  states	  that	  prednisolone	  could	  be	  generated	  under	  the	  influence	  of	  stress,	  
since	   most	   of	   the	   prednisolone	   positive	   bovine	   urine	   samples	   were	   collected	   at	   the	  
slaughterhouse	  so	  far.	  To	  take	  into	  account	  this	  possible	  endogenous	  formation	  of	  prednisolone,	  
the	   European	   Reference	   Laboratories	   have	   suggested	   a	   threshold	   level	   for	   prednisolone	   in	  
bovine	  urine	  of	  5	  µg	  L-­‐1.	  To	   investigate	   this	  hypothesis	  and	   the	   related	   threshold	   level,	  bovine	  
urinary	  levels	  of	  cortisol,	  prednisolone	  and	  their	  main	  phase	  I	  and	  II	  metabolites	  were	  evaluated	  
under	   conditions	   differing	   in	   degree	   of	   stress:	   at	   the	   farm,	   after	   slaughter	   and	   upon	  
administration	   of	   a	   synthetic	   analogue	   of	   adrenocorticotropic	   hormone.	   Besides,	   the	   urinary	  
metabolic	   fingerprint	   of	   the	   different	   urine	   batches	   was	   evaluated	   and	   differentiating	  
metabolites	  were	  assigned	  that	  have	  a	  key	  role	  in	  the	  urinary	  metabolome	  in	  response	  to	  stress.	  
This	  could	  be	  a	  powerful	  tool	  to	  classify	  an	  unknown	  bovine	  urine	  sample	  and	  offer	  information	  
about	  the	  animal’s	  individual	  condition	  (Chapter	  IV).	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In	   literature,	   the	   use	   of	   prednisolone/cortisol	   urinary	   concentration	   ratios	   and	   the	   analysis	   of	  
20β-­‐dihydroprednisolone	  were	   suggested	   as	   potential	   screening	   tools	   to	   confirm	   the	  origin	   of	  
prednisolone.	   Little	   is	   however	   known	   about	   the	   pharmacokinetics	   of	   the	   known	   main	  
metabolites	   of	   prednisolone.	   Therefore,	   the	   pharmacokinetic	   and	   urinary	   excretion	   profile	   of	  
prednisolone,	   prednisone,	   20α-­‐dihydroprednisolone	   and	   20β-­‐dihydroprednisolone	   were	  
assessed	  during	  a	  growth-­‐promoting	  and	  therapeutic	  prednisolone	  treatment	  on	  the	  one	  hand	  
and	   during	   pharmacologically-­‐induced	   increase	   of	   cortisol	   on	   the	   other	   hand.	   In	   addition,	   the	  
biotransformation	   of	   cortisol	   was	   investigated	   by	   profiling	   urinary	   glucocorticoid	   metabolites	  
during	  these	  treatments	  (Chapter	  V).	  	  
Because	  the	  need	  exists	  for	  a	  specific	  biomarker	  that	  has	  the	  ability	  to	  discriminate	  endogenous	  
formation	   from	   exogenous	   administration	   of	   the	   synthetic	   glucocorticoid	   prednisolone,	   a	  
strategy	  of	  metabolic	  fingerprinting	  was	  implemented	  to	  assess	  potential	  metabolite	  differences	  
in	  the	  urine	  of	  cows,	  exposed	  to	  a	  growth-­‐promoting	  and	  therapeutic	  prednisolone	  treatment.	  
This	   encompassed	   metabolite	   discovery,	   but	   also	   evaluation	   of	   classification	   performance	   by	  
defining	  the	  sensitivity,	  specificity,	  urinary	  excretion	  kinetics	  and	  selectivity	  (Chapter	  VI).	  	  
Finally,	  Chapter	   VII	   summarizes	   and	   reflects	   on	   the	   eliciting	   findings	   of	   the	   different	   research	  
chapters	  and	  some	  conclusions	  are	  formulated.	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Due	  to	  their	  growth-­‐promoting	  effects,	  the	  use	  of	  synthetic	  glucocorticoids	   is	  strictly	  regulated	  
in	  the	  European	  Union	  (Council	  Directive	  2003/74/EC).	  In	  the	  frame	  of	  the	  national	  control	  plans,	  
which	  should	  ensure	  the	  absence	  of	  residues	  in	  food	  products	  of	  animal	  origin,	  in	  recent	  years,	  a	  
higher	   frequency	   of	   prednisolone	   positive	   bovine	   urines	   has	   been	   observed.	   This	   has	   raised	  
questions	  with	  respect	  to	  the	  stability	  of	  natural	  corticoids	  in	  the	  respective	  urine	  samples	  and	  
their	   potential	   to	   be	   transformed	   into	   synthetic	   analogues.	   In	   this	   study,	   an	   ultra-­‐high	  
performance	   liquid	   chromatography-­‐high	   resolution	   mass	   spectrometry	   (UHPLC-­‐HRMS)	  
methodology	  was	  developed	   to	   examine	   the	   stability	   of	   glucocorticoids	   in	   bovine	  urine	  under	  
various	   storage	   conditions	   (up	   to	   20	   weeks)	   and	   to	   define	   suitable	   conditions	   for	   sample	  
handling	   and	   storage,	   using	   an	  Orbitrap	   ExactiveTM.	   To	   this	   end,	   an	   extraction	   procedure	  was	  
optimized	   using	   a	   Plackett-­‐Burman	   experimental	   design	   to	   determine	   the	   key	   conditions	   for	  
optimal	   extraction	  of	   glucocorticoids	   from	  urine.	  Next,	   the	   analytical	  method	  was	   successfully	  
validated	   according	   to	   the	   guidelines	   of	   CD	   2002/657/EC.	   Decision	   limits	   and	   detection	  
capabilities	  for	  prednisolone,	  prednisone	  and	  methylprednisolone	  ranged,	  respectively,	  from	  0.1	  
to	  0.5	  μg	  L-­‐1	  and	  from	  0.3-­‐0.8	  μg	  L-­‐1.	  For	  the	  natural	  glucocorticoids	  limits	  of	  detection	  and	  limits	  
of	   quantification	   for	   dihydrocortisone,	   cortisol	   and	   cortisone	   ranged,	   respectively,	   from	  0.1	   to	  
0.2	  μg	  L-­‐1	  and	  from	  0.3	  to	  0.8	  μg	  L-­‐1.	  	  
The	   stability	   study	   demonstrated	   that	   filter-­‐sterilization	   of	   urine,	   storage	   at	   -­‐80	   °C,	   and	   acidic	  
conditions	   (pH	   3)	   were	   optimal	   for	   preservation	   of	   glucocorticoids	   in	   urine	   and	   able	   to	  
significantly	  limit	  degradation	  up	  to	  20	  weeks.	  	  




The	  well-­‐known	   anti-­‐inflammatory	   properties	   of	   the	   natural	   glucocorticoid	   cortisol,	   has	   led	   to	  
the	   development	   of	   synthetic	   glucocorticoid	   analogues,	   which	   exert	   even	   higher	   anti-­‐
inflammatory	  activities	   [1].	  Nowadays,	   the	   commonly	  used	   therapeutic	   glucocorticoid	  drugs	   in	  
veterinary	   medicine	   comprise	   betamethasone,	   dexamethasone,	   methylprednisolone	   and	  
prednisolone,	  with	  prednisone	  as	  prodrug.	  Beside	  the	  anti-­‐inflammatory	  properties,	  these	  drugs	  
also	  induce	  body	  weight	  gain	  in	  production	  animals	  by	  improving	  feed	  intake	  and	  lowering	  feed	  
conversion.	   However,	   due	   to	   their	   growth-­‐promoting	   effects	   and	   potential	   consumer’s	   health	  
risks	   [2][3],	   the	   use	   of	   glucocorticoids	   in	   livestock	   has	   been	   strongly	   restricted	   within	   the	  
European	  Union	  [4].	  	  
The	   analysis	   of	   glucocorticoids,	   which	   is	   of	   critical	   importance	   in	   light	   of	   the	   national	   control	  
plans	  within	  the	  EU,	  remains,	  however,	  a	  challenging	  task.	  After	  all,	  glucocorticoid	  residues	  are	  
typically	  present	   in	  urine	  at	  very	   low	  concentrations	   in	  a	  background	  of	  a	  wide	   range	  of	  more	  
abundant	  primary	  and	  secondary	  metabolites	  [5].	  Besides,	  chromatographic	  separation	  of	  these	  
compounds	   is	   not	   straightforward	   due	   to	   their	   similar	   chemical	   configurations	   and	  
chromatographic	  behaviour	   [6][7].	  Because	  of	   the	   identical	  molecular	  masses	  of	  cortisone	  and	  
prednisolone,	  co-­‐elution	  may	  result	  in	  a	  loss	  of	  selectivity.	  Indeed,	  the	  natural	  prevalence	  of	  the	  
glucocorticoids	  cortisol	  and	  cortisone	  in	  urine	  at	  low	  concentrations	  may	  hamper	  the	  analysis	  of	  
prednisolone	   and	   prednisone	   [5].	   Nevertheless	   liquid	   chromatography	   coupled	   to	   mass	  
spectrometry	  has	  been	  proven	  suitable	  to	  enable	  sensitive	  detection	  of	  glucocorticoids	  in	  urine	  
[6][8][9][10].	  Because	  conventional	  liquid	  chromatography	  presents	  some	  limitations	  in	  terms	  of	  
a	   longer	   run	   time	   and	   lower	   chromatographic	   resolution,	   ultra-­‐high	   performance	   liquid	  
chromatography	  (UHPLC)	  using	  columns	  with	  sub	  2	  μm	  particles,	  is	  more	  commonly	  used	  these	  
days	  [11][12][13].	  Due	  to	  the	  very	  narrow	  peaks	  produced	  by	  UHPLC,	  a	  compatible	  fast	  scanning	  
MS	   device	   is	   required.	   The	   most	   applied	   mass	   spectrometric	   technique	   in	   hormone	   and	  
veterinary	  drug	   residue	  analysis	   is	   quadrupole	   tandem	  mass	   spectrometry	   (QqQ-­‐MS/MS)	   [14],	  
relying	  on	  the	  high	  sensitivity	  and	  selectivity	  of	  the	  selected	  reaction-­‐monitoring	  (SRM)	  mode	  of	  
QqQ-­‐MS/MS.	   This	   technology	   has	   certain	   limitations	   since	   there	   is	   no	   possibility	   of	   post-­‐
acquisition	  re-­‐interrogation	  of	  data	  and	  only	  a	  limited	  number	  of	  compounds	  can	  be	  measured	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within	   one	   run	   (max.	   100	   -­‐	   120	   using	   timed	   SRM).	   Also	   the	   screening	   for	   unidentified	   and	  
unknown	  compounds	  is	  not	  possible	  because	  the	  fragmentation	  behaviour	  of	  the	  compound	  is	  
unknown	  [15][16].	  Because	  of	  these	  limitations,	  there	  is	  currently	  a	  trend	  towards	  full	  scan	  high	  
resolution	   MS	   analysis	   using	   amongst	   others	   ToF	   (time	   of	   flight)	   instruments,	   with	   mass	  
deviations	   below	   5	   parts	   per	  million	   (ppm)	   and	   resolutions	   of	   about	   15,000	   full	  width	   at	   half	  
maximum	   (FWHM)	   [11][15].	   However,	   in	   complex	   matrices	   this	   resolution	   is	   inadequate	   for	  
accurate	  mass	  measurements.	  One	  of	   the	  most	  attractive	  and	  relatively	  new	  techniques	   is	   the	  
Fourier	  Transform	  Orbitrap	  mass	  spectrometric	  technology	  with	  a	  resolving	  power	  up	  to	  100,000	  
FWHM	  and	  a	  precise	  mass	  deviation	  below	  2	  ppm	  [15],	  allowing	  fast,	  reproducible	  and	  reliable	  
analytical	  results	  for	  multiple	  residue	  analysis	  [12].	  	  
Prior	  to	  HRMS	  analysis,	  it	  is	  common	  to	  apply	  a	  generic	  extraction	  to	  allow	  as	  much	  as	  possible	  
relevant	  analytes	   to	  be	   retained	   in	   the	  extract,	  but	  at	   the	   same	   time	   remove	  potential	  matrix	  
interferences.	  The	  Plackett-­‐Burman	  experimental	  design	   is	  a	  highly	  efficient	  and	  useful	   tool	   to	  
screen	  for	  the	  main	  variables	  within	  a	  large	  number	  of	  variables	  that	  may	  affect	  the	  extraction	  
yield	   [17][18].	   This	   time	   saving	   approach,	   providing	   the	   opportunity	   to	   identify	   the	   optimal	  
conditions	   for	   extraction	   of	   a	   certain	   number	   of	   analytes	   from	   a	  matrix	   by	   evaluating	   a	   large	  
number	  of	  variables	  with	  a	  minimum	  of	  experiments.	  It	  also	  permits	  estimation	  of	  random	  error	  
variability	  and	  testing	  the	  statistical	  significance	  of	  the	  variables	  [17][19].	  
The	  European	  Commission	  reported	  in	  2012	  in	  the	  Commission	  Staff	  Working	  Document	  on	  the	  
implementation	  of	  national	  residue	  monitoring	  plans	  in	  the	  member	  states	  in	  2010	  that	  0.14%	  of	  
the	  bovine	  urine	  samples	  were	  non-­‐compliant	  for	  prednisolone	  (3.12	  μg	  L-­‐1	  -­‐	  179.72	  μg	  L-­‐1)	  [20].	  
This	  high	  frequency	  of	  bovine	  urine	  samples	  found	  positive	  for	  prednisolone	  without	  any	  direct	  
evidence	  for	  unauthorized	  use,	  has	  raised	  many	  questions	  [8][9][10][21].	  A	  possible	  hypothesis	  
is	   the	  conversion	  of	   the	  natural	  glucocorticoid	  cortisol	   into	  prednisolone,	  during	   inappropriate	  
storage	  [9][10].	  The	  prevalence	  of	  faecal	  microbiota	   in	  urine	  may	  indeed	  alter	  the	  endogenous	  
concentration	   of	   steroid	   hormones	   [22][23].	   A	   well-­‐known	   example	   of	   such	   a	   process	   is	   the	  
microbial	  transformation	  of	  testosteron	  to	  boldenone	  by	  a	  Δ1-­‐dehydrogenation	  [24][25].	  Due	  to	  
structural	   similarities,	   similar	   reactions	   may	   be	   expected	   from	   cortisol	   to	   prednisolone	   and	  
cortisone	   to	   prednisone	   [23].	   Research	   with	   respect	   to	   the	   long-­‐term	   stability	   of	   these	  
CHAPTER	  II	  
50	  
compounds	   and	   possible	   changes	   occurring	   during	   storage	   is,	   however,	   scarce	   and	   mainly	  
targeted	  oriented.	  	  
Therefore,	   the	  present	  study	  examined	  the	  changes	   in	  glucocorticoid	  concentrations	  of	  bovine	  
urine	   samples	  during	   a	   long-­‐term	   storage	  experiment,	   in	  which	   the	  effect	  of	  different	   storage	  
conditions	   such	  as	  pH	  and	   temperature	  were	  considered.	  Additionally,	   the	  preservation	  under	  
aerobe	   and	   anaerobe	   environments,	   as	   well	   as	   the	   contamination	   with	   faecal	   bacteria,	   was	  
evaluated.	  Furthermore,	  this	  stability	  study	  included	  the	  determination	  of	  losses	  during	  multiple	  
freeze-­‐thaw	   cycles.	   The	   compounds	   of	   interest	   were	   the	   natural	   glucocorticoids	   cortisol,	  
cortisone	  and	  dihydrocortisone	  and	  the	  synthetic	  glucocorticoids	  prednisolone,	  prednisone	  and	  
methylprednisolone.	   To	   this	   extent,	   a	   generic	   extraction	   and	   targeted	   UHPLC-­‐Orbitrap-­‐HRMS	  
approach,	  with	  the	  possibility	  of	  untargeted	  screening,	  was	  developed	  and	  validated	  according	  
to	  the	  guidelines	  of	  CD	  2002/657/EC	  [26].	  
2. Material	  and	  methods	  
2.1. Reagents	  and	  chemicals	  
Standards	   of	   prednisolone,	   prednisone,	   cortisone,	   cortisol,	   dihydrocortisone	   and	  
methylprednisolone	  were	  purchased	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO,	  USA).	  Internal	  standards	  
were	  cortisol-­‐d4	  (Sigma-­‐Aldrich)	  and	  prednisolone-­‐d8	  (TRC,	  Canada).	  Reagents	  were	  of	  analytical	  
grade	   when	   used	   for	   extraction	   purposes	   and	   obtained	   from	   VWR	   International	   (Merck,	  
Darmstadt,	  Germany).	  The	  reagents	  were	  of	  LC-­‐MS	  Optima	  grade	  for	  UHPLC-­‐HRMS	  application.	  
These	   were	   obtained	   from	   Fisher	   Scientific	   UK	   (Loughborough,	   UK).	   Ultrapure	   water	   was	  
obtained	  by	  usage	  of	  a	  purified-­‐water	  system.	  For	  filter-­‐sterilization	  of	  urine,	  membrane	  filters	  
of	  polyvinylidene	  fluoride	  (0.22	  μm	  pore	  size)	  were	  purchased	  from	  Millipore	  (Billerica,	  USA).	  	  
Primary	  stock	  solutions	  were	  prepared	  in	  ethanol	  at	  a	  concentration	  of	  200	  μg	  mL-­‐1	  and	  stored	  in	  





Analyses	  were	  carried	  out	  on	  an	  UHPLC	  system,	  which	  consisted	  of	  an	  Accela	  UHPLC	  pump,	  an	  
Accela	  Autosampler	   and	  Degasser	   (Thermo	  Fisher	   Scientific,	   San	   José,	   CA,	  USA).	   Separation	  of	  
the	  glucocorticoids	  was	   carried	  out	  on	  a	   reverse	  phase	  Nucleodur	  C18	   Isis	  UHPLC	  column	   (1.8	  
μm,	  100	  ×	  2	  mm,	  Macherey-­‐Nagel,	  Düren,	  Germany)	  at	  a	  column	  oven	  temperature	  of	  30	  °C.	  The	  
elution	  gradient	  was	  carried	  out	  with	  a	  binary	  solvent	  system	  consisting	  of	  0.1%	  aqueous	  formic	  
acid	   (A)	   and	   0.1%	   formic	   acid	   in	   acetonitrile	   (B)	   at	   a	   constant	   flow	   rate	   of	   0.3	   mL	   min-­‐1.	  
Optimized	  separation	  of	  all	  analytes	  was	  obtained	  using	  a	  linear	  gradient	  starting	  with	  a	  solvent	  
mixture	   (v/v)	  of	  75%	  A	  and	  25%	  B,	  which	  was	  held	   for	  4.0	  min.	  The	  percentage	  of	  acetonitrile	  
was	   increased	   to	   95%	   in	   0.1	  min,	   and	   further	   to	   100%	   in	   1.4	  min	   and	  held	   there	   for	   2.0	  min.	  
Between	  samples,	  the	  column	  was	  allowed	  to	  re-­‐equilibrate	  at	  initial	  conditions	  for	  1.5	  min.	  A	  10	  
μL	  aliquot	  of	  each	  sample	  was	  injected	  for	  analysis.	  High-­‐resolution	  mass	  spectrometric	  analysis	  
was	   performed	   on	   an	   ExactiveTM	   benchtop	   mass	   spectrometer	   (Thermo	   Fisher	   Scientific)	  
equipped	  with	   a	   heated	   electrospray	   ionization	  probe	   (HESI	   II),	   operating	   in	   both	   the	   positive	  
and	   negative	   ionization	  mode.	   Ionization	   source	  working	   parameters	  were	   optimized	   and	   are	  
reported	  in	  Table	  2.1.	  	  
Table	  2.1.	  Instrumental	  parameters	  used	  for	  HESI	  (II)-­‐ionization	  of	  glucocorticoids.	  
Instrumental	  Parameter	   Value	  
Spray	  voltage	   4	  kV	  
Sheath	  gas	  flow	  rate	   75	  au*	  
Auxiliary	  gas	  flow	  rate	   7	  au	  
Sweep	  gas	  flow	  rate	   2	  au	  
Capillary	  temperature	   280	  °C	  
Heater	  temperature	   300	  °C	  
Capillary	  voltage	   45	  (-­‐32)	  V	  
Tube	  lens	  voltage	   95	  (-­‐100)	  V	  
Skimmer	  voltage	   16	  (-­‐20)	  V	  
*au:	  arbitrary	  units	  
The	  resolution	  was	  set	  at	  50,000	  FWHM	  at	  1	  Hz	  and	  a	  scan	  range	  of	  m/z	  150-­‐800	  was	  chosen.	  
The	  automatic	  gain	  control	   (AGC)	  target	  was	  set	  at	  balanced	  (1	  x	  e6	   ions)	  and	  the	  High	  Energy	  
Collision	   Dissociation	   (HCD)	   cell	  was	   turned	   off.	   Instrument	   control	   and	   data	   processing	  were	  




Urine	  was	  collected	  from	  five	  healthy,	  adult	  Holstein-­‐Friesian	  cows,	  housed	  at	  the	   Institute	  for	  
Agricultural	   and	   Fisheries	   Research	   (ILVO)	   in	  Merelbeke,	   Belgium.	   Urine	   was	   collected	   during	  
spontaneous	  urination	  and	  immediately	  processed.	  	  
2.4. Sample	  preparation	  
2.4.1. Fractional	  factorial	  design	  
A	  sequential	   strategy	  of	  experimental	  design	  was	  used	   to	  optimize	   the	  analytical	  extraction	  of	  
glucocorticoids	  from	  urine.	  The	  dependent	  variables	  that	  might	  significantly	  affect	  the	  extraction	  
were	   screened	   with	   a	   Plackett-­‐Burman	   design.	   This	   design	   is	   useful	   to	   screen	   for	   the	   main	  
variables	  from	  a	  large	  number	  of	  variables	  that	  may	  affect	  the	  response	  and	  consists	  of	  a	  two-­‐
level	  design	   to	   investigate	  N-­‐1	   variables,	  with	  N	   runs,	  where	  N	   should	  be	  a	  multiple	  of	  4.	   The	  
variables	  that	  might	  influence	  the	  extraction	  of	  glucocorticoids	  in	  urine	  were	  selected	  based	  on	  
conditions	  found	  in	  literature	  [11][23][27][28].	  Table	  2.2.	  shows	  the	  ten	  different	  variables	  that	  
were	  investigated	  as	  well	  as	  the	  levels	  of	  each	  variable	  used.	  The	  excessive	  variable	  was	  set	  as	  
dummy	  [29][30].	  	  
Table	  2.2.	  Parameter	  variable	  values	  selected	  for	  the	  Plackett-­‐Burman	  design.	  
Variable	   Unit	   Lower	  value	   Upper	  value	  
Volume	  urine	  	   mL	   3	   5	  
pH	  buffer	   -­‐	   5	   7	  
Time	  of	  hydrolysis	  	   h	   1	   2	  
Temperature	  	   °C	   37	   50	  
pH	  adjustment	  solvent	   -­‐	   Carbonate	  buffer	   NaOH	  
Extraction	  solvent	   -­‐	   TBME*	   Diethylether	  
Volume	  of	  extraction	  solvent	  	   mL	   5	   10	  
Time	  of	  shaking	  	   min	   5	   20	  
Way	  of	  shaking	   -­‐	   Shaking	   Rotation	  
Volume	  of	  2th	  LL	  phase	   mL	   5	   10	  
*TBME:	  tert-­‐butyl	  methylether	  
In	  this	  study,	  it	  sufficed	  to	  perform	  12	  experimental	  runs	  to	  specify	  a	  particular	  combination	  of	  
settings	  for	  the	  different	  variables	  included	  in	  the	  design.	  Next,	  the	  main	  effect	  of	  each	  variable	  
was	   calculated.	   When	   statistical	   significant	   differences	   (p	   <	   0.05)	   were	   obtained	   for	   certain	  
variables,	   these	   critical	   variables	   i.e.	   volume	   of	   the	   urine,	   temperature	   during	   hydrolysis	   and	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volume	   of	   the	   extraction	   solvent	   were	   subjected	   to	   further	   optimization	   by	   response	   surface	  
methodology.	   To	   this	   extent,	   a	   Central	   Composite	   Face	   (CCF)	   design	   was	   used.	   The	   software	  
program	  Modde	  5.0	  (Umetrics,	  Umea,	  Sweden)	  was	  used	  to	  carry	  out	  the	  experimental	  design	  
matrix	  and	  data	  analysis.	  
2.4.2. Sample	  extraction	  
Five	  mL	  of	  blank	  urine	  was	  spiked	  with	  the	  internal	  standards	  (cortisol-­‐d4	  and	  prednisolone-­‐d8)	  
to	  obtain	  a	  final	  concentration	  of	  10	  μg	  L-­‐1.	  A	  liquid-­‐liquid	  extraction	  was	  performed	  by	  adding	  a	  
volume	  of	  7.5	  mL	   tert-­‐butyl	  methylether.	  After	  5	  min	  of	   rotating	  at	  1200	  ×	  g,	   the	   sample	  was	  
centrifuged	  at	  5500×g	  for	  5	  min	  at	  7	  °C.	  The	  organic	  layer	  was	  collected	  and	  transferred	  to	  a	  15	  
mL	   tube.	  This	  procedure	  was	   repeated	  by	  adding	  5	  mL	  of	   tert-­‐butyl	  methylether	   to	   the	  urine.	  
The	  organic	  phase	  was	  dried	  under	  a	  gentle	  stream	  of	  nitrogen	  at	  a	  temperature	  of	  50	  °C.	  The	  
residue	  was	  redissolved	  in	  100	  μL	  solvent,	  corresponding	  to	  the	  initial	  mobile	  phase	  conditions	  
and	  transferred	  to	  vials	  for	  UHPLC-­‐MS	  analysis.	  	  
2.5. Analytical	  method	  validation	  
Validation	  of	  the	  method	  was	  performed	  by	  adopting	  the	  protocol	  proposed	  by	  Antignac	  et	  al.	  
(2003)	  [31].	  This	  protocol	  was	  tailored	  for	  validating	  analytical	  methods	  based	  on	  MS	  detection	  
and	  offers	  a	  compromise	  between	  CD	  2002/657/EC	  [26]	  and	  the	  practical	  aspects	  and	  limitations	  
related	  to	  laboratory	  work.	  The	  validation	  protocol	  was	  designed	  as	  follows.	  Analysis	  of	  18	  blank	  
pooled	  bovine	   urine	   samples	  was	   performed	   to	   check	   the	   ruggedness	   of	   the	  method	   and	   the	  
endogenous	   level	   of	   the	   natural	   glucocorticoids	   cortisol,	   cortisone	   and	   the	   metabolite	  
dihydrocortisone.	   This	   permitted	   to	   determine	   the	   specificity	   by	   calculating	   the	   average	   and	  
standard	  deviation	  of	  the	  noise	  amplitude,	  expressed	  relative	  to	  the	  selected	  internal	  standard	  
signal	  amplitude.	  The	  calibration	  curves	  consisted	  of	  eight	  fortification	  levels.	  The	  linearity	  was	  
evaluated	   by	   calculation	   of	   the	   regression	   coefficient	   (R2).	   The	   bovine	   urine	   samples	   were	  
fortified	   with	   concentrations,	   ranging	   from	   0.25	   to	   10	   μg	   L-­‐1	   for	   cortisol,	   cortisone,	  
dihydrocortisone	   and	   1.25	   to	   50	   μg	   L-­‐1	  for	   prednisolone,	   prednisone	   and	  methylprednisolone.	  
For	   each	   sample	   the	   endogenous	   concentrations	   of	   the	   natural	   glucocorticoids,	   cortisol,	  
cortisone	   and	   the	  metabolite	   dihydrocortisone,	   calculated	   as	   the	   average	   concentration	   of	   18	  
non-­‐spiked	  samples,	  were	  subtracted	  from	  the	  calculated	  total	  concentrations.	  To	  evaluate	  the	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precision	  of	  the	  developed	  analytical	  method,	  repeatability	  and	  within-­‐laboratory	  reproducibility	  
were	  determined	  and	  evaluated.	  Both	  validation	  parameters	  were	  evaluated	  by	  calculating	  the	  
relative	  standard	  deviations	  (%RSD).	  For	  the	  endogenous	  compounds,	  the	  limit	  of	  detection	  and	  
limit	  of	  quantification	  were	  determined	   in	  18	  unfortified	  urine	   samples,	   as	   the	   lowest	   level	   at	  
which	   a	   compound	   could	   be	   identified	   with	   a	   signal-­‐to-­‐noise	   ratio	   greater	   than	   3	   and	   10	  
respectively	  [24].	  
2.6. Quality	  assurance	  
Prior	  to	  sample	  analysis,	  10	  μL	  standard	  mixture	  of	  the	  targeted	  glucocorticoids	  at	  10	  μg	  L-­‐1	  was	  
injected	   to	   check	   the	   operational	   conditions	   of	   the	   UHPLC-­‐HRMS	   device.	   A	   mixture	   of	   the	  
internal	  standards	  cortisol-­‐d4	  and	  prednisolone-­‐d8,	  at	  a	  concentration	  of	  10	  μg	  L-­‐1,	  was	  added	  to	  
every	   sample,	   prior	   to	   extraction	   (Table	   2.3.).	   The	   compounds	  were	   identified	   based	   on	   their	  
retention	   time	   relative	   to	   the	   retention	   time	   of	   the	   internal	   standard	   of	   choice	   and	   on	   the	  
13C/12C	   isotopic	   ratio	   according	   to	   the	   criteria	   described	   in	   CD	   2002/657/EC	   [26].	   After	  
identification,	  the	  concentrations	  of	  the	  detected	  glucocorticoids	  were	  calculated	  by	  fitting	  their	  
area	   ratios	   into	   eight-­‐point	   calibrations	   curves,	   set	   up	   in	   bovine	   urine.	   Area	   ratios	   were	  
determined	  by	  integration	  of	  the	  area	  of	  an	  analyte	  under	  the	  specific	  extracted	  chromatograms	  
in	  reference	  to	  the	  integrated	  area	  of	  the	  internal	  standard.	  
Table	   2.3.	   UHPLC-­‐HRMS	   parameters	   used	   for	   the	   various	   glucocorticoids	   with	   indication	   of	   elemental	  
composition,	  accurate	  mass,	  internal	  standard	  used,	  retention	  time	  and	  ionization	  modus.	  






(min)	   Ion	  mode	  
Dihydrocortisone	   C21H30O5	   363.21588	   Cortisol-­‐d4	   2.3	   +	  
Cortisol	   C21H30O5	   363.21588	   Cortisol-­‐d4	   3.6	   +	  
Cortisone	   C21H28O5	   361.20062	   Cortisol-­‐d4	   3.9	   +	  
Prednisolone	   C21H28O5	   361.20062	   Prednisolone-­‐d8	  	   3.4	   +	  
Prednisone	   C21H26O5	   359.18478	   Prednisolone-­‐d8	  	   3.5	   +	  
Methylprednisolone	   C22H30O5	   375.21627	   Prednisolone-­‐d8	  	   5.4	   +	  
2.7. Interlaboratory	  collaborative	  trial	  
The	   Belgian	   Federal	   Agency	   for	   the	   Safety	   of	   the	   Food	   Chain,	   Laboratories	   Administration	  
organised	  a	  quantitative	   interlaboratory	  collaborative	  trial	   for	  prednisolone	   in	  urine.	  The	  study	  
on	  the	  quantitative	  determination	  of	  prednisolone	  in	  urine	  included	  5	  international	  laboratories.	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Each	  participant	   received	  18	  coded	  samples	   (6	  samples	   from	  slaughterhouses,	  4	   samples	   from	  
administration	   trials	   and	   8	   blind	   duplicates).	   On	   these	   samples,	   the	   newly	   developed	   and	  
validated	  UHPLC-­‐HRMS	  method	  was	  applied.	  	  
2.8. Stability	  study	  
To	  determine	  the	  stability	  of	  glucocorticoids	  in	  bovine	  urine,	  a	  long-­‐term	  stability	  study	  was	  set	  
up.	   The	   glucocorticoids	   investigated	   comprised	   cortisol,	   cortisone,	   dihydrocortisone,	  
prednisolone,	   prednisone	   and	   methylprednisolone.	   Aliquots	   of	   five	   mL	   of	   pooled	   urine	   were	  
fortified	  with	  a	  standard	  mixture	  of	  the	  six	  glucocorticoids	  at	  20	  μg	  L-­‐1.	  During	  the	  stability	  study	  
three	  major	  parameters	  were	  investigated:	  pH,	  faecal	  contamination	  and	  redox	  conditions.	  In	  a	  
first	  batch	  of	  samples,	  the	  stability	  of	  glucocorticoids	  was	  tested	  under	  different	  pHs.	  The	  urine	  
aliquots	  were	  brought	  to	  pH	  1,	  3,	  5,	  7	  or	  10	  by	  means	  of	  HCl	  or	  NaOH.	  During	  a	  second	  batch,	  
urine	   samples	   were	   divided	   into	   three	   groups.	   The	   first	   group	   comprised	   urine	   with	   0.5%	   of	  
faecal	   contamination.	   The	   second	  group	   consisted	  of	   filter-­‐sterilized	  urine	   (0.22	  μm	  pore	   size)	  
and	  the	  last	  group	  comprised	  of	  untreated	  urine.	  In	  the	  last	  part	  of	  the	  study,	  urine	  samples	  with	  
or	   without	   faecal	   contamination	   were	   flushed	   with	   N2	   during	   30	   min	   to	   obtain	   an	   anaerobe	  
environment	  (Figure	  2.1.).	  	  
	  
Figure	  2.1.	  Overview	  of	  the	  experimental	  protocol	  of	  the	  stability	  study.	  
For	  each	  time	  point	  in	  the	  stability	  study	  and	  for	  each	  parameter	  set,	  samples	  was	  prepared	  in	  
triplicate	  and	  stored	  respectively	  at	  -­‐80	  °C,	  -­‐20	  °C,	  4	  °C	  or	  at	  room	  temperature	  (15	  -­‐	  20	  °C)	  up	  to	  
20	  weeks.	  After	  week	  1,	  2,	  4,	  10	  and	  20,	  the	  six	  glucocorticoids	   in	  each	  batch	  of	  samples	  were	  
quantitatively	   analysed.	   Additionally,	   the	   effect	   of	   freeze/thaw	   cycles	   was	   investigated	   by	  
CHAPTER	  II	  
56	  
consecutively	  thawing	  the	  frozen	  samples	  (i.e.	  remove	  from	  freezer	  and	  allow	  to	  thaw	  at	  room	  
temperature)	   in	   the	   first	   week,	   refreezing	   the	   samples	   and	   finally	   thawing	   them	   again	   for	  
analysis	  at	  the	  next	  time	  of	  sampling	  (after	  2,	  4,	  10	  and	  20	  weeks).	  
2.9. Statistical	  analysis	  
To	   evaluate	   the	   Plackett-­‐Burman	   design,	   a	   one-­‐way	   analysis	   of	   variance	   (ANOVA)	   test	   was	  
performed	   using	   Modde	   5.0.	   Data	   of	   the	   stability	   study	   were	   analysed	   by	   multiple	   linear	  
regression	  analysis	  using	  SPSS	  Statistics	  20	  (IBM,	  United	  States).	  A	  p-­‐value	  below	  0.05	  indicated	  a	  
significant	  difference.	  	  
3. Results	  and	  discussion	  
3.1. Optimization	  of	  extraction	  procedure	  
A	  Plackett–Burman	  experimental	  design	  was	  employed	  to	  statistically	  evaluate	  the	  effects	  of	  ten	  
variables	   in	   the	   extraction	   procedure	   [17][29][30].	   The	   following	   variables	   were	   considered:	  
volume	  of	  the	  urine,	  pH	  of	  the	  buffer	  during	  hydrolysis,	  time	  of	  hydrolysis,	  temperature	  during	  
hydrolysis,	   pH	   adjustment	   solvent,	   type	   of	   extraction	   solvent,	   volume	   of	   extraction	   solvent,	  
duration	  of	  shaking,	  way	  of	  shaking,	  volume	  of	  the	  second	  liquid-­‐liquid	  extraction	  phase	  (Table	  
2.2.).	  To	  identify	  the	  most	  significant	  variables,	  the	  difference	  between	  a	  low	  and	  high	  level	  was	  
set	  in	  this	  way	  to	  obtain	  a	  maximal	  statistical	  difference.	  This	  experimental	  design	  was	  executed	  
in	  a	  random	  order	  (Supplementary	  table).	  	  
The	  volume	  of	  the	  urine,	  the	  temperature	  during	  hydrolysis	  and	  the	  volume	  of	  the	  second	  liquid-­‐
liquid	  extraction	  phase,	  demonstrated	  significant	  positive	  effects	  on	  the	  extraction	  efficiency	  (p	  
<	   0.05).	   It	   was	   observed	   that	   for	   methylprednisolone	   and	   dihydrocortisone,	   the	   extraction	  
solvent	   tert-­‐butyl	   methylether	   had	   a	   positive	   regression	   coefficient,	   which	   resulted	   in	   an	  
increased	   recovery.	   The	   same	   effect	   was	   noticed	   for	   NaOH	   as	   pH	   adjustment	   solvent	   and	  
rotation	   as	   way	   of	   shaking	   (Supplementary	   table).	   After	   further	   optimization	   of	   the	   main	  
variables	   with	   a	   CCF	   design	   (Figure	   2.2.),	   the	  most	   promising	   settings	  were	   included	   into	   the	  
extraction	  procedure.	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The	   absolute	   areas	   of	   the	   individual	   compounds	   were	   considered	   to	   evaluate	   the	   absolute	  
effects	   of	   the	   different	   variables.	   Finally,	   an	   extraction	   procedure	   without	   hydrolysis	   was	  
selected	  in	  order	  to	  maintain	  the	  generic	  character	  of	  the	  extraction	  and	  to	  ensure	  the	  potential	  
of	  a	  full-­‐scan	  untargeted	  screening	  in	  a	  later	  phase	  (cfr.	  2.4.2).	  
 
Figure	  2.2.	  Response	  surface	  plots	  obtained	  for	  the	  variables	  volume	  of	  the	  extraction	  solvent	  and	  volume	  
of	   the	   urine	   for	   cortisol	   (A)	   and	   prednisolone	   (B)	   after	   statistical	   analysis	   of	   the	   Plackett-­‐Burman	  
experimental	  design.	  	  
3.2. UHPLC	  and	  MS	  parameters	  
Due	   to	   their	   equal	  molecular	  masses	   and	   similar	   chromatographic	  behavior,	   the	   separation	  of	  
prednisolone	   and	   cortisone	   poses	   a	   true	   analytical	   challenge.	   For	   the	   chromatographic	  
separation,	  two	  different	  columns	  were	  tested,	  i.e.	  the	  Nucleodur	  C18	  Isis	  (1.8	  μm,	  100	  ×	  2	  mm,	  
Macherey-­‐Nagel)	  and	  Acquity	  BEH	  C18	  (1.7	  μm,	  100	  ×	  2.1	  mm,	  Waters)	  columns.	  Based	  on	  the	  
achieved	  baseline	  peak	  separation	  of	  prednisolone	  and	  cortisone	  and	  the	  retention	  time	  of	  the	  
first	   and	   last	   eluting	   analytes,	   the	   Nucleodur	   C18	   Isis	   column	   was	   retained.	   For	   additional	  
separation	   of	   prednisolone	   and	   cortisone	   several	   flow	   rates	   (from	   0.3	   to	   0.5	   ml	   min-­‐1)	   and	  
different	   column	   oven	   temperature	   settings	   (from	   20	   to	   50	   °C)	   were	   tested.	   Several	   mobile	  
phases	  were	   tested	   including	  0.1%	  and	  0.2%	   formic	   acid	   in	   acetonitrile/water;	   0.1%	  and	  0.2%	  
acetic	   acid	   in	   acetonitrile/water,	  where	   the	  optimal	  mobile	   phases	   solvents	  were	   0.1%	   formic	  
acid	   in	   water	   and	   (B)	   0.1%	   formic	   acid	   in	   acetonitrile,	   as	   Touber	   et	   al.	   (2007)	   demonstrated	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before	   [11].	   The	   optimal	   retention	   times	   were	   achieved	   by	   careful	   adaption	   of	   the	   gradient	  
program.	  	  
Before	   determining	   the	   optimal	   MS	   conditions,	   each	   glucocorticoid	   standard	   and	   deuterium-­‐
labelled	   internal	  standard	  (10	  μg	  L-­‐1)	  was	   infused	  on	  the	  HRMS	  and	  the	  observed	  masses	  were	  
compared	  with	  the	  theoretical	  masses,	  which	  were	  calculated	  using	  Xcalibur	  2.1	  software.	  The	  
mass	  deviations,	  expressed	  in	  parts	  per	  million	  (ppm)	  and	  defined	  as:	  106	  x	  [(measured	  mass	  –	  
theoretical	   mass)	   /	   theoretical	   mass],	   were	   found	   to	   be	   below	   2	   ppm.	   The	   CD	   2002/657/EC	  
states,	   in	   case	   of	   HRMS	   application,	   that	   the	   presence	   of	   the	   [M+H]+	   or	   [M-­‐H]-­‐	   ion	  with	   their	  
specified	  retention	  times	  and	  respective	  accurate	  masses	  is	  insufficient	  for	  the	  identification	  and	  
confirmation	   of	   the	   selected	   analytes,	   since	   at	   least	   two	   diagnostic	   ions	   are	   requisite	   [26].	  
Therefore,	   the	   mono-­‐isotopic	   pattern	   (13C	   ion)	   may	   assist	   in	   the	   further	   confirmation	   of	   a	  
compound’s	   identity.	   An	   isotopic	   ion	   was	   only	   found	   suitable	   as	   a	   diagnostic	   ion	   when	   the	  
corresponding	  [M+H]+	  or	  [M-­‐H]-­‐	  was	  also	  detected	  and	  the	  calculated	  relative	  ion	  intensity	  was	  
in	  compliance	  with	  CD	  2002/657/EC	  requirements	  [26].	  	  
Instrumental	  HRMS	  parameters,	  which	  are	  reported	  in	  Table	  2.1.,	  were	  optimized	  based	  on	  the	  
peak	   intensities,	   peak	   areas	   and	   signal-­‐to-­‐noise	   ratios	   of	   the	   individual	   analytes.	   The	   optimal	  
AGC	  value	  was	  found	  to	  be	  balanced	  scan	  (1	  x	  e6	   ions).	  Based	  on	  the	  analysis	  of	  fortified	  urine	  
samples	   at	   different	   mass	   resolutions	   (i.e.	   50,000	   and	   100,000	   FWHM)	   a	   mass	   resolution	   of	  
50,000	  FWHM	  at	  1	  Hz	  was	  selected.	  	  
3.3. Method	  validation	  
During	   the	   validation	  pooled	  urine	  was	   used.	   This	  was	   a	  mixture	   of	   visually	   different	   types	   of	  
urine	  (dark	  and	  light	  coloured).	  Dark	  urines	  indicate	  a	  strong	  abundancy	  of	  matrix	  interferences.	  
As	  a	  consequence,	  a	  good	  outcome	  of	  the	  validation	  using	  dark	  urine	  allows	  expecting	  equal	  or	  
even	   better	   results	  when	   using	   other	   urine	   samples.	   The	   analytical	  method	  was	   validated	   for	  
quantitative	  confirmation	  [26].	  The	  performance	  characteristics	  of	  the	  validation	  are	  presented	  
in	  Table	  2.4.	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Table	   2.4.	   Decision	   limits	   (CCα)	   and	  detection	   capabilities	   (CCβ)	   calculated	   for	   prednisolone,	   prednisone	  
and	  methylprednisolone	   in	  urine	  according	  to	  2002/657/EC	  [26].	  Limits	  of	  Detection	  (LOD)	  and	  Limits	  of	  
Quantification	   (LOQ)	   calculated	   for	   cortisol,	   cortisone	   and	   dihydrocortisone	   in	   urine.	   Overview	   of	  main	  





























































































1:	  natural	  glucocorticoids,	  2:	  synthetic	  glucocorticoids	  
3.3.1. Specificity	  
Since	   the	   ‘blank’	   samples,	   i.e.	   samples	   that	  were	  not	  enriched	  with	   glucocorticoids,	   contained	  
cortisol,	   cortisone	   and	   the	  metabolite	   dihydrocortisone	   [32],	   an	   actual	   blank	   sample	   was	   not	  
available.	  As	  a	  consequence,	  specificity	  could	  not	  be	  evaluated	  for	  all	  targeted	  glucocorticoids	  by	  
comparing	  the	  chromatograms	  of	  blank	  and	  enriched	  samples.	  For	   the	  natural	  glucocorticoids,	  
cortisol	  and	  cortisone	  and	  the	  metabolite	  dihydrocortisone,	  specificity	  was	  exclusively	  based	  on	  
the	   chromatograms	   from	  18	  non-­‐fortified	  urine	   samples.	   These	   chromatograms	   indicated	   that	  
no	   other	   matrix	   substances	   significantly	   interfered	   with	   these	   glucocorticoids	   since	   signal-­‐to-­‐
noise	   ratios	  were	   at	   least	   3.	   To	   evaluate	   the	   specificity	   of	   the	   other	   glucocorticoids,	   18	   urine	  
samples	   were	   fortified	   with	   glucocorticoids	   standards	   to	   reach	   concentrations	   of	   5	   μg	   L-­‐1	   for	  
prednisolone,	   prednisone	   and	   methylprednisolone.	   For	   each	   analyte	   spiked,	   the	   obtained	  
chromatograms	  showed	  a	  significant	  increase	  in	  peak	  area	  at	  the	  specific	  retention	  time	  of	  the	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compounds,	  taking	  a	  signal-­‐to-­‐noise	  ratio	  of	  at	  least	  3	  into	  account	  (Figure	  2.3.).	  As	  a	  result,	  the	  
developed	  method	  was	   found	   to	   be	   specific	   for	   cortisol,	   cortisone,	   prednisolone,	   prednisone,	  
dihydrocortisone	  and	  methylprednisolone	  in	  the	  presence	  of	  matrix	  compounds.	  
	  
Figure	   2.3.	   Chromatogram	   of	   a	   ‘blank’	   urine	   sample,	   i.e.	   a	   sample	   that	   was	   not	   enriched	   with	  
glucocorticoid	  standards	  (A),	  and	  chromatogram	  of	  a	  urine	  sample	  fortified	  with	  a.	  Prednisolone	  5	  μg	  L-­‐1;	  
b.	   Cortisone	   1	   μg	   L-­‐1;	   c.	   Dihydrocortisone	   1	   μg	   L-­‐1;	   d.	   Cortisol	   1	   μg	   L-­‐1	   ;	   e.	   Prednisone	   5	   μg	   L-­‐1	   ;	   f.	  
Methylprednisolone	  5	  μg	  L-­‐1	  (B).	  The	  maximum	  mass	  deviation	  was	  set	  at	  2	  ppm.	  
3.3.2. Selectivity	  
Analytes	   were	   identified	   on	   the	   basis	   of	   their	   relative	   retention	   time,	   i.e.	   the	   ratio	   of	   the	  
retention	  time	  of	  the	  analyte	  to	  that	  of	  the	  corresponding	  internal	  standard	  [26].	  In	  addition,	  the	  
accurate	  mass	  of	  the	   ions	  ([M+H]+)	  was	  taken	  into	  account	  when	  the	  chromatographic	  peak	  of	  
interest	  had	  a	   signal-­‐to-­‐noise	  of	   at	   least	  3.	  A	  maximum	  mass	  deviation	  of	  2	  ppm	  was	  allowed	  




Eight-­‐point	   calibration	   curves	   in	   ‘blank’	   samples	   were	   used	   to	   evaluate	   the	   linearity	   of	   the	  
developed	   method	   for	   the	   different	   compounds.	   The	   samples	   were	   fortified	   with	  
concentrations,	  ranging	  from	  0.25	  to	  10	  μg	  L-­‐1	  for	  cortisol,	  cortisone,	  dihydrocortisone	  and	  1.25	  
to	   50	   μg	   L-­‐1	   for	   prednisolone,	   prednisone	   and	   methylprednisolone.	   For	   each	   sample	   the	  
endogenous	  concentration,	  which	  was	  calculated	  as	  the	  average	  concentration	  of	  18	  non-­‐spiked	  
samples,	  was	  subtracted	  from	  the	  calculated	  total	  concentration.	  Linearity	  performed	  well	  since	  
regression	  coefficients	  (R2)	  were	  all	  ≥	  0.99.	  	  
3.3.4. Precision	  
To	  evaluate	  the	  repeatability,	  three	  series	  of	  six	  replicates	  of	  urine	  samples	  were	  analysed,	  and	  
this	   at	   three	   fortification	   levels.	   For	   the	   natural	   glucocorticoids,	   cortisol,	   cortisone	   and	   the	  
metabolite	  dihydrocortisone,	  the	  fortification	  levels	  were	  based	  on	  the	  determined	  endogenous	  
concentrations	   and	   are	   reported	   in	   Table	   2.4.	   For	   the	   synthetic	   glucocorticoids,	   prednisolone,	  
prednisone	   and	   methylprednisolone,	   the	   fortification	   levels	   were	   based	   on	   the	   established	  
maximum	   residue	   limits	   (4	   μg	   kg-­‐1	   and	   10	   μg	   kg-­‐1	   in	   bovine	   muscle	   for	   prednisolone	   and	  
methylprednisolone	   respectively)	   [33],[34].	   These	   analyses	   were	   carried	   out	   on	   different	  
occasions	  by	  the	  same	  operator	  under	  repeatable	  conditions.	  To	  evaluate	  the	  repeatability	   for	  
the	   three	   fortification	   levels	   as	   such,	   additional	   calculations	   were	   made	   for	   the	   natural	  
glucocorticoids	  and	  the	  metabolite,	  dihydrocortisone,	  whereby	  for	  each	  sample	  the	  endogenous	  
concentration	   was	   substracted	   from	   the	   calculated	   total	   concentration.	   The	   endogenous	  
concentration	  was	  calculated	  as	  the	  average	  concentration	  of	  18	  ‘blank’	  samples.	  As	  presented	  
in	  Table	  2.4.,	  the	  calculated	  RSD	  values	  were	  below	  10%	  for	  the	  targeted	  glucocorticoids,	  which	  
indicated	   excellent	   repeatability	   since	   values	   have	   to	   be	   below	   15%	   according	   to	   CD	  
2002/657/EC	  [26].	  	  
The	  within-­‐laboratory	  reproducibility	  was	  evaluated	  with	  four	  series	  of	  six	  replicates	  of	  samples,	  
at	   three	   fortification	   levels.	   These	   analyses	   were	   carried	   out	   on	   different	   days,	   by	   different	  
operators.	   The	   calculated	   RSD	   values	   for	   all	   glucocorticoids	  were	   below	   15%,	   as	   presented	   in	  




3.3.5. Limit	  of	  detection	  and	  limit	  of	  quantification	  
The	  limit	  of	  detection	  (LOD)	  and	  limit	  of	  quantification	  (LOQ)	  were	  defined	  as	  the	  lowest	  level	  at	  
which	  a	  compound	  could	  be	  identified	  in	  blank	  urine	  samples	  with	  a	  signal-­‐to-­‐noise	  ratio	  greater	  
than	   3	   and	   10	   respectively	   [24].	   For	   the	   natural	   glucocorticoids,	   cortisol,	   cortisone	   and	   the	  
metabolite	  dihydrocortisone,	  the	  limit	  of	  detection	  and	  limit	  of	  quantification	  were	  theoretically	  
calculated	  based	  on	  eight-­‐point	  calibration	  curves	  in	  matrix.	  The	  LOD	  ranged	  from	  0.10	  to	  0.25	  
μg	  L-­‐1	  for	  cortisol,	  cortisone,	  dihydrocortisone	  and	  the	  LOQ	  ranged	  from	  0.30	  to	  0.83	  μg	  L-­‐1	  (Table	  
2.4.).	  Compared	  to	  other	  studies,	  the	  developed	  method	  resulted	  in	  comparable	  or	  better	  LOD	  
and	  LOQ	  values	  [6][9][10][11].	  	  
3.3.6. Decision	  limit	  (CCα)	  and	  detection	  capacity	  (CCβ)	  
For	   the	   synthetic	   glucocorticoids,	   prednisolone,	   prednisone	   and	  methylprednisolone,	   decision	  
limits	   (CCα)	   and	   detection	   capabilities	   (CCβ)	  were	   calculated	   according	   to	   the	   guidelines	   of	   CD	  
2002/657/EC	  [26].	  The	  CCα	  was	  calculated	  as	  the	  mean	  of	   the	  noise	  amplitude	  plus	  2.33	  times	  
the	  standard	  deviation	  of	  the	  noise	  amplitude.	  For	  calculating	  CCβ,	  18	  blank	  urine	  samples	  were	  
spiked	   at	   the	   determined	   CCα	   level,	   subsequently	   the	   CCβ	   was	   determined	   by	   calculating	   the	  
mean	  concentration	  at	  the	  corresponding	  decision	   limit	  plus	  1.64	  times	  the	  standard	  deviation	  
of	   the	  mean	  measured	   concentration	   [26].	   Table	   2.4.	   summarizes	   the	   calculated	   CCα	  and	   CCβ	  
values	   for	   the	   different	   glucocorticoids.	   Decision	   limits	   and	   detection	   capabilities	   ranged	  
respectively,	  from	  0.09	  to	  0.50	  μg	  L-­‐1	  and	  from	  0.29	  to	  0.79	  μg	  L-­‐1.	  	  
3.3.7. Mean	  recovery	  
As	   no	   certified	   reference	   material	   was	   available,	   trueness	   was	   determined	   as	   the	   mean	  
corrected	  recovery	  by	  using	   fortified	  urine	  samples.	  To	  this	  end,	   three	  fortification	   levels	  were	  
considered	  with	   six	   replicates	   for	  each	   level.	   For	  each	   sample,	   calculated	   concentrations	  were	  
adjusted	  with	  the	  determined	  endogenous	  concentration	  levels	  where	  necessary.	  The	  calculated	  




3.3.8. Interlaboratory	  collaborative	  trial	  	  
The	  results	  of	  the	  ring	  trial	  demonstrated	  that	  all	  methods	  used,	  were	  suited	  for	  the	  detection	  
and	  identification	  of	  prednisolone	  in	  urine.	  The	  measurement	  uncertainty	  (%)	  and	  the	  bias	  (%)	  of	  
the	  methods	  ranged	  respectively	  from	  42.9	  to	  54.4	  %	  and	  -­‐16.7	  to	  18.5	  %.	  Our	  newly	  developed	  
method	  ranked	  second	  in	  performance	  with	  a	  measurement	  uncertainty	  of	  44.8%	  and	  a	  bias	  of	  -­‐
10%,	   which	  may	   be	   considered	   as	   satisfactory	   taking	   into	   account	   the	   low	   concentrations	   of	  
prednisolone	  that	  were	  present	  in	  the	  test	  samples	  (0.38	  -­‐	  5.49	  μg	  L-­‐1).	  
3.4. Stability	  of	  glucocorticoids	  in	  urine	  
In	  recent	  years,	  the	  high	  frequency	  of	  bovine	  urine	  samples	  found	  positive	  for	  prednisolone	  has	  
raised	   many	   questions.	   One	   hypothesis	   put	   forward	   is	   the	   potential	   transformation	   of	   the	  
natural	   glucocorticoids	   cortisol	   and	   cortisone	   into	   prednisolone	   and	   prednisone,	   respectively	  
[9][10].	   The	   concentration	   of	   natural	   steroids	   present	   in	   urine	   may	   alter	   by	   inappropriate	  
storage	  and	  the	  presence	  of	  microorganisms	  [22][23].	  For	  this	  reason	  the	  influence	  of	  different	  
conditions	  of	  sample	  handling	  and	  storage	  were	  examined.	  Studied	  storage	  conditions	  included	  
temperature	  (room	  temperature,	  refrigerator,	  and	  freezer),	  storage	  time,	  sample	  pH	  and	  faecal	  
contamination.	   The	   Variable	   Importance	   on	   Projections	   plot	   shows	   that	   the	   contributions	   of	  
temperature	  during	  conservations	  had	  the	  most	  impact,	  followed	  by	  pH	  and	  time	  (Figure	  2.4.).	  
	  




3.4.1. Effect	  of	  pH	  at	  different	  temperatures	  
It	  was	   noticed	   that	   the	   observed	   concentrations	   of	   glucocorticoids	  were	   highly	   dependent	   on	  
the	   temperature	   of	   preservation	   and	   the	   pH-­‐value.	   In	   the	   present	   study,	   changes	   in	  
glucocorticoid	  concentrations	   in	  bovine	  urine	  samples	  stored	  at	  various	  pH-­‐values	  for	  up	  to	  20	  
weeks	  were	  examined	  (Figure	  2.5.).	  	  
	  
Figure	   2.5.	   Concentration	   of	   the	   different	   glucocorticoids	   in	   urine	   at	   different	   pH-­‐values	   and	   storage	  
temperatures	   (A)	   Cortisol;	   (B)	   Cortisone:	   (C)	   Prednisolone;	   (D)	   Prednisone;	   (E)	   Dihydrocortisone;	   (F)	  
Methylprednisolone	  with	  pH	  1	  (Black);	  pH	  5	  (Red);	  pH	  10	  (Green).	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For	  all	  glucocorticoids,	  a	  significant	  difference	   (p	  <	  0.05)	  was	  noticeable	  between	  the	  different	  
pH	  values	  of	  the	  samples	  (pH	  1,	  pH	  3,	  pH	  5,	  pH	  7	  or	  pH	  10)	  when	  preserved	  at	  4	  °C	  and	  room	  
temperature.	   In	   figure	   2.5.	   the	   results	   at	   pH	   1,	   pH	   5	   and	   pH	   10	   are	   presented.	   Under	   acidic	  
conditions,	   the	   highest	   concentrations	  were	   retrieved	   for	   all	   analytes	  while	   a	   pH-­‐value	   higher	  
than	  3	   significantly	   stimulated	   the	  degradation	  of	   glucocorticoids	   in	   urine.	   In	   terms	  of	   sample	  
storage	   this	   implies	   that	   a	   pH-­‐value	   lower	   than	   3	   allows	   preservation	   for	   up	   to	   10	  weeks.	   At	  
extreme	  pH-­‐values	  the	  denaturation	  of	  microbial	  (e.g.	  Escherichia	  coli)	  enzymes	  may	  occur.	  This	  
might	   cause	   various	   interruptions	   to	   the	   biochemical	   processes	   and	   kill	   of	   bacteria,	   thereby	  
preventing	  microbial	  degradation	  of	  glucocorticoids.	  For	  many	  microorganisms	  a	  pH	  of	  5	  to	  7	  is,	  
however,	   optimal	   for	   enzymatic	   and	   bacterial	   activity	   [6][35],	  which	   can	   be	   confirmed	   by	   the	  
observation	  that	  at	  pH-­‐values	  higher	   than	  3,	  significant	  degradation	  of	  glucocorticoids	   in	  urine	  
occurred.	  This	   implies	  that	  glucocorticoid	  recoveries	  negatively	  correlate	  with	  urine	  pH.	  On	  the	  
other	  hand,	  when	  stored	  at	  -­‐20	  °C	  and	  -­‐80	  °C,	  glucocorticoids	  displayed	  an	  analogous	  behaviour,	  
irrespective	  of	  the	  pH	  of	  the	  urine.	  
3.4.2. Effect	  of	  faecal	  contamination	  at	  different	  temperatures	  
Based	  on	  literature	  findings	  faecal	  contamination	  of	  urine	  may	  play	  a	  role	  in	  the	  transformation	  
of	  cortisol	  into	  prednisolone	  [25].	  Hence,	  faecal	  contamination	  was	  included	  as	  a	  test	  condition	  
in	   this	   study.	  Major	   discrepancies	   are,	   however,	   noticed	   between	   the	   different	   contaminated	  
samples	  depending	  on	  the	  temperature	  of	  preservation.	  When	  urine	  samples	  are	  stored	  in	  the	  
freezer	  (-­‐20	  °C	  and	  -­‐80	  °C),	  glucocorticoids	  displayed	  an	  analogous	  behaviour	  irrespective	  of	  the	  
contamination	  status	  (Figure	  2.6.).	  The	  glucocorticoid	  concentrations	  in	  urine	  samples	  stored	  at	  
4	   °C	   and	   at	   room	   temperature	   encountered	  more	   variation	   throughout	   time.	  After	   1	  week	   of	  
preservation,	   at	   different	   temperatures,	   no	   significant	   differences	   in	   concentrations	   could	   be	  
observed	   between	   urine	   samples	   with	   and	   without	   faecal	   contamination	   and	   filter-­‐sterilized	  
urine.	  After	  2	  weeks,	  the	  concentration	  in	  faecally	  contaminated	  urine	  dropped	  ca.	  20%	  for	  the	  





Figure	  2.6.	  Concentration	  of	  the	  different	  glucocorticoids	  in	  urine	  at	  different	  contamination	  degrees	  and	  
redox	   conditions	   (A)	   Cortisol;	   (B)	   Cortisone;	   (C)	   Prednisolone,	   (D)	   Prednisone;	   (E)	   Dihydrocortisone;	   (F)	  
Methylprednisolone	  with	   Faecal	   contamination	   O2	   (Black);	   Faecal	   contamination	   N2	   (Red);	   Sterile	   urine	  
(Green).	  	  
It	   is	  known	  that	  bacterial	  growth	  is	  well	  sustained	  in	  urine,	  especially,	  when	  specimens	  are	  not	  
frozen	   immediately	  upon	  sampling	  [23].	  This	  may	  explain	  the	  observed	  degradation	   in	  most	  of	  
the	   samples.	   On	   the	   other	   hand,	   also	   the	   increase	   in	   concentration	   after	   20	   weeks	   of	  
preservation	  in	  urine	  at	  -­‐20	  °C	  and	  -­‐80	  °C	  could	  be	  explained	  by	  induced	  bacterial	  hydrolysis	  of	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conjugates	   through	   several	   microbial	   enzymes	   (e.g.	   Escherichia	   coli,	   Nocardioides	   simplex,	  
Aspergillus	   flavus)	   [22][25][36][37].	   Only	   in	   one	   urine	   sample,	   however,	   an	   increased	  
concentration	   of	   prednisolone	   was	   found	   after	   faecal	   contamination	   under	   an	   anaerobic	  
environment	  when	  preserved	  at	  4	  °C	  during	  20	  weeks.	  This	  was	  the	  only	  case	  of	  neoformation	  of	  
prednisolone.	   Faecal	   contamination	   under	   aerobe	   conditions	   did,	   however,	   not	   promote	   the	  
neoformation	  of	  prednisolone	  or	  prednisone	  in	  contrast	  to	  the	  results	  of	  Arioli	  et	  al.	  (2010)	  [25].	  	  
Only	  in	  filter-­‐sterilized	  urine,	  five	  glucocorticoids	  appeared	  up	  to	  20	  weeks	  at	  room	  temperature.	  
Jiménez	   et	   al.	   (2006)	   demonstrated	   that	   differences	   between	   testosteron	   and	   epitestosteron	  
concentrations	  obtained	  before	  and	  after	  filtration	  of	  urine	  were	  not	  statistically	  significant	  (p	  <	  
0.05)	  [38].	  This	   indicates	  that	  filtration	  of	  urine	  has	  no	  influence	  on	  the	  initial	  concentration.	   It	  
may	  as	  a	  result	  be	  concluded	  that	  prior	  to	  long-­‐term	  preservation	  of	  steroidal	  substances	  such	  as	  
glucocorticoids,	  filtration	  (over	  0.22	  μm	  filters)	  is	  recommended.	  
3.4.3. Freeze-­‐thaw	  cycles	  
Evaluation	  of	  freeze	  and	  thaw	  stability	  was	  performed	  by	  preservation	  of	  glucocorticoids	  in	  urine	  
at	  -­‐20	  °C.	  Each	  sample	  was	  subjected	  to	  five	  freeze-­‐thaw	  cycles	  at	  each	  round	  of	  sampling	  during	  
the	  long-­‐term	  stability	  study.	  All	  glucocorticoids	  showed	  a	  similar	  progress	  over	  time	  except	  for	  
methylprednisolone,	   for	   which	   a	   significant	   decrease	   in	   concentration	   could	   be	   noticed	   only	  
after	  five	  freeze-­‐thaw	  cycles	  (Figure	  2.7.).	  	  
	  
Figure	   2.7.	   Concentration	  of	   the	  different	   glucocorticoids	   in	   urine	   exposed	   to	   a	   number	  of	   freeze-­‐thaw	  
cycles.	  (A)	  Natural	  glucocorticoids;	  (B)	  Synthetic	  glucocorticoid.	  




In	   this	   study	   the	  successful	  development	  and	  validation	  of	  a	  generic	  extraction	  procedure	  and	  
detection	   method	   for	   glucocorticoids	   in	   urine	   according	   to	   the	   criteria	   set	   in	   Commission	  
Decision	  2002/657/EC	  was	  described	  [26].	  The	  first	  step	  within	  the	  development	  of	  this	  generic	  
extraction	   protocol	   comprised	   the	   identification	   of	   the	   variables	   that	   significantly	   affect	   the	  
recoveries	  of	  the	  natural	  glucocorticoids	  cortisol,	  cortisone	  and	  the	  metabolite	  dihydrocortisone,	  
and	   the	   synthetic	   analogues	   prednisolone,	   prednisone	   and	   methylprednisolone	   in	   urine.	  
Therefore	  a	  Plackett-­‐Burman	  experimental	  design	  was	  set	  up.	  This	  design	  allowed	  to	  develop,	  in	  
the	  most	  efficient	  statistically	  proven	  manner,	  a	  generic	  extraction	  procedure	  and	  reduced	  the	  
number	  of	   experiments.	  Besides,	   the	   suitability	  of	   the	  UHPLC-­‐Orbitrap-­‐HRMS	  platform	   for	   the	  
targeted	  detection	  of	  the	  free	  glucocorticoids,	   i.e.	  cortisol,	  cortisone,	  prednisolone,	  prednisone	  
and	   methylprednisolone	   and	   the	   metabolite	   dihydrocortisone	   was	   demonstrated.	   Since	   this	  
method	  employs	  a	  full	  scan	  working	  principle,	  it	  allows	  retrospective	  screening,	  i.e.	  screening	  for	  
non	  a-­‐prior	  selected	  analytes	  and	  unidentified,	  unknown	  compounds	  and	  metabolomics	  studies.	  
The	   long-­‐term	   stability	   study	   (20	   weeks)	   executed	   in	   this	   study	   provided	   evidence	   for	   the	  
optimal	   conditions	   for	   medium	   to	   long-­‐term	   storage	   of	   glucocorticoids	   in	   bovine	   urine.	   To	  
preserve	  glucocorticoids	  in	  bovine	  urine	  for	  a	  long	  period	  (20	  weeks)	  it	  is	  recommended	  to	  filter-­‐
sterilize	   the	   urine	   and	   preserve	   under	   acidic	   conditions,	   preferentially	   at	   pH	   3	   and	   at	   a	  









Cortisol	   Cortisone	   Dihydrocortisone	   Prednisolone	   Prednisone	   Methylprednisolone	  
	  
Coeff.	  SC	   p-­‐value	   Coeff.	  SC	   p-­‐value	   Coeff.	  SC	   p-­‐value	   Coeff.	  SC	   p-­‐value	   Coeff.	  SC	   p-­‐value	   Coeff.	  SC	   p-­‐value	  
Volume	  urine	   491054	   0.0025
*	   220968	   0.0002*	   154116	   0.0811	   311622	   0.0017*	   294468	   0.0033*	   238456	   0.0004*	  
pH	  buffer	   42615	   0.5895	   5800.06	   0.7540	   121239	   0.1420	   16142.1	   0.7178	   15757	   0.7542	   -­‐5661.72	   0.8135	  
Time	  of	  hydrolysis	   111944	   0.1987	   26063.1	   0.2060	   -­‐62144.7	   0.4025	   71756.8	   0.1597	   64643.3	   0.2409	   63686.8	   0.0471
*	  
Temperature	   -­‐267947	   0.0211
*	   -­‐100745	   0.0043*	   58802.3	   0.4261	   -­‐150495	   0.0224*	   -­‐170709	   0.0220*	   -­‐7367.53	   0.7594	  
pH	  adjustment	  solvent	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	  	  Carbonate	  buffer	   -­‐46488.4	   0.5667	   -­‐45205	   0.0631	   -­‐138468	   0.1117	   -­‐23387	   0.6126	   -­‐30221	   0.5642	   12451.3	   0.6174	  
	  	  	  NaOH	   46488.4	   0.5667	   45205	   0.0631	   138468	   0.1117	   23387	   0.6126	   30221	   0.5642	   -­‐12451.3	   0.6174	  
Extraction	  solvent	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	  	  TBME	   119397	   0.1845	   1799.6	   0.9239	   165073	   0.0723	   70440.3	   0.1739	   42862.9	   0.4236	   108967	   0.0090
*	  
	  	  	  Diethylether	   -­‐119397	   0.1845	   -­‐1799.6	   0.9239	   -­‐165073	   0.0723	   -­‐70440.3	   0.1739	   -­‐42862.9	   0.4236	   -­‐108967	   0.0090
*	  
Volume	  of	  extraction	  
solvent	   246890	   0.0274
*	   63015.8	   0.0218*	   235005	   0.0240*	   113285	   0.0428*	   132081	   0.0482*	   -­‐47948.5	   0.0998	  
Time	  of	  shaking	   30860.4	   0.6933	   12615.4	   0.5059	   -­‐104600	   0.1904	   26219.7	   0.5629	   24451.3	   0.6302	   30709.5	   0.2435	  
Way	  of	  shaking	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	  	  Rotation	   7279.43	   0.9269	   -­‐12446	   0.5209	   78289.6	   0.3142	   7509.18	   0.8687	   -­‐8817.8	   0.8635	   53029.9	   0.0826	  
	  	  	  Shaking	   -­‐7279.43	   0.9269	   12446	   0.5209	   -­‐78289.6	   0.3142	   -­‐7509.18	   0.8687	   8817.8	   0.8635	   -­‐53029.9	   0.0826	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Faecal	   glucocorticoid	   analysis	   is	   a	   powerful	   non-­‐invasive	   tool	   for	   the	   study	   of	   the	   animal	  
endocrine	   status	   and	   stress	   physiology,	   which	   is	   mainly	   carried	   out	   by	   immunoassays,	  
characterized	   by	   some	   limitations.	   In	   this	   study,	   an	   ultra	   high-­‐performance	   liquid	  
chromatography	  coupled	  to	  high-­‐resolution	  Orbitrap	  mass	  spectrometry	  (UHPLC-­‐HRMS)	  method	  
was	  developed	  to	  confirm	  the	  presence	  of	  glucocorticoids	   in	  bovine	   faeces	  during	  a	   long-­‐term	  
stability	   study.	   Because	   of	   the	   complex	   nature	   of	   faeces,	   an	   appropriate	   extraction	   and	  
purification	   procedure	  was	   developed.	   To	   this	   extent,	   a	   Plackett-­‐Burman	   experimental	   design	  
was	   successfully	   applied	   to	   determine	   the	   key	   conditions	   for	   optimal	   extraction	   of	  
glucocorticoids	   from	   faeces.	   The	   targeted	   analysis,	   including	   natural	   and	   synthetic	  
glucocorticoids,	   was	   successfully	   validated	   according	   to	   CD	   2002/657/EC.	   Decision	   limits	   and	  
detection	   capabilities	   for	   prednisolone,	   prednisone,	   methylprednisolone	   and	   the	   metabolites	  
20α-­‐dihydroprednisolone	  and	  20β-­‐dihydroprednisolone	  ranged,	   respectively,	   from	  0.15	  to	  2.95	  
μg	  kg-­‐1	  and	  from	  0.40	  to	  5.20	  μg	  kg-­‐1.	  For	  the	  natural	  glucocorticoids	  limits	  of	  detection	  and	  limits	  
of	  quantification	  for	  dihydrocortisone,	  cortisol	  and	  cortisone	  ranged,	  respectively,	  from	  0.55	  to	  
2.10	  μg	  kg-­‐1	  and	  from	  0.70	  to	  5.00	  μg	  kg-­‐1.	  	  
The	  stability	  study	  of	  glucocorticoids	  in	  faecal	  matrix	  demonstrated	  that	  lyophilizing	  the	  faeces,	  
storage	  at	  -­‐80	  °C,	  and	  aerobe	  conditions	  were	  optimal	  for	  preservation	  and	  able	  to	  significantly	  








The	   glucocorticoids	   cortisol	   and	   cortisone	   are	   steroid	   hormones	   naturally	   synthesized	   in	   the	  
adrenal	  cortex.	  Their	  well-­‐known	  anti-­‐inflammatory	  properties	  have	   led	  to	  the	  development	  of	  
synthetic	   glucocorticoid	   analogues,	   which	   exert	   even	   higher	   anti-­‐inflammatory	   activities	   i.e.	  
betamethasone,	   dexamethasone,	   methylprednisolone	   and	   prednisolone,	   with	   prednisone	   as	  
prodrug	   [1].	   In	   the	   European	   Union,	   these	   compounds	   are	   permitted	   for	   therapeutic	   use	   in	  
livestock.	  Beside	  the	  anti-­‐inflammatory	  properties,	  these	  drugs	  also	  induce	  body	  weight	  gain	  in	  
production	  animals	  by	  improving	  feed	  intake	  and	  lowering	  feed	  conversion.	  Due	  to	  their	  growth-­‐
promoting	  effects	  and	  the	  potential	  consumer’s	  health	  risks	  of	  residues	  thereof	  [2][3],	  the	  use	  of	  
synthetic	  glucocorticoids	   in	   livestock	  has	  been	   strictly	   regulated	   in	   the	  European	  Union	   [4],	  by	  
setting	  maximum	   residue	   limits	   for	   betamethasone,	   dexamethasone,	  methylprednisolone	   and	  
prednisolone	  in	  selected	  tissues	  of	  animal	  origin	  [5].	  	  
In	   the	   frame	   of	   the	   National	   Residue	  Monitoring	   Plans,	   liver,	   urine	   and	   faeces	   are	   frequently	  
analysed	   to	   ensure	   the	   absence	   of	   residues	   in	   food	   products	   of	   animal	   origin	   and	   to	   detect	  
possible	   illegal	   use	   as	   growth-­‐promoter	   [6][7].	   The	   European	   Union	   Reference	   Laboratories	  
made	  a	  consensus	  to	  set	  the	  MRPL	  for	  prednisolone	   in	  bovine	  urine	  at	  5	  μg	  L-­‐1	   [8].	  While	   liver	  
samples	  can	  be	  merely	  obtained	  upon	  slaughtering	  [9][10]	  urine	  and	  faeces	  are	  easily	  accessible	  
through	   non-­‐invasive	   sampling.	   The	   use	   of	   faecal	   samples	   has	   some	   advantages	   over	   that	   of	  
urine	  when	  focusing	  on	  the	  hormonal	  status	  of	  the	  animals	  and	  their	  long-­‐term	  endocrine	  profile	  
[11][12].	  The	  sampling	  is	  easy,	  does	  not	  interfere	  with	  the	  stress	  response	  itself	  and	  permits	  on-­‐
farm	  monitoring.	   Faecal	   analyses	   are	   increasingly	   being	   used	   to	   examine	   glucocorticoids	   as	   a	  
potential	   indicator	   of	   adrenal	   activity	   and	   animal	   stress	   [13].	   They	   reflect	   an	   average	   level	   of	  
circulating	   glucocorticoids	   over	   a	   time	   period,	   rather	   than	   a	   point	   sample,	   since	   the	   levels	   in	  
faeces	   are	   less	   affected	   by	   episodic	   fluctuations	   or	   the	   pulsatility	   of	   hormone	   secretion.	  
Therefore	   the	   measured	   faecal	   glucocorticoid	   concentrations	   might	   represent	   the	   hormonal	  
status	  of	  an	  animal	  more	  accurately	  than	  in	  a	  single	  plasma	  or	  urine	  sample	  [13][14][15][16].	  	  
In	   recent	   years,	   a	   higher	   frequency	  of	   prednisolone	  positive	   bovine	  urines	   has	   been	  observed	  
[17][18].	   Several	   hypotheses	   have	  been	  put	   forward	   for	   this	   finding	   including	   the	   influence	  of	  





cortisone	  to	  respectively	  prednisolone	  and	  prednisone	   [19][20].	  This	  has	   rendered	  the	  analysis	  
of	   glucocorticoids	   into	   a	   complicated	   business,	   since	   besides	   the	   mere	   presence	   of	   residues,	  
their	   origin	   (either	   endogenous	   and/or	   exogenous)	   has	   become	   a	   matter	   of	   debate.	   As	   the	  
glucocorticoid	   metabolism	   gives	   rise	   to	   large	   number	   of	   derivates	   with	   similar	   chemical	  
structures	  and	  molecular	  weights,	  the	  search	  for	  biomarker	  candidates	  proved	  quite	  challenging	  
[21][22].	   At	   this	   point,	   one	   of	   the	   principal	   metabolites	   of	   prednisolone,	   i.e.	   20β-­‐
dihydroprednisolone	   has	   been	   put	   forward	   as	   potential	   biomarker	   for	   specifying	   endogenous	  
traces	  of	  prednisolone	  [22][23].	  	  
In	  the	  past,	  steroid	  analysis	  in	  faecal	  samples	  was	  mainly	  carried	  out	  by	  immunoassays	  [14][24].	  
Although	   these	   techniques	   have	   proven	   their	   usefulness	   in	   wildlife	   studies	   [25][26],	   some	  
limitations	  exist	  with	   respect	   to	   specificity.	   Cross-­‐reactivity	  of	   the	   specific	   antibody	  with	  other	  
similar	  steroids	  can	  lead	  to	  controversial	  results	  [27][28].	   In	  this	  context,	  LC-­‐MS	  techniques	  are	  
more	   fit	   to	   distinguish	   similar	   glucocorticoid	   compounds	   [29].	   Ultra-­‐high	   performance	   liquid	  
chromatography	   (UHPLC)	   using	   columns	   with	   sub	   2	   μm	   particles,	   which	   results	   in	   a	   higher	  
chromatographic	   resolution,	   are	   commonly	   used	   these	   days	   [30].	   From	   literature,	   it	   may	   be	  
concluded	   that	   tandem	   MS	   using	   selected	   reaction	   monitoring	   is	   currently	   the	   preferred	  
detection	   method	   for	   glucocorticoid	   analysis	   [12][29].	   An	   inherent	   limitation	   of	   this	   targeted	  
approach	   is	   the	   inability	   to	   screen	   for	   unidentified	   and	   unknown	   compounds	   such	   as	  
metabolites.	   Therefore	   in	   this	   study,	   the	   UHPLC	   system	   was	   coupled	   to	   a	   high	   resolution	  
Orbitrap	   mass	   spectrometer,	   which	   allows	   the	   production	   of	   full	   scan	   MS	   spectra	   with	   a	  
resolving	  power	  up	  to	  100,000	  FWHM	  and	  a	  high	  mass	  accuracy	  (mass	  deviations	  below	  2	  ppm)	  
[31].	   This	   detection	   technique	   offers	   the	   possibility	   to	   simultaneously	   analyze	   a	   virtually	  
unlimited	  number	  of	  compounds,	  provides	  sufficient	  selectivity	  for	  complex	  matrix	  extracts	  such	  
as	   faeces	   and	   allows	   post-­‐acquisition	   re-­‐interrogation	   of	   data	   and	   screening	   for	   unidentified	  
and/or	  unknown	  compounds.	  	  
Because	   of	   the	   complex	   nature	   of	   faeces,	   appropriate	   sample	   preparation	   procedures	   are	  
required,	  but	   in	   terms	  of	   the	  metabolomic	  approach	   to	  be	  kept	  as	  generic	  as	  possible.	  To	   this	  
extent,	   Plackett-­‐Burman	   experimental	   design	   is	   a	   useful	   tool	   to	   screen	   for	   the	  main	   variables	  
within	  a	  large	  number	  of	  variables	  that	  may	  affect	  the	  extraction	  yield	  [32].	  This	  highly	  efficient	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design	  provides	  the	  opportunity	  to	  identify	  the	  significant	  extraction	  conditions	  with	  a	  minimum	  
of	  experiments.	  	  
Although	   the	   use	   of	   non-­‐invasive	   sampling	   techniques	   has	   increased,	   several	   confounding	  
factors	  inhibit	  its	  wide	  spread	  use	  [33].	  A	  long-­‐term	  stability	  study	  of	  glucocorticoids	  in	  urine	  has	  
for	  example	  shown	  that	  the	  environmental	  conditions	  during	  preservation	  have	  a	  big	   influence	  
on	  the	  recovery	  [34].	  This	  is	  particularly	  true	  for	  urine	  contaminated	  with	  faecal	  material	  which	  
can	  contain	  a	  microbial	  flora	  up	  to	  1011	  CFU/g	  faeces	  [35].	  This	  microbial	  activity	  may	  seriously	  
interfere	  with	  the	  concentration	  of	  the	  extracted	  compounds	  as	  it	  has	  been	  shown	  that	  bacteria	  
and	   bacterial	   enzymes	   in	   faeces	   decompose	   steroid	   metabolites	   within	   hours	   in	   untreated	  
faeces	  [24][36].	  Therefore,	  in	  the	  present	  study,	  an	  extensive	  stability	  study	  of	  glucocorticoids	  in	  
bovine	   faeces	   was	   performed	   in	   which	   the	   effect	   of	   different	   storage	   conditions	   such	   as	  
lyophilization	   and	   temperature	  were	   considered.	  Additionally,	   the	  preservations	  under	   aerobe	  
and	  anaerobe	  environments,	  as	  well	  as	  the	  addition	  of	  ethanol	  was	  evaluated.	  Furthermore,	  this	  
stability	   study	   included	   the	   determination	   of	   losses	   during	   multiple	   freeze-­‐thaw	   cycles.	   The	  
compounds	  of	  interest	  were	  the	  natural	  glucocorticoids	  cortisol,	  cortisone	  and	  dihydrocortisone	  
(4-­‐pregnene-­‐17α,20β,21-­‐triol-­‐3,11-­‐dione)	   and	   the	   synthetic	   glucocorticoids	   prednisolone,	  
prednisone	   and	   methylprednisolone	   and	   several	   potential	   biomarker	   candidate	   prednisolone	  
metabolites	   including	   20α-­‐dihydroprednisolone	   and	   20β-­‐dihydroprednisolone	   (Figure	   3.1.).	   To	  
this	  extent,	  a	  generic	  extraction	  and	  analytical	  method	  to	  measure	  glucocorticoids	  and	  a	  number	  
of	   their	  metabolites	   in	   faecal	   samples	  of	   cattle	  was	  developed	   and	   validated	   according	   to	   the	  






Figure	  3.1.	  Chemical	  structure	  of	  the	  glucocorticoids	  under	  study.	  
2. Material	  and	  methods	  
2.1.	   	  Reagents	  and	  chemicals	  
Standards	   of	   prednisolone,	   prednisone,	   cortisone,	   cortisol,	   dihydrocortisone	   and	  
methylprednisolone	  were	   purchased	   from	   Sigma-­‐Aldrich	   (St.	   Louis	  MO,	  USA).	   The	  metabolites	  
20α-­‐dihydroprednisolone	  and	  20β-­‐dihydroprednisolone	  were	  purchased	  from	  Steraloids	  (Rhode	  
Island,	  USA).	  Internal	  standards	  were	  cortisol-­‐d4	  (Sigma-­‐Aldrich,	  USA)	  and	  prednisolone-­‐d8	  (TRC,	  
Canada).	   Reagents	   were	   of	   analytical	   grade	   when	   used	   for	   extraction	   purposes	   and	   obtained	  
from	   VWR	   International	   (Merck,	   Darmstadt,	   Germany).	   The	   reagents	   were	   of	   LC-­‐MS	   Optima	  
grade	   for	   UHPLC-­‐HRMS	   application.	   These	   were	   obtained	   from	   Fisher	   Scientific	   UK	  
(Loughborough,	  UK).	  Ultrapure	  water	  was	  produced	  with	   an	  Arium	  611	  UV	   system	   (Sartorium	  
Stedim	  Biotech,	  Aubagne,	  France).	   Isolute	  C18	  (EC)	  (500	  mg,	  10	  mL)	  cartridges	  were	  purchased	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from	   Biotage	   (Uppsala,	   Sweden).	   Strata-­‐X	   (200	   mg,	   6	   mL)	   cartridges	   were	   purchased	   from	  
Phenomenex,	   Inc.	   (Torrance,	   USA).	   Primary	   stock	   solutions	   were	   prepared	   in	   ethanol	   at	   a	  
concentration	  of	  200	  μg	  mL-­‐1	  and	  stored	  in	  dark	  glass	  bottles	  at	  -­‐20	  °C.	  Working	  solutions	  were	  
made	  in	  ethanol	  at	  a	  range	  of	  0.1	  -­‐	  10	  μg	  mL-­‐1.	  
2.2.	   	  Instrumentation	  
Analyses	  were	  carried	  out	  on	  an	  UHPLC	  system,	  which	  consisted	  of	  an	  Accela	  UHPLC	  pump,	  an	  
Accela	  Autosampler	   and	  Degasser	   (Thermo	  Fisher	   Scientific,	   San	   José,	   CA,	  USA).	   Separation	  of	  
the	  glucocorticoids	  was	   carried	  out	  on	  a	   reverse	  phase	  Nucleodur	  C18	   Isis	  UHPLC	  column	   (1.8	  
μm,	  100	  ×	  2	  mm,	  Macherey-­‐Nagel,	  Düren,	  Germany)	  at	  a	  column	  oven	  temperature	  of	  30	  °C.	  The	  
elution	  gradient	  was	  carried	  out	  with	  a	  binary	  solvent	  system	  consisting	  of	  0.1%	  aqueous	  formic	  
acid	   (A)	   and	   0.1%	   formic	   acid	   in	   acetonitrile	   (B)	   at	   a	   constant	   flow	   rate	   of	   0.3	   mL	   min-­‐1.	  
Optimized	  separation	  of	  all	  analytes	  was	  obtained	  using	  a	  linear	  gradient	  starting	  with	  a	  solvent	  
mixture	  (v/v)	  of	  80%	  A	  and	  20%	  B.	  The	  percentage	  of	  acetonitrile	  was	  increased	  to	  25%	  in	  1	  min,	  
and	  held	  there	  for	  5.0	  min.	  Next,	  a	  linear	  increase	  to	  95%	  B	  in	  1	  min	  was	  performed,	  and	  further	  
up	  to	  100%	  in	  1	  min	  and	  held	  there	  for	  2.0	  min.	  In	  between	  samples,	  the	  column	  was	  allowed	  to	  
re-­‐equilibrate	   at	   initial	   conditions	   for	   2	  min.	   A	   10	   μL	   aliquot	   of	   each	   sample	  was	   injected	   for	  
analysis.	  High-­‐resolution	  mass	  spectrometric	  analysis	  was	  performed	  on	  an	  ExactiveTM	  benchtop	  
mass	   spectrometer	   (Thermo	   Fisher	   Scientific)	   equipped	   with	   a	   heated	   electrospray	   ionization	  
probe	  (HESI	  II),	  operating	  in	  the	  polarity	  switching	  mode.	  Ionization	  source	  working	  parameters	  
were	  optimized	  and	  reported	  in	  Table	  3.1.	  	  
Table	  3.1.	  Instrumental	  parameters	  used	  for	  HESI	  (II)-­‐ionization	  of	  glucocorticoids.	  
Instrumental	  Parameter	   Value	  
Spray	  voltage	   4	  Kv	  
Sheath	  gas	  flow	  rate	   75	  au*	  
Auxiliary	  gas	  flow	  rate	   7	  au	  
Sweep	  gas	  flow	  rate	   2	  au	  
Capillary	  temperature	   280	  °C	  
Heater	  temperature	   300	  °C	  
Capillary	  voltage	   45	  (-­‐32)	  V	  
Tube	  lens	  voltgae	   95	  (-­‐100)	  V	  
Skimmer	  voltage	   16	  (-­‐20)	  V	  






The	  resolution	  was	  set	  at	  50,000	  FWHM	  at	  1	  Hz	  and	  a	  scan	  range	  of	  m/z	  150-­‐650	  was	  chosen.	  
The	  automatic	  gain	  control	   (AGC)	   target	  was	  set	  at	  balanced	   (1	  x	  e6	   ions)	  and	  the	  High	  Energy	  
Collision	   Dissociation	   (HCD)	   cell	   was	   turned	   off.	   Instrument	   control	   and	   data	   processing	  were	  
carried	  out	  by	  Xcalibur	  2.1	  software	  (Thermo	  Fisher	  Scientific).	  
2.3.	   	  Samples	  
Faeces	   samples	   were	   obtained	   on	   two	   different	   occasions	   from	   three	   adult	   Holstein-­‐Friesian	  
cows,	  housed	  at	   the	  Faculty	  of	  Veterinary	  Medicine	   (Ghent	  University)	   in	  Merelbeke,	  Belgium.	  
The	   first	   three	   faeces	   samples	   were	   pooled	   and	   used	   during	   the	   validation	   of	   the	   analytical	  
method,	  the	  second	  sampling	  pool	  was	  employed	  as	  matrix	  for	  the	  stability	  study.	  An	  additional	  
18	  blank	  faecal	  samples	  were	  used	  for	  evaluating	  the	  ruggedness	  and	  specificity	  of	  the	  analytical	  
method	  originated	  from	  18	  different	  cows	  housed	  in	  the	  animal	  facilities	  of	  Centre	  d’Economie	  
Rurale	  (CER)	  (Marloie,	  Belgium).	  Faeces	  was	  collected	  by	  rectal	  grab	  sampling,	  mixed	  thoroughly	  
by	  manual	  stirring	  and	  divided	  into	  aliquots.	  
2.4.	   	  Sample	  preparation	  
2.4.1. Fractional	  factorial	  design	  
Because	  of	  the	  complex	  nature	  of	  faeces,	  an	  appropriate	  extraction	  and	  purification	  procedure	  is	  
required.	   A	   sequential	   strategy	   of	   experimental	   design	   was	   used	   to	   optimize	   the	   analytical	  
extraction	   of	   glucocorticoids	   from	   faeces.	   To	   screen	   the	   dependent	   variables	   that	   might	  
significantly	   affect	   the	   extraction,	   a	   Plackett-­‐Burman	   design	   was	   used	   [32][38].	   This	   design	   is	  
useful	   to	   screen	   for	   the	  main	   variables	   from	   a	   large	   number	   of	   variables	   that	  may	   affect	   the	  
response	  and	  consists	  of	  a	   two-­‐level	  design	   to	   investigate	  N-­‐1	  variables,	  with	  N	  runs,	  where	  N	  
should	   be	   a	   multiple	   of	   4.	   This	   Plackett-­‐Burman	   design	   is	   known	   as	   a	   Saturated	  Main	   Effect	  
design	  because	  all	  degrees	  of	  freedom	  are	  utilized	  to	  estimate	  the	  main	  effects	  [39].	  The	  starting	  
point	   for	   the	   development	   of	   the	   extraction	   procedure	   consisted	   of	   liquid-­‐liquid	   extraction	  
followed	  by	  defatting	  and	  clean-­‐up	  by	  solid-­‐phase	  extraction	  [40][41][42].	  Table	  3.2.	  shows	  the	  
eight	   variables	   that	  were	   considered	   as	  well	   as	   the	   level	   of	   each	   variable	   used.	   The	   excessive	  
variable	   was	   set	   as	   dummy	   [43].	   For	   a	   Plackett-­‐Burman	   design	   consisting	   of	   11	   variables,	   12	  
experimental	  runs	  were	  sufficient	  to	  calculate	  the	  main	  effect	  of	  each	  variable.	  The	  experimental	  
design	   matrix	   and	   data	   analysis	   were	   carried	   out	   with	   the	   software	   program	   Modde	   5.0	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(Umetrics,	  Umea,	  Sweden).	  
Table	  3.2.	  Parameter	  variable	  values	  selected	  for	  the	  Plackett-­‐Burman	  design.	  
Variable	   Unit	   Lower	  value	   Upper	  value	  
Qualitative	   	   	   	  
	  	  	  Extraction	  solvent	  	   -­‐	   TBME*	   Diethylether	  
	  	  	  2th	  Extraction	  	   -­‐	   Yes	   no	  
	  	  	  Defatting	  step	   -­‐	   Yes	   no	  
	  	  	  Solvent	  for	  defatting	   -­‐	   n-­‐Hexane	   Petroleum	  benzine	  
	  	  	  Type	  of	  SPE	  columns	   -­‐	   C18	  (EC)	   Strata	  X	  
Quantitative	   	   	   	  
	  	  	  Volume	  of	  extraction	  solvent	   mL	   5	   10	  
	  	  	  Volume	  2th	  extraction	  solvent	   mL	   5	   10	  
	  	  	  Time	  of	  rotating	   min	   10	   30	  
*TBME:	  tert-­‐butyl	  methylether	  
2.4.2. Sample	  extraction	  
Five	   grams	   of	   pooled	   faecal	   material	   was	   spiked	   with	   the	   internal	   standards	   (cortisol-­‐d4	   and	  
prednisolone-­‐d8)	   to	  obtain	  a	   final	   concentration	  of	  10	  μg	  kg-­‐1.	  After	  adding	  4	  mL	  of	  ultra	  pure	  
water	  and	  2	  mL	  of	  10%	  sodium	  carbonate	  buffer,	  the	  samples	  were	  vortexed	  for	  1	  min.	  A	  liquid-­‐
liquid	  extraction	  was	  performed	  by	  adding	  10	  mL	  of	  tert-­‐butyl	  methylether	  (TBME).	  After	  10	  min	  
of	  rotating	  at	  1200	  x	  g,	  the	  sample	  was	  centrifuged	  at	  7600	  x	  g	  for	  10	  min	  at	  7	  °C.	  The	  organic	  
layer	  was	  collected	  and	  transferred	  to	  a	  15	  mL	  tube.	  This	  liquid-­‐liquid	  extraction	  was	  repeated	  by	  
adding	  another	  5	  mL	  of	  TBME	  to	  the	  faecal	  material.	  The	  organic	  phase	  was	  dried	  under	  a	  gentle	  
stream	  of	  nitrogen	  at	  a	  temperature	  of	  60	  °C	  and	  reconstituted	  in	  1.5	  mL	  of	  methanol	  and	  375	  
μL	  of	  ultra	  pure	  water,	  vortexed	  for	  1	  min	  and	  twice	  defatted	  with	  2.5	  mL	  of	  petroleum	  benzine	  
prior	   to	   the	  SPE.	  Prior	   to	  sample	   loading,	   the	  C18	   (EC)	  cartridge	  was	  conditioned	  with	  5	  mL	  of	  
methanol	  and	  5	  mL	  of	  water	  and	  afterwards	  washed	  with	  5	  mL	  of	  water,	  5	  mL	  of	  methanol	   in	  
water	  (20:80,	  v/v)	  and	  2.5	  mL	  of	  n-­‐hexane.	  The	  analytes	  were	  eluted	  with	  6	  mL	  of	  ethyl	  acetate.	  
Next,	  the	  pooled	  organic	  phase	  was	  dried	  under	  a	  gentle	  stream	  of	  nitrogen	  at	  a	  temperature	  of	  
60	  °C	  and	  reconstituted	  in	  100	  μL	  of	  eluens,	  corresponding	  to	  the	  initial	  mobile	  phase	  conditions	  
and	  transferred	  to	  UHPLC-­‐MS	  vials	  for	  analysis.	  
2.5.	   	  Analytical	  method	  validation	  
Validation	  of	  the	  method	  was	  performed	  by	  adopting	  the	  protocol	  proposed	  by	  Antignac	  et	  al.	  





and	  offers	  a	  compromise	  between	  CD	  2002/657/EC	  [37]	  and	  the	  practical	  aspects	  and	  limitations	  
related	  to	  laboratory	  work.	  The	  validation	  protocol	  was	  designed	  as	  follows.	  	  
Analysis	   of	   18	   blank	   samples,	   originating	   from	  18	   different	   cows	  was	   performed	   to	   check	   the	  
ruggedness	   and	   specificity	   of	   the	   method.	   Pooled	   faeces	   of	   three	   adult	   cows	   was	   used	   to	  
evaluate	  the	  specificity,	  selectivity,	  linearity,	  precision,	  limit	  of	  detection,	  limit	  of	  quantification,	  
decision	  limit,	  detection	  capacity	  and	  mean	  recovery.	  Analysis	  of	  20	  blank	  samples	  of	  this	  bovine	  
faecal	   pool	   (mixture	   of	   three	   cows)	  was	   performed	   to	   calculate	   the	   endogenous	   levels	   of	   the	  
natural	   glucocorticoids	   cortisol,	   cortisone	  and	   the	  metabolite	  dihydrocortisone.	  This	  permitted	  
to	   determine	   the	   specificity	   of	   each	   compound	   by	   calculating	   the	   average	   and	   standard	  
deviation	  of	  the	  noise	  amplitude	  within	  the	  retention	  time	  window	  of	  that	  compound,	  expressed	  
relative	   to	   the	   selected	   internal	   standard	   signal	   amplitude.	  The	   calibration	   curves	   consisted	  of	  
eight	  fortification	  levels.	  The	  linearity	  and	  lack-­‐of-­‐fit	  were	  evaluated	  by	  calculating	  the	  regression	  
coefficient	  (R2)	  and	  by	  building	  an	  univariate	  linear	  regression	  model.	  The	  pooled	  bovine	  faecal	  
samples	   were	   fortified	   with	   concentrations,	   ranging	   from	   1.25	   to	   50	   μg	   kg-­‐1.	   To	   evaluate	   the	  
precision	  of	  the	  developed	  analytical	  method,	  repeatability	  and	  within-­‐laboratory	  reproducibility	  
were	   determined	   by	   calculating	   the	   relative	   standard	   deviations	   (%RSD).	   For	   the	   endogenous	  
compounds,	  the	  limit	  of	  detection	  and	  limit	  of	  quantification	  were	  determined	  in	  20	  unfortified	  
pooled	   faecal	   samples,	   as	   the	   lowest	   level	   at	   which	   a	   compound	   could	   be	   identified	   with	   a	  
signal-­‐to-­‐noise	  ratio	  greater	  than	  3	  and	  10	  respectively	  [45].	  
2.6.	   Quality	  assurance	  
A	  mixture	  of	  the	  internal	  standards	  cortisol-­‐d4	  and	  prednisolone-­‐d8,	  at	  a	  concentration	  of	  10	  μg	  
kg-­‐1,	  was	  added	  to	  every	  sample,	  prior	  to	  extraction	  (Table	  3.3.).	  Prior	  to	  sample	  analysis,	  10	  μL	  
standard	   mixture	   of	   the	   targeted	   glucocorticoids	   at	   10	   μg	   L-­‐1	   was	   injected	   to	   check	   the	  
operational	   conditions	   of	   the	   UHPLC-­‐HRMS	   device.	   The	   compounds	  were	   identified	   based	   on	  
their	  retention	  time	  relative	  to	  the	  retention	  time	  of	  the	  internal	  standard	  of	  choice	  and	  on	  the	  
13C/12C	   isotopic	   ratio	   according	   to	   the	   criteria	   described	   for	   high-­‐resolution	   MS	   in	   CD	  
2002/657/EC	  [37].	  After	  identification,	  the	  concentrations	  of	  the	  detected	  glucocorticoids	  were	  
calculated	  by	  fitting	  their	  area	  ratios	  into	  eight-­‐point	  calibrations	  curves,	  set	  up	  in	  bovine	  faeces.	  
Area	   ratios	   were	   determined	   by	   integration	   of	   the	   area	   of	   an	   analyte	   under	   the	   specific	  
CHAPTER	  III	  
84	  
extracted	  chromatograms	  in	  reference	  to	  the	  integrated	  area	  of	  the	  internal	  standard.	  
Table	   3.3.	   UHPLC-­‐HRMS	   parameters	   used	   for	   the	   various	   glucocorticoids	   with	   indication	   of	   elemental	  
composition,	  accurate	  mass,	  internal	  standard	  used,	  retention	  time	  and	  ionization	  modus.	  









Dihydrocortisone	   C21H30O5	   363.21588	   Cortisol-­‐d4	   3.92	   +	  
Cortisol	   C21H30O5	   363.21588	   Cortisol-­‐d4	   5.32	   +	  
Cortisone	   C21H28O5	   361.20062	   Cortisol-­‐d4	   5.66	   +	  
Prednisolone	   C21H28O5	   361.20062	   Prednisolone-­‐d8	  	   5.09	   +	  
Prednisone	   C21H26O5	   359.18478	   Prednisolone-­‐d8	  	   5.16	   +	  
Methylprednisolone	   C22H30O5	   375.21627	   Prednisolone-­‐d8	  	   7.81	   +	  
20α-­‐dihydroprednisolone	   C21H30O5	   363.21588	   Prednisolone-­‐d8	   3.31	   +	  
20β-­‐dihydroprednisolone	   C21H30O5	   363.21588	   Prednisolone-­‐d8	   3.62	   +	  
Cortisol-­‐d4	   C21H27D4O5	   367.24171	   -­‐	   5.27	   +	  
Prednisolone-­‐d8	   C21H21D8O5	   369.25034	   -­‐	   4.96	   +	  
2.7.	   Stability	  study	  
During	  the	  long-­‐term	  stability	  study,	  the	  changes	  in	  glucocorticoid	  concentrations	  were	  studied	  
under	   different	   conditions	   including	   multiple	   freeze-­‐thaw	   cycles.	   The	   glucocorticoids	  
investigated	   comprised	   cortisol,	   cortisone,	   dihydrocortisone,	   prednisolone,	   prednisone	   and	  
methylprednisolone.	   Aliquots	   of	   five	   gram	   of	   pooled	   faeces	   (mixture	   of	   three	   cows)	   were	  
fortified	  with	   a	   standard	  mixture	  of	   the	   six	   glucocorticoids	   at	   20	  μg	   kg-­‐1.	   In	   total,	   three	  major	  
parameters	  were	  investigated:	  redox	  conditions,	  influence	  of	  ethanol	  addition	  and	  lyophilization	  
(Figure	   3.2.).	   In	   the	   first	   batch	   of	   samples,	   the	   stability	   of	   glucocorticoids	   was	   tested	   under	  
different	  redox	  potentials.	  To	  obtain	  an	  anaerobe	  environment	  the	  faecal	  samples	  were	  flushed	  
with	  N2	  during	  30	  min.	  The	  second	  group	  consisted	  of	  faecal	  samples	  to	  which	  10	  mL	  of	  ethanol	  
was	  added.	  In	  the	  last	  part	  of	  the	  study,	  faecal	  samples	  were	  lyophilized	  during	  4	  days	  to	  obtain	  
dry	   faecal	  matrix.	   For	  each	   time	  point	   in	   the	   study	  and	   for	  each	  parameter	   set,	   samples	  were	  
prepared	  in	  triplicate	  and	  stored	  respectively	  at	  -­‐80	  °C,	  -­‐20	  °C,	  4	  °C	  and	  room	  temperature	  (15	  -­‐	  
20	  °C)	  up	  to	  20	  weeks.	  At	  different	  time	  intervals,	  the	  six	  glucocorticoids	  in	  each	  batch	  of	  faecal	  






Figure	  3.2.	  Overview	  of	  the	  experimental	  protocol	  of	  the	  stability	  study.	  
Additionally,	   the	   effect	   of	   freeze/thaw	   cycles	   was	   investigated	   by	   consecutively	   thawing	   the	  
frozen	   samples	   (i.e.	   remove	   from	   freezer	   and	  allow	   to	   thaw	  at	   room	   temperature)	   in	   the	   first	  
week,	   refreezing	   the	   samples	   and	   finally	   thawing	   them	   again	   for	   analysis	   at	   the	   next	   time	   of	  
sampling	  (after	  2,	  4,	  10	  and	  20	  weeks).	  
2.8.	   	  Statistical	  analysis	  
To	   evaluate	   the	   Plackett-­‐Burman	   design,	   a	   one-­‐way	   analysis	   of	   variance	   (ANOVA)	   test	   was	  
performed	   using	   Modde	   5.0.	   Data	   of	   the	   stability	   study	   were	   analysed	   by	   multiple	   linear	  
regression	  analysis	  using	  SPSS	  Statistics	  20	  (IBM,	  United	  States).	  A	  p-­‐value	  below	  0.05	  indicated	  a	  
significant	  difference.	  
3. Results	  and	  discussion	  
3.1.	  	   Optimization	  of	  extraction	  procedure	  
Sample	   preparation	   is	   a	   crucial	   step	   towards	   the	   unambiguous	   detection	   and	   accurate	  
quantification	  of	  glucocorticoids	  in	  bovine	  faeces.	  For	  evaluating	  the	  effects	  of	  eight	  variables	  in	  
the	   extraction	   procedure,	   a	   Plackett-­‐Burman	   experimental	   design	   was	   employed.	   Based	   on	  
literature	  information,	  faecal	  material	  can	  contain	  about	  20%	  fat	  [40][41]	  so	  a	  defatting	  step	  was	  
included.	   Since	   in	  most	   species,	   steroids	   are	   excreted	   in	   faeces	   in	   the	   unconjugated	   form,	   no	  
deconjugation	   step	   was	   included	   in	   the	   extraction	   procedure	   [11][12][46].	   The	   following	  
variables	  were	   esteemed:	   extraction	   solvent,	   volume	   of	   the	   extraction	   solvent,	   2nd	   extraction,	  
volume	  of	  the	  2nd	  extraction	  solvent,	   time	  of	  rotating,	  defatting	  step,	  solvent	   for	  defatting	  and	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type	  of	  SPE	  column	  (Table	  3.2.).	  The	  difference	  between	  a	  low	  and	  high	  level	  was	  set	  in	  this	  way	  
to	  obtain	  a	  maximal	  statistical	  difference.	  Hence	  it	  was	  possible	  to	  identify	  the	  most	  significant	  
variables.	  The	  experimental	  design	  was	  executed	  in	  a	  random	  order.	  	  
The	   critical	   variables	  were	   volume	   of	   extraction	   solvent,	   whether	   or	   not	   a	   2nd	   extraction	  was	  
performed	  and	   the	  presence	  of	   a	   defatting	   step	   (Supplementary	   table).	   These	   variables	  had	   a	  
significant	   statistical	   influence	   (p	   <	   0.05)	   on	   the	   extraction	   efficiency.	   Further	   optimization	   of	  
these	  categorical	  variables	  was	  not	  necessary.	  
For	  the	  non-­‐critical	  variables	  it	  was	  observed	  that	  for	  prednisolone	  and	  cortisone,	  using	  10	  mL	  of	  
the	   extraction	   solvent	   TBME	   displayed	   a	   positive	   regression	   coefficient,	   which	   resulted	   in	   an	  
increased	   recovery.	   Both	   SPE	   procedures	   gave	   satisfactory	   results,	   but	   the	   C18	   (EC)	   cartridge	  
proved	  more	  suitable	  for	  the	  intended	  generic	  extraction	  since	  the	  40%	  loss	  of	  metabolites	  i.e.	  
20α-­‐dihydroprednisolone	   and	   20β-­‐dihydroprednisolone,	   was	   limited	   during	   clean-­‐up.	   For	  
prednisone,	  cortisol	  and	  dihydrocortisone	  the	  defatting	  step	  showed	  a	  significant	  positive	  effect	  
on	  the	  extraction	  efficiency.	  The	  solvents	  commonly	  used	  for	  defatting	  purposes	  are	  hexane	  and	  
petroleum	  benzine	  [41].	  The	  best	  results	  were	  obtained	  after	  defatting	  with	  petroleum	  benzine.	  	  
The	  most	  promising	  settings	  were	  included	  into	  the	  extraction	  procedure	  (cf.	  2.4.2.).	  
3.2.	   UHPLC	  and	  MS	  parameters	  
Chromatographic	   separation	   of	   glucocorticoids	   poses	   a	   true	   analytical	   challenge,	   due	   to	   the	  
equal	   molecular	   masses	   of	   prednisolone	   and	   cortisone	   on	   the	   one	   hand	   and	   20α-­‐
dihydroprednisolone,	   20β-­‐dihydroprednisolone,	   dihydrocortisone	   and	   cortisol	   on	   the	   other	  
hand,	   rendering	  mass	  spectrometric	   separation	   impossible.	   In	  a	  previous	  study,	   several	  UHPLC	  
columns	  were	   tested	   and	   compared	   for	   the	   chromatographic	   separation	   of	   glucocorticoids	   in	  
urine,	  leading	  to	  the	  selection	  of	  the	  Nucleodur	  C18	  Isis	  (1.8	  μm,	  100	  x	  2	  mm,	  Macherey-­‐Nagel)	  
column	  [34].	  The	  mobile	  phases	  were	  also	  adopted	  from	  this	  study	  i.e.	  0.1%	  formic	  acid	  in	  water	  
and	  0.1%	  formic	  acid	  in	  acetonitrile.	  To	  achieve	  chromatographic	  separation	  of	  the	  isomers	  20α-­‐







Figure	   3.3.	   Chromatogram	   of	   a	   blank	   faecal	   sample,	   i.e.	   a	   sample	   that	   was	   not	   enriched	   with	  
glucocorticoid	   standards	   (A),	   and	   chromatogram	   of	   a	   faecal	   sample	   fortified	   with	   5	   μg	   kg-­‐1	   of	   (a)	  
Prednisolone	  (RT:	  5.09;	  MA:	  1742418;	  S/N:	  634);	  (b)	  Cortisone	  (RT:	  5.66;	  MA:	  1053589;	  S/N:	  333);	  (c)	  20α-­‐
dihydroprednisolone	  (RT:	  3.31;	  MA:	  517958;	  S/N:	  43);	  (d)	  20β-­‐dihydroprednisolone	  (RT:	  3.62;	  MA:	  573864;	  
S/N:	  32);	  (e)	  Dihydrocortisone	  (RT:	  3.92;	  MA:	  304443;	  S/N:	  35);	  (f)	  Cortisol	  (RT:	  5.32;	  MA:	  1036409;	  S/N:	  
288);	   (g)	   Prednisone	   (RT:5.16;	  MA:	   858750;	   S/N:	   596);	   (h)	  Methylprednisolone	   (RT:	   7.81;	  MA:	   1875146;	  
S/N:	  698)	  (B).	  The	  maximum	  mass	  deviation	  was	  set	  at	  4	  ppm.	  
Before	  determining	  the	  optimal	  MS	  conditions,	  for	  each	  glucocorticoid	  standard	  and	  deuterium-­‐
labeled	   internal	   standard	   (10	  μg	  L-­‐1)	   the	  observed	  masses	  were	  compared	  with	   the	   theoretical	  
masses,	   which	   were	   calculated	   using	   Xcalibur	   2.1,	   by	   direct	   infusion	   on	   the	   HRMS.	   The	  mass	  
deviations,	   expressed	   in	   parts	   per	   million	   (ppm)	   and	   defined	   as:	   106	   x	   [(measured	   mass	   –	  
theoretical	   mass)	   /	   theoretical	   mass],	   were	   found	   to	   be	   below	   3	   ppm.	   In	   case	   of	   HRMS	  
applications,	   CD	   2002/657/EC	   states	   that	   the	   presence	   of	   the	   [M+H]+	   or	   [M-­‐H]-­‐	   ion	  with	   their	  
specified	  retention	  times	  and	  respective	  accurate	  masses	  is	  insufficient	  for	  the	  identification	  and	  
confirmation	  of	   the	   selected	   analytes	   since	   at	   least	   two	  diagnostic	   ions	   are	   requisite,	   i.e.	   four	  
identification	  points	  for	  forbidden	  substances	  such	  as	  corticosteroids	  [37].	  Therefore,	  the	  mono-­‐
isotopic	  pattern	  (13C	   ion)	  may	  assist	   in	  the	  further	  confirmation	  of	  a	  compound’s	   identity	  since	  
then	  two	  additional	  identification	  points	  may	  be	  granted.	  An	  isotopic	  ion	  was	  only	  found	  suitable	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as	   a	   diagnostic	   ion	   when	   the	   corresponding	   [M+H]+	   or	   [M-­‐H]-­‐	   was	   also	   detected	   and	   the	  
calculated	  relative	  ion	  intensity	  was	  in	  compliance	  with	  CD	  2002/657/EC	  requirements	  [37].	  	  
Based	  on	  peak	  intensities,	  peak	  areas	  and	  signal-­‐to-­‐noise	  ratios,	  the	  optimal	  HRMS	  parameters	  
were	  set	  for	  each	  individual	  analyte	  (Table	  3.3.).	  Based	  on	  the	  analysis	  of	  fortified	  faecal	  samples	  
at	   different	   mass	   resolutions	   (i.e.	   50,000	   and	   100,000	   FWHM)	   a	   mass	   resolution	   of	   50,000	  
FWHM	  at	  1	  Hz	  was	  selected.	  The	  optimal	  AGC	  value	  was	  found	  to	  be	  the	  balanced	  scan	  (1	  x	  e6	  
ions).	  
3.3.	   	  Method	  validation	  
In	  order	  to	  validate	  the	  analytical	  method	  for	  quantitative	  confirmation	  (CD	  2002/657/EC)	  [37]	  
pooled	   faeces	   of	   three	   adult	   cows	   were	   used.	   After	   homogenization,	   the	   performance	  
characteristics	  of	   the	  method	  were	  evaluated.	   Since	   cortisol	   and	   cortisone	  detection	   in	   faeces	  
has	  been	   reported	   [14],	   the	   endogenous	   concentration	  of	   ‘blank’	   faeces	   samples,	   i.e.	   samples	  
that	  were	  not	  enriched	  with	  glucocorticoids,	  was	  measured.	  In	  the	  pooled	  faeces	  batch	  (n	  =	  20)	  
obtained	  in	  light	  of	  this	  validation	  and	  in	  18	  faecal	  samples,	  originating	  from	  18	  different	  cows,	  
the	  endogenous	  concentrations	  of	  cortisol,	  cortisone	  and	  the	  metabolite	  dihydrocortisone	  were	  
below	   LOD	   and	   therefore	   not	   granted	   any	   further	   consideration	   during	   the	   validation	   study.	  
These	   findings	   are	   in	   line	   with	   Arioli	   et	   al.	   (2010)	   who	   state	   that	   cortisol	   and	   cortisone	   are	  
frequently	  below	  LOD	  in	  faeces	  except	  for	  cattle	  find	  under	  stressful	  situations	  [47].	  During	  the	  
validation,	   several	   variations	   i.e.	   variation	   of	   time,	   different	   persons,	   different	   origins	   of	  
matrices,	   solvents,	   stock	   solutions,	   etc.	   were	   introduced	   to	   evaluate	   the	   ruggedness	   of	   the	  
method.	  	  
3.3.1. Specificity	  
To	  establish	  the	  specificity	  of	  the	  analytical	  methods,	  18	  aliquots	  of	  pooled	  faeces	  samples	  were	  
fortified	  with	  each	  glucocorticoid	  standard	  in	  order	  to	  reach	  a	  concentration	  of	  5	  μg	  kg-­‐1.	  During	  
the	  additional	  analysis	  of	  18	  faecal	  samples,	  originating	  from	  18	  different	  cows	  no	  interferences	  
were	  noticed.	  The	  specificity	  of	  the	  analytical	  approach	  was	  confirmed	  since	  no	  interfering	  peaks	  
with	  a	  signal-­‐to-­‐noise	  of	  3	  or	  more	  were	  observed	  at	  the	  specific	  retention	  times	  of	  the	  targeted	  







Analytes	  were	   identified	  on	   the	  basis	  of	   their	   relative	   retention	   time,	  which	   is	   the	   ratio	  of	   the	  
retention	  time	  of	  the	  analyte	  to	  that	  of	  the	  corresponding	  internal	  standard	  [37].	  Besides,	  when	  
a	  chromatographic	  peak	  of	  interest	  had	  a	  signal-­‐to-­‐noise	  of	  at	  least	  3,	  the	  accurate	  mass	  of	  the	  
ion	  [M+H]+	  was	  taken	  into	  account.	  Within	  this	  study,	  a	  maximum	  mass	  deviation	  of	  4	  ppm	  was	  
allowed.	  
3.3.3. Linearity	  
Linearity	  was	  evaluated	  in	  faeces	  for	  each	  compound	  by	  using	  an	  unweighted	  linear	  regression	  in	  
the	   1.25	   -­‐	   50	   μg	   kg-­‐1	   concentration	   range.	   Eight-­‐point	   calibration	   curves	   were	   constructed	   in	  
pooled	  faeces.	  The	  mean	  regression	  coefficients	  (R2)	  of	  the	  calibration	  curves	  were	  calculated	  by	  
plotting	   area	   ratio	   versus	   concentration.	   For	   all	   target	   compounds,	   regression	   coefficients	   of	  
0.9940	  or	  higher	  were	  found.	  This	  suggests	  a	  good	  linear	  correlation	  (Table	  3.4.).	  Additionally	  the	  
lack-­‐of-­‐fit	   was	   assessed	   by	   building	   an	   univariate	   linear	   regression	  model	   (SPSS	   version	   21.0)	  
with	   the	   triplicate	   calibration	   concentrations	   as	   independent	   variable	   and	   the	   respective	   area	  
ratio	   as	   dependent	   variables.	   The	   resulting	   regression	   model	   equations	   were	   all	   reported	   as	  
linear	  (F-­‐test;	  p	  <	  0.05;	  R2	  ≥	  0.99).	  Model	  validity	  was	  additionally	  confirmed	  by	  absence	  of	  any	  
lack-­‐of-­‐fit	  (95%	  confidence	  interval).	  
3.3.4. Precision	  
Evaluation	  of	  the	  precision	  included	  the	  determination	  of	  the	  repeatability	  and	  within-­‐laboratory	  
reproducibility	   of	   this	   new	  method.	   Both	   validation	   parameters	  were	   evaluated	   by	   calculating	  
the	  relative	  standard	  deviation	  (%RSD)	  of	  three	  fortification	  levels	  (Table	  3.4.).	  These	  levels	  were	  
based	  on	  the	  established	  maximum	  residue	  limits	  (4	  μg	  kg-­‐1	  and	  10	  μg	  kg-­‐1	  in	  bovine	  muscle	  for	  
prednisolone	   and	   methylprednisolone	   respectively)	   [5].	   Three	   series	   of	   six	   replicates	   were	  
analysed	   to	   determine	   repeatability	   and	  were	   carried	   out	   on	   different	   occasions	   by	   the	   same	  
operator	   under	   repeatable	   conditions.	   As	   presented	   in	   Table	   3.4.,	   the	   calculated	   RSD	   values	  
were	  below	  15%,	  indicating	  a	  good	  repeatability	  according	  to	  European	  Criteria	  2002/657	  [37].	  
The	  within-­‐laboratory	  reproducibility	  was	  evaluated	  with	  four	  series	  of	  six	  replicates	  of	  samples	  
analysed	   by	   two	   different	   operators	   on	   three	   different	   days.	   The	   calculated	   RSD	   values	  were	  
below	   20%,	   indicating	   a	   comparable	   precision	   with	   the	   method	   of	   Arioli	   et	   al.	   (2010)	   and	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Weltring	  et	  al.	  (2012)	  where	  the	  RSD	  values	  were	  respectively	  5.2	  -­‐	  16.2	  and	  5.5	  -­‐	  9.1	  [12][47].	  
Table	  3.4.	  Decision	  limits	  (CCα)	  and	  detection	  capabilities	  (CCβ)	  calculated	  for	  the	  synthetic	  glucocorticoids	  
in	   faeces	   according	   to	   2002/657/EC	   [37].	   Limits	   of	   Detection	   (LOD)	   and	   Limits	   of	   Quantification	   (LOQ)	  
calculated	  for	  the	  natural	  glucocorticoids	  in	  faeces.	  Overview	  of	  the	  main	  performance	  characteristics	  for	  
the	  eight	  glucocorticoids,	  analysed	  in	  faeces,	  according	  to	  2002/657/EC	  [37].	  

























































































































1:	  natural	  and	  2:	  synthetic	  glucocorticoids.	  
3.3.5. Limit	  of	  detection	  and	  limit	  of	  quantification	  
For	   the	   natural	   glucocorticoids	   cortisol,	   cortisone	   and	   the	   metabolite	   dihydrocortisone,	   the	  
limits	   of	   detection	   (LOD,	   S/N	   ≥	   3)	   and	   quantification	   (LOQ,	   S/N	   ≥	   10)	   were	   theoretically	  
calculated	  based	  on	  eight-­‐point	   calibration	   curves.	   The	   LODs	   ranged	   from	  0.55	   to	  2.10	  μg	  kg-­‐1	  
and	   the	   LOQs	   ranged	   from	   0.70	   to	   5.00	   μg	   kg-­‐1	   (Table	   3.4,	   Figure	   3.4.).	   After	   theoretically	  







Figure	  3.4.	  Chromatogram	  of	  a	  blank	  faecal	  sample	  fortified	  with	  (a)	  0.5	  μg	  kg-­‐1	  prednisone,	  (b)	  0.5	  μg	  kg-­‐1	  
prednisolone,	   (c)	   1.25	  μg	   kg-­‐1	   cortisone,	   (d)	   1.25	  μg	   kg-­‐1	   20α-­‐dihydroprednisolone,	   (e)	   1.25	  μg	   kg-­‐1	   20β-­‐
dihydroprednisolone,	   (f)	   1.25	   μg	   kg-­‐1	   dihydrocortisone,	   (g)	   1.25	   μg	   kg-­‐1	   cortisol,	   (h)	   2.5	   μg	   kg-­‐1	  
methylprednisolone.	  
3.3.6. Decision	  limit	  (CCα)	  and	  detection	  capacity	  (CCβ)	  
For	   the	   synthetic	   glucocorticoids,	   prednisolone,	   prednisone	   and	   methylprednisolone,	   blank	  
material	   is	   available	   and	   therefore	   the	  CCα	   and	  CCβ	  were	   experimentally	   determined.	   The	  CCα	  
was	  calculated	  as	  the	  mean	  of	  the	  noise	  amplitude	  plus	  2.33	  times	  the	  standard	  deviation	  of	  the	  
noise	  amplitude.	  For	  calculating	  CCβ,	  20	  blank	  faeces	  samples	  were	  spiked	  at	  the	  determined	  CCα	  
level,	   subsequently	   the	   CCβ	   was	   determined	   by	   calculating	   the	   mean	   concentration	   at	   the	  
corresponding	   decision	   limit	   plus	   1.64	   times	   the	   standard	   deviation	   of	   the	   mean	   measured	  
concentration	  [47].	  Table	  3.4.	  and	  Figure	  3.4.	  summarizes	  the	  calculated	  CCα	  and	  CCβ	  values	  for	  
the	   different	   glucocorticoids.	   Compared	   to	   values	   reported	   in	   literature	   [47],	   ranging	  
respectively,	   from	   0.15	   to	   2.95	   μg	   kg-­‐1	   and	   from	   0.40	   to	   5.20	   μg	   kg-­‐1,	   the	   calculated	   decision	  
limits	  and	  detection	  capabilities	  from	  this	  study	  were	  in	  the	  same	  order	  of	  magnitude.	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3.3.7. Mean	  recovery	  
As	  no	  certified	  reference	  material	  was	  available,	  fortified	  faecal	  samples	  were	  used	  to	  determine	  
trueness	   as	   the	   mean	   corrected	   recovery.	   Three	   fortification	   levels	   were	   considered	   with	   six	  
replicates	   for	   each	   level.	   The	   calculated	  mean	   recoveries	   ranged	   from	   81	   to	   110%	   and	   were	  
considered	   to	   be	   satisfactory	   according	   to	   CD	   2002/657/EC	   and	   results	   found	   in	   literature	  
[12][37][47]	  (Table	  3.4.).	  
3.4.	  	   Stability	  of	  glucocorticoids	  in	  faecal	  material	  
The	  concentration	  of	  natural	  and	  synthetic	  steroids	  may	  alter	  by	  inappropriate	  storage	  and	  the	  
present	  bacterial	  activity	  in	  faecal	  matrix.	  In	  the	  present	  study,	  the	  stability	  of	  glucocorticoids	  in	  
bovine	  faeces	  was	  investigated	  under	  different	  experimental	  conditions.	  
3.4.1. Effect	  of	  temperature	  during	  storage	  
The	   temperature	   during	   preservation	   can	   be	   easily	   manipulated	   and	   controlled	   for	   a	   longer	  
period.	  Analysis	  of	  samples	  stored	  for	  1,	  2,	  4,	  10	  and	  20	  weeks,	  demonstrated	  that	  the	  observed	  
glucocorticoid	  concentrations	  were	  highly	  dependent	  on	   the	   temperature	  during	  preservation.	  
For	  all	  glucocorticoids,	  a	  significant	  difference	   (p	  <	  0.05)	  was	  noticeable	  between	  the	  different	  
temperatures	  (-­‐80	  °C,	  -­‐20	  °C,	  4	  °C,	  room	  temperature).	  When	  faecal	  samples	  were	  stored	  in	  the	  
freezer	  (-­‐20	  °C	  and	  -­‐80	  °C),	  bacterial	  metabolism	  is	  minimized	  [48].	  This	  effect	  was	  noticed	  for	  all	  
compounds:	  after	  20	  weeks,	  more	  than	  80%	  of	  the	  initial	  concentration	  of	  cortisol	  was	  found	  at	  -­‐
80	  °C.	  Prednisolone	  showed	  an	  increase	  of	  45%	  after	  20	  weeks.	  Glucocorticoids	  in	  faecal	  samples	  
stored	  at	  higher	   temperatures	   (4	   °C	  and	   room	  temperature)	  are	   subjected	   to	  higher	  microbial	  
activity	   and	   after	   10	   weeks	   in	   none	   of	   the	   samples	   glucocorticoids	   were	   detected.	   For	   the	  
natural	   glucocorticoid	   cortisol	   and	   the	   synthetic	   analogue	   prednisolone	   data	   are	   presented	   in	  
Figure	  3.5.A.	  A	  similar	  behaviour	  over	  time	  for	  both	  compounds	  was	  observed.	  
3.4.2. Effects	  of	  lyophilization	  
During	  the	  first	  4	  weeks,	  a	  slight	  increase	  in	  glucocorticoid	  concentrations	  was	  noticed.	  After	  10	  
and	   20	   weeks,	   the	   concentrations	   dropped	   to	   ca.	   80	   and	   20%	   of	   the	   initial	   concentration	  
respectively	   (Figure	   3.5.B).	   These	   concentration	   changes	  were	   not	   dependent	   on	   preservation	  
temperature,	   which	   is	   in	   contrast	   to	   what	   previous	   studies	   have	   observed	   [36][49],	   where	  





3.4.3. Effect	  of	  adding	  ethanol	  
Based	   on	   literature	   findings,	   faecal	   samples	   used	   for	   faecal	   glucocorticoid	  metabolite	   analysis	  
are	  sometimes	  stored	  in	  a	  preservative	  solution.	  Ethanol	  had	  been	  investigated	  before	  [49]	  and	  
showed	  good	  results	  during	  14	  days.	  However,	  these	  treatments	  could	  influence	  the	  stability	  of	  
the	  glucocorticoids	   since	  oxidation	  and	   formation	  of	  hydroxyl	   groups	  on	   faecal	   glucocorticoids	  
may	  occur	   [33].	  Hence,	  addition	  of	  ethanol	  was	   included	  as	  a	   test	   condition	   in	   this	   study.	  The	  
results	  showed	  that	  the	  addition	  of	  ethanol	  influenced	  the	  extraction	  efficiency,	  therefore	  these	  
results	  were	  not	  discussed	  in	  detail.	  Only	  the	  main	  results	  are	  shown	  in	  Figure	  3.5.C.	  	  
3.4.4. Effect	  of	  redox	  potentials	  
It	  has	  been	  indicated	  that	  the	  microbial	  population	  of	  the	  large	  intestinal	  bacteria	  of	  cattle	  are	  
dominated	  by	   strict	  anaerobes	   such	  as	  Bacteriodes	  spp.,	  Clostridium	  spp.,	   and	  Bifidobacterium	  
spp.	   [35]	   and	   facultative	   anaerobes	   i.e.	   Eschericia	   coli.	   To	   investigate	   their	   effect	   on	  
glucocorticoid	   concentrations	   upon	   storage,	   faecal	   samples	   were	   placed	   under	   anaerobe	  
conditions	  during	  20	  weeks.	  These	  anaerobe	  conditions	  exerted	  significant	  effects	  (p	  <	  0.05)	  on	  
the	   glucocorticoid	   concentrations	  when	   preserved	   at	   4	   °C	   and	   room	   temperature.	   The	   results	  
are	  presented	  for	  cortisol	  and	  prednisolone	  (Figure	  3.5.D).	  An	  increase	  of	  40%	  was	  observed	  for	  
prednisolone	   after	   4	   weeks	   at	   room	   temperature,	   which	   reflects	   a	   possible	   neoformation,	  




Figure	  3.5.	  Effect	  of	  (A)	  different	  temperatures	  on	  the	  concentrations	  of	  prednisolone	  (black)	  and	  cortisol	  
(white);	  (B)	  lyophilization;	  (C)	  addition	  of	  ethanol;	  and	  (D)	  redox	  potential	  during	  20	  weeks.	  The	  mean	  ±	  SD	  
of	  3	  replicates	  is	  shown.	  
3.4.5. Freeze-­‐thaw	  cycles	  
Evaluation	   of	   freeze	   and	   thaw	   stability	   was	   performed	   by	   preservation	   of	   glucocorticoids	   in	  
faeces	  at	  -­‐20	  °C.	  Each	  sample	  was	  subjected	  to	  five	  freeze-­‐thaw	  cycles	  at	  each	  round	  of	  sampling	  
during	  the	  long-­‐term	  stability	  study.	  For	  the	  natural	  glucocorticoids	  a	  recovery	  of	  20%	  was	  found	  
after	   the	   first	   freeze-­‐thaw	  cycle.	   The	   reason	  of	   this	  decrease	   is	  unknown.	  After	   the	  3th	   freeze-­‐
thaw	  cycle,	  a	  more	  extensive	  standard	  deviation	  was	  observed,	  which	  clearly	  demonstrated	  that	  






Figure	  3.6.	  Recovery	  of	  the	  different	  glucocorticoids	  in	  faeces	  exposed	  to	  a	  number	  of	  freeze-­‐thaw	  cycles:	  
(A)	  natural	  glucocorticoids	  and	  (B)	  synthetic	  glucocorticoids.	  The	  mean	  ±	  SD	  of	  3	  replicates	  is	  shown.	  
4. Conclusion	  
This	   study	   describes	   the	   successful	   development	   and	   validation	   of	   a	   generic	   extraction	  
procedure	   and	   detection	  method	   for	   glucocorticoids	   in	   faeces	   according	   to	   the	   criteria	   set	   in	  
Commission	  Decision	  2002/657/EC	  [37].	  By	  making	  use	  of	  a	  sequential	  strategy	  of	  experimental	  
design	   i.e.	   Plackett-­‐Burman	   design,	   a	   generic	   extraction	   protocol	   was	   developed	   in	   a	   more	  
efficient	   way.	   This	   design	   allows	   identifying	   those	   variables	   that	   significantly	   affect	   the	  
recoveries	   of	   the	   glucocorticoids	   from	   faeces	   with	   a	   reduced	   number	   of	   experiments.	   The	  
developed	  HR-­‐Orbitrap-­‐MS	  method	  offers	  a	  great	  potential	  in	  targeted	  and	  untargeted	  analysis.	  
Because	  a	  virtually	  unlimited	  number	  of	  compounds	  can	  be	  comprised	  in	  the	  detection	  method	  
while	  providing	  accurate	  mass	  determination	  at	  the	  same	  time,	  it	  can	  pursue	  the	  perspective	  of	  
untargeted	  strategies	  and	  retrospective	  analysis	  for	  future	  experiments.	  
In	   conclusion,	   the	   long-­‐term	   stability	   study	   (20	   weeks)	   of	   glucocorticoids	   in	   bovine	   faeces	  
demonstrates	  freezing	  (-­‐80	  °C)	  faecal	  samples	  without	  any	  chemical	  treatment	  such	  as	  addition	  
of	   ethanol,	   increases	   the	   recovery	   of	   glucocorticoids.	   The	   addition	   of	   ethanol	   influenced	   the	  
extraction	   efficiency	   and	   analysis	   results	   of	   the	   glucocorticoids	   and	   is	   therefore	   not	  
recommended.	  Lyophilization	  of	  the	  faecal	  matrix	  proved	  however	  a	  worthy	  alternative	  for	  long-­‐
term	   storage	   of	   faecal	   samples	   prior	   to	   glucocorticoid	   analysis.	   Withdrawing	   water	   from	   the	  
matrix,	   made	   it	   possible	   to	   store	   the	   matrix	   for	   long	   periods	   (up	   to	   10	   weeks)	   at	   room	  
temperature	   without	   significant	   (p	   <	   0.05)	   loss	   of	   glucocorticoids.




Cortisol	   Cortisone	   Dihydrocortisone	   Prednisolone	   Prednisone	   Methylprednisolone	  
	  
Coeff.	  SC	   p-­‐value	   Coeff.	  SC	   p-­‐value	   Coeff.	  SC	   p-­‐value	   Coeff.	  SC	   p-­‐value	   Coeff.	  SC	   p-­‐value	   Coeff.	  SC	   p-­‐value	  
Extraction	  solvent	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	  	  TBME	   0.1413	   0.3076	   0.4495	   0.1954	   0.7092	   0.2289	   0.03645	   0.4867	   0.1491	   0.005689	   0.4166	   0.2811	  
	  	  	  Diethylether	   -­‐0.1413	   0.3076	   -­‐0.4495	   0.1954	   -­‐0.7092	   0.2289	   -­‐0.03645	   0.4867	   -­‐0.1491	   0.005689	   -­‐0.4166	   0.2811	  
2th	  Extraction	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	  	  Yes	   0.2113	   0.0150*	   -­‐0.4674	   0.1810	   -­‐0.8208	   0.1736	   0.09593	   0.0105*	   0.008501	   0.8024	   -­‐0.6435	   0.1211	  
	  	  	  	  No	   -­‐0.2113	   0.0150*	   0.4674	   0.1810	   0.8208	   0.1736	   -­‐0.09593	   0.0105*	   -­‐0.008501	   0.8024	   0.6435	   0.1211	  
Defatting	  step	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	  	  Yes	   54897	   0.0304*	   -­‐2236	   0.6862	   20189	   0.1558	   5804	   0.5729	   5292	   0.0158*	   -­‐4184	   0.4537	  
	  	  	  No	   -­‐54897	   0.0304*	   2236	   0.6862	   -­‐20189	   0.1558	   -­‐5804	   0.5729	   -­‐5292	   0.0158*	   4184	   0.4537	  
Solvent	  of	  defatting	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	  	  n-­‐Hexane	   -­‐1948	   0.4921	   5520	   0.236	   -­‐9021	   0.0624	   -­‐8892	   0.1998	   159	   0.492	   -­‐8819	   0.0928	  
	  	  	  Petroleum	  benzene	   1948	   0.4921	   -­‐5520	   0.236	   9021	   0.0624	   8892	   0.1998	   -­‐159	   0.492	   8819	   0.0928	  
Type	  of	  SPE	  column	   	   	   	   	   	   	   	   	   	   	   	   	  
	  	  	  C18	  (EC)	   -­‐48658	   0.3606	   859	   0.8763	   12729	   0.3585	   9207	   0.3759	   427	   0.9053	   387	   0.3922	  
	  	  	  Strata	  X	   48658	   0.3606	   -­‐859	   0.8763	   -­‐12729	   0.3585	   -­‐9207	   0.3759	   -­‐427	   0.9053	   -­‐387	   0.3922	  
Volume	  of	  extraction	  
solvent	   16481	   0.7476	   -­‐13920	   0.0217*	   -­‐8772	   0.0413*	   -­‐18998	   0.0462*	   -­‐866	   0.8055	   692	   0.5039	  
Volume	  of	  2th	  
extraction	  solvent	   902	   0.4820	   -­‐6395	   0.5830	   7837	   0.5936	   1682	   0.2959	   372	   0.3841	   836	   0.3923	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Recent	  studies	  support	  the	  hypothesis	  that	  the	  glucocorticoid	  prednisolone	  can	  be	  formed	  from	  
cortisol	  under	  influence	  of	  stress.	  To	  evaluate	  this	  hypothesis,	  urine	  samples	  of	  supposedly	  non-­‐
stressed	  bovines	  (at	  the	  farm)	  and	  bovines	  subjected	  to	  two	  different	  forms	  of	  stress,	  i.e.	  upon	  
slaughter	   (natural	   stress)	   or	   following	   administration	   of	   a	   synthetic	   analogue	   of	   the	  
adrenocorticotropic	   hormone	   (pharmacologically-­‐induced	   increase	   of	   cortisol)	   were	   analysed,	  
and	  their	  urinary	  cortisol	  and	  prednisolone	  levels	  evaluated.	  At	  the	  farm,	  none	  of	  the	  examined	  
samples	  exhibited	  urinary	  prednisolone	  levels	  higher	  than	  the	  CCα	  (0.09	  μg	  L-­‐1).	  Upon	  slaughter	  
or	  following	  synthetically	  induced	  stress,	  significantly	  positive	  correlations	  between	  cortisol	  and	  
prednisolone	   could	   be	   demonstrated,	   0.52	   and	   0.69,	   respectively.	  Of	   all	   prednisolone-­‐positive	  
urine	   samples	   (n	   =	   84),	   only	   one	   showed	   a	   prednisolone	   levels	   (i.e.	   6.45	   μg	   L-­‐1)	   above	   the	  
threshold	  level	  of	  5	  μg	  L-­‐1	  suggested	  by	  the	  European	  Reference	  Laboratories.	  Subsequently,	  an	  
untargeted	   analysis	   was	   performed	   (metabolic	   fingerprinting)	   to	   characterize	   the	   urinary	  
metabolite	   patterns	   related	   to	   the	   three	   different	   cattle	   groups.	   In	   this	   context,	   multivariate	  
statistics	  assigned	  a	  total	  of	  169	  differentiating	  metabolites	  as	  playing	  a	  key	  role	   in	  the	  urinary	  
pattern	   in	   response	   to	   stress.	   Three	   of	   these	   ions	  were	   defined	   as	   steroids	   using	   an	   in-­‐house	  
created	  database.	  As	   a	   result,	   the	  metabolic	   fingerprinting	   approach	  proved	   to	   be	   a	   powerful	  
tool	   to	   classify	   unknown	   bovine	   urine	   samples	   that	   tested	   positive	   for	   prednisolone,	   while	  
providing	  information	  about	  the	  stress	  status	  of	  the	  animal.	  	  




The	  main	  glucocorticoid	  cortisol	  and	  its	  precursor	  cortisone	  have	  been	  acknowledged	  to	  fulfil	  a	  
wide	   range	   of	   physiological	   functions,	   being	   amongst	   others	   related	   to	   stress	   responses,	  
homeostatic	   effects,	   and	   anti-­‐inflammatory	   actions	   [1][2].	   Based	   on	   these	   functions,	   more	  
potent	   synthetic	   analogues	   such	   as	   dexamethasone,	   betamethasone,	   prednisolone,	   and	  
methylprednisolone	  have	  been	  introduced	  and	  are	  routinely	  used	  in	  veterinary	  practice	  for	  the	  
treatment	   of	   diverse	   inflammatory	   diseases	   and	   metabolic	   disorders	   [3].	   Besides	   their	  
therapeutic	   actions,	   glucocorticoids	   have	   also	  been	   associated	  with	   growth-­‐promoting	   effects,	  
(alone	  or	  in	  combination	  with	  anabolic	  steroids)	  for	  fattening	  purposes	  as	  well	  [4].	  However,	  the	  
therapeutic	  use	  of	  synthetic	  glucocorticoids	  is	  been	  strictly	  regulated	  in	  the	  European	  Union	  [5]	  
in	  order	  to	  protect	  consumers	  against	  potential	  harmful	  residues,	  present	  in	  animal	  derived	  food	  
products.	  More	  specifically,	  maximum	  residue	   limits	   (MRLs)	  have	  been	  set	   for	  betamethasone,	  
dexamethasone,	  methylprednisolone,	   and	   prednisolone	   in	   diverse	   tissues	   of	   animal	   origin	   [6].	  
Moreover,	  the	  use	  of	  synthetic	  glucocorticoids	  is	  completely	  prohibited	  for	  the	  sole	  purpose	  of	  
increasing	   the	   body	  weight	   of	   bovines.	   For	   this	   reason,	   national	   residue	  monitoring	   plans	   are	  
implemented	   in	   the	   various	  member	   states	   to	   detect	   any	  misuse	   of	   glucocorticoids,	  whereby	  
urine	  is	  considered	  as	  the	  preferred	  matrix.	  	  
In	   this	   context,	   the	   European	   Commission	   declared	   more	   non-­‐compliant	   urine	   samples	   for	  
prednisolone	   in	   the	  past	   few	  years,	  which	  has	  been	  reported	   in	   their	  annual	  Commission	  Staff	  
Working	  Document	  on	  the	  implementation	  of	  the	  established	  national	  glucocorticoid	  monitoring	  
plans.	  Moreover,	  there	  was	  no	  direct	  evidence	  of	  unauthorized	  use.	  These	  findings,	   in	  essence	  
originating	  from	  the	  increased	  analytical	  sensitivity	  of	  the	  applied	  screening	  methods,	  led	  to	  the	  
hypothesis	  of	   an	  endogenous	  prednisolone	  origin.	   In	   addition,	   since	  most	  of	   the	  prednisolone	  
positive	  urine	  samples	  were	  collected	  at	   the	  slaughterhouse,	   it	  has	  been	  suggested	  that	  stress	  
may	   induce	   the	   involved	   metabolic	   processes	   [7].	   Indeed,	   various	   studies	   report	   on	   the	  
detection	   of	   prednisolone	   residues	   in	   urine	   samples	   that	   were	   either	   collected	   at	   the	  
slaughterhouse	  [7][8][9]	  or	  after	  therapeutic	  stress	   inducement	  [10].	   In	  contrast,	  during	  a	   field	  
survey,	   no	   prednisolone	  was	   detected	   in	   the	  majority	   of	   urine	   samples	   from	  untreated	   cattle	  
[11].	   These	   observations	   are	   supported	   by	   the	   underlying	   mechanisms,	   associated	   with	   the	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physiological	   stress	   response.	   In	   response	   to	   stress,	   the	   hypothalamic-­‐pituitary-­‐adrenal	   (HPA)	  
axis	   is	  stimulated	  whereby	  the	  hypothalamus	  produces	  corticotropin-­‐releasing	  hormone	  (CRH),	  
which	   in	   turns	   triggers	   the	   secretion	   of	   adrenocorticotropic	   hormone	   (ACTH).	   This	   latter	  
hormone	  may	  affect	  the	  adrenal	  gland,	  as	  such	  promoting	  the	  synthesis	  and	  release	  of	  cortisol	  
[1][12]	  (Figure	  4.1.).	  	  
	  
Figure	  4.1.	  Systematic	  regulation	  of	  circulating	  cortisol	  levels	  by	  the	  hypothalamic-­‐pituitary-­‐adrenal	  (HPA)	  
axis	  and	  the	  possible	  pathways	  of	  endogenous	  prednisolone	  formation.	  
Since	  cortisol	  (Δ4-­‐pregnene-­‐11β,17α,21-­‐triol-­‐3,20-­‐dione)	  is	  only	  differing	  from	  prednisolone	  (Δ1,4-­‐
pregnadiene-­‐11β,17α,21-­‐triol-­‐3,20-­‐dione)	   by	   a	   single	   ring	   double	   bond,	   the	   formation	   of	  
prednisolone	  from	  cortisol	  may	  be	  assumed.	  This	  has	  recently	  been	  evidenced	  by	  the	  study	  of	  de	  
Rijke	  et	  al.	  (2014)	  [13],	  whereby	  a	  significant	  decrease	  of	  cortisol	  and	  formation	  of	  prednisolone	  
within	  6	  h	  was	  observed	  during	  an	   in	  vitro	   incubation	  experiment	  with	  bovine	  S9	   liver	  enzyme	  
extract.	  Based	  on	  the	  possible	  endogenous	  formation	  of	  prednisolone,	  the	  European	  Reference	  
Laboratories	   have	   suggested	   a	   threshold	   level	   for	   prednisolone	   in	   bovine	   urine	   of	   5	   µg	   L-­‐1,	  






















In	  this	  study,	  the	  influence	  of	  stress	  on	  the	  prevalence	  of	  prednisolone	  and	  prednisone	  in	  bovine	  
urine	  was	  evaluated	  to	  respond	  towards	  the	  inconsistent	  data	  reported	  in	  literature	  and	  confirm	  
the	   validity	   of	   the	   above-­‐mentioned	   threshold	   level.	   To	   this	   extent,	   12	   healthy	   bovines	   were	  
subjected	   to	   a	   treatment	   of	   intramuscular	   injection	   with	   a	   synthetic	   analogue	   of	   ACTH,	   i.e.	  
tetracosactide	   hexaacetate,	   to	   induce	   pharmacologically-­‐induced	   increase	   of	   cortisol.	   In	  
addition,	  bovine	  urine	  was	  collected	  from	  144	  meat	  and	  milk	  producing	  bovines	  under	  real	   life	  
conditions	   differing	   in	   degree	   of	   stress	   imposed,	   i.e.	   under	   normal	   housing	   conditions	   at	   the	  
farm	  and	  upon	  slaughter.	  The	  collected	  urine	  samples	  were	  analysed	  by	  usage	  of	  full-­‐scan	  high-­‐
resolution	  Orbitrap	  mass	  spectrometry	  to	  acquire	  the	  samples’	  metabolic	  fingerprints,	  allowing	  
the	   identification	  of	  metabolite	  patterns	   that	  are	  characteristic	   for	  bovines	  under	  well-­‐defined	  
stress	   conditions.	   Parallel	   to	   this	   untargeted	  metabolic	   fingerprinting,	   a	   targeted	   strategy	  was	  
considered	  as	  well,	  thereby	  determining	  the	  concentration	  levels	  of	  relevant	  glucocorticoids	  and	  
derived	   products;	   i.e.	   cortisol,	   cortisone,	   dihydrocortisone,	   prednisolone,	   prednisone,	  
methylprednisolone,	  20α-­‐dihydroprednisolone	  and	  20β-­‐dihydroprednisolone.	  
2. Material	  and	  methods	  
2.1. 	  Bovine	  urine	  collected	  during	  ACTH	  treatment	  
2.1.1. Test	  animals	  
Twelve	  healthy	  cows	  of	  a	  mixed	  breed	  were	  subjected	  to	  the	  ACTH	   in	  vivo	  study	  and	  housed	  in	  
the	  animal	   facilities	  of	   the	  Centre	  d’Economie	  Rurale	   (CER,	  Marloie	  Belgium)	  under	   controlled	  
experimental	  conditions.	  Age	  of	  the	  selected	  animals	  ranged	  from	  2	  to	  6	  years	  and	  body	  weight	  
was	  between	  360	  and	  570	  kg.	  Animals	  were	  fed	  a	  commercially	  available	  diet,	  commonly	  applied	  
in	   zootechnical	   practice,	   with	   ad	   libitum	   access	   to	   water	   and	   hay.	   During	   the	   entire	   study,	  
animals	  were	  kept	   in	   three	  separate	  and	  equal-­‐sized	  groups,	  all	  housed	   in	  a	  half-­‐covered	  pen.	  
Prior	   to	   the	   actual	   ACTH	   treatment,	   an	   initial	   acclimatization	   of	   18	   days	  was	   considered.	   This	  
study	  was	  approved	  by	  CER’s	  Ethical	  Committee	  (CE/Sante/ET/004).	  
2.1.2. Experimental	  protocol	  for	  ACTH	  treatment	  
Subsequent	   to	   the	   acclimatization	   period,	   all	   test	   animals	   received	   at	   8	   a.m.	   a	   daily	   2	   mg	  
intramuscular	   (IM)	   injection	   of	   tetracosactide	   hexaacetate	   (Pharmacy	   Department,	   Faculty	   of	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Veterinary	  Medicine,	  Utrecht	  University),	  which	  corresponds	  to	  200	  I.U.	  of	  ACTH,	  and	  this	  for	  4	  
consecutive	  days.	  	  
2.1.3. Urine	  sample	  collection	  
During	  the	  acclimatization	  period,	  urine	  samples	  were	  collected	  daily	  in	  the	  morning	  at	  8	  a.m.	  by	  
a	   veterinarian	   with	   the	   help	   of	   a	   probe	   (to	   prevent	   faecal	   contamination)	   and	   immediately	  
stored	  in	  the	  dark	  at	  -­‐80	  °C	  until	  analysis	  [15].	  During	  the	  ACTH	  treatment	  period,	  urine	  samples	  
were	  collected	  twice	  a	  day,	  one	  sample	  prior	  to	  IM	  injection	  of	  ACTH	  and	  a	  second	  4	  h	  (on	  the	  
first	   and	   second	   day)	   or	   6	   h	   (on	   the	   third	   and	   fourth	   day	   of	   ACTH	   administration)	   post-­‐
administration.	  Until	  four	  days	  after	  the	  termination	  of	  the	  ACTH	  treatment,	  daily	  urine	  samples	  
were	  collected	  in	  the	  morning	  at	  8	  a.m.	  (post-­‐treatment	  samples).	  
2.2. 	  Bovine	  urine	  collected	  at	  the	  farm	  
2.2.1. Test	  animals	  
Urine	  samples	  were	  collected	  from	  11	  clinically	  healthy	  Belgian	  Beef	  cows	  and	  31	  milking	  cows,	  
covering	  an	  age	  range	  between	  5	  months	  and	  7	  years.	  The	  animals	  were	  housed	  at	  four	  different	  
farms	  (CER,	  n=11;	  JPW,	  n=8;	  PDW,	  n=12;	  DD,	  n=11)	  located	  in	  Belgium,	  whereby	  the	  respective	  
breeders	   stated	   that	   cows	   had	   not	   been	   subjected	   to	   any	   drug	   treatment	   30	   days	   prior	   to	  
effective	  urine	  sampling.	  	  
2.2.2. Urine	  sample	  collection	  
Urine	   samples	   were	   collected	   during	   feeding	   (between	   8	   and	   11	   a.m.),	   thereby	   waiting	   for	  
spontaneous	   micturition,	   while	   carefully	   avoiding	   fecal	   contamination.	   These	   samples	   were	  
stored	  within	  2	  h	  at	  -­‐80	  °C	  in	  the	  dark,	  until	  analysis.	  	  
2.3. Bovine	  urine	  collected	  at	  slaughter	  
2.3.1. Test	  animals	  
Urine	   samples	   at	   the	   slaughterhouse	   (Flanders	   Meat	   Group,	   Zele)	   were	   collected	   from	   102	  
healthy	  bovines,	  originating	   from	  43	  different	   farms.	  The	   selected	  animals	   comprised	  64	   cows	  
and	   38	   bulls,	   all	   aging	   between	   10	  months	   and	   12	   years.	   Although	   no	   formal	   statement	  with	  
respect	   to	   a	   potential	   therapeutic	   pre-­‐treatment	   could	   be	   obtained	   for	   all	   farms,	   all	   animals	  
were	  considered	  healthy.	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2.3.2. Urine	  sample	  collection	  
Urine	  samples	  were	  randomly	  collected	  upon	  slaughter	  (between	  7	  and	  9	  a.m.),	  according	  to	  the	  
order	   of	   animal	   arrival.	   Urine	   was	   thereby	   obtained	   from	   the	   intact	   bladder	   using	   a	   sterile	  
needle	  and	  stored	  within	  3	  h	  at	  -­‐80	  °C	  in	  the	  dark,	  until	  analysis.	  	  
2.4. Chemicals	  and	  reagents	  
Analytical	   standards	   of	   prednisolone,	   prednisone,	   cortisone,	   cortisol,	   dihydrocortisone,	   and	  
methylprednisolone	   were	   purchased	   from	   Sigma-­‐Aldrich	   (St.	   Louis,	   USA).	   The	   derived	  
metabolites	   20α-­‐dihydroprednisolone	   and	   20β-­‐dihydroprednisolone	   were	   obtained	   from	  
Steraloids	   (Rhode	   Island,	   USA).	   Internal	   standards	   were	   cortisol-­‐d4	   (Sigma-­‐Aldrich)	   and	  
prednisolone-­‐d8	  (TRC,	  Toronto,	  Canada).	  Primary	  stock	  solutions	  were	  prepared	  in	  ethanol	  at	  a	  
concentration	  of	  200	  μg	  mL-­‐1	  and	  stored	  in	  dark	  glass	  bottles	  at	  -­‐20	  °C.	  Working	  solutions	  were	  
made	  in	  ethanol	  at	  concentration	  levels	  ranging	  from	  0.1	  to	  10	  μg	  mL-­‐1.	  
Reagents	   were	   of	   analytical	   grade	   when	   used	   for	   extraction	   purposes	   and	   of	   LC-­‐MS	   Optima	  
grade	   for	   UHPLC-­‐HRMS	   applications.	   These	   reagents	   were	   respectively	   obtained	   from	   VWR	  
International	  (Merck,	  Darmstadt,	  Germany)	  and	  Fisher	  Scientific	  (Loughborough,	  UK).	  Ultrapure	  
water	  was	  produced	  with	  an	  Arium	  611	  UV	  system	  (Sartorium	  Stedim	  Biotech,	  Aubagne,	  France).	  
2.5. Sample	  preparation	  
A	  detailed	  description	  of	  the	  analytical	  procedure	  for	  glucocorticoid	  extraction	  and	  purification	  
of	  bovine	  urine	  has	  been	  described	  in	  earlier	  work	  [15].	   In	  brief,	  a	  five-­‐mL	  aliquot	  of	  urine	  was	  
enriched	  with	  internal	  standards	  (cortisol-­‐d4	  and	  prednisolone-­‐d8)	  to	  reach	  concentration	  levels	  
of	   10	   μg	   L-­‐1.	   Next,	   a	   twofold	   liquid-­‐liquid	   extraction	   with	   pure	   tert-­‐butyl	   methylether	   was	  
performed.	   The	   organic	   phases	   were	   collected,	   pooled	   and	   dried	   under	   a	   gentle	   stream	   of	  
nitrogen	  at	  a	  temperature	  of	  50	  °C.	  The	  residue	  was	  dissolved	  in	  100	  μL	  of	  solvent,	  reflecting	  the	  
initial	  mobile	  phase	  conditions,	  and	  transferred	  to	  a	  vial	  for	  UHPLC-­‐HRMS	  analysis.	  	  
2.6. UHPLC-­‐Orbitrap-­‐MS	  
Analysis	  of	  the	  urine	  extracts	  was	  performed	  by	  UHPLC-­‐Orbitrap	  mass	  spectrometry,	  according	  
to	  De	  Clercq	  et	  al.	   (2013)	   [15].	   The	   chromatographic	   separation	  was	  achieved	  using	  an	  Accela	  
UHPLC	   system	   (Thermo	   Fisher	   Scientific,	   San	   José,	   USA),	   equipped	   with	   a	   Nucleodur	   Isis	   C18	  
column	  (1.8	  μm,	  100	  mm	  x	  2	  mm,	  Macherey-­‐Nagel,	  Düren,	  Germany).	  The	  binary	  solvent	  system	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consisted	   of	   0.1%	   aqueous	   formic	   acid	   and	   0.1%	   formic	   acid	   in	   acetonitrile	   (80/20,	   v/v)	   at	   a	  
constant	  flow	  rate	  of	  300	  µL	  min-­‐1.	  High-­‐resolution	  mass	  spectrometric	  analysis	  was	  performed	  
on	  an	  ExactiveTM	  single-­‐stage	  Orbitrap	  mass	  spectrometer	   (Thermo	  Fisher	  Scientific),	  equipped	  
with	   a	   heated	   electrospray	   ionization	   probe	   (HESI-­‐II),	   operating	   in	   polarity	   switching	   mode.	  
Instrument	   control	   and	   data	   processing	   were	   carried	   out	   by	   Xcalibur	   2.1	   software	   (Thermo	  
Fisher	   Scientific).	   This	   method	   has	   been	   validated	   according	   to	   Commission	   Decision	  
2002/657/EC	  with	  a	  CCα	  of	  0.09	  μg	  L-­‐1	  and	  CCβ	  0.37	  μg	  L-­‐1	  for	  prednisolone	  [16].	  
2.7. Quantitation	  and	  normalization	  
Absolute	   quantitation	   of	   the	   targeted	   glucocorticoids	   and	   related	   metabolites	   (i.e.	   cortisol,	  
cortisone,	   dihydrocortisone,	   prednisolone,	   prednisone,	   methylprednisolone,	   20α-­‐
dihydroprednisolone	   and	   20β-­‐dihydroprednisolone)	   was	   established	   by	   usage	   of	   eight-­‐point	  
matrix-­‐matched	   calibration	   curves.	   In	   this	   regard,	   urine	   collected	   before	   ACTH	   treatment,	  
containing	   no	   residues	   of	   prednisolone,	   prednisone	   and	   their	   metabolites,	   was	   used.	   For	  
cortisol,	   cortisone	   and	   dihydrocortisone,	   resulting	   calibration	   curves	   were	   adjusted	   for	   the	  
endogenously	   present	   concentration	   levels,	  which	  were	   determined	   as	   the	   average	   of	   5	   non-­‐
enriched	  urine	  samples.	  Adjusted	  calibration	  curve	  concentration	  levels	  ranged	  from	  0.50	  to	  75	  
μg	  L-­‐1	  for	  the	  various	  targeted	  metabolites	  and	  were	  constructed	  by	  means	  of	  peak	  area	  ratios	  
(i.e.	   ratio	   of	   analyte	   to	   internal	   standard	   peak	   area).	   Untargeted	   metabolites	   were	   relatively	  
quantified	  by	  using	  the	  peak	  abundances.	  	  
Normalization	  of	  the	  determined	  relative	  and	  absolute	  quantitative	  values	  was	  performed	  based	  
on	   the	  creatinine	  content,	  which	  allowed	   to	  account	   for	  variation	   that	  may	  occur	   in	   individual	  
excretion	  patterns	  and	  daily	  fluid	  consumption	  [17].	  
2.8. Statistical	  analysis	  
Equal	  of	  variances	  was	  verified	  by	  Levene’s	  Test	  and	  normality	  of	   the	  various	  data	  sets	  by	   the	  
Kolmogorov-­‐Smirnov	   method	   whereas	   statistical	   differences	   were	   evaluated	   using	   one-­‐way	  
ANOVA	   and	   post-­‐hoc	   Tukey’s	   multiple	   comparisons	   test	   (p-­‐value	   ≤	   0.05).	   The	   significance	   of	  
correlation	   between	   two	   variables	   was	   tested	   using	   Pearson’s	   correlation	   coefficients	   and	  
multiple	  linear	  regression	  analysis	  (p-­‐value	  ≤	  0.05)	  (SPSSTM	  statistics	  21).	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2.9. Metabolic	  fingerprinting	  of	  urine	  samples	  
First	   the	  metabolic	   fingerprints	  were	   established	   for	   the	   acquired	   full-­‐scan	   data	   files	   by	   using	  
SieveTM	   2.1	   software	   (Thermo	   Fisher	   Scientific,	   San	   José,	   USA),	   thereby	   aiming	   at	   the	  
characterization	  of	   the	   detected	  metabolite	   ions	   in	   terms	  of	   signal	   abundance,	  m/z-­‐value	   and	  
retention	  time.	  Metabolite	  screening	  was	  separately	  performed	  for	  the	  positively	  and	  negatively	  
charged	  ions,	  on	  the	  basis	  of	  optimized	  parameter	  settings,	  including	  an	  m/z	  scan	  range	  of	  150	  -­‐	  
650	  Da,	   an	  m/z	  width	  of	  10	  ppm,	  a	   retention	   time	   range	   from	  1.0	  –	  9.5	  min,	   a	  peak	   intensity	  
threshold	  of	  50,000	  arbitrary	  units,	  a	  maximum	  peak	  width	  of	  0.5	  min,	  and	  a	  maximum	  number	  
of	   30,000	   frames.	   In	   addition,	   peak	   alignment	   was	   applied	   whereby	   corrections	   for	   inherent	  
chromatographic	   variability	   during	   analysis	   were	   made.	   The	   generated	   data	   matrix	   of	   ion	  
abundances	   was	   normalized	   by	   the	   signal	   intensities	   of	   two	   deuterium-­‐labeled	   internal	  
standards	  i.e.	  cortisol-­‐d4	  and	  prednisolone-­‐d8,	  which	  were	  supplemented	  prior	  to	  extraction	  and	  
by	  creatinine	  content	  [17].	  	  
Subsequently,	  multivariate	  data	  analysis	  was	  performed	  using	  SIMCATM	  13	  software	   (Umetrics,	  
Malmö,	   Sweden),	   thereby	   aiming	   to	   reveal	   differences	   in	   the	   urinary	   profiles	   that	   are	   due	   to	  
different	   stress	   conditions.	   For	   this	   purpose,	   the	   normalized	   data	   matrix	   was	   used	   and	   pre-­‐
processed	   by	   logarithmic	   transformation	   and	   center	   scaling	   in	   order	   to	   induce	   normality	   and	  
standardize	   the	   range	   of	   metabolite	   ions,	   respectively.	   First	   orthogonal	   partial	   least	   squares	  
discriminant	   analysis	   (OPLS-­‐DA)	   was	   applied	   to	   model	   the	   three	   different	   stress	   conditions,	  
reflected	  by	  the	  urinary	  metabolic	  fingerprints	  of	  the	  samples	  collected	  from	  the	  farm	  (FARM),	  
at	   slaughter	   (SLAUGHTER)	   and	   during	   ACTH	   treatment	   (ACTH).	   Validation	   of	   the	   constructed	  
models	  was	  performed	  by	  CV-­‐ANOVA	   (p-­‐value	  <	  0.05),	  permutation	   testing	   (n	  =	  150),	   and	   the	  
three	  model	   characteristics	   R2(X),	   R2(Y),	   and	  Q2(Y),	   calculated	  by	   7-­‐fold	   cross-­‐validation	  with	   a	  
Q2(Y)	  of	  0.5	  indicating	  good	  model	  predictability	  [18].	  Based	  on	  the	  validated	  models,	  a	  selection	  
of	   relevant	   metabolites,	   significantly	   contributing	   towards	   the	   discrimination	   of	   the	   various	  
stress	   conditions,	   was	   performed.	   To	   reveal	   the	   significance	   of	   the	   various	   metabolite	   ions	  
during	   the	   different	   stress	   conditions,	   three	   different	   plots	   were	   created.	   First,	   the	   Variable	  
Importance	  in	  Projection	  (VIP)	  plot	  was	  created	  to	  characterize	  the	  discriminating	  power	  of	  each	  
metabolite	   [19].	   In	   addition,	   S-­‐plots	   were	   constructed,	   in	   which	   the	   relationship	   between	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covariance	  and	   correlation	  among	   the	  OPLS-­‐DA	   results	  was	   visualized.	   Finally,	   an	  extension	  of	  
the	   S-­‐plot,	   the	   shared	   and	   unique	   structure	   (SUS)-­‐plot,	   was	   generated.	   By	   combining	   the	  
selected	  ions	  in	  each	  of	  the	  used	  tools,	  the	  discriminative	  ions	  were	  determined’	  	  
Next,	  principal	  component	  analysis	  (PCA)	  and	  hierarchical	  cluster	  analysis	  (HCA)	  (single	  linkage)	  
were	   performed	   based	   on	   the	   metabolite	   profile	   to	   reveal	   similarities	   among	   samples	   and	  
clustering	  according	  to	  the	  concerned	  stress	  conditions.	  	  
Subsequently,	   to	   investigate	   the	   role	   of	   steroidal	   compounds	   in	   this	   process,	   the	   retained	  
metabolites	   were	   screened	   against	   an	   in-­‐house	   created	   database,	   which	   comprised	   the	  
elemental	   composition	   of	   1693	   steroidal	   compounds	   (based	   on	   the	   11th	   catalogue	   edition	   of	  
steroids	   from	  Steraloids	   Inc.).	   For	   this	   purpose,	   the	   software	  programme	  ToxID	  2.1.2	   (Thermo	  
Fisher	  Scientific)	  was	  used,	   thereby	  setting	  a	  minimum	  peak	   intensity	  of	  1000	  and	  a	  maximum	  
mass	  deviation	  of	  5	  ppm.	  
3. Results	  
3.1. 	  Natural	  glucocorticoids	  in	  bovine	  urine	  
3.1.1.	  Supposedly	  non-­‐stressed	  cattle	  
To	   evaluate	   the	   presence	   of	   prednisolone	   residues	   in	   random	   farm	   animals	   under	   normal	  
housing	  and	  assumed	  stress-­‐free	  conditions,	  urine	  samples	  of	  animals	  from	  four	  different	  farms	  
were	  analysed.	  The	  urinary	  cortisol	  levels	  ranged	  from	  0.349	  to	  5.81	  μg	  L-­‐1	  (average	  1.80	  μg	  L-­‐1),	  
cortisone	  levels	  from	  0.437	  to	  8.37	  μg	  L-­‐1	  (average	  2.49	  μg	  L-­‐1)	  and	  dihydrocortisone	  levels	  from	  
0.176	  to	  10.31	  μg	  L-­‐1	  (average	  2.83	  μg	  L-­‐1).	  The	  observed	  concentration	  levels	  were	  independent	  
of	  the	  farm	  (p-­‐value	  >	  0.05)	  (Figure	  4.2.).	  	  
The	   urinary	   concentration	   levels	   of	   the	   animals	   of	   the	   ACTH	   trial	   during	   the	   acclimatization	  
period	   (i.e.	   no	   stress),	   ranged	   for	   cortisol	   from	   0.411	   to	   4.26	   μg	   L-­‐1	   (average	   1.79	   μg	   L-­‐1),	   for	  
cortisone	  from	  0.472	  to	  5.53	  μg	  L-­‐1	  (average	  2.68	  μg	  L-­‐1)	  and	  for	  dihydrocortisone	  from	  0.222	  to	  
9.36	  μg	  L-­‐1	  (average	  2.27	  μg	  L-­‐1)	  (Figure	  4.2.).	  No	  significant	  differences	  (p-­‐value	  >	  0.05)	  in	  urinary	  
natural	  glucocorticoid	  concentrations	  could	  be	  detected	  between	  the	  two	  groups	  of	  supposedly	  




Figure	   4.2.	   Box	   plot	   representing	   cortisol	   (A),	   cortisone	   (B)	   and	   dihydrocortisone	   (C)	   concentrations	   in	  
bovine	   urine	   collected	   at	   the	   farm,	   before	   ACTH	   administration	   (pre-­‐ACTH),	   at	   the	   slaughterhouse	   and	  
during	  ACTH	  administration	  (4h	  and	  6h	  post-­‐ACTH	  administration).	  
3.1.2.	  Naturally	  stressed	  cattle	  
All	  urine	  samples	  collected	  at	  the	  slaughterhouse	  contained	  cortisol	  (average	  18.9	  μg	  L-­‐1,	  range	  
0.368	  –	  155	  μg	  L-­‐1),	  cortisone	  (average	  21.8	  μg	  L-­‐1,	  range	  0.593	  –	  177	  μg	  L-­‐1)	  and	  dihydrocortisone	  
(average	   30.5	   μg	   L-­‐1,	   range	   1.28	   –	   218	   μg	   L-­‐1).	   Hereby,	   it	   was	   verified	   that	   the	   cortisol	   and	  
cortisone	  levels	  were	  independent	  of	  animal	  age	  or	  farm	  of	  origin	  (p-­‐value	  >	  0.05).	  Although	  the	  
male	   animals	   had	   lower	   mean	   cortisol	   levels	   than	   the	   females,	   11.9	   μg	   L-­‐1	   and	   23.1	   μg	   L-­‐1,	  
respectively,	  this	  could	  not	  be	  linked	  to	  age	  (p-­‐value	  >	  0.05)	  (Table	  4.1.).	  	  
Table	  4.1.	  Urinary	  concentrations	  (mean	  ±	  SD)	  of	  cortisol	  and	  prednisolone	  in	  cattle	  at	  slaughter,	  with	  
indication	  of	  gender	  and	  age.	  	  
Age	  
(Year)	  
Bulls	   Cows	  
N°	   Cortisol	   N°	   Prednisolone	   N°	   Cortisol	   N°	   Prednisolone	  
0	   5	   1.83	  ±	  0.948	   0	   NF	   0	   NF	   0	   NF	  
1	   24	   12.9	  ±	  14.3	   4	   0.654	  ±	  1.06	   2	   78.8	  ±	  109	   2	   1.22	  ±	  1.59	  
2	   5	   21.1	  ±	  11.7	   3	   0.157	  ±	  0.0633	   3	   24.1	  ±	  28.4	   3	   0.228	  ±	  0.0227	  
3	   1	   14.1	   0	   NF	   7	   19.7	  ±	  23.9	   2	   0.623	  ±	  0.408	  
4	   0	   NF	   0	   NF	   16	   17.5	  ±	  17.7	   4	   0.281	  ±	  0.104	  
5	   1	   3.50	   0	   NF	   14	   23.6	  ±	  30.1	   8	   0.379	  ±	  0.284	  
6	   0	   NF	   0	   NF	   7	   24.4	  ±	  13.9	   4	   0.178	  ±	  0.0614	  
7	   0	   NF	   0	   NF	   7	   20.7	  ±	  17.1	   3	   0.264	  ±	  0.136	  
8	   0	   NF	   0	   NF	   3	   12.1	  ±	  10.2	   1	   0.1422	  
9	   0	   NF	   0	   NF	   4	   34.8	  ±	  26.9	   1	   0.109	  
10	   0	   NF	   0	   NF	   0	   NF	   0	   NF	  
11	   2	   NF	   0	   NF	   1	   11.7	   1	   NF	  






3.1.3.	  ACTH	  treatment	  
During	   ACTH	   treatment,	   the	   urinary	   cortisol,	   cortisone	   and	   dihydrocortisone	   levels	   increased	  
significantly	   (p-­‐value	   ≤	   0.05)	   after	   4	   h	   (Day+1	   and	  Day+2)	   to	   values	   ranging	   from	   respectively	  
38.2	  to	  368	  μg	  L-­‐1,	  41.5	  to	  342	  μg	  L-­‐1and	  37.3	  to	  515	  μg	  L-­‐1.	  After	  6	  h	  (Day+3	  and	  Day+4),	  urinary	  
concentration	   levels	   were	   still	   significantly	   higher	   (p-­‐value	   ≤	   0.05)	   compared	   to	   the	  
acclimatization	  period,	  although	  less	  pronounced	  than	  after	  4	  h	  (Figure	  4.2.).	  The	  concentrations	  
of	   cortisol,	   cortisone	   and	   dihydrocortisone	   24	   h	   post-­‐treatment	   were	   similar	   to	   those	   before	  
tetracosactide	  hexaacetate	  treatment.	  	  
3.2.	  Synthetic	  glucocorticoids	  in	  bovine	  urine	  
3.2.1.	  Supposedly	  non-­‐stressed	  cattle	  
Prednisolone,	  prednisone,	  20α-­‐dihydroprednisolone	  and	  20β-­‐dihydroprednisolone	  could	  not	  be	  
detected	   in	   any	   of	   the	   urine	   samples	   that	   were	   collected	   at	   the	   farm	   or	   during	   the	  
acclimatization	  period	  prior	  to	  the	  tetracosactide	  hexaacetate	  treatment.	  
3.2.2.	  Naturally	  stressed	  cattle	  
In	   36	   of	   the	   102	   examined	   urine	   samples	   collected	   at	   slaughter,	   prednisolone	   residues	   were	  
detected	   at	   a	   level	   higher	   than	   the	   CCα,	  whereby	   the	   average	   concentration	  was	   0.391	   μg	   L-­‐1	  
(range	  0.900	  –	  2.35	  μg	  L-­‐1)	  (Figure	  4.3.).	  Moreover,	  for	  some	  of	  the	  remaining	  urine	  samples	  (33	  
out	   of	   102	   analysed	   samples),	   prednisolone	   was	   detected,	   but	   at	   very	   low	   signal	   intensities,	  
corresponding	  to	  calculated	  concentration	  levels	  below	  the	  CCα.	  These	  samples	  were	  therefore	  
not	  considered	  as	  prednisolone	  positive.	  Only	  19.4%	  of	  the	  steers	  were	  positive	  for	  prednisolone	  
compared	  to	  45.3%	  of	   the	  cows,	  although	  no	  significant	  differences	   (p-­‐value	  >	  0.05)	   in	  urinary	  
prednisolone	  concentration	  could	  be	  detected.	  
In	   59.8%	   of	   the	   analysed	   samples	   (61/102)	   prednisone	   could	   be	   detected	   at	   an	   average	  
concentration	   of	   1.49	   μg	   L-­‐1,	   ranging	   from	   0.137	   to	   10.0	   μg	   L-­‐1.	   The	   metabolites	   20α-­‐
dihydroprednisolone	   and	  20β-­‐dihydroprednisolone	   could	  not	   be	  detected	   in	   any	  urine	   sample	  
(Figure	  4.3.).	  
The	  95%	  confidence	  interval	  for	  the	  proportion	  of	  prednisolone	  positive	  urine	  samples	  (i.e.	  the	  





Figure	  4.3.	  Box	  plot	  representing	  prednisolone	  (A),	  prednisone	  (B),	  20α-­‐dihydroprednisolone	  (C)	  and	  20β-­‐
dihydroprednisolone	   concentrations	   in	   bovine	   urine	   collected	   at	   the	   farm,	   before	   ACTH	   administration	  
(pre-­‐ACTH),	  at	  the	  slaughterhouse	  and	  during	  ACTH	  administration	  (4h	  and	  6h	  post-­‐ACTH	  administration).	  	  
3.2.3.	  ACTH	  treatment	  
Prednisolone,	   prednisone,	   20α-­‐dihydroprednisolone	   and	   20β-­‐dihydroprednisolone	   were	  
consistently	  detected	  in	  urine	  4	  h	  after	  IM	  injections	  (Day+1	  and	  Day+2).	  Prednisolone	  levels	  in	  
urine	   collected	  6	  h	  after	   injection	  were	   significantly	   lower	   (p-­‐value	  ≤	  0.05)	   (Day+3	  and	  Day+4)	  
compared	  to	  4	  h,	  although	  still	  detectable	  (Figure	  4.3.).	  	  
3.3.	  Correlation	  between	  natural	  and	  synthetic	  glucocorticoids	  during	  stress	  
The	  correlation	  between	  cortisol,	  prednisolone	  and	  both	  their	  metabolites	  was	  calculated	  using	  
Pearson’s	  correlation.	  In	  general	  a	  Pearson’s	  correlation	  higher	  than	  0.7	  is	  considered	  as	  strong,	  
while	  0.3	  to	  0.7	  is	  considered	  as	  weak	  and	  0	  to	  0.3	  implies	  no	  or	  little	  correlation	  [8].	  Our	  results	  
indicated	   a	   strong	   correlation	   between	   cortisol,	   cortisone	   and	   dihydrocortisone	   and	   between	  
prednisolone,	   prednisone,	   20α-­‐dihydroprednisolone	   and	   20β-­‐dihydroprednisolone	   upon	   ACTH	  
treatment	  and	  after	  slaughter	  (Table	  4.2.).	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Table	   4.2.	   Pearson’s	   correlation	   between	   the	   urinary	   levels	   of	   cortisol,	   cortisone,	   dihydrocortisone,	  
prednisolone,	   prednisone,	   20α-­‐dihydroprednisolone	   (20α-­‐DHP)	   and	   20β-­‐dihydroprednisolone	   (20β-­‐DHP)	  
of	  urine	  samples	  collected	  upon	  ACTH	  treatment	  and	  slaughter.	  
3.4.	  Metabolic	  fingerprinting	  of	  urine	  samples	  
In	   this	   study,	   it	   was	   aimed	   to	   correctly	   classify	   animals	   according	   to	   the	   imposed	   stress	  
condition,	  thereby	  solely	  using	  the	  urinary	  metabolite	  fingerprints.	  For	  this	  purpose,	  a	  metabolic	  
fingerprinting	   approach	   was	   carried	   out,	   whereby	   ions	   were	   detected	   and	   characterized	   by	  
SieveTM.	  The	  established	  fingerprints	  comprised	  16269	  positively	  and	  11366	  negatively	  charged	  
monoisotopic	  ions	  (13C	  isotope	  ion	  species	  were	  excluded).	  The	  associated	  data	  matrices,	  mainly	  
including	  the	   ions’	  abundances,	  were	  then	  normalized	  by	  usage	  of	  the	  signal	   intensities	  of	  two	  
deuterium-­‐labeled	   internal	   standards	   i.e.	   cortisol-­‐d4	   and	   prednisolone-­‐d8,	   which	   were	  
supplemented	  prior	  to	  extraction	  and	  by	  creatinine	  abundances,	  which	  reflect	  urinary	  densities.	  	  
With	   regard	   to	   the	   subsequent	  multivariate	  data	  analysis,	   it	  was	   in	   first	   instance	  envisaged	   to	  
reveal	  any	  clustering	  among	  urine	  samples	  that	  relates	  to	  the	  stress	  condition.	  More	  specifically,	  
supervised	   OPLS-­‐DA	  modeling	   was	   applied	   to	   highlight	  metabolite	   ions	   with	   a	   leading	   role	   in	  
class	   discrimination.	   For	   this	   purpose,	   quantitative	   data	   (peak	   abundances)	   of	   129	   randomly	  
selected	  urine	  samples,	  which	  were	  collected	  at	  the	  farm	  (n	  =	  40,	  FARM),	  the	  slaughterhouse	  (n	  
=	  67,	  SLAUGHTER),	  or	  during	  ACTH	  treatment	  (n	  =	  22,	  ACTH).	  With	  respect	  to	  the	  latter,	  it	  should	  
Correlations	  
	   Cortisone	   Dihydrocortisone	   Prednisolone	   Prednisone	   20α-­‐DHP	   20β-­‐DHP	  
A.	  ACTH	  treatment	  
Cortisol	   0.960**	   0.931**	   0.695**	   0.566**	   0.508**	   0.693**	  
Dihydrocortisone	   0.915**	   1	   0.751**	   0.656**	   0.599**	   0.746**	  
Prednisolone	   0.671**	   	   1	   0.820**	   0.850**	   0.853**	  
Prednisone	   0.568**	   	   	   1	   0.919**	   0.828**	  
20α-­‐DHP	   0.485**	   	   	   	   1	   0.855**	  
20β-­‐DHP	   0.657**	   	   	   	   	   1	  
B.	  Urine	  samples	  collected	  at	  slaughter	  
Cortisol	   0.983**	   0.440**	   0.521**	   0.676**	   0.124	   0.151	  
Dihydrocortisone	   0.386*	   1	   -­‐0.212	   0.450**	   0.142	   0.180	  
Prednisolone	   0.537**	   	   1	   0.717**	   0.726**	   0.763**	  
Prednisone	   0.642**	   	   	   1	   0.801**	   0.829**	  
20α-­‐DHP	   0.201	   	   	   	   1	   	  
20β-­‐DHP	   0.183	   	   	   	   	   1	  
**	  Correlation	  is	  significant	  at	  the	  0.01	  level	  (2-­‐tailed).	  
*	  Correlation	  is	  significant	  at	  the	  0.05	  level	  (2-­‐tailed).	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be	  noted	  that	  only	  urine	  samples,	  collected	  at	  4	  h	  post-­‐ACTH	  administration,	  were	  used	   in	  the	  
ACTH-­‐group.	  These	  data	  were	  center-­‐scaled	  and	  logarithmically	  transformed.	  Two-­‐class	  OPLS-­‐DA	  
models	  were	  constructed	  with	  FARM	  as	  the	  common	  reference	  class,	   i.e.	   the	  models	  aimed	  at	  
discriminating	   between	   FARM	   and	   SLAUGHTER	   (i),	   and	   between	   FARM	   and	   ACTH	   (ii)	   (Figure	  
4.4.A).	  	  
	  
Figure	  4.4.	  OPLS-­‐DA	  model	  output	  to	  discriminate	  between	  the	  metabolic	  fingerprints	  of	  FARM	  and	  ACTH	  
(A).	  Selection	  of	  relevant	  discriminating	  metabolite	  ions	  was	  performed	  for	  each	  of	  the	  validated	  two-­‐class	  
models	   by	   using	  VIP-­‐scores	   (B),	   S-­‐plot	   (C)	   and	   SUS-­‐plot	   (D).	   Shaded	   areas	   represent	   the	   ions	   that	  were	  
considered	  relevant	  and	  retained.	  	  
Quality	  of	   the	   constructed	  models	  was	  evaluated	  by	  CV-­‐ANOVA	   (p-­‐value	  ≤	   0.05),	   permutation	  
testing,	   and	   the	   model	   characteristics	   R2(X),	   R2(Y),	   and	   Q2(Y).	   With	   respect	   to	   the	   model	  
characteristics,	   the	   following	  values	  were	  obtained	   (considering	  either	   the	  positive	  or	  negative	  
ions,	  respectively):	  (i)	  0.513,	  0.997	  and	  0.984,	  (ii)	  0.463,	  0.985	  and	  0.975;	  and	  (i)	  0.571,	  0.978	  and	  
0.965,	   (ii)	   0.425,	   0.988	   and	   0.983.	   Based	   on	   the	   various	   validation	   parameters,	   overall	   good	  
model	   predictability	   was	   concluded	   [20].	   Selection	   of	   discriminating	   metabolites	   was	   in	   first	  
instance	  based	  on	  the	  VIP	  score	  (Figure	  4.4.B),	  which	  describes	  the	  relative	  importance	  of	  each	  
metabolite	   ion	   towards	   the	   OPLS-­‐DA	   based	   class	   separation.	   Generally,	   a	   VIP-­‐score	   >	   1	   is	  
associated	  with	  a	  significantly	  discriminating	  ion	  [19].	  However,	  given	  the	  large	  number	  of	  ions,	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enclosed	   by	   the	   metabolite	   fingerprints,	   a	   more	   rigorous	   threshold	   of	   2	   was	   adopted	   in	   this	  
study.	   The	   second	   selection	   step	   focused	   on	   both	   the	   contribution	   and	   reliability	   of	   each	  
metabolite	  ion	  towards	  the	  predictive	  model	  component	  and	  is	  visualized	  by	  the	  S-­‐plot	  [21][22].	  
In	   this	   context,	   metabolite	   ions	   with	   cut-­‐off	   values	   of	   |p1|	   ≥	   0.03	   and	   |p(corr)|	   ≥	   0.75	   were	  
considered	  as	  relevant	  and	  reliably	  differentiating	  metabolites	  [22]	  (Figure	  4.4.C).	  An	  extension	  
of	   the	   S-­‐plot	   is	   the	   SUS-­‐plot	   (Figure	   4.4.D).	   This	   plot	   was	   applied	   to	   combine	   the	   correlation	  
p(corr)	  of	   the	  predictive	  component	   from	  each	  model,	   i.e.	   (i)	  and	   (ii),	   compared	   to	  a	  common	  
control,	  i.e.	  FARM.	  In	  this	  plot,	  the	  position	  of	  an	  ion	  relative	  to	  the	  diagonal	  is	  indicative	  for	  its	  
importance	   towards	   each	  of	   the	   various	   classes,	  which	   is	   interesting	   to	   find	   shared	   as	  well	   as	  
unique	  metabolite	  ions	  [23].	  The	  ions	  with	  a	  unique	  contribution	  towards	  model	  (i)	  or	  model	  (ii)	  
are	   located	  close	   to	  either	   the	  X-­‐	  or	  Y-­‐axis,	   respectively,	  when	  |p(corr)|	  ≥	  0.75.	   In	  contrast,	   ions	  
with	   shared	   effects	   are	   situated	   close	   to	   the	   plot’s	   diagonal.	   As	   such,	   six	   areas	   in	   terms	   of	  
metabolite	   abundance	   can	   be	   defined	   within	   the	   SUS-­‐plot	   (exemplified	   in	   Figure	   4.4.D):	   (1)	  
increased	   for	   ACTH	   only,	   (2)	   decreased	   for	   ACTH	   only,	   (3)	   increased	   for	   SLAUGHTER	   only,	   (4)	  
decreased	  for	  SLAUGHTER	  only,	  (5)	  increased	  for	  both	  SLAUGHTER	  and	  ACTH,	  (6)	  decreased	  for	  
both	  SLAUGHTER	  and	  ACTH.	  This	  revealed	  a	  total	  of	  169	  metabolites	  (Supplementary	  table	  4.1.),	  
which	  were	   thus	   assigned	  discriminative	   value	   towards	   the	   imposed	   stress	   conditions	   as	   their	  
urinary	   concentration	   levels	   were	   significantly	   altered	   in	   response	   to	   stress	   compared	   to	   the	  
assumed	  stress-­‐free	  conditions	  at	  the	  farm.	  
PCA-­‐modeling	   indicated	   the	   potential	   of	   the	   presented	   profiling	   strategy.	   Hereby	   quantitative	  
data	   regarding	   the	   169	   differentiating	  metabolites	  were	   gathered	   for	   urine	   samples	   collected	  
before	  the	  first	  ACTH	  treatment	  (ACTH	  pre-­‐treatment)	  and	  the	  three	  different	  stress	  conditions	  
(FARM,	  ACTH	  and	  SLAUGHTER).	  Good	  performance	  of	  the	  PCA-­‐models,	  separately	  generated	  for	  
the	   positively	   and	   negatively	   charged	   ions,	   was	   indicated	   by	   the	   validation	   parameters	   R2(X),	  
representing	  the	  explained	  variation	  in	  X	  and	  Q2(X),	  which	  represents	  the	  goodness	  of	  prediction	  
calculated	   by	   7-­‐fold	   cross	   validation.	   The	   obtained	   values	   were,	   for	   positive	   and	   negative	  
ionization	  respectively,	  0.752	  and	  0.635,	  and	  0.754	  and	  0.669.	  This	  PCA-­‐modeling	  revealed	  four	  




Figure	   4.5.	   Principal	   component	   analysis	   score	   plot	   for	   urine	   samples	   and	   their	   inherent	   metabolite	  
fingerprints,	   representing	   different	   stress	   conditions.	   (A).	   Dendrogram	   enclosing	   information	   about	   the	  
similarities	  of	  samples	  (i.e.	  clusters)	  (B).	  	  
This	  HCA	  clustering	  projects	  sample	  similarities	  on	  a	  two-­‐dimensional	  diagram	  (i.e.	  dendrogram)	  
and	   allowed	   to	   conclude	   that	   the	   observed	   clustering	   strongly	   related	   to	   the	   imposed	   stress	  
condition.	   In	   addition,	   the	   accuracy	   of	   linking	   unknown	   samples	   to	   their	   true	   stress	   condition	  
was	  evaluated	  by	  means	  of	  a	  misclassification	  matrix.	  With	  this	  approach,	  a	  matrix	  is	  generated	  
by	   which	   a	   comparison	   can	   be	   made	   between	   the	   true	   and	   predicted	   class	   [24],	   i.e.	   stress	  
condition.	  An	  independent	  test	  set,	  consisting	  of	  5	  urinary	  fingerprints	  for	  each	  stress	  condition,	  
was	  correctly	  classified,	  whereby	  the	  true	  class	  equals	  the	  predicted	  class	  and	  a	  100%	  prediction	  
score	  was	  achieved.	  	  
To	   visualize	   the	   effects	   of	   the	   various	   stress	   conditions	   on	   the	   revealed	   discriminating	  
metabolites,	  heat	  map	  plots	  were	  constructed	  (Figure	  4.6.),	  whereby	  coloration	  was	  performed	  




Figure	  4.6.	  Heat	  map	  representing	  the	  169	  differentiating	  ions	  (rows)	  grouped	  by	  sample	  type	  (columns).	  
The	  ion	  intensities	  of	  each	  ion	  were	  averaged	  along	  samples	  and	  then	  log	  transformed.	  Shades	  of	  red	  and	  
yellow	  represent	  elevation	  and	  decrease	  of	  a	  metabolite,	  respectively,	  relative	  to	  the	  median	  metabolite	  
level.	  Right	  are	  the	  number	  of	  differentiating	  ions	  indicated	  that	  are	  significantly	  different	  (p	  <	  0.05)	  with	  
at	  least	  one	  group	  of	  sample	  types	  and	  the	  class	  specificity	  of	  the	  different	  ions	  for	  the	  positively	  (A)	  and	  
negatively	  charged	  ions	  (B).	  
These	  heat	  maps	  showed	  that	  38	  ions	  were	  upregulated	  and	  35	  ions	  were	  downregulated	  when	  
animals	   were	   under	   stress,	   independently	   of	   the	   origin	   of	   stress.	   Besides	   these	   ‘shared’	  
metabolite	  ions,	  96	  metabolites	  were	  assigned	  significant	  importance	  towards	  separation	  of	  the	  
various	  stress	  origins.	  More	  specifically,	  45	  ions	  were	  found	  upregulated	  during	  ACTH	  treatment	  
compared	  to	  the	  samples	  collected	  at	  the	  farm	  or	  upon	  slaughter.	  After	  evaluating	  the	  Pearson’s	  
correlation,	  11	  of	  these	  45	  ions	  were	  positively	  correlated	  (p-­‐value	  ≤	  0.05)	  with	  urinary	  cortisol	  
and/or	   prednisolone	   concentration	   levels	   (Supplementary	   table	   4.1.,	   in	   bold).	   For	   the	   urine	  
samples	   collected	   at	   slaughter,	   in	   total	   17	   ions	   were	   upregulated	   and	   10	   ions	   were	  
downregulated	   compared	   to	   the	   control	   samples	   collected	   at	   the	   farm	   or	   during	   ACTH	  
treatment.	   Moreover,	   no	   correlations	   (p-­‐value	   >	   0.05)	   with	   urinary	   cortisol	   or	   prednisolone	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levels	  were	  noticed	  for	  these	  particular	  metabolites.	  	  
Subsequently,	   the	   169	   discriminating	  metabolites	   were	   screened	   against	   an	   in-­‐house	   created	  
steroidal	  database,	  by	  using	   the	   software	  programme	  ToxID	  2.1.2.	  Three	  compounds	  could	  be	  
tentatively	   identified	   based	   on	   the	   presence	   of	   two	   diagnostic	   ions:	   the	   (M+H)+	   ion	   and	   the	  
corresponding	   13C	   isotopic	   ion	   (Table	   4.3.).	   However,	   unequivocal	   identification	   could	   not	   be	  
guaranteed	   because	   of	   the	   presence	   of	   isomers,	  which	  may	   lead	   to	   the	   detection	   of	  multiple	  
chromatographic	  peaks.	  Taking	  these	   findings	   into	  account,	  ToxID	  enabled	  a	   first	  screening	   for	  
relevant	  steroidal	  compounds.	  	  
Table	  4.3.	  Steroidal	  compounds	  detected	  in	  the	  urine	  samples.	  The	  software	  program	  ToxID	  was	  applied	  
for	  screening	  of	  steroidal	  compounds	  for	  which	  a	  minimum	  peak	  intensity	  of	  1000	  and	  a	  maximum	  mass	  
deviation	  of	  5	  ppm	  were	  used.	  	  
4. Discussion	  
In	  the	  present	  study,	  bovine	  urinary	  levels	  of	  cortisol,	  prednisolone	  and	  their	  main	  metabolites	  
were	  evaluated	  in	  cattle	  under	  three	  different	  conditions:	  supposedly	  non-­‐stressed	  (at	  the	  farm),	  
natural	  stress	  (at	  the	  slaughterhouse)	  and	  pharmacologically-­‐induced	  increase	  of	  cortisol	  (upon	  
administration	   of	   tetracosactide	   hexaacetate).	   The	   baseline	   cortisol,	   cortisone	   and	  
dihydrocortisone	   levels	   in	   non-­‐stressed	   animals	   and	   prior	   to	   first	   tetracosactide	   hexaacetate	  
treatment	   were	   similar.	   In	   both	   situations	   neither	   prednisolone	   nor	   its	   metabolites	   could	   be	  
detected	  in	  any	  urine	  sample,	  which	  is	  in	  line	  with	  the	  results	  of	  the	  survey	  study	  performed	  by	  















Influence	   Tentative	  name	  
C27H44	   8.54	   369.35131	   -­‐0.536	   +	   29.2	   SLAUGHTER+	   2,4-­‐cholestadiene	  
	   	   	   	   	   	   	   3,5-­‐cholestadiene	  
	   	   	   	   	   	   	   4,6-­‐cholestadiene	  
C33H38O4	   8.40	   499.27923	   0.93	   +	   35.7	   ACTH-­‐	   5-­‐androsten-­‐3β,	  
16β-­‐diol	  dibenzoate	  
	   	   	   	   	   	   	   5-­‐androsten-­‐3β,	  
17β-­‐diol	  dibenzoate	  
C33H40O4	   8.79	   501.29437	   1.42	   +	   35.7	   ACTH+	   5α-­‐androstan-­‐3α,	  
17β-­‐diol	  dibenzoate	  
	   	   	   	   	   	   	   5α-­‐androstan-­‐3β,	  
17α	  -­‐diol	  dibenzoate	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The	  way	   livestock	   is	  handled,	  transported,	  restrained	  and	  slaughtered	  can	   induce	  stress,	  which	  
results	   in	   elevated	   cortisol,	   cortisone	   and	   dihydrocortisone	   concentrations	   [25].	   In	   our	   study,	  
only	   in	  5	  urine	   samples,	   cortisol	   levels	  above	  70	  μg	   L-­‐1	  occurred.	  This	   could	  be	  an	   indicator	  of	  
rough	  handling	  [26].	  On	  the	  other	  hand,	  cortisol	   levels	  close	  to	  the	  baseline	   indicated	  that	  the	  
procedure	  was	   either	   non-­‐stressful	   or	   very	   fast,	   since	   it	   takes	   10	   to	   20	  min	   to	   reach	   elevated	  
cortisol	  levels	  [27].	  Besides,	  it	  is	  important	  for	  meat	  quality	  that	  animals	  are	  not	  stressed	  prior	  to	  
slaughter	  to	  avoid	  unnecessary	  depletion	  of	  muscle	  glycogen	  reserves.	  In	  a	  non-­‐stressed	  animal,	  
the	  glycogen	  content	  of	  the	  muscle	  is	  high.	  After	  slaughter,	  glycogen	  is	  converted	  into	  lactic	  acid,	  
which	   contributes	   towards	   meat	   that	   is	   tasteful,	   tender	   and	   of	   overall	   good	   quality.	   Stress	  
before	  or	  during	  slaughter	  decreases	  glycogen	  content	  and	  reduces	  meat	  quality	  [28][29].	  	  
During	   ACTH	   treatment,	   cortisol	   levels	   where	   slightly	   higher	   than	   at	   slaughter	   but	   a	   large	  
variation	   in	   the	   results	   was	   noticed.	   These	   results	   confirm	   the	   knowledge	   concerning	  
interindividual	  differences	  in	  behavioural	  and	  HPA	  axis	  responses	  observed	  in	  cattle	  [30][31][32].	  
This	   variation	  has	  also	  been	  described	  by	  Bertocchi	  et	  al.	   (2013)	   [7]	  and	  was	  explained	  by	   the	  
relationship	  between	  the	  circadian	  rhythm	  and	  cortisol	  excretion	  in	  bovine	  animals.	  
A	  significant	  positive	  correlation	  between	  the	  concentration	  of	  cortisol	  and	  that	  of	  prednisolone	  
in	   urine	   was	   observed.	   In	   case	   of	   stress,	   either	   at	   slaughter	   or	   pharmacologically-­‐induced	  
increase	   of	   cortisol,	   cortisol	   levels	   were	   elevated	   and	   the	   prevalence	   of	   prednisolone	   was	  
increased,	  with	  prednisolone	  levels	  ranging	  from	  0.120	  to	  6.45	  μg	  L-­‐1.	  The	  urine	  sample	  with	  the	  
highest	  prednisolone	  concentration	  also	  showed	  the	  highest	  cortisol	   level	  of	  all	  collected	  urine	  
samples	  (i.e.	  368	  μg	  L-­‐1).	  The	  European	  Union	  Reference	  Laboratories	  [33]	  proposed	  a	  regulatory	  
threshold	   for	   prednisolone	   based	   on	   the	  mean	   of	   100	   urine	   samples	   ±	   3	   times	   the	   standard	  
deviation	  [13].	  Based	  on	  their	  results	  and	  previously	  published	  data,	  a	  threshold	  level	  of	  5	  μg	  L-­‐1	  
was	  suggested.	  Only	  one	  urine	  sample	  collected	  during	  ACTH	  treatment,	  demonstrated	  a	  urinary	  
prednisolone	   concentration	   (i.e.	   6.45	   μg	   L-­‐1)	   above	   the	   cited	   threshold	   level	   of	   5	   μg	   L-­‐1.	   No	  
significant	   differences	   in	   prednisolone	   concentration	   were	   observed	   between	   the	   two	   stress	  
conditions.	  The	  prednisolone	  concentrations	  found	  in	  this	  study,	  were	  in	  line	  with	  Pompa	  et	  al.	  
(2011)	   [10],	   where	   prednisolone	   concentrations	   up	   to	   4.08	   μg	   L-­‐1	   were	   observed	   upon	  
tetracosactide	  hexaacetate	  injection	  in	  bovines.	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An	   interesting	   finding	   of	   this	   study	   relates	   to	   the	   fact	   that	   none	   of	   the	   bovines	   excreted	  
prednisolone,	  prior	  to	  ACTH	  administration,	  while	  all	  urine	  samples	  contained	  prednisolone	  after	  
the	   first	   administration	   of	   ACTH.	   This	   can	   only	   be	   explained	   by	   assuming	   that	   prednisolone	   is	  
endogenously	  produced	  in	  the	  animal.	  Bertocchi	  et	  al.	  (2013)	  [7]	  showed	  that	  a	  bovine,	  testing	  
negative	   for	  prednisolone	  at	   the	   farm,	  became	  positive	  after	   transport	   to	   the	   slaughterhouse.	  
Indeed,	   it	   has	   been	   demonstrated	   by	   de	   Rijke	   et	   al.	   (2014)	   [13],	   using	   in	   vitro	   incubation	  
experiments,	   that	   endogenous	   cortisol	   and	   cortisone	  may	   be	   converted	   by	   liver	   enzymes	   and	  
through	  faecal	  bacterial	  contamination	  to,	  respectively,	  prednisolone	  and	  prednisone.	  Previous	  
studies	   on	   the	   effects	   of	   microbial	   urine	   contamination	   already	   revealed	   the	   enzymatic	  
transformation	  of	  endogenous	  testosterone	  into	  boldenone	  through	  Δ1-­‐dehydrogenation	  [35].	  A	  
similar	   reaction	   was	   proposed	   for	   cortisol	   and	   cortisone	   since	   both	   enclose	   a	   3-­‐oxo-­‐4-­‐ene	  
structure,	   which	   is	   a	   potential	   target	   for	   enzymatic	   1,2-­‐dehydrogenation,	   resulting	   in	   the	  
formation	  of	  prednisolone	  and	  prednisone,	  respectively	  [10][36].	  Therefore,	  urine	  sampling	  and	  
storage	  was	  strictly	  executed	  as	  recommended	  by	  De	  Clercq	  et	  al.	  (2013)	  [15]	  and	  particular	  care	  
was	  taken	  to	  exclude	  the	  possible	  generation	  of	  prednisolone	  due	  to	  cross-­‐contamination	  with	  
faecal	  or	  other	  bacteria	  [13][35][36],	  which	  renders	  ex	  vivo	  neoformation	  of	  prednisolone	  due	  to	  
microbial	  contamination	  very	  unlikely.	  
Next	   to	  determining	   the	  prevalence	  of	   prednisolone,	   a	  main	   goal	   of	   this	  work	  was	   to	   link	   the	  
urinary	   metabolic	   fingerprint	   of	   bovines	   to	   the	   different	   degrees	   of	   stress	   experienced.	  
Multivariate	  data	  analysis	   indicated	  that	  urine	  samples	  could	   indeed	  be	  clustered	  according	  to	  
the	   metabolite	   fingerprints	   of	   the	   newly	   discovered	   differentiating	   metabolites	   (n	   =	   169),	  
reflecting	   the	   imposed	   stress	   condition.	   As	   such,	   the	   metabolic	   fingerprinting	   and	   associated	  
modelling	   represents	   a	   powerful	   tool	   to	   classify	   an	   unknown	   bovine	   urine	   sample,	   offering	  
information	  about	  the	  animal’s	  condition	  and	  handling.	  This	  is	  particularly	  interesting	  as	  it	  may	  
indicate	  the	  origin	  of	  prednisolone	  in	  allegedly	  non-­‐compliant	  urine	  samples.	  	  
Multivariate	   statistics	   revealed	   169	   metabolite	   ions	   with	   discriminative	   value	   towards	   the	  
imposed	  stress	  conditions.	  These	  were	  screened	  against	  an	  in-­‐house	  created	  steroidal	  database.	  
This	  revealed	  that	  3	  of	  them	  were	  putative	  steroidal	  compounds..	  Although	  this	  number	  of	  hits	  
was	  considered	  low,	  it	  is	  in	  line	  with	  Gronowska	  et	  al.	  (2009)	  [37]	  who	  also	  reported	  that	  major	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fluctuations	   in	   the	   urinary	   steroid	   profile	   under	   influence	   of	   stressogenic	   factors	   and	  
physiological	  activity	  are	  unlikely.	  	  
Eleven	   ions,	   which	   were	   considered	   discriminative	   for	   the	   ACTH	   treatment	   versus	   the	   other	  
conditions,	  showed	  a	  positive	  correlation	  with	  urinary	  cortisol	  and/or	  prednisolone	  levels.	  Since	  
it	   is	   known	   that	  ACTH	   treatment	   stimulates	   the	  HPA-­‐axis	   and	   results	   in	  higher	  urinary	   cortisol	  
and	  possibly	  also	  prednisolone	  levels,	  these	  11	  ions	  were	  linked	  to	  either	  the	  HPA-­‐axis	  response	  
during	   stress	   or	   the	   associated	   metabolism	   of	   cortisol	   and	   prednisolone.	   Using	   our	   in-­‐house	  
created	  database,	  one	  of	  these	  ions	  was	  tentatively	  identified	  as	  5α-­‐androstan-­‐3(α)(β),17(β)(α)-­‐
diol	  dibenzoate	  (C33H40O4),	  which	  is	  a	  compound	  that	  has	  been	  linked	  to	  stress	  before	  [38].	  	  
Seventeen	  ions,	  which	  were	  solely	  excreted	  during	  slaughter,	  could	  not	  be	  correlated	  to	  cortisol	  
or	  prednisolone.	  This	  can	  be	  explained	  since	  stress	  may	  affect	  the	  adrenal	  gland	  in	  two	  ways.	  On	  
the	  one	  hand,	  the	  short-­‐term	  stress	  response	  at	  the	  adrenal	  medulla	  causes	  the	  hypothalamus	  
to	  activate	  the	  adrenal	  medulla	  via	  nerve	  impulses.	  This	  sympathomedullary	  pathway	  results	  in	  
secretion	   of	   epinephrine	   and	   norepinephrine	   [39].	   On	   the	   other	   hand,	   the	   long-­‐term	   stress	  
response	   at	   the	   adrenal	   cortex	   causes	   the	   hypothalamus	   to	   activate	   the	   adrenal	   cortex	   via	  
hormonal	   signals	   i.e.	   CRH	   and	   ACTH.	   This	   results	   in	   secretion	   of	   mineralocorticoids	   and	   the	  
glucocorticoid	   cortisol	   [40][41].	   These	   17	  up	   and	  down	   regulated	   ions	   indicated	   that	   probably	  
other	  mechanisms	  beside	  the	  HPA-­‐axis	  are	   involved	   in	   the	  stress	  response.	  Further	  research	   is	  
however	   warranted	   to	   elucidate	   the	   identity	   of	   these	   ions	   as	   a	   requisite	   to	   determine	   their	  
relation	  to	  stress.	  	  
5. Conclusion	  
In	  the	  present	  study,	  bovine	  urinary	  levels	  of	  cortisol,	  prednisolone	  and	  their	  main	  metabolites	  
were	   evaluated	  under	   different	   stress	   conditions.	   This	   revealed	   that	   urine	  of	   supposedly	   non-­‐
stressed	   cattle	   (at	   the	   farm)	   contained	   no	   prednisolone.	   In	   case	   of	   stress,	   i.e.	   slaughter	   and	  
pharmacologically-­‐induced	  increase	  of	  cortisol,	  cortisol	  levels	  were	  elevated	  and	  the	  prevalence	  
of	  prednisolone	  increased.	  As	  a	  consequence,	  a	  significant	  positive	  correlation	  between	  cortisol	  
and	  prednisolone	  in	  bovine	  urine	  was	  demonstrated.	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At	  slaughter,	  about	  60%	  of	   the	  collected	  urine	  samples	  contained	  prednisolone,	  whereas	  after	  
IM	  tetracosactide	  hexaacetate	  treatment	  prednisolone	  was	  detected	  in	  all	  samples.	  However,	  no	  
significant	   difference	   in	   prednisolone	   concentrations	   could	   be	   noticed.	   Of	   all	   prednisolone-­‐
positive	  urine	  samples,	  only	  one	  showed	  prednisolone	  levels	  above	  the	  threshold	  level	  of	  5	  μg	  L-­‐1	  
i.e.	   6.45	  μg	   L-­‐1.	   This	   indicates	   the	   relevance	  of	   the	   threshold	   level	   suggested	  by	   the	   European	  
Reference	  Laboratories.	  	  
After	   supervised	  modeling,	  169	  metabolites	  were	  assigned	  discriminating	  power	   towards	   class	  
separation	  (i.e.	  stress	  condition).	  For	  17	  differentiating	  ions	  that	  were	  upregulated	  in	  urine	  upon	  
slaughter,	  no	  correlation	  with	  urinary	  cortisol	  levels	  could	  be	  noticed.	  This	  indicates	  that	  besides	  
the	  HPA-­‐axis,	  also	  other	  processes	  such	  as	  the	  sympathomedullary	  pathway	  are	  involved	  in	  the	  
metabolic	  urinary	  pattern	  during	  stress.	  For	  11	  metabolites	  upregulated	  during	  ACTH	  treatment,	  
a	   positive	   correlation	   with	   urinary	   cortisol	   and/or	   prednisolone	   concentrations	   was	   revealed,	  
linking	   ACTH	   treatment	   to	   the	   HPA-­‐axis.	   The	   specific	   origin	   of	   these	   ions	   needs	   to	   be	   further	  
explored	  since	  it	  could	  give	  a	  better	  insight	  in	  the	  stress	  response	  of	  cattle	  and	  the	  endogenous	  
formation	  of	  prednisolone.	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Supplementary	   table	   4.1.	   The	   169	   differentiating	   ions	   with	   a	   unique	   positive	   (+)	   or	   negative	   (-­‐)	  
contribution	  during	  ACTH	   treatment,	   at	   slaughter,	  or	  during	  both.	   This	   last	   is	   indicated	  as	   ‘shared’.	   The	  
order	   of	   appearance	   in	   the	   heat	   map	   was	   respected.	   Ions	   with	   positive	   correlation	   to	   urinary	   cortisol	  


















1157	   442.3315	   3.52	   Shared	  +	   2015	   531.3099	   7.69	   Shared	  +	  
1	   432.3461	   1.19	   Shared	  +	   6470	   477.2102	   3.24	   Shared	  +	  
620	   428.3155	   1.58	   Shared	  +	   16056	   571.3131	   7.85	   Shared	  +	  
101	   430.3315	   1.51	   Shared	  +	   601	   405.1927	   6.02	   Shared	  +	  
1156	   430.3314	   3.52	   Shared	  +	   5205	   265.0182	   6.79	   ACTH	  +	  
8	   432.3466	   1.61	   Shared	  +	   13447	   164.0019	   1.35	   ACTH	  +	  
1398	   432.3470	   3.10	   Shared	  +	   15592	   224.0116	   2.84	   ACTH	  +	  
2803	   448.3420	   2.67	   Shared	  +	   8609	   259.0610	   4.36	   ACTH	  +	  
226	   430.3314	   1.85	   Shared	  +	   1020	   309.0443	   5.73	   ACTH	  +	  
67	   430.3315	   2.14	   Shared	  +	   7523	   203.0178	   7.36	   ACTH	  +	  
75	   432.3463	   1.88	   Shared	  +	   9949	   266.0687	   2.29	   ACTH	  +	  
142	   448.3420	   1.97	   Shared	  +	   2363	   467.1917	   3.05	   ACTH	  +	  
2081	   462.3208	   1.72	   Shared	  +	   14005	   437.2312	   3.67	   ACTH	  +	  
9928	   494.2941	   6.07	   Shared	  +	   7707	   461.1613	   7.83	   ACTH	  +	  
466	   430.3313	   3.26	   Shared	  +	   2313	   458.1859	   7.80	   ACTH	  +	  
12	   430.3312	   2.41	   Shared	  +	   3288	   473.1796	   5.81	   SLAUGHTER	  +	  
1689	   494.2939	   5.80	   Shared	  +	   9352	   511.1595	   8.01	   SLAUGHTER	  +	  
391	   448.3412	   1.53	   Shared	  +	   16589	   503.2527	   7.97	   SLAUGHTER	  +	  
525	   428.3157	   3.14	   Shared	  +	   18650	   533.3350	   8.02	   SLAUGHTER	  +	  
425	   446.3258	   2.19	   Shared	  +	   12964	   349.2608	   7.97	   SLAUGHTER	  +	  
1209	   446.3258	   1.57	   Shared	  +	   15724	   491.0522	   8.33	   Shared	  -­‐	  
384	   474.3213	   3.15	   Shared	  +	   9963	   293.7551	   7.66	   Shared	  -­‐	  
1882	   428.3161	   2.84	   Shared	  +	   10640	   293.7582	   7.66	   Shared	  -­‐	  
90	   416.3156	   2.32	   Shared	  +	   9968	   489.0555	   8.22	   Shared	  -­‐	  
342	   430.3316	   2.70	   Shared	  +	   7521	   296.7019	   7.66	   Shared	  -­‐	  
5	   432.3463	   2.22	   Shared	  +	   5127	   555.5416	   7.68	   Shared	  -­‐	  
3484	   578.3818	   8.47	   Shared	  +	   7114	   296.7104	   7.66	   Shared	  -­‐	  
350	   446.3266	   1.82	   Shared	  +	   6887	   296.7053	   7.66	   Shared	  -­‐	  
141	   446.3258	   1.31	   Shared	  +	   3268	   555.5349	   7.66	   Shared	  -­‐	  
73	   302.2146	   7.71	   Shared	  +	   8969	   290.3419	   7.69	   Shared	  -­‐	  
274	   428.3160	   2.55	   Shared	  +	   4509	   296.7137	   7.66	   Shared	  -­‐	  
692	   430.3315	   2.95	   Shared	  +	   2747	   587.5783	   7.66	   Shared	  -­‐	  
4051	   618.9231	   8.85	   Shared	  +	   18861	   261.0448	   5.14	   Shared	  -­‐	  
69	   446.3259	   1.01	   Shared	  +	   4136	   296.7171	   7.66	   Shared	  -­‐	  
10692	   410.3991	   8.87	   ACTH	  +	   5486	   525.1207	   7.60	   Shared	  -­‐	  
23479	   167.0562	   8.41	   ACTH	  +	   5163	   296.7419	   7.66	   Shared	  -­‐	  
29028	   230.8931	   7.66	   ACTH	  +	   2770	   587.5709	   7.66	   Shared	  -­‐	  
12555	   219.1490	   7.26	   ACTH	  +	   3866	   296.7205	   7.66	   Shared	  -­‐	  
18823	   187.0391	   2.20	   ACTH	  +	   7843	   296.7378	   7.69	   Shared	  -­‐	  
19570	   302.0573	   2.31	   ACTH	  +	   4144	   296.7341	   7.66	   Shared	  -­‐	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27340	   182.0754	   1.58	   ACTH	  +	   3578	   296.7272	   7.66	   Shared	  -­‐	  
18137	   560.4460	   8.25	   ACTH	  +	   3947	   296.7303	   7.66	   Shared	  -­‐	  
17229	   509.3836	   5.94	   ACTH	  +	   17242	   356.2568	   8.55	   ACTH	  -­‐	  
11539	   293.2221	   1.54	   ACTH	  +	   2696	   367.1075	   3.55	   ACTH	  -­‐	  
14184	   491.3730	   5.94	   ACTH	  +	   8614	   293.0495	   9.51	   SLAUGHTER	  -­‐	  
12324	   210.0745	   8.14	   ACTH	  +	   9089	   242.9663	   5.99	   SLAUGHTER	  -­‐	  
2211	   225.1595	   9.04	   ACTH	  +	   2372	   611.2275	   7.92	   SLAUGHTER	  -­‐	  
18743	   409.2840	   9.28	   ACTH	  +	   254	   285.1134	   5.78	   SLAUGHTER	  -­‐	  
23248	   501.2944	   8.79	   ACTH	  +	   	   	   	   	  
13108	   384.2528	   5.19	   ACTH	  +	   	   	   	   	  
29815	   501.2576	   8.47	   ACTH	  +	   	   	   	   	  
12206	   643.4955	   7.72	   ACTH	  +	   	   	   	   	  
733	   278.2475	   2.61	   ACTH	  +	   	   	   	   	  
6830	   353.1494	   1.28	   ACTH	  +	   	   	   	   	  
14804	   463.3051	   2.14	   ACTH	  +	   	   	   	   	  
11410	   181.0722	   7.44	   ACTH	  +	   	   	   	   	  
6276	   181.0719	   4.80	   ACTH	  +	   	   	   	   	  
9211	   181.0721	   6.51	   ACTH	  +	   	   	   	   	  
6907	   181.0721	   4.47	   ACTH	  +	   	   	   	   	  
8709	   181.0722	   5.94	   ACTH	  +	   	   	   	   	  
9144	   181.0721	   6.22	   ACTH	  +	   	   	   	   	  
7281	   181.0720	   5.07	   ACTH	  +	   	   	   	   	  
8395	   181.0721	   5.60	   ACTH	  +	   	   	   	   	  
20811	   539.3337	   8.62	   ACTH	  +	   	   	   	   	  
5710	   181.0720	   3.51	   ACTH	  +	   	   	   	   	  
7943	   562.2725	   8.72	   ACTH	  +	   	   	   	   	  
27581	   562.2731	   8.46	   ACTH	  +	   	   	   	   	  
5437	   589.3636	   2.62	   SLAUGHTER	  +	   	   	   	   	  
2877	   414.3364	   9.28	   SLAUGHTER	  +	   	   	   	   	  
18572	   474.2867	   4.41	   SLAUGHTER	  +	   	   	   	   	  
7490	   570.3511	   3.61	   SLAUGHTER	  +	   	   	   	   	  
1955	   607.3668	   8.17	   SLAUGHTER	  +	   	   	   	   	  
17444	   290.1783	   3.71	   SLAUGHTER	  +	   	   	   	   	  
15531	   637.3314	   7.76	   SLAUGHTER	  +	   	   	   	   	  
6277	   369.3513	   8.55	   SLAUGHTER	  +	   	   	   	   	  
8422	   428.3156	   9.30	   SLAUGHTER	  +	   	   	   	   	  
1354	   379.3052	   4.79	   SLAUGHTER	  +	   	   	   	   	  
900	   635.3965	   8.48	   SLAUGHTER	  +	   	   	   	   	  
276	   473.3373	   7.77	   SLAUGHTER	  +	   	   	   	   	  
28541	   281.4962	   7.71	   Shared	  -­‐	   	   	   	   	  
24146	   292.9006	   7.69	   Shared	  -­‐	   	   	   	   	  
26891	   281.5191	   7.69	   Shared	  -­‐	   	   	   	   	  
26604	   281.5028	   7.69	   Shared	  -­‐	   	   	   	   	  
26935	   281.5154	   7.69	   Shared	  -­‐	   	   	   	   	  
25336	   281.5125	   7.69	   Shared	  -­‐	   	   	   	   	  
22806	   281.5062	   7.69	   Shared	  -­‐	   	   	   	   	  
24941	   281.5091	   7.69	   Shared	  -­‐	   	   	   	   	  
11126	   349.1185	   1.13	   Shared	  -­‐	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9556	   271.7227	   7.69	   Shared	  -­‐	   	   	   	   	  
15114	   309.0867	   4.80	   Shared	  -­‐	   	   	   	   	  
7327	   274.3594	   7.69	   Shared	  -­‐	   	   	   	   	  
2157	   485.3000	   8.39	   Shared	  -­‐	   	   	   	   	  
21850	   499.2792	   8.40	   ACTH	  -­‐	   	   	   	   	  
24859	   420.0221	   1.11	   ACTH	  -­‐	   	   	   	   	  
18169	   259.1117	   7.70	   ACTH	  -­‐	   	   	   	   	  
10086	   279.8425	   7.73	   ACTH	  -­‐	   	   	   	   	  
13236	   279.8741	   7.73	   ACTH	  -­‐	   	   	   	   	  
18437	   279.8394	   7.70	   ACTH	  -­‐	   	   	   	   	  
24544	   259.0524	   7.69	   ACTH	  -­‐	   	   	   	   	  
12350	   275.4802	   7.67	   ACTH	  -­‐	   	   	   	   	  
11955	   275.4772	   7.72	   ACTH	  -­‐	   	   	   	   	  
29338	   274.3875	   7.72	   ACTH	  -­‐	   	   	   	   	  
17934	   405.5032	   8.47	   ACTH	  -­‐	   	   	   	   	  
24581	   274.3847	   7.69	   ACTH	  -­‐	   	   	   	   	  
9764	   279.8364	   7.72	   ACTH	  -­‐	   	   	   	   	  
17690	   405.4390	   8.49	   ACTH	  -­‐	   	   	   	   	  
10438	   259.1215	   7.73	   ACTH	  -­‐	   	   	   	   	  
11681	   259.1241	   7.73	   ACTH	  -­‐	   	   	   	   	  
14500	   405.4498	   8.49	   ACTH	  -­‐	   	   	   	   	  
21416	   405.4451	   8.48	   ACTH	  -­‐	   	   	   	   	  
19989	   264.0320	   7.69	   ACTH	  -­‐	   	   	   	   	  
3627	   264.1046	   7.67	   ACTH	  -­‐	   	   	   	   	  
3494	   264.1016	   7.72	   ACTH	  -­‐	   	   	   	   	  
3407	   264.0986	   7.72	   ACTH	  -­‐	   	   	   	   	  
4418	   274.4437	   7.67	   ACTH	  -­‐	   	   	   	   	  
26802	   239.1137	   1.04	   SLAUGHTER	  -­‐	   	   	   	   	  
20739	   255.1373	   8.32	   SLAUGHTER	  -­‐	   	   	   	   	  
5990	   344.1488	   8.28	   SLAUGHTER	  -­‐	   	   	   	   	  
14092	   367.3023	   5.96	   SLAUGHTER	  -­‐	   	   	   	   	  
25034	   233.1511	   6.31	   SLAUGHTER	  -­‐	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Abstract	  
In	  Europe,	  synthetic	  corticosteroids,	  such	  as	  prednisolone,	  are	  not	  allowed	  as	  growth-­‐promoting	  
agents	  in	  animal	  breeding.	  In	  the	  past	  few	  years,	  however,	  a	  higher	  prevalence	  of	  non-­‐compliant	  
urine	  samples	  for	  prednisolone	  without	  any	  direct	  evidence	  of	  unauthorized	  use	  was	  reported.	  
Since	  the	  urinary	  prednisolone	  concentrations	  after	  growth-­‐promoting	  administration	  are	  below	  
the	   threshold	   suggested	   by	   the	   EURL	   (5	   µg	   L-­‐1),	   the	   use	   of	   urinary	   prednisolone/cortisol	  
concentration	   ratios	   and	   the	   analysis	  of	   20β-­‐dihydroprednisolone	  were	   suggested	  as	  potential	  
screening	   tools	   to	  confirm	  the	  origin	  of	   the	  urinary	  prednisolone.	  To	  evaluate	   the	  applicability	  
and	   validity	   of	   these	   suggested	   screening	   tools,	   the	   pharmacokinetic	   and	   urinary	   excretion	  
profiles	   of	   prednisolone,	   prednisone,	   20α-­‐dihydroprednisolone	   and	   20β-­‐dihydroprednisolone	  
were	   recorded	   in	   cattle,	   subjected	   to	   an	   oral	   and	   intramuscular	   growth-­‐promoting	   and	  
therapeutic	  prednisolone	  treatment,	  and	  to	  pharmacologically-­‐induced	  increase	  of	  cortisol.	  The	  
latter	   was	   induced	   by	   administration	   of	   tetracosactide	   hexaacetate,	   a	   synthetic	   analogue	   of	  
adrenocorticotropic	   hormone	   (ACTH).	   In	   addition,	   the	  metabolism	  of	   cortisol	  was	   investigated	  
by	  profiling	  natural	  urinary	  glucocorticoid	  metabolites	  during	   the	  different	   treatments.	   To	   this	  
extent,	  bovine	  urine	  and	  plasma	  samples	  were	  collected	  and	  analysed	  using	  UHPLC	  coupled	  to	  
full-­‐scan	  high-­‐resolution	  Orbitrap-­‐MS	  and	  UHPLC-­‐MS/MS,	   respectively.	  Hereby,	  already	  15	  min	  
after	   treatment,	   20β-­‐dihydroprednisolone	   surfaced	   as	   the	  main	  metabolite	   of	   prednisolone	   in	  
plasma.	   No	   significant	   differences	   were	   however	   noticed	   between	   the	   urinary	   20β-­‐
dihydroprednisolone	  levels	  following	  growth-­‐promoting	  prednisolone	  administration	  and	  at	  6	  h	  
upon	  ACTH	   treatment.	  Determining	  an	  appropriate	   threshold	  value	  was	  hard	  due	   to	   the	   large	  
variation	   in	   data	   and	   overlay	   between	   endogenous	   and	   exogenous	   concentrations.	   The	  
prednisolone/cortisol	   ratios	   indicated	   a	   clear	   trend	   during	   the	   different	   treatments,	   however,	  
further	  evaluation	  of	  ratios	  obtained	  in	  the	  field	  remains	  necessary.	  	  
	  




Synthetic	  glucocorticoids	  are	  extensively	  employed	  in	  cattle	  for	  therapeutic	  purposes	  because	  of	  
their	   well-­‐recognized	   anti-­‐inflammatory	   and	   immunosuppressive	   properties.	   Among	   these	  
glucocorticoids,	   the	   most	   commonly	   used	   are	   dexamethasone,	   prednisolone,	   and	  
methylprednisolone.	   Prednisolone	   is	   used	   in	   cattle,	   including	  dairy	   cows,	   for	   the	   treatment	  of	  
allergic	   dermatitis,	   otitis,	   pruritus	   and	   musculoskeletal	   inflammation	   [1][2].	   Apart	   from	   the	  
therapeutic	   applications,	   synthetic	   glucocorticoids	   may	   also	   be	   unauthorized	   administered	   to	  
promote	  the	  growth	  of	  veal	  calves,	  finishing	  bulls	  and	  cows	  at	  the	  end	  of	  their	  production	  cycle	  
[3].	   Indeed,	   glucocorticoids	   tend	   to	   increase	   live	  weight	  gain,	   improve	   feed	   intake,	   reduce	   the	  
feed	   conversion	   ratio,	   reduce	  nitrogen	   retention,	   increase	   the	   fat	   content	   and	  promote	  water	  
retention	  [4].	  As	  such,	  growth-­‐promoting	  effects	  have	  been	  demonstrated	  for	  beef	  cattle	  after	  
oral	   administration	   of	   prednisolone	   acetate	   (15	   -­‐	   30	   mg	   per	   animal/day)	   for	   30-­‐35	   days	   [5].	  
Because	   of	   the	   strong	   pharmacological	   activity,	   the	   residues	   of	  most	   synthetic	   corticosteroids	  
might	   impose	   a	   risk	   for	   food	   safety.	   Therefore,	   to	   protect	   consumer’s	   health,	   the	   use	   of	  
synthetic	   glucocorticoids	   in	   livestock	   is	   restricted	   to	   therapeutic	   applications	   only	   and	  
administration	   by	   a	   licensed	   veterinarian	   is	   requisite	   [6].	   Moreover,	   appropriate	   withdrawal	  
times	   have	   been	   defined	   for	   glucocorticoid	   treatment	   in	   order	   to	   comply	   with	   the	  maximum	  
residue	  limits	  (MRLs),	  established	  for	  bovine	  edible	  tissues	  [6][7].	  	  
In	  the	  past	  few	  years,	  the	  European	  Commission	  reported	  a	  higher	  prevalence	  of	  non-­‐compliant	  
urine	  samples	  for	  prednisolone	  [8][9][10][11]	  without	  any	  direct	  evidence	  of	  unauthorized	  use.	  
To	   account	   for	   potential	   endogenous	   prednisolone,	   the	   European	   Reference	   Laboratories	  
suggested	  a	   threshold	   level	   for	  prednisolone	   in	  bovine	  urine	  of	   5	  μg	   L-­‐1	   [12][13].	   In	   literature,	  
however,	  the	  use	  of	  prednisolone/cortisol	  urinary	  concentration	  ratios	  and	  the	  analysis	  of	  20β-­‐
dihydroprednisolone	   were	   suggested	   as	   potential	   screening	   tools	   to	   confirm	   the	   exogenous	  
origin	  of	  prednisolone	  [14][15][16][17],	  but	  these	  have	  not	  been	  confirmed	  or	  validated	  yet.	  To	  
evaluate	  the	  applicability	  and	  validity	  of	  these	  suggested	  screening	  tools,	  the	  pharmacokinetics	  
and	  urinary	  excretion	  profiles	  of	  prednisolone,	  prednisone,	  20α-­‐dihydroprednisolone	  and	  20β-­‐
dihydroprednisolone	   were	   assessed	   during	   both	   growth-­‐promoting	   and	   therapeutic	  
prednisolone	  treatment	  (Figure	  5.1.).	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Figure	   5.1.	   Biotransformation	   pathway	   of	   prednisolone	   into	   prednisone,	   20α-­‐dihydroprednisolone	   and	  
20β-­‐dihydroprednisolone	  by	  hydroxysteroid	  dehydrogenases	  (HSD).	  
Recently,	  the	  presence	  of	  prednisolone	  was	  confirmed	  in	  bovine	  urine	  after	  stress	  induction	  with	  
a	   synthetic	   analogue	   of	   ACTH,	   i.e.	   tetracosactide	   hexaacetate	   (Chapter	   V).	   Therefore,	   the	  
pharmacokinetics	   and	   urinary	   excretion	   of	   prednisolone	   and	   its	   metabolites	   during	  
pharmacologically-­‐induced	   increase	  of	   cortisol	  were	  considered	  as	  well	   in	   this	   study.	  Only	   few	  
studies	  have	  been	  devoted	  to	  correlate	  endogenous	  (e.g.	  cortisol)	  and	  exogenous	  administered	  
(e.g.	   dexamethasone,	   prednisolone)	   glucocorticoids	   as	   a	   means	   to	   estimate	   the	   degree	   of	  
glucocorticoid	  resistance	  or	  supersensitivity	  [18][19].	  Here,	  the	  overall	  cortisol	  secretion	  during	  
both	   growth-­‐promoting	   and	   therapeutic	   prednisolone	   administrations	   and	   during	   HPA-­‐axis	  
stimulation	   was	   assessed,	   by	   profiling	   the	   urinary	   natural	   glucocorticoid	   metabolites,	   i.e.	  
cortisone,	   dihydrocortisone,	   allotetrahydrocortisol,	   urocortisol,	   tetrahydrocortisone,	  
corticosterone,	  deoxycorticosterone,	  α-­‐cortolone	  and	  6β-­‐hydroxycortisol.	  
	  










2. Material	  and	  methods	  
2.1. Animals	  
In	   this	   study	   twelve	   clinically	   healthy	   cows	   of	   a	   mixed	   breed	   were	   housed	   under	   controlled	  
experimental	   conditions	   at	   the	   animal	   facilities	   of	   Centre	   d’Economie	   Rurale	   (CER,	   Marloie,	  
Belgium).	  These	  cows	  were	  2	  to	  6	  years	  of	  age	  and	  had	  a	  body	  weight	  (b.w.)	  between	  370	  and	  
600	  kg.	  They	  were	   fed	  a	  commercial	  diet,	  with	  ad	   libitum	  access	   to	  water	  and	  hay.	  During	  the	  
entire	  study,	  animals	  were	  kept	  in	  three	  separate	  groups	  (4	  animals	  per	  group),	  all	  housed	  in	  a	  
half	   covered	   pen.	   Prior	   to	   the	   in	   vivo	   study,	   an	   initial	   acclimatization	   period	   of	   10	   days	   was	  
foreseen,	  allowing	  adaptation	  to	  the	  specific	  environmental	  and	  feeding	  conditions.	  This	  in	  vivo	  
study	  was	  approved	  by	  CER’s	  Ethical	  Committee	  (CE/Sante/ET/004).	  	  	  
2.2. Experimental	  protocol	  
After	  the	  acclimatization	  period	  (Blank),	  all	  animals	  were	  subjected	  to	  a	  similar	  oral	  (per	  os,	  PO)	  
and	  intramuscular	  (IM)	  prednisolone	  treatment	  sequence.	  First,	  a	  growth-­‐promoting	  treatment	  
(long-­‐term,	  40	  mg	  per	  cow	  a	  day,	  PO	  and	  IM)	  was	  applied,	  which	  was	  followed	  by	  a	  therapeutic	  
treatment	  (short-­‐term,	  0.5	  mg	  kg-­‐1	  bodyweight	  a	  day,	  PO	  and	  IM)	  (Figure	  5.2.A).	  	  
	  
Figure	   5.2.	   Schematic	   representation	   of	   the	   in	   vivo	   study,	   indicating	   the	   various	   experimental	   sections	  
with	   oral	   (PO)	   and	   intramuscular	   (IM)	   prednisolone	   administrations	   (A)	   and	   the	   treatment	   with	  
tetracosactide	  hexaacetate,	  a	  synthetic	  analogue	  of	  ACTH	  (B).	  The	  wash-­‐out	  periods	  are	  indicated	  in	  blue.	  
This	  experimental	  procedure	  was	  implemented	  to	  each	  animal	  (n	  =	  12).	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Then,	  a	  washout	  period	  of	  11	  weeks	  was	   incorporated,	  after	  which	  tetracosactide	  hexaacetate	  
was	   administered	   intramuscularly	   for	   4	   days	   to	   increase	   cortisol	   (Figure	   5.2.B).	   All	   types	   of	  
administration	  were	  executed	  at	  8	  a.m.	  	  
2.2.1. Phase	  I:	  Prednisolone	  treatment	  
The	  growth-­‐promoting	   treatment	   started	  with	  30	  consecutive	  days	  of	  PO	  administration	  of	  40	  
mg	  day-­‐1	   of	   prednisolone	   in	   gelulles	   (prednisolone,	   Fagron)	   (Day+1	   till	   Day+30),	   followed	  by	   a	  
washout	   period	   of	   10	   days.	   Next,	   IM	   injections	   of	   40	   mg	   day-­‐1	   of	   Solu-­‐Delta-­‐Cortef®	  
(prednisolone	  sodium	  succinate,	  Zoetis,	  Belgium)	  were	  given	  for	  30	  consecutive	  days	  (Day+41	  till	  
Day+70).	   Before	   the	   start	   of	   the	   therapeutic	   prednisolone	   treatment,	   a	  washout	   period	   of	   35	  
days	  was	  foreseen.	  	  
During	  the	  therapeutic	  prednisolone	  treatment,	  a	  similar	  experimental	  set-­‐up	  was	  implemented.	  
First,	  the	  animals	  received	  0.5	  mg	  kg-­‐1	  b.w.	  of	  prednisolone	  PO	  for	  5	  days	  (Day+106	  till	  Day+110),	  
which	  was	  followed	  by	  a	  washout	  period	  of	  25	  days.	  Next,	   IM	   injections	  of	  0.5	  mg	  kg-­‐1	  b.w.	  of	  
Solu-­‐Delta-­‐Cortef®	  were	  administered	  during	  5	  consecutive	  days	  (Day+136	  till	  Day+140).	  Until	  32	  
days	   (Day+141	   till	   Day+172)	   after	   the	   last	   prednisolone	   administration,	   urine	   samples	   were	  
collected	  in	  order	  to	  monitor	  the	  reconversion	  to	  the	  natural	  glucocorticoid	  body	  state.	  	  
During	   the	   periods	   of	   oral	   administration,	   one	   capsule	   containing	   the	   appropriate	   amount	   of	  
prednisolone	   was	   given	   in	   the	   morning	   just	   after	   feeding,	   using	   a	   capsule	   launcher.	   The	   IM	  
injections	  were	  placed	  in	  the	  neck	  and	  were	  alternated	  every	  day	  from	  the	  left	  to	  the	  right	  neck	  
side	  in	  order	  to	  reduce	  irritation.	  
2.2.2. Phase	  II:	  ACTH	  treatment	  
After	  phase	  I,	  a	  washout	  period	  of	  11	  weeks	  was	  respected.	  Subsequently,	  all	  animals	  received	  
IM	   injections	   of	   2	   mg	   tetracosactide	   hexaacetate	   (Utrecht	   University,	   Faculty	   of	   Veterinary	  
Medicine,	  Utrecht,	  The	  Netherlands),	  corresponding	  to	  200	  I.U.	  of	  adrenocorticotropic	  hormone	  
(ACTH),	  during	  4	  consecutive	  days.	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2.3. Sample	  collection	  
During	   the	   prednisolone	   treatments,	   urine	   samples	   were	   collected	   in	   the	   morning,	   prior	   to	  
prednisolone	   treatment.	   These	   samples	   were	   obtained	   by	   a	   veterinarian	   using	   a	   probe	   (to	  
prevent	   faecal	   contamination)	  and	  were	   immediately	  portioned	   into	  15-­‐mL	   tubes,	  which	  were	  
then	  stored	  in	  the	  dark	  at	  -­‐80	  °C	  until	  analysis	  according	  to	  De	  Clercq	  et	  al.	  (2013)	  [20](Chapter	  
II).	   During	   the	   growth-­‐promoting	   prednisolone	   treatment,	   samples	   were	   collected	   every	   five	  
days	  whereas	  during	  the	  therapeutic	  treatment,	  urine	  samples	  were	  collected	  the	  first,	  third	  and	  
last	   day.	   In	   addition,	   samples	  were	   also	   collected	   every	   day	   during	   the	   acclimatization	   period	  
and	  every	  five	  days	  during	  the	  washout	  periods.	  Also,	  urine	  samples	  were	  collected	  twice	  a	  day	  
during	  the	  ACTH	  treatment	  period,	  whereby	  samples	  were	  collected	  prior	  to	  and	  at	  4	  h	  (Day+1	  
and	  Day+2)	  or	  at	  6	  h	  (Day+3	  and	  Day+4)	  after	  ACTH	  administration.	  	  
Blood	  samples	  were	  collected	  in	  the	  morning,	  thereby	  applying	  a	  similar	  sampling	  strategy	  as	  for	  
urine.	   In	  addition,	  blood	  samples	   for	  pharmacokinetic	  analysis	  were	  collected	  at	   the	  beginning	  
and	  end	  of	  each	  treatment	  period	  at	  time	  0	  (just	  before	  administration),	  15	  min,	  30	  min,	  45	  min,	  
1	  h,	  2	  h,	  4	  h,	  6	  h,	  and	  24	  h	  (post-­‐	  administration,	  p.a).	  With	  each	  collection,	  5	  mL	  of	  blood	  was	  
sampled	  into	  heparin	  tubes.	  One	  hour	  after	  collection,	  blood	  was	  centrifuged	  at	  600	  x	  g	  during	  
15	  minutes	  at	  4	  °C	  and	  divided	  into	  2	  mL	  plasma	  aliquots.	  Aliquots	  were	  then	  immediately	  stored	  
at	  -­‐20	  °C	  until	  analysis.	  	  
2.4. Reagents	  and	  chemicals	  
Standards	   of	   prednisolone,	   prednisone,	   cortisone,	   cortisol,	   dihydrocortisone,	   aldosterone,	  
allotetrahydrocortisol,	  urocortisol,	  tetrahydrocortisone,	  corticosterone,	  deoxycorticosterone,	  α-­‐
cortolone	   and	   6β-­‐hydroxycortisol	   were	   purchased	   from	   Sigma-­‐Aldrich	   (St.	   Louis,	   MO,	   USA).	  
Internal	  standards	  were	  cortisol-­‐d4	  (Sigma-­‐Aldrich)	  and	  prednisolone-­‐d8	  (TRC,	  Canada).	  Reagents	  
were	  of	  analytical	  grade	  (Merck,	  Darmstadt,	  Germany)	  when	  used	  for	  extraction	  purposes	  and	  of	  
LC-­‐MS	   Optima	   grade	   (Fisher	   Scientific,	   Loughborough,	   UK)	   for	   UHPLC-­‐HRMS	   applications.	  
Ultrapure	  water	  was	  obtained	  by	  usage	  of	  a	  purified-­‐water	  system	  (VWR	  International,	  Merck,	  
Darmstadt,	  Germany).	  Primary	   stock	   solutions	  were	  prepared	   in	  ethanol	  at	   a	   concentration	  of	  
200	  μg	  mL-­‐1	  and	  stored	  in	  dark	  glass	  bottles	  at	  -­‐20	  °C.	  Working	  solutions	  were	  made	  in	  ethanol	  at	  
a	  range	  of	  0.1	  –	  10	  μg	  mL-­‐1.	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2.5. Sample	  preparation	  
2.5.1. Urine	  	  
A	  detailed	  description	  of	  the	  analytical	  procedure,	  which	  was	  used	  for	  glucocorticoid	  extraction	  
from	  urine,	  has	  been	  given	   in	  earlier	  work	   [20].	   In	  brief,	   5	  mL	  of	  urine	  was	  enriched	  with	   the	  
internal	  standards	  cortisol-­‐d4	  and	  prednisolone-­‐d8	  to	  reach	  final	  concentration	  levels	  of	  10	  µg	  L-­‐1.	  
Next,	  a	  twofold	  liquid-­‐liquid	  extraction	  with	  pure	  tert-­‐butyl	  methyl	  ether	  was	  applied,	  whereby	  
the	   organic	   phases	   were	   collected,	   pooled	   and	   dried	   under	   a	   gentle	   stream	   of	   nitrogen	   at	   a	  
temperature	  of	  50	  °C.	  The	  residue	  was	  then	  dissolved	  in	  100	  µL	  of	  solvent,	  corresponding	  to	  the	  
initial	  mobile	  phase	  conditions,	  and	  transferred	  into	  an	  UHPLC-­‐vial.	  	  
2.5.2. Plasma	  
Two	  mL	  of	   vortexed	  plasma	  was	   spiked	  with	   the	   internal	   standard	   cortisol-­‐d4	   to	  obtain	  a	   final	  
concentration	   of	   10	   μg	   L-­‐1.	   Glucocorticoids	  were	   extracted	   by	   liquid-­‐liquid	   extraction,	   thereby	  
using	  5	  mL	  acetonitrile.	  After	  30	  minutes	  of	  extraction,	  samples	  were	  centrifuged	  at	  3760	  x	  g	  for	  
10	  min	  at	  10	  °C.	  Then,	  the	  supernatants	  were	  collected	  and	  evaporated	  under	  a	  gentle	  stream	  of	  
nitrogen	  at	  a	  temperature	  of	  40	  °C.	  The	  residue	  was	  suspended	  in	  200	  μL	  of	  water-­‐acetonitrile	  
(80/20,	  v/v)	  and	  transferred	  into	  an	  UHPLC-­‐vial.	  	  
2.6. Instrumentation	  
2.6.1. UHPLC-­‐Orbitrap	  MS	  for	  urine	  
Glucocorticoid	   analysis	   of	   urine	   was	   performed	   by	   UHPLC-­‐Orbitrap	   mass	   spectrometry,	  
according	   to	   the	   method	   of	   De	   Clercq	   et	   al.	   (2013)[20].	   Chromatographic	   separation	   of	   the	  
target	  analytes	  was	   thereby	  achieved	  using	  an	  Accela	  UHPLC	  system	  (Thermo	  Fisher	  Scientific,	  
San	  José,	  USA),	  equipped	  with	  a	  Nucleodur	  Isis	  C18	  column	  (1.8	  μm,	  100	  mm	  x	  2	  mm,	  Macherey-­‐
Nagel,	  Düren,	  Germany).	  	  
The	   binary	   solvent	   system	   consisted	   of	   0.1%	   aqueous	   formic	   acid	   (A)	   and	   0.1%	   formic	   acid	   in	  
acetonitrile	  (B)	  (Table	  5.1.).	  High-­‐resolution	  mass	  spectrometric	  analysis	  was	  performed	  with	  an	  
ExactiveTM	  single-­‐stage	  Orbitrap	  mass	  spectrometer	  (Thermo	  Fisher	  Scientific),	  equipped	  with	  a	  
heated	  electrospray	  ionization	  probe	  (HESI	  II),	  operating	  in	  polarity	  switching	  mode.	  Instrument	  
control	  and	  data	  processing	  were	  carried	  out	  by	  Xcalibur	  2.1	  software	  (Thermo	  Fisher	  Scientific).	  
This	  method	  has	  been	  validated	  according	  to	  Commission	  Decision	  2002/657/EC	  [20][21].	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2.6.2. UHPLC-­‐MS/MS	  analysis	  for	  plasma	  
The	  chromatographic	  analysis	  of	  glucocorticoids	   in	  plasma	  was	  performed	  by	  a	  Waters	  Acquity	  
system	   (Waters,	   Manchester,	   UK)	   according	   to	   Delahaut	   et	   al.	   (2013)	   [16].	   Chromatographic	  
separation	  of	  the	  target	  analytes	  was	  thereby	  achieved	  using	  an	  Acquity	  C18	  column	  (1.7	  μm,	  125	  
mm	  x	  3	  mm).	  The	  injection	  volume	  was	  20	  μl.	  The	  binary	  solvent	  system	  consisted	  of	  0.1%	  formic	  
acid	   in	  water-­‐acetonitrile	  (78:22,	  v/v)	  (A)	  and	  0.1%	  formic	  acid	   in	  methanol-­‐acetonitrile	  (78:22,	  
v/v)	  (B)	  at	  a	  constant	  flow	  of	  0.6	  mL	  min-­‐1.	  The	  gradient	  started	  with	  a	  solvent	  mixture	  (v/v)	  of	  
99.2%	  A	  and	  0.8%	  B.	  The	  percentage	  of	  B	   increased	  to	  5%	  in	  the	  next	  4	  min,	  then	  to	  15%	  in	  5	  
min,	   and	   further	   up	   to	   100%	   in	   0.5	   min.	   This	   condition	   was	   held	   for	   1.5	   min.	   During	   UHPLC	  
analysis,	   the	   column	  was	  maintained	   at	   50	   °C	   and	   the	   samples	   at	   10	   °C.	  Mass	   spectrometric	  
analysis	  was	  performed	  with	  a	  Waters	  Xevo	  TQS	  tandem	  mass	  spectrometer	  (Waters),	  operating	  
in	   the	   positive	   ion	   electrospray	   mode	   and	   applying	   multiple	   reaction	   monitoring	   (MRM).	   For	  
each	   target	   compound,	   two	   transitions	   were	   monitored	   (Table	   5.1.),	   the	   first	   being	   the	  
quantifier	   and	   the	   second,	   the	  qualifier.	   For	  quantification,	   two	   internal	   standards	  were	  used:	  
prednisolone-­‐d4	   and	   cortisol-­‐d4.	   Instrument	   control	   and	   data	   processing	   were	   carried	   out	   by	  
MassLynx	  and	  QuanLynx	  software	  (Waters)	  respectively.	  	  
Table	  5.1.	  MS/MS-­‐parameters	  for	  the	  target	  glucocorticoid	  compounds	  and	  internal	  standards	  







Prednisolone	   361.2	   147.0	   20	   24	  
	   	   343.0	   20	   10	  
Cortisol	   363.1	   120.8	   30	   30	  
	   	   309.0	   30	   15	  
Prednisone	   359.3	   313.3	   20	   10	  
	   	   295.0	   20	   12	  
Cortisone	   361.2	   163.0	   30	   22	  
	   	   120.9	   30	   30	  
Dihydrocortisone	   363.2	   163.2	   36	   20	  
	   	   105.2	   36	   40	  
20β-­‐dihydroprednisolone	   363.1	   267.1	   30	   15	  
	   	   171.1	   30	   20	  
20α-­‐dihydroprednisolone	   363.1	   267.1	   30	   15	  
	   	   171.1	   30	   20	  
Prednisolone-­‐d4	   365.3	   347.3	   20	   10	  
Cortisol-­‐d4	   367.2	   312.2	   30	   15	  
A	   brief	   validation	   of	   the	   newly	   developed	   method	   for	   glucocorticoid	   analysis	   of	   plasma	   was	  
performed	   based	   on	   Commission	   Decision	   2002/657/EC	   guidelines	   [21].	   The	   method	  
performance	   in	   terms	   of	   repeatability,	   within-­‐laboratory	   reproducibility,	   recovery,	   CCα	   and	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specificity	  was	   thereby	  assessed.	  Plasma	  samples	   that	  were	  used	   for	  validation	  were	  obtained	  
from	  non-­‐medicated	  cows	   (n	  =	  3),	  which	  were	  housed	  at	   the	  animal	   facilities	  of	  CER.	  Linearity	  
was	  evaluated	  based	  on	  eight-­‐point	  matrix-­‐matched	  calibration	  curves	  with	  concentration	  levels	  
ranging	  from	  0.25	  to	  20	  µg	  L-­‐1	  for	  prednisolone,	  prednisone,	  20α-­‐dihydroprednisolone,	  and	  20β-­‐
dihydroprednisolone	   and	   from	   0.5	   to	   40	   µg	   L-­‐1	   for	   cortisol,	   cortisone,	   and	   dihydrocortisone.	  
Repeatability	   was	   determined	   by	   analysis	   of	   samples	   that	   were	   spiked	   with	   the	   target	  
compounds,	   thereby	   considering	   two	   different	   concentration	   levels,	   i.e.	   0.5	   and	   5	   μg	   L-­‐1	   for	  
prednisolone,	  prednisone,	  20α-­‐dihydroprednisolone,	  and	  20β-­‐dihydroprednisolone	  and	  1	  to	  10	  
μg	   L-­‐1	   for	   cortisol,	   cortisone,	   and	   dihydrocortisone.	   At	   each	   level,	   the	   analysis	  was	   performed	  
with	   seven	   replicates.	   For	   evaluation	   of	   the	   within-­‐laboratory	   reproducibility,	   the	   specified	  
analyses	  were	  repeated	  on	  two	  different	  occasions,	  the	  second	  occasion	  by	  a	  different	  operator.	  
The	  CCα	  was	  estimated	  from	  chromatograms	  and	  corresponded	  to	  a	  concentration	  giving	  a	  peak	  
with	   a	   signal-­‐to-­‐noise	   ratio	   of	   3.	   Specificity	   was	   evaluated	   by	   analyzing	   potential	   interfering	  
substance	  (methylprednisolone)	  to	  identify	  potential	  cross-­‐talk	  during	  analysis.	  
2.7. Quantitation	  and	  normalization	  
Due	   to	   the	   broad	   concentration	   range	   expected	   in	   the	   urine	   samples	   during	   the	   different	  
prednisolone	   treatments,	   quantitation	   of	   the	   various	   urinary	   glucocorticoid	   compounds	   was	  
based	  on	  two	  eight-­‐point	  calibration	  curves,	  which	  were	  prepared	  in	  urine	  matrix.	  Samples	  were	  
thereby	  fortified	  with	  all	  glucocorticoid	  standards	  to	  reach	  concentrations	  that	  ranged	  from	  0.50	  
to	   75	   ng	   mL-­‐1	   and	   from	   100	   to	   200	   ng	   mL-­‐1	   for	   cortisol,	   cortisone,	   dihydrocortisone,	  
prednisolone,	   prednisone,	   methylprednisolone,	   20α-­‐dihydroprednisolone,	   and	   20β-­‐
dihydroprednisolone.	  In	  this	  regard,	  corresponding	  peak	  area	  ratios	  of	  the	  analytes	  towards	  the	  
internal	  standard	  were	  used	  to	  construct	  the	  calibration	  curves.	  The	  employed	  urine	  matrix	  was	  
previously	  verified	  to	  contain	  no	  residues	  of	  prednisolone,	  prednisone,	  20α-­‐dihydroprednisolone	  
and	   20β-­‐dihydroprednisolone	   but	   the	   other	   glucocorticoids	   were	   found	   to	   be	   endogenously	  
present.	   Therefore,	   the	   endogenous	   concentration	   levels	   of	   cortisol,	   cortisone,	   and	  
dihydrocortisone	  were	  determined	  as	  the	  average	  of	  five	  non-­‐fortified	  urine	  samples	  and	  taken	  
into	   account	   during	   quantitation.	   In	   addition,	   since	   urine	   is	   a	   matrix	   prone	   to	   dilution,	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normalization	   by	   means	   of	   the	   specific	   gravity	   (Pocket	   RefractometerTM,	   Atago,	   Tokyo)	   was	  
implemented.	  Calculations	  were	  thereby	  based	  on	  the	  Levine-­‐Fahy	  equation	  [22].	  
2.8. Pharmacokinetic	  analysis	  
Pharmacokinetic	   (PK)	   analysis	   was	   performed	   with	  WinNonlin	   6.3	   (Pharsight	   Corporation,	   St-­‐
Louis,	   USA).	   Plasma	   concentration-­‐time	   profiles	   were	   modeled	   using	   a	   one-­‐	   or	   two-­‐
compartmental	   model	   for	   PO	   and	   IM	   prednisolone	   administration,	   respectively.	   The	   most	  
important	  PK	  parameters	  were	  calculated	  comprising	  the	  peak	  plasma	  concentration	  (Cmax),	  time	  
to	  reach	  the	  peak	  plasma	  concentration	  (Tmax),	  area	  under	  the	  plasma	  concentration-­‐time	  curve	  
from	   time	   0	   to	   time	   inf	   (AUC0-­‐inf),	   absorption	   rate	   constant	   (ka),	   absorption	   half-­‐life	   (T1/2a),	  
apparent	   clearance	   (Cl/F)	   and	   apparent	   volume	   of	   distribution	   (Vd/F).	   Additionally,	   for	   two-­‐
compartmental	   models	   the	   distribution	   rate	   constant	   (kelα),	   elimination	   rate	   constant	   (kelβ),	  
elimination	  half-­‐life	  (T1/2elβ)	  were	  determined.	  The	  coefficient	  of	  determination	  was	  hereby	  used	  
as	  an	  indicator	  for	  the	  goodness-­‐of-­‐fit.	  For	  the	  main	  metabolites,	  only	  Cmax,	  Tmax,	  AUC0-­‐inf,	  kel	  en	  
T1/2el	  were	  calculated.	  	  
2.9. Statistical	  analysis	  
All	   toxicokinetic	   parameters	   from	   each	   administered	   dose	   were	   compared	   between	   the	  
administration	   routes	   using	   one-­‐way	   analysis	   of	   variance	   (ANOVA)	   (p-­‐value	   ≤	   0.05)	   (SPSS	   21,	  
IBM,	   USA).	   The	   urinary	   concentrations	   were	   statistically	   evaluated	   using	   Student’s	   t-­‐test	   and	  
one-­‐way	  ANOVA	  with	  post-­‐hoc	  Tukey’s	  multiple	  comparisons	  test.	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3. Results	  and	  discussion	  
3.1. Method	  validation	  	  
For	  each	  target	  compound,	  the	  correlation	  coefficient	  (R2)	  was	  above	  0.99	  for	  each	  of	  the	  three	  
calibration	   curves,	   established	   in	   plasma	   and	   analyzed	   on	   three	   different	   days.	   The	   other	  
performance	  characteristics	  of	  the	  validation	  are	  presented	  in	  Table	  5.2.	  Recoveries	  ranged	  from	  
92	   to	   107%	   (Table	   5.2.).	   Repeatability	   and	   within-­‐laboratory	   reproducibility	   were	   evaluated	  
based	  on	  the	  coefficients	  of	  variation	  (RSD)	  and	  were	  below	  the	  15%-­‐tolerance	  level,	  specified	  in	  
CD	   2002/657/EC,	   except	   for	   20α-­‐dihydroprednisolone	   (22.3%	   at	   0.5	   μg	   L-­‐1),	   which	   was	  
nevertheless	  considered	  acceptable	  because	  of	  the	  low	  target	  concentration	  [21].	  	  




	   	  






































































3.2. Pharmacokinetics	  of	  prednisolone	  and	  its	  metabolites	  
The	   PK	   parameters	   were	   determined	   for	   prednisolone	   during	   the	   growth-­‐promoting	   and	  
therapeutic	   treatments,	   thereby	   using	   a	   one-­‐	   (PO)	   or	   two-­‐compartmental	   (IM)	  model	   (Figure	  
5.3.).	  	  
	  
Figure	   5.3.	   Log	  plasma	  concentration-­‐time	  profile	  of	  prednisolone	  during	   the	   first	  8	  h	  after	  oral	   (round)	  
and	   intramuscular	   (triangle)	   administration	   of	   prednisolone	   for	   growth-­‐promoting	   (blue)	   or	   therapeutic	  
(pink)	  treatment	  of	  cattle	  (n=12).	  Results	  are	  expressed	  as	  mean	  plasma	  concentration	  levels	  ±	  SD.	  
A	   growth-­‐promoting	   (40	   mg	   day-­‐1)	   and	   therapeutic	   (0.5	   mg	   kg-­‐1	   day-­‐1)	   PO	   administration	   of	  
prednisolone	   to	   cattle	   resulted	   in	  a	   relatively	   fast	   absorption	  with	  a	  Cmax	   at	  2.95	  h	  and	  3.84	  h	  
(Tmax),	   respectively.	   The	   absorption	   (T1/2a)	   and	   elimination	   half-­‐life	   (T1/2el)	   for	   unbound	  
prednisolone	   after	   PO	   and	   IM	  administration	   seemed	   independent	   of	   the	   dose.	  However,	   the	  
highest	  IM	  dose	  (0.5	  mg	  kg-­‐1	  day-­‐1)	  had	  an	  increased	  T1/2el,	  which	  can	  be	  explained	  by	  saturation	  
of	  biotransformation	  in	  the	  liver	  [23].	  This	  saturation	  explains	  the	  significant	  dose	  dependency	  of	  
biotransformation	   of	   prednisolone	   after	   therapeutic	   administration.	   Therefore,	   therapeutic	  
dosage	  of	  prednisolone	  resulted	  in	  significant	  (p-­‐value	  ≤	  0.05)	  higher	  Cl/F	  values	  (Table	  5.3.).	  The	  
Vd/F	  for	  oral	  administered	  prednisolone	  increased	  from	  11.95	  to	  30.06	  L	  kg-­‐1	  during	  respectively,	  
growth-­‐promoting	  and	  therapeutic	  treatment.	  The	  same	  effect	  was	  noticed	  during	  the	  two	  types	  
of	   IM	  prednisolone	  administration.	  This	  could	  be	  explained	  by	  nonlinear	   transcortin	  binding	  of	  
prednisolone	   since	   this	   binding	   is	   saturated	   with	   increased	   prednisolone	   concentration	  
[24][25][26].	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Table	  5.3.	  Pharmacokinetic	  parameters	  (mean	  ±	  SD)	  (n	  =	  12)	  for	  prednisolone	  after	  oral	  and	  intramuscular	  
administration	   of	   a	   growth-­‐promoting	   (40	  mg	  day-­‐1)	   and	   a	   therapeutic	   (0.5	  mg	   kg-­‐1	   day-­‐1)	   treatment	   to	  
cattle.	  
	  
Pharmacokinetic	   parameters	   (one-­‐compartmental)	   of	   the	   main	   prednisolone	   metabolites,	   i.e.	  
prednisone,	   20α-­‐dihydroprednisolone	   and	   20β-­‐dihydroprednisolone,	   could	   only	   be	   considered	  
for	  the	  IM	  therapeutic	  prednisolone	  treatment	  (Table	  5.4),	  since	  the	  plasma	  concentration	  levels	  
of	  all	   these	  metabolites	  were	  below	  the	  associated	  decision	   limit	  CCα	  during	  growth-­‐promoting	  
treatments	  (PO	  and	  IM)	  and	  oral	  therapeutic	  treatment.	  	  
Table	  5.4.	  Pharmacokinetic	  parameters	  (mean	  ±	  SD)	  (n	  =	  12)	  of	  prednisone,	  20α-­‐dihydroprednisolone	  and	  
20β-­‐dihydroprednisolone	   after	   intramuscular	   administration	   of	   a	   therapeutic	   (0.5	   mg	   kg-­‐1	   day-­‐1)	  
prednisolone	  treatment	  to	  cattle.	  
	  
Prednisone	   20α-­‐dihydroprednisolone	   20β-­‐dihydroprednisolone	  
Cmax	  (μg	  L
-­‐1)	   13.3	  ±	  2.56	   1.64	  ±	  0.677	   19.2	  ±	  4.31	  
Tmax	  (h)	   0.857	  ±	  0.136	   1.42	  ±	  0.413	   2.17	  ±	  0.571	  
AUC0-­‐inf	  (h	  μg	  L
-­‐1)	   58.5	  ±	  12.1	   7.07	  ±	  3.33	   121	  ±	  26.9	  
kel	  (h
-­‐1)	   0.307	  ±	  0.101	   0.553	  ±	  0.184	   0.349	  ±	  0.086	  
T1/2el	  (h)	   2.43	  ±	  0.649	   1.53	  ±	  1.02	   2.09	  ±	  0.522	  
	  
Based	  on	  these	  results,	  it	  was	  concluded,	  based	  on	  AUC0-­‐inf,	  that	  20β-­‐dihydroprednisolone	  is	  the	  
most	   abundant	   prednisolone-­‐derived	   metabolite	   in	   plasma.	   Additionally,	   20β-­‐
dihydroprednisolone	   could	   be	   detected	   already	   15	  min	   after	   IM	   prednisolone	   administration.	  
Maximum	  plasma	  concentration	  levels	  for	  this	  metabolite	  were	  reached	  about	  2	  h	  after	  start	  of	  
the	  treatment	  (Figure	  5.4.).	  
	  
40	  mg	  day-­‐1	  PO	   0.5	  mg	  kg-­‐1	  day-­‐1	  PO	   40	  mg	  day-­‐1	  IM	   0.5	  mg	  kg-­‐1	  day-­‐1	  IM	  
Cmax	  (μg	  L
-­‐1)	   2.96	  ±	  1.50	   7.01	  ±	  1.52	   117	  ±	  25.8	   156	  ±	  78.1	  
Tmax	  (h)	   2.95	  ±	  0.820	   3.85	  ±	  0.909	   0.168	  ±	  0.063	   0.866	  ±	  0.273	  
AUC0-­‐tinf(h	  μg	  L
-­‐1)	   26.1	  ±	  19.1	   75.5	  ±	  25.0	   232	  ±	  17.5	   678	  ±	  11.5	  
ka	  (h
-­‐1)	   0.363	  ±	  0.099	   0.307	  ±	  0.129	   17.1	  ±	  11.2	   1.93	  ±	  0.395	  
T1/2a	  (h)	   2.05	  ±	  0.588	   2.53	  ±	  0.854	   0.064	  ±	  0.052	   0.370	  ±	  0.083	  
kel	  (h
-­‐1)	   0.362	  ±	  0.091	   0.245	  ±	  0.053	   0.325	  ±	  0.046	   0.132	  ±	  0.092	  
T1/2el	  (h)	   2.04	  ±	  0.553	   2.97	  ±	  0.728	   2.16	  ±	  0.308	   3.80	  ±	  0.499	  
Vd/F	  (L	  kg-­‐1)	   11.9	  ±	  4.89	   30.1	  ±	  9.98	   0.503	  ±	  0.215	   2.47	  ±	  1.61	  




Figure	  5.4.	  Log	  plasma	  concentration-­‐time	  profile	  of	  prednisolone	  (blue)	  after	   intramuscular	  therapeutic	  
administration	  of	  prednisolone	  (0.5	  mg	  kg-­‐1	  day-­‐1)	  to	  cattle	  (n=12)	  and	  formation	  of	  the	  metabolites	  20β-­‐
dihydroprednisolone	   (pink),	   prednisone	   (grey)	   and	   20α-­‐dihydroprednisolone	   (turquoise).	   Results	   are	  
presented	  as	  means	  ±	  SD	  (n	  =	  12).	  
The	   Tmax	   of	   prednisolone	   and	   prednisone	  were	   similar,	   0.866	   and	   0.857	   h	   respectively,	   which	  
indicates	   a	   very	   fast	   conversion	   by	   the	   11β-­‐hydroxysteroid	   dehydrogenase	   type	   2	   (11β-­‐HSD2)	  
enzyme	  in	  the	  liver	  [27].	  	  
During	   tetracosactide	  hexaacetate	  administration,	   traces	  of	  prednisolone	  could	  be	  detected	   in	  
plasma	  below	  the	  CCα.	  
3.3. Urinary	  excretion	  profile	  of	  prednisolone	  and	  its	  metabolites	  	  
3.3.1. Growth-­‐promoting	  treatment	  
Based	   on	   the	   analysis	   of	   the	   urine	   samples	   that	   were	   collected	   prior	   to	   prednisolone	  
administration,	   it	   was	   verified	   that	   prednisolone,	   prednisone,	   20α-­‐dihydroprednisolone,	   and	  
20β-­‐dihydroprednisolone	  were	  not	  present	  at	  detectable	  concentration	  levels.	  After	  five	  days	  of	  
oral	   prednisolone	   treatment	   (40	   mg	   day-­‐1),	   urinary	   prednisolone	   reached	   an	   average	  
concentration	  of	  0.832	  µg	  L-­‐1.	  However,	  when	  animals	  were	  given	  a	  same	  dose	  by	  IM	  injection,	  a	  
mean	   prednisolone	   concentration	   of	   1.16	   µg	   L-­‐1	   was	   reached	   (Table	   5.5.).	   These	   urinary	  
prednisolone	   concentrations	   are	   below	   the	   threshold	   of	   5	  µg	   L-­‐1	   suggested	   by	   the	   EURL.	   This	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During	  the	  following	  25	  days,	  the	  urinary	  prednisolone	  concentrations	  remained	  rather	  constant	  
for	   both	   treatments.	   Eventually,	   24	   h	   after	   the	   growth-­‐promoting	   treatment	   was	   ended,	  
prednisolone	   concentrations	   started	   to	   decrease.	   Undetectable	   levels	   were	   thereby	   reached	  
after	  5	  days,	  which	  appeared	  to	  be	  independent	  of	  the	  administration	  route.	  The	  rapid	  excretion	  
profile	   of	   prednisolone	  was	   demonstrated	   earlier	   by	   Cannizzo	   et	   al.	   (2011)	   [5],	  who	   reported	  
that	   prednisolone	   residues	   were	   completely	   eliminated	   6	   days	   after	   a	   growth-­‐promoting	  
treatment	  of	  35	  days.	  In	  addition,	  after	  PO	  dexamethasone	  administration,	  no	  residues	  could	  be	  
detected	  in	  urine	  after	  seven	  days	  [5][28].	  During	  oral	  administration	  of	  prednisolone,	  all	  urine	  
samples	   contained	   prednisolone	   and	   20β-­‐dihydroprednisolone,	   but	   20α-­‐dihydroprednisolone	  
was	  detected	  in	  the	  urine	  of	  only	  8	  out	  of	  12	  animals.	  In	  none	  of	  the	  urine	  samples,	  prednisone	  
could	  be	  detected	  (Table	  5.5.).	  	  
Table	   5.5.	   Urinary	   prednisolone,	   prednisone,	   20α-­‐dihydroprednisolone	   and	   20β-­‐dihydroprednisolone	  
concentrations	   (μg	   L-­‐1)	   during	   oral	   (PO)	   and	   intramuscular	   (IM)	   growth-­‐promoting	   (40	   mg	   day-­‐1)	  
prednisolone	   treatment	   to	   cattle	   (n	   =	   12).	   Means	   ±	   SD	   were	   determined	   based	   on	   the	   positive	   urine	  
samples.	  
	   Prednisolone	   Prednisone	   20α-­‐dihydroprednisolone	   20β-­‐dihydroprednisolone	  
Growth-­‐promoting	  PO	   	   	   	  
N°	  positive	   12	   0	   8	   12	  
Cmin	  (µg	  L
-­‐1)	   0.027	   -­‐	   0.153	   0.695	  
Cmax	  (µg	  L
-­‐1)	   1.17	   -­‐	   3.41	   14.10	  
Mean	  (µg	  L-­‐1)	   0.832	   -­‐	   0.771	   4.35	  
SD	  (µg	  L-­‐1)	   0.381	   -­‐	   0.544	   2.44	  
Growth-­‐promoting	  IM	   	   	   	  
N°	  positive	   12	   4	   8	   12	  
Cmin	  (µg	  L
-­‐1)	   0.014	   0.030	   0.138	   0.938	  
Cmax	  (µg	  L
-­‐1)	   8.44	   2.17	   1.79	   14.2	  
Mean	  (µg	  L-­‐1)	   1.16	   0.311	   0.472	   4.91	  
SD	  (µg	  L-­‐1)	   1.08	   0.413	   0.308	   3.15	  
	  
This	  is	  in	  contrast	  with	  the	  urinary	  excretion	  profile	  that	  was	  monitored	  during	  IM	  prednisolone	  
administration.	   Indeed,	   prednisone	  was	   detected	   in	   the	   urine	   samples	   from	   4	   animals.	   These	  
results	  are	   in	   line	  with	  Leporati	  et	  al.	   (2013)	   [17].	   In	   this	   study	   it	  was	  demonstrated	   that	  20α-­‐
dihydroprednisolone,	  6β-­‐hydroxyprednisolone	  and	  20β-­‐dihydroprednisone	  were	  not	  present	   in	  
the	  urine	  of	  PO	  growth-­‐promoting	  treated	  cattle.	  However	  the	  major	  prednisolone	  metabolite,	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i.e.	   20β-­‐dihydroprednisolone,	   was	   found	   until	   24	   h	   after	   the	   end	   of	   the	   IM	   treatment,	   with	  
undetectable	  levels	  after	  five	  days.	  
3.3.2. Therapeutic	  treatment	  
After	   three	   days	   of	   PO	   and	   IM	   therapeutic	   administration	   of	   prednisolone,	   mean	   urinary	  
prednisolone	   concentrations	   of	   respectively	   0.922	  μg	   L-­‐1	   and	   20.1	   μg	   L-­‐1	  were	   retrieved.	   After	  
five	  days	  of	  IM	  injection,	  the	  urinary	  prednisolone	  concentration	  further	  increased	  to	  42.4	  μg	  L-­‐1,	  
whereas	  the	  concentration	  after	  PO	  treatment	  remained	  rather	  constant.	  	  
The	  urinary	  excretion	  profile	  of	  prednisolone	  revealed	  a	  very	  strong	  decrease	  after	  ending	  the	  
PO	   therapeutic	   treatment.	   Within	   48h	   after	   the	   final	   administration,	   urinary	   prednisolone	  
concentration	   levels	   were	   diminished	   with	   about	   80%.	   Eventually,	   after	   5	   days,	   no	   more	  
prednisolone	  or	  derived	  metabolites	  could	  be	  detected	  at	  concentration	  levels	  above	  the	  CCαs.	  
For	   the	   IM	   prednisolone	   injections,	   prednisolone	   levels	   above	   the	   CCα	   were	   detected	   in	   two	  
animals	  up	  to	  10	  days	  after	  treatment.	  This	  is	  in	  line	  with	  the	  Nebbia	  et	  al.	  (2014)	  [3],	  who	  found	  
urinary	  prednisolone	  concentrations	  above	  the	  CCα	  in	  3	  out	  of	  6	  animals	  until	  19	  days	  after	  the	  
last	  therapeutic	  treatment,	  but	  in	  contrast	  with	  Vincenti	  et	  al.	  (2009)	  [29]	  where	  it	  took	  5	  days	  to	  
eliminate	  and	  excrete	  the	  administered	  IM	  therapeutic	  dexamethasone	  treatment.	  In	  the	  study	  
of	   Ferranti	   et	   al.	   (2013)	   [30],	   no	   dexamethasone	   residues	   could	   be	   detected	   in	   bovine	   urine,	  
seven	  days	  after	  a	  three-­‐day	  treatment	  with	  2	  mg	  prednisolone.	  
During	  oral	  administration	  of	  prednisolone,	  all	  urine	  samples	  contained	  prednisolone	  and	  20β-­‐
dihydroprednisolone.	  On	   the	  other	  hand,	  prednisone	  and	  20α-­‐dihydroprednisolone	  could	  only	  
be	  detected	  in	  2	  and	  8	  animals,	  respectively	  (Table	  5.6.).	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Table	   5.6.	   Urinary	   prednisolone,	   prednisone,	   20α-­‐dihydroprednisolone	   and	   20β-­‐dihydroprednisolone	  
concentrations	   (μg	   L-­‐1)	   during	   oral	   (PO)	   and	   intramuscular	   (IM)	   therapeutic	   (0.5	   mg	   kg-­‐1	   day-­‐1)	  
prednisolone	  treatment	  to	  cattle	  (n	  =	  12).	  Mean	  ±	  SD	  were	  determined	  on	  the	  number	  of	  positive	  urine	  
samples.	  
	   Prednisolone	   Prednisone	   20α-­‐dihydroprednisolone	   20β-­‐dihydroprednisolone	  
Therapeutic	  PO	   	   	   	  
N°	  positive	   12	   2	   8	   12	  
Cmin	  (µg	  L
-­‐1)	   0.038	   0.033	   0.156	   1.07	  
Cmax	  (µg	  L
-­‐1)	   1.36	   0.306	   2.85	   15.15	  
Mean	  (µg	  L-­‐1)	   0.922	   0.125	   0.552	   5.13	  
SD	  (µg	  L-­‐1)	   0.428	   0.108	   0.635	   1.20	  
Therapeutic	  IM	   	   	   	  
N°	  positive	   12	   12	   12	   12	  
Cmin	  (µg	  L
-­‐1)	   0.528	   1.08	   3.32	   8.97	  
Cmax	  (µg	  L
-­‐1)	   189	   22.5	   127	   100	  
Mean	  (µg	  L-­‐1)	   31.3	   8.17	   14.9	   37.9	  
SD	  (µg	  L-­‐1)	   40.7	   5.91	   26.0	   25.0	  
	  
It	   is	  remarkable	  is	  that	  20α-­‐dihydroprednisolone	  was	  detected	  in	  the	  same	  8	  animals	  as	  during	  
growth-­‐promoting	   treatment.	   This	   was	   independent	   of	   the	   body	   weight	   but	   indicated	   that	  
individual	   metabolism	   was	   responsible	   for	   the	   presence	   of	   20α-­‐dihydroprednisolone	   in	   urine	  
after	  prednisolone	  administration.	  This	   is	   in	  contrast	  with	  the	  observations	  made	  for	  the	  urine	  
samples	   collected	   during	   IM	   prednisolone	   administration.	   Indeed,	   all	   of	   the	   target	  
glucocorticoids	   could	   be	   detected	   in	   the	   urine	   along	   all	   animals,	   probably	   due	   to	   the	   higher	  
bioavailability	  concentrations	  reaching	  the	  plasma.	  	  
At	   the	   end	   of	   the	   PO	   and	   IM	   prednisolone	   treatment,	   20β-­‐dihydroprednisolone	   could	   be	  
detected	  in	  urine	  until	  24	  h	  and	  5	  days,	  respectively.	  The	  other	  metabolites	  were	  not	  found	  after	  
PO	  administration	  and	  only	  until	  24	  h	  after	  the	  end	  of	  the	  IM	  treatment.	  
For	  both	  administration	  routes,	   it	  may	  be	  concluded	  that	  20β-­‐dihydroprednisolone	   is	  the	  main	  
known	   metabolite	   of	   prednisolone.	   This	   is	   in	   agreement	   with	   Nebbia	   et	   al.	   (2014)	   [3],	   who	  
assigned	   20β-­‐dihydroprednisolone	   as	   the	   main	   urinary	   metabolite	   of	   prednisolone	   in	   treated	  





3.3.3. ACTH	  treatment	  
According	  to	  Chapter	   IV,	  the	  synthesis	  of	  various	  glucocorticoids	  may	  be	  induced	  by	  treatment	  
with	  tetracosactide	  hexaacetate.	  In	  this	  study,	  detectable	  concentration	  levels	  of	  prednisolone,	  
prednisone,	   20β-­‐dihydroprednisolone	   and	   20α-­‐dihydroprednisolone	  were	   observed	   under	   this	  
pharmacologically-­‐induced	   increase	   of	   cortisol.	   Concentration	   levels	   for	   prednisolone	   in	   urine	  
ranged	   from	  0.120	   to	  6.45	  µg	  L-­‐1	   (average	  1.45	  µg	  L-­‐1),	  at	  4	  h	  after	   tetracosactide	  hexaacetate	  
treatment	   (Day+1	   and	   Day+2).	   After	   6	   h,	   prednisolone	   concentration	   levels	   were	   significantly	  
lower	   (p-­‐value	   ≤	   0.05),	   although	   still	   detectable	   (ranging	   from	   0.169	   to	   0.729	   μg	   L-­‐1,	   average	  
0.318	  μg	  L-­‐1).	  	  
The	  metabolites	  prednisone,	  20α-­‐dihydroprednisolone	  and	  20β-­‐dihydroprednisolone	  could	  also	  
be	   observed	   at	   4	   h	   after	   tetracosactide	   hexaacetate	   (Day+1	   and	   Day+2)	   in	   concentrations	  
ranging	  from	  0.697	  to	  14.4	  µg	  L-­‐1	  (average	  3.51	  µg	  L-­‐1),	  3.31	  to	  19.1	  µg	  L-­‐1	  (average	  6.31	  µg	  L-­‐1),	  
0.407	  to	  33.2	  µg	  L-­‐1	  (average	  8.12	  µg	  L-­‐1),	  respectively.	  At	  6	  h	  after	  treatment	  (Day+3	  and	  Day+4),	  
the	  metabolite	  concentrations	  were	  2-­‐3	  fold	  lower,	  but	  still	  detectable	  in	  all	  animals.	  Eventually,	  
24	  h	  after	  the	  last	  tetracoasctide	  hexaacetate	  administration,	  no	  residues	  of	  prednisolone	  or	  its	  
metabolites	  could	  be	  detected.	  	  
In	   literature,	   20β-­‐dihydroprednisolone	   was	   suggested	   as	   potential	   biomarker	   to	   ascertain	  
unauthorized	   growth-­‐promoting	   prednisolone	   treatment.	   However,	   this	   particular	   metabolite	  
has	  been	  detected	  in	  control	  animals	  as	  well	  [31].	   In	  our	  results,	  20β-­‐dihydroprednisolone	  was	  
detected	   upon	   growth-­‐promoting	   (PO	   and	   IM)	   prednisolone	   treatment	   and	   after	  
pharmacologically-­‐induced	  increase	  of	  cortisol	  (Figure	  5.5.).	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Figure	  5.5.	  Log	  concentrations	  of	  20β-­‐dihydroprednisolone	  (20β-­‐DHP)	  in	  bovine	  urine	  collected	  during	  oral	  
and	  intramuscular	  growth-­‐promoting	  prednisolone	  treatment	  and	  during	  ACTH	  administration.	  	  
No	   significant	   difference	   (p	   ≥	   0.05)	   between	   the	   urinary	   20β-­‐dihydroprednisolone	  
concentrations	  after	  PO	  and	  IM	  prednisolone	  administration,	  and	  at	  6	  h	  upon	  pharmacologically-­‐
induced	  increase	  of	  cortisol	  was	  noticed.	  This	  is	  in	  contrast	  with	  the	  urinary	  concentrations	  at	  4	  
h	   post-­‐ACTH	   treatment,	   where	   a	   significant	   difference	   (p	   ≤	   0.05)	   was	   seen	   compared	   to	   the	  
other	   time	   points.	   However,	   it	   is	   hard	   to	   determine	   a	   threshold	   value	   for	   20β-­‐
dihydroprednisolone	  since	  the	  urinary	  concentration	  quickly	  decreased	  when	  the	  time	  between	  
ACTH	  administration	   and	  urine	   sampling	   increased.	   In	   addition,	   the	   large	   variation	   among	   the	  
detected	  urinary	  20β-­‐dihydroprednisolone	  concentration	  levels	  hinders	  to	  use	  this	  metabolite	  to	  
discriminate	  between	  endogenous	  and	  exogenous	  prednisolone.	  
3.4. Urinary	  excretion	  profile	  of	  natural	  glucocorticoids	  
3.4.1. Acclimatization	  
During	   the	   acclimatization	   period,	   the	   three	   most	   abundant	   steroids	   in	   urine	   were	   cortisol	  
(ranging	  0.411	  to	  4.26	  μg	  L-­‐1,	  average	  1.79	  μg	  L-­‐1),	  cortisone	  (ranging	  0.472	  to	  5.53	  μg	  L-­‐1,	  average	  
2.68	   μg	   L-­‐1)	   and	   dihydrocortisone	   (ranging	   0.222	   to	   9.36	   μg	   L-­‐1,	   average	   2.27	   μg	   L-­‐1).	   These	  
concentrations	  are	  in	  line	  with	  recent	  in	  vivo	  studies	  [15][32][33].	  Other	  steroids	  and	  associated	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3.4.2. Growth-­‐promoting	  and	  therapeutic	  treatment	  
The	   relative	   intensity	   changes	   of	   the	   urinary	   metabolites	   during	   the	   various	   treatments	   are	  
visualized	  by	  means	  of	  a	  heat	  map	  (Figure	  5.6.).	  It	  was	  hereby	  noted	  that	  the	  intensity	  of	  most	  
metabolites	   showed	   a	   steady	   decrease	   when	   prednisolone	   dose	   increased.	   Moreover,	   a	  
significant	   decrease	   (p-­‐value	   ≤	   0.05)	   of	   the	   urinary	   concentration	   was	   observed	   for	   cortisol,	  
cortisone,	   dihydrocortisone,	   and	   deoxycorticosterone	   when	   a	   growth-­‐promoting	   dose	   of	  
prednisolone	  was	  administered,	  regardless	  of	  the	  administration	  route.	  It	  took	  5	  days	  after	  the	  
end	  of	  each	  growth-­‐promoting	  treatment,	  before	  cortisol	  and	  its	  associated	  metabolites	  reached	  
their	  basal	  concentration	  levels	  again.	  	  
	  
Figure	   5.6.	   Heat	   map,	   representing	   the	   relative	   abundance	   of	   the	   selected	   urinary	   steroids	   and	  
metabolites	   during	   acclimatization	   (blank),	   growth-­‐promoting	   (PO1	   and	   IM1)	   and	   therapeutic	   (PO2	   and	  
IM2)	  prednisolone	  treatment,	  and	  during	  administration	  of	  tetracosactide	  hexaacetate.	  The	  ion	  intensities	  
of	   each	   ion	   were	   averaged	   and	   then	   log	   transformed.	   Shades	   of	   red	   and	   yellow	   represent	   higher	   and	  
lower	  ion	  intensities,	  respectively	  during	  the	  different	  treatments.	  	  
During	   PO	   therapeutic	   administration,	   a	   2-­‐	   to	   5-­‐fold	   intensity	   decrease	   for	   the	   urinary	  
metabolites	   was	   noticed,	   while	   during	   IM	   therapeutic	   treatment,	   almost	   no	   residues	   of	   the	  
glucocorticoids	   dihydrocortisone,	   allotetrahydrocortisol,	   corticosterone,	   deoxycorticosterone,	  
6β-­‐hydrocycortisol	   and	   α-­‐cortolone	   could	   be	   detected.	   It	   took	   12	   days	   after	   the	   end	   of	   the	  
therapeutic	  IM	  treatment,	  before	  cortisol	  and	  its	  metabolites	  reached	  their	  basal	  concentration	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These	   findings	   indicate	  a	   significant	  effect	  of	  prednisolone	  administration	  on	   the	   regulation	  of	  
the	   synthesis	   of	   endogenous	   glucocorticoids	   through	   suppression	   of	   the	   HPA-­‐axis.	   This	  
suppression	  relates	   to	   the	   inhibited	  CRH	  transcription	  by	  prednisolone	  and	  the	  decreased	  pro-­‐
opiomelanocortin	   (POMC)	  gene	   transcription.	   Indeed,	   the	  associated	  POMC	  polypeptide	   is	   the	  
precursor	   of	   ACTH	   and	   its	   formation	   is	   normally	   stimulated	   by	   CRH.	   As	   such,	   through	   the	  
inhibition	   of	   ACTH	   synthesis,	   the	   administration	   of	   prednisolone	   leads	   to	   a	   decreased	   cortisol	  
production	   [34].	   This	   negative	   feedback	   is	   influenced	   by	   both	   the	   dosage	   and	   route	   of	  
administration	  of	  prednisolone	  [23],	  as	  was	  observed	  in	  this	  study	  as	  well.	  
3.4.3. ACTH	  treatment	  
Urinary	  glucocorticoid	  profiles	  were	  evaluated	  during	  the	  first	  2	  days	  of	  ACTH	  treatment	  (Figure	  
5.6.).	   It	   was	   thereby	   concluded	   that	   treatment	   with	   tetracosactide	   hexaacetate	   significantly	  
affected	   urinary	   secretion	   of	   cortisol,	   cortisone,	   dihydrocortisone,	   tetrahydrocortisol,	   6β-­‐
hydrocycortisol	   and	   α-­‐cortolone,	   whereby	   higher	   concentration	   levels	   were	   observed	   (Figure	  
5.6.).	  The	  most	  intense	  increases	  were	  noticed	  for	  cortisol	  (70-­‐fold),	  cortisone	  (40-­‐fold),	  and	  6β-­‐
hydrocycortisol	  (35-­‐fold).	  Besides,	  the	  mineralocorticoid	  aldosterone	  was	  evaluated	  as	  well	  [35],	  
but	   only	   a	   1.5-­‐fold	   increase	   could	   be	   noticed	   which	   is	   much	   less	   than	   the	   observed	   70-­‐fold	  
increase	   of	   cortisol.	   Increased	   cortisol	   production	   following	   ACTH	   treatment	   confirmed	   the	  
potency	  of	   this	  hormone	  to	  stimulate	   the	  glucocorticoid	  synthesis	  by	   the	  adrenal	  gland.	  These	  
results	   endorse	   the	   findings	   of	   Pavlovic	   et	   al.	   (2013)	   [32],	   whereby	   2-­‐	   to	   5-­‐fold	   increases	   of	  
cortisol,	  tetrahydrocortisone	  and	  allotetrahydrocortisol	  were	  observed	  under	  influence	  of	  stress	  
at	  slaughter.	  The	  concentrations	  of	  cortisol	  and	  its	  associated	  metabolites	  24	  h	  post-­‐treatment	  
were	  similar	  to	  those	  before	  tetracosactide	  hexaacetate	  treatment.	  These	  results	  are	  in	  line	  with	  
Pompa	  et	  al.	  (2011)	  [36].	  	  
The	   increased	   cortisol	   secretion	   resulted	   in	   lower	   prednisolone/cortisol	   ratios	   during	   ACTH	  
treatment	   than	   during	   growth-­‐promoting	   prednisolone	   treatments.	   In	   this	   study,	   this	   ratio	  
ranged	   from	   0.0603	   to	   9.55	   during	   PO	   growth-­‐promoting	   prednisolone	   administration,	   from	  
1.57	  to	  36.9	  during	  IM	  growth-­‐promoting	  prednisolone	  administration,	  from	  0.00379	  to	  0.0763	  
at	  4	  h	  after	  ACTH	  treatment,	  and	  from	  0.0147	  to	  0.129	  at	  6	  h	  after	  ACTH	  treatment	  (Figure	  5.7.).	  
A	   significant	  difference	   (p	  ≤	  0.05)	  between	   the	  prednisolone/cortisol	   ratios	  could	  be	  detected,	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however,	   the	   ratios	   changed	   quickly	   when	   the	   time	   between	   ACTH	   administration	   and	   urine	  
sampling	   increased.	   Therefore,	   the	   determination	   of	   a	   valid	   threshold	   level	   for	   the	  
prednisolone/cortisol	   level	   remains	  hard.	  Consequently,	   these	   results	  give	  a	   first	   insight	   in	   the	  
prednisolone/cortisol	   ratios	   under	   different	   circumstances	   (growth-­‐promoting	   prednisolone	  
administration	   and	   artificial	   induced	   cortisol	   levels).	   However,	   further	   evaluation	   of	  
prednisolone/cortisol	   ratios	   in	   case	   of	   natural	   endogenous	   prednisolone	   levels	   in	   the	   field	  
remains	  necessary.	  	  
	  
	  
Figure	  5.7.	  Log	  prednisolone/cortisol	  urinary	  concentration	  ratios	  in	  bovine	  urine	  collected	  during	  oral	  and	  
intramuscular	  growth-­‐promoting	  prednisolone	  treatment	  and	  during	  ACTH	  administration.	  	  
4. Conclusion	  
In	   this	   study,	   the	   pharmacokinetics	   and	   urinary	   excretion	   profiles	   of	   prednisolone	   and	   its	  
metabolites	  were	  determined,	  thereby	  considering	  different	  types	  of	  prednisolone	  treatments.	  
Based	   on	   these	   results,	   it	   was	   concluded	   that	   20β-­‐dihydroprednisolone	   is	   the	   main	  
prednisolone-­‐derived	  metabolite	  in	  bovine	  plasma	  and	  urine.	  Although	  other	  metabolites	  were	  
detected	   as	   well,	   these	   were	   only	   sporadically	   present	   in	   plasma.	   During	   ACTH	   treatment,	  
prednisolone	   and	   its	   metabolites	   could	   be	   detected	   in	   urine	   until	   24	   h	   after	   the	   end	   of	   the	  
treatment.	  This	  study	  confirmed	  the	  presence	  of	  a	  negative	  feedback	   loop	  within	  the	  HPA-­‐axis	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after	  prednisolone	  treatment.	  On	  the	  other	  hand,	  following	  ACTH	  treatment,	  cortisol	  secretion	  
increased.	  Since	  the	  urinary	  prednisolone	  concentrations	  after	  growth-­‐promoting	  administration	  
were	  below	  the	  threshold	  suggested	  by	  the	  EURL	  (5	  µg	  L-­‐1),	  proper	  screening	  tools	  are	  necessary	  
to	   confirm	   the	   origin	   of	   prednisolone	   in	   bovine	   urine.	   Therefore,	   the	   validity	   of	   20β-­‐
dihydroprednisolone	   and	   the	   prednisolone/cortisol	   ratios	   as	   potential	   screening	   tools	   were	  
evaluated.	  For	  the	  metabolite	  20β-­‐dihydroprednisolone	  it	  was	  hard	  to	  determine	  an	  appropriate	  
threshold	   due	   to	   the	   large	   variation	   and	   overlay	   between	   endogenous	   and	   exogenous	  
concentrations.	   The	   prednisolone/cortisol	   ratio	   gave	   a	   more	   clear	   discrimination,	   however,	  
further	  evaluation	  of	  ratios	  obtained	  in	  the	  field	  remains	  necessary.	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The	  use	  of	  glucocorticoids	  as	  growth	  promoters	  for	  meat-­‐producing	  animals	  is	  strictly	  regulated	  
within	  the	  European	  Union.	  However,	  in	  the	  past	  few	  years,	  a	  higher	  frequency	  of	  non-­‐compliant	  
bovine	  urine	  samples	  for	  prednisolone	  has	  been	  noticed,	  which	  could	  not	  be	  directly	  related	  to	  
fraudulent	  use	  of	  prednisolone.	  As	  such,	  questions	  have	  risen	  about	  the	  origin	  of	  this	  compound.	  
Unfortunately,	   at	   present,	   no	   decisive	   strategy	   has	   been	   established	   to	   discriminate	   between	  
endogenous	  and	  exogenous	  prednisolone.	   In	   this	  study,	  an	  untargeted	  metabolomics	  strategy,	  
based	  on	  Orbitrap	  and	  QqTOF	  mass	  spectrometry,	  was	  deployed	  to	  reveal	  urinary	  biomarkers,	  
which	   are	   indicative	   for	   the	   exogenous	   administration	   of	   the	   synthetic	   glucocorticoid	  
prednisolone.	  For	  this	  purpose,	  prednisolone	  was	  administered	  intramuscularly	  and	  per	  os	  to	  12	  
bovines	   and	  a	   total	   of	   2700	  urine	   samples	  were	   collected	  before,	   during	  and	  after	   treatment.	  
Multivariate	  statistical	  data	  analysis	  (i.e.	  OPLS-­‐DA)	  revealed	  four	  differentiating	  metabolites	  that	  
allowed	   discrimination	   between	   urine	   samples	   collected	   before	   and	   during	   prednisolone	  
administration.	   None	   of	   these	   compounds	   were	   present	   in	   urine	   containing	   endogenous	  
prednisolone,	  of	  which	  the	  formation	  was	  induced	  by	  the	  administration	  of	  a	  synthetic	  analogue	  
of	  adrenocorticotropic	  hormone	  (ACTH).	  Only	  one	  metabolite	  was	  retained	  as	  a	  highly	  suitable	  
biomarker	   during	   growth-­‐promoting	   and	   therapeutic	   prednisolone	   treatment,	   with	   93.4%	  
sensitivity	  and	  96.3%	  specificity.	  Besides,	  this	  compound	  could	  be	  detected	  up	  to	  four	  days	  after	  
a	   single	   therapeutic	   per	   os	   prednisolone	   administration.	   Based	   on	   accurate	   mass,	   isotope	  
pattern,	   and	  MS/MS	   spectra,	   this	   compound	  was	  putatively	   annotated	  and	   is	   suggested	  as	   an	  







Natural	  glucocorticoids	   (cortisol	  and	  cortisone)	  are	   involved	   in	  various	  physiological	  processes,	  
closely	   related	   to	   immune	   activity	   (inflammation).	   As	   such,	   their	   anti-­‐inflammatory	   properties	  
have	   led	  to	  the	  development	  of	  synthetic	  analogs,	  which	  proved	  even	  more	  potent.	  Prolonged	  
exposure	   to	   synthetic	   glucocorticoids,	   like	   prednisolone, results	   in	   growth-­‐promoting	   side	  
effects.	   Therefore,	   synthetic	   glucocorticoids	   may	   be	   fraudulently	   administered	   to	   meat-­‐
producing	   animals	   [1][2].	   In	   order	   to	   protect	   consumers	   against	   potential	   harmful	   residues,	  
present	   in	   animal	   derived	   food	   products,	   the	   therapeutic	   use	   of	   synthetic	   glucocorticoids	   in	  
livestock	  has	  been	  strictly	  regulated	  in	  the	  European	  Union	  [3].	  Maximum	  residue	  limits	  (MRLs)	  
have	   been	   introduced	   for	   betamethasone,	   dexamethasone,	   methylprednisolone	   and	  
prednisolone	   in	   various	   edible	   tissues	   of	   animal	   origin	   [4].	   Moreover,	   the	   use	   of	   synthetic	  
glucocorticoids	   is	   completely	  prohibited	   for	   the	   sole	  purpose	  of	   increasing	   the	  body	  weight	  of	  
bovines.	  	  
In	   light	   of	   the	  national	   control	   plans	  within	   the	   European	  Union,	   urine	   analyses	   are	   of	   critical	  
importance	   in	   monitoring	   illegal	   administration	   of	   glucocorticoids.	   Recently,	   the	   European	  
Commission	  reported	   in	   the	  Commission	  Staff	  Working	  Document	   ‘Implementation	  of	  national	  
residue	   monitoring	   plans	   in	   the	   member	   states’	   [5][6][7][8]	   an	   increasing	   occurrence	   of	  
prednisolone	  residues	  (3.12	  -­‐	  179.72	  μg	  L-­‐1)	  in	  bovine	  urine	  samples	  without	  any	  direct	  evidence	  
for	   illegal	  administration.	  A	  number	  of	  hypotheses	  have	  been	  suggested	  to	  explain	  this	  specific	  
finding,	  i.e.	  prednisolone	  could	  be	  generated	  by	  physiologic	  metabolic	  processes	  under	  influence	  
of	  stress,	  which	  resulted	  in	  higher	  cortisol	  levels	  (during	  transport	  and	  slaughtering)	  [9][10][11]	  
or	  by	   faecal	  microbial	   contamination	  of	  urine	   [12].	   The	   latter	  hypothesis	   arose	   from	   the	   close	  
structural	  relationship	  of	  prednisolone	  to	  cortisol,	  only	  differing	  by	  one	  double	  bond	  on	  ring	  A	  at	  
the	  C1-­‐C2	  position,	  which	  has	  recently	  been	  evidenced	  by	  de	  Rijke	  et	  al.	  (2014)	  [13].	  Indeed,	  in	  
vitro	  incubation	  experiments	  of	  cortisol	  with	  bovine	  liver	  enzymes	  showed	  a	  significant	  decrease	  
of	   cortisol	   together	   with	   formation	   of	   prednisolone	   within	   six	   hours.	   To	   take	   into	   account	  
potential	   other	   origins	   for	   prednisolone	   at	   concentration	   levels	   below	   5	   μg	   L-­‐1,	   European	  




At	   this	   time,	   a	   method	   for	   direct	   discrimination	   between	   endogenous	   and	   exogenous	  
prednisolone	  has	  not	  yet	  been	  established.	  One	  powerful	  and	  promising	  strategy	  could	  be	  the	  
use	   of	   isotope	   ratio	  mass	   spectrometry	   (IRMS).	   This	   has	   already	   been	   applied	   to	   differentiate	  
synthetic	   testosterone	   and	   estradiol	   from	   natural	   hormones	   in	   urine,	   by	   considering	   their	  
inherent	  and	  different	  13C/12C	  ratios	  [15][16][17].	  However,	  some	  significant	  disadvantages	  such	  
as	  low	  sensitivity	  and	  labour-­‐intensive	  clean-­‐up	  are	  associated	  with	  this	  technique	  [18].	  A	  second	  
promising	  approach	  would	  be	  an	  untargeted	  metabolomics	  strategy,	  aiming	  at	  the	  identification	  
of	   potential	   biomarkers	   that	   allow	   discrimination	   between	   endogenous	   formation	   and	  
exogenous	   administration	   of	   prednisolone.	   This	   biomarker	   could,	   after	   evaluation,	   be	  
implemented	   in	   the	   frame	  of	  national	   control	  plans	  as	   screening	  method	   [19].	  The	  use	  of	   full-­‐
scan	  methods,	  preferably	  by	  means	  of	  high-­‐resolution	  mass	  spectrometry	  (HRMS),	  such	  as	  Time-­‐
of-­‐Flight	   (TOF)	   [20],	   Fourier	   Transform	   Ion	   Cyclotron	   Resonance	   [21]	   or	   Fourier	   Transform	  
Orbitrap	   MS	   [22][23],	   is	   highly	   encouraged	   for	   such	   biomarker	   investigations.	   Indeed,	   by	  
screening	   biological	   samples	  with	   full-­‐scan	  HRMS,	   a	   virtually	   unlimited	  number	   of	   compounds	  
can	  be	  analyzed	  simultaneously	  and	  retrospective	  post-­‐acquisition	  evaluation	  of	  data	  can	  reveal	  
unidentified	   and/or	   unknown	   metabolites	   [23].	   The	   identification	   of	   these	   metabolites	   is	  
currently	  seen	  as	  the	  major	  bottleneck	  in	  the	  interpretation	  of	  metabolomics	  experiments	  [24].	  
In	   this	   regard,	  MS/MS	  or	   fragmentation	  data	  may	  enclose	  valuable	   identification	  potential.	   To	  
obtain	  these	  types	  of	  data	  (i.e.	  both	  accurate	  molecular	  mass	  and	  fragmentation	  pattern)	  within	  
a	   single	  analytical	   run,	  hybrid	  HRMS	   instruments	   like	  Q-­‐Orbitrap-­‐MS	  and	  Quadrupole	  Time-­‐of-­‐
Flight-­‐MS	   are	   most	   designated	   [24][25][26][27].	   For	   further	   identity	   confirmation,	   it	   is	  
recommended	  to	  validate	  the	  structure	  candidates	  by	  nuclear	  magnetic	  resonance	  spectroscopy	  
(NMR)	   [28][29]	   or	   by	  matching	   the	   retention	   time	   and	  mass	   spectra	   with	   those	   of	   authentic	  
reference	  standards	  [30],	  although	  these	  are	  of	  course	  not	  readily	  available	  for	  every	  compound	  
[31].	  	  
The	   aim	   of	   this	   work	   was	   to	   reveal	   potential	   biomarkers	   for	   exogenous	   prednisolone	  
administration	  in	  bovine	  urine	  by	  using	  a	  metabolic	  fingerprinting	  approach.	  To	  this	  extent,	  an	  in	  
vivo	   study	  was	   conducted	  with	   12	   adult	   cows	   that	   subsequently	  were	   subjected	   to	   a	   growth-­‐
promoting	   treatment	   (low	  dosage	   long-­‐term)	  and	  a	   therapeutic	   treatment	   (high	  dosage	   short-­‐
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term)	   with	   prednisolone.	   Collected	   urine	   samples	   were	   analyzed	   by	   both	   full-­‐scan	   UHPLC-­‐
Orbitrap-­‐MS	  and	  UHPLC-­‐QqTOF-­‐MS	  to	  acquire	  the	  specific	  metabolic	  fingerprints	  corresponding	  
to	   the	  different	  prednisolone	   treatments.	  Next,	  multivariate	  analysis	  by	  means	  of	  Orthogonal-­‐
Partial	  Least	  Squares-­‐Discriminant	  Analysis	  (OPLS-­‐DA)	  was	  employed	  to	  search	  for	  differentiating	  
metabolites	   linked	   to	  exogenous	  prednisolone	  administration.	  After	  metabolite	  discovery,	   it	   is	  
necessary	  to	  evaluate	  the	  classification	  performance	  of	  the	  newly	  defined	  compounds	  [32].	  The	  
performance	   of	   the	   newly	   obtained	   metabolites	   was	   defined	   by	   sensitivity	   and	   specificity	  
[33][34].	   In	  addition,	  the	  urinary	  excretion	  kinetics	  of	  the	  revealed	  biomarkers	  were	  monitored	  
after	  a	  single	  therapeutic	  per	  os	  dose	  of	  prednisolone	  [35].	  Insights	  in	  these	  metabolites’	  kinetics	  
could	  indeed	  be	  of	  special	  interest	  to	  extend	  the	  detection	  period	  of	  illegal	  prednisolone	  abuse,	  
i.e.	   when	   the	   detection	   limit	   of	   prednisolone	   is	   more	   rapidly	   reached	   than	   that	   of	   the	  
biomarker(s).	  	  
2. Material	  and	  methods	  
2.1. 	  Animals	  
In	  this	  study,	  a	  diverse	  group	  of	  cattle	  was	  compiled	  in	  order	  to	  include	  the	  potential	  influence	  of	  
biological	   variation	   on	   the	   specific	   biomarker	   identification.	   More	   specifically,	   twelve	   healthy	  
cows	  of	  a	  mixed	  breed,	  varying	  age	  (2	  -­‐	  6	  years),	  with	  a	  body	  weight	  between	  360	  -­‐	  570	  kg	  were	  
housed	   for	   8	  months	   under	   controlled	   experimental	   conditions	   in	   the	   animal	   facilities	   of	   the	  
Centre	   d’Economie	   Rurale	   (CER)	   (Marloie,	   Belgium).	   The	   animals	   were	   fed	   a	   commercially	  
available	  diet,	  commonly	  applied	   in	  zootechnical	  practice,	  with	  ad	   libitum	  access	   to	  water	  and	  
hay.	  During	  the	  entire	  study,	  animals	  were	  kept	  in	  three	  separate	  groups	  (4	  animals	  per	  group)	  
and	  all	  housed	  in	  a	  half	  covered	  pen.	  Prior	  to	  the	  in	  vivo	  study,	  an	  initial	  acclimatization	  period	  of	  
14	  days	  was	  considered.	  In	  order	  to	  consider	  animal	  growth	  during	  the	  in	  vivo	  study,	  the	  animals	  
were	  weighted	  at	  the	  start	  and	  at	  the	  end	  of	  the	  experiment,	  but	  no	  significant	  differences	  were	  
observed.	  The	  in	  vivo	  study	  was	  approved	  by	  CER’s	  Ethical	  Committee	  (CE/Sante/ET/004).	  	  
2.2. 	  Experimental	  protocol	  
After	   the	   acclimatization	   period,	   which	   served	   as	   control,	   all	   animals	   underwent	   the	   same	  
sequential	   prednisolone	   treatments:	   a	   growth-­‐promoting	   treatment	   (long-­‐term,	   40	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mg/cow/day)	   followed	   by	   a	   therapeutic	   treatment	   (short-­‐term,	   0.5	   mg	   kg-­‐1	   b.w./day)	   (Figure	  
6.1.).	   The	   specific	   dosages	   were	   based	   on	   literature	   findings	   [10][36][37]	   to	   ensure	   relevant	  
levels	  of	  prednisolone	  and	  potential	  metabolites	  in	  urine.	  
	  
Figure	   6.1.	   Schematic	   representation	   of	   the	   in	   vivo	   study,	   indicating	   the	   various	   experimental	   sections	  
with	  oral	  (PO)	  and	  intramuscular	  (IM)	  prednisolone	  administrations	  and	  their	  duration.	  This	  experimental	  
protocol	  was	  specifically	  executed	  to	  each	  individual	  animal	  (n	  =	  12)	  
The	  growth-­‐promoting	  treatment	  started	  with	  30	  consecutive	  days	  of	  oral	  administration	  of	  40	  
mg/day	  of	  prednisolone	  (Sigma-­‐Aldrich	  St.	  Louis,	  USA)	  (Day+1	  till	  Day+30)	  (PO1),	  followed	  by	  a	  
washout	   period	   of	   10	   days	   (WO1).	  Next,	   intramuscular	   injections	   of	   40	  mg/day	   of	   Solu-­‐Delta-­‐
Cortef®	   (prednisolone	   sodium	   succinate,	   Zoetis,	   Zaventem,	   Belgium)	   were	   given	   for	   30	  
consecutive	   days	   (Day+41	   till	   Day+70)	   (IM1).	   Before	   the	   start	   of	   the	   therapeutic	   prednisolone	  
treatment,	  a	  washout	  period	  of	  35	  days	  was	  considered	  (WO2).	  	  
During	  the	  therapeutic	  prednisolone	  treatment,	  a	  similar	  experimental	  set-­‐up	  was	  implemented.	  
First,	   the	   animals	   received	   0.5	   mg	   kg-­‐1	   b.w.	   of	   prednisolone	   per	   os	   for	   5	   days	   (Day+106	   till	  
Day+110)	  (PO2),	  which	  was	  followed	  by	  a	  washout	  period	  of	  25	  days	  (WO3).	  Next,	  intramuscular	  
injections	   of	   0.5	   mg	   kg-­‐1	   b.w.	   of	   Solu-­‐Delta-­‐Cortef®	   (Zoetis)	   were	   administered	   during	   5	  
consecutive	  days	  (Day+136	  till	  Day+140)	  (IM2).	  A	  final	  washout	  period	  of	  32	  days	  (Day+141	  till	  
Day+172)	  was	  respected	  (WO4).	  
During	   the	   periods	   of	   oral	   administration,	   one	   capsule	   containing	   the	   appropriate	   amount	   of	  
prednisolone,	   using	   lactose	   as	   excipient,	   was	   given	   in	   the	  morning	   just	   after	   feeding,	   using	   a	  
capsule	   launcher.	   The	   intramuscular	   injections	   were	   placed	   in	   the	   neck	   and	   were	   alternated	  
every	  day	  from	  the	  left	  to	  the	  right	  side	  in	  order	  to	  minimize	  irritation.	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2.3. 	  Sample	  collection	  
Urine	  samples	  were	  collected	  in	  the	  morning,	  5	  minutes	  before	  prednisolone	  administration,	  by	  
a	  veterinarian	  using	  a	  probe	   (to	  prevent	   faecal	  contamination),	   immediately	  portioned	   into	  15	  
mL	  tubes,	  and	  stored	  in	  the	  dark	  at	  -­‐80	  °C	  until	  analysis	  [38].	  As	  for	  the	  sampling	  rate,	  during	  the	  
acclimatization	  period,	  urine	  samples	  were	  collected	  daily.	  During	  the	  therapeutic	  and	  growth-­‐
promoting	   prednisolone	   treatments	   and	   washout	   periods,	   samples	   were	   collected	   every	   five	  
days.	  
2.4. 	  Reagents	  and	  Chemicals	  
Standards	   of	   prednisolone,	   prednisone,	   cortisone,	   cortisol,	   20β-­‐dihydrocortisone	   and	  
methylprednisolone	   were	   purchased	   from	   Sigma-­‐Aldrich	   (St.	   Louis,	   USA).	   Standards	   of	   20α-­‐
dihydroprednisolone	   and	   20β-­‐dihydroprednisolone	   were	   from	   Steraloids	   (Rhode	   Island,	   USA).	  
Internal	  standards	  were	  cortisol-­‐d4	   (Sigma-­‐Aldrich)	  and	  prednisolone-­‐d8	   (TRC,	  Canada).	  Primary	  
stock	  solutions	  were	  prepared	  in	  ethanol	  at	  a	  concentration	  of	  200	  μg	  mL-­‐1	  and	  stored	  in	  dark	  	  
glass	  bottles	  at	  -­‐20	  °C.	  Working	  solutions	  were	  made	  in	  ethanol	  at	  a	  range	  of	  0.1	  –	  10	  μg	  mL-­‐1.	  
Reagents	  were	  of	  analytical	  grade	  when	  used	  for	  extraction	  purposes	  and	  obtained	  from	  VWR	  
International	  (Merck,	  Darmstadt,	  Germany).	  For	  UHPLC-­‐HRMS	  applications,	  reagents	  were	  of	  LC-­‐
MS	  Optima	  grade	  and	  obtained	  from	  Fisher	  Scientific	  (Loughborough,	  UK).	  Ultrapure	  water	  was	  
produced	  with	  an	  Arium	  611	  UV	  system	  (Sartorium	  Stedim	  Biotech,	  Aubagne,	  France).	  	  
2.5. Sample	  preparation	  
A	   detailed	   description	   of	   the	   analytical	   procedure	   for	   extraction	   and	   purification	   of	   urine	  
samples	  has	  been	  described	  by	  De	  Clercq	  et	  al.	   (2013)	   [38].	   In	  brief,	  a	   five	  mL	  aliquot	  of	  urine	  
was	   spiked	   with	   internal	   standards	   (cortisol-­‐d4	   and	   prednisolone-­‐d8)	   to	   obtain	   final	  
concentration	   levels	   of	   10	   μg	   L-­‐1.	   Next,	   a	   twofold	   liquid-­‐liquid	   extraction	   with	   pure	   tert-­‐butyl	  
methylether	   was	   performed.	   The	   organic	   phases	   were	   collected,	   pooled	   and	   dried	   under	   a	  
gentle	  stream	  of	  nitrogen	  at	  a	  temperature	  of	  50	  °C.	  The	  residue	  was	  dissolved	  in	  100	  μL	  solvent,	  





Untargeted	   analysis	   of	   urine	   samples	   was	   performed	   by	   UHPLC-­‐Orbitrap	   mass	   spectrometry,	  
according	  to	  the	  validated	  method	  of	  De	  Clercq	  et	  al.	   (2013)	  [38].	  Chromatographic	  separation	  
was	   thereby	   achieved	   on	   an	   Accela	   UHPLC	   system	   (Thermo	   Fisher	   Scientific,	   San	   José,	   USA),	  
equipped	  with	  a	  Nucleodur	  Isis	  C18	  column	  (1.8	  μm,	  100	  mm	  x	  2	  mm,	  Macherey-­‐Nagel,	  Düren,	  
Germany).	  The	  binary	  solvent	  system	  consisted	  of	  0.1%	  aqueous	  formic	  acid	  (A)	  and	  0.1%	  formic	  
acid	   in	   acetonitrile	   (B).	   The	   applied	   gradient	   program	   and	   other	   chromatographic	   parameters	  
are	   presented	   in	   Table	   6.1.	  High-­‐resolution	  mass	   spectrometric	   analysis	  was	  performed	  on	   an	  
ExactiveTM	   single-­‐stage	   Orbitrap	  mass	   spectrometer	   (Thermo	   Fisher	   Scientific,	   San	   José,	   USA),	  
equipped	   with	   a	   heated	   electrospray	   ionization	   probe	   (HESI-­‐II),	   operating	   in	   the	   polarity	  
switching	   mode.	   Instrument	   control	   and	   data	   processing	   were	   carried	   out	   by	   Xcalibur	   2.1	  
software	  (Thermo	  Fisher	  Scientific,	  San	  José,	  USA).	  
2.6.2. UHPLC-­‐QqTime-­‐of-­‐Flight	  
For	  structure	  elucidation	  of	  the	  differentiating	  metabolites,	  urine	  samples	  were	  also	  analysed	  by	  
UHPLC-­‐QqTOF-­‐MS.	  This	  hybrid	  system	  enables	  full-­‐scan	  HRMS	  analysis	  in	  combination	  with	  HR-­‐
MRM	   like	   fragmentation	   (MRMHR).	   The	   TripleTOF®	   4600	  mass	   analyser	   (SCIEX,	   California,	  USA)	  
was	   coupled	   to	   a	   UHPLC	   UltraLC	   100-­‐XL	   system	   (SCIEX),	   consisting	   of	   an	   Eksigent	   pumping	  
system,	  autosampler	  and	  degasser.	  The	  parameters	  of	  the	  chromatographic	  separation,	  using	  a	  
Nucleodur	  C18	  Isis	  column	  (1.8	  μm,	  100	  mm	  x	  2	  mm,	  Macherey-­‐Nagel)	  (Table	  6.1.).	  
The	   TripleTOF®	   4600	   mass	   analyser	   was	   equipped	   with	   a	   DuoSprayTM	   source,	   comprising	   an	  
electrospray	  (TIS)	  as	  well	  as	  an	  atmospheric	  pressure	  chemical	  ionization	  (APCI)	  inlet.	  Ionization	  
of	  the	  compounds	  was	  achieved	  using	  the	  electrospray	  inlet	  (TurboIonSpray®	  TIS)	  and	  operated	  
separately	   in	  the	  positive	  and	  negative	  ion	  mode.	  For	  every	  10	  samples,	  automated	  calibration	  
was	   performed	   using	   an	   external	   calibrant	   delivery	   system	   (CDS),	   which	   infuses	   calibration	  
solution	   prior	   to	   sample	   analysis.	   The	   mass	   spectrometer	   was	   operated	   in	   the	   information-­‐
dependent	  acquisition	  (IDA)	  mode,	  combining	  full-­‐scan	  TOF-­‐MS	  survey	  and	  MS/MS	  experiments.	  
During	   the	   full-­‐scan	   survey,	   spectral	   data	   about	   all	   ions,	   present	  within	   the	   selected	  m/z	   scan	  
range	  of	  150-­‐650	  Da,	  were	  acquired	  for	  each	  scan.	  In	  addition,	  for	  every	  scan	  the	  fragmentation	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profiles	  of	  the	  top	  five	  abundant	   ions	  were	  generated	  by	  MS/MS.	  However,	   ions	  that	  occurred	  
seven	   consecutive	   times	  within	   the	   top	   five	  of	  most	   abundant	   ions	  were	  excluded	   for	  MS/MS	  
experiments	   for	   1	   sec.	   Instrument	   control	  was	   carried	  out	   by	  Analyst®	   TF	   1.6	   software	   (SCIEX,	  
California,	  USA).	  	  
Table	   6.1.	   Overview	   of	   the	   specific	   UHPLC-­‐Orbitrap-­‐MS	   and	  UHPLC-­‐QqTOF-­‐MS	   parameters	   used	   during	  
urine	  analysis.	  	  
	   UHPLC-­‐Orbitrap-­‐MS	   UHPLC-­‐QqTOF-­‐MS	  
UHPLC	   	   	  
Column	  oven	  temperature	   30	  °C	   40	  °C	  
Flow	   0.30	  µL	  min-­‐1	   0.35	  µL	  min-­‐1	  
Gradient	   Time	  (min)	   B%	  (v/v)	   Time	  (min)	   B%	  (v/v)	  
	   0.0	   20	   0.0	   25	  
	   1.0	   25	   7.0	   25	  
	   6.0	   25	   8.0	   95	  
	   7.0	   95	   9.0	   100	  
	   8.0	   100	   11.0	   100	  
	   10.0	   100	   11.1	   25	  
	   10.1	   20	   13.0	   25	  
	   12.0	   20	   	   	  
	   	   	   	   	  
Ionization	   HESI	  (II)	   DuoSprayTM	  (TIS)	  
	   Spray	  voltage	   4	  kV	   Ion	  source	  gas	  1	   50	  psib	  
	   Sheath	  gas	  flow	  rate	   75	  aua	   Ion	  source	  gas	  2	   60	  psi	  
	   Auxiliary	  gas	  flow	  rate	   7	  au	   Curtain	  gas	   25	  psi	  
	   Sweep	  gas	  flow	  rate	   2	  au	   Temperature	   450	  °C	  
	   Capillary	  temperature	   280	  °C	   Ion	  spray	  voltage	   5500	  (-­‐4500)	  V	  
	   Heater	  temperature	   300	  °C	   	   	  
	   Capillary	  voltage	   45	  (-­‐32)	  V	   	   	  
	   Tube	  lens	  voltage	   95	  (-­‐100)	  V	   	   	  
	   Skimmer	  voltage	   16	  (-­‐20)	  V	   	   	  
	   	   	   	   	  
Full-­‐scan	  MS	   	   	   	   	  
Mass	  resolution	   50,000	  FWHM	  at	  m/z	  200	   30,000	  FWHM	  at	  m/z	  956	  
m/z	  range	  (Da)	   150	  to	  650	   150	  to	  650	  
Maximum	  injection	  time	   500	  ms	   200	  ms	  
	   	   	  
MS/MS	   	   	  
Fragmentation	  mode	   -­‐	   IDA	  
m/z	  range	   -­‐	   50	  to	  450	  
Max.	  N°	  of	  candidate	  ions	   -­‐	   5	  
Accumulation	  time	   -­‐	   150	  ms	  
Collision	  Energy	   -­‐	   30	  eV	  
Collision	  Energy	  Spread	   -­‐	   15	  eV	  





The	  NMR	  spectra	  of	  the	  revealed	  metabolite	  biomarker	  were	  measured	  on	  an	  Avance	  II	  Bruker	  
spectrometer	  operating	  at	  a	  1H	  frequency	  of	  700	  MHz	  and	  equipped	  with	  a	  1-­‐mm	  1H/13C/15N	  TXI-­‐
z	   probe	   to	   allow	   maximum	   sensitivity,	   taking	   into	   account	   the	   limited	   amount	   of	   available	  
sample.	  	  The	  dried	  sample	   (<	  10	  µg)	  was	  dissolved	   in	  ±	  10	  µL	  MeOD-­‐d4	   (99.96%	  D)	   in	  order	   to	  
minimize	   potential	   signal	   interferences	   from	   the	   solvent.	   All	   spectra	   were	   referenced	   to	   the	  
residual	  solvent-­‐signals	  at	  3.31	  (5)	  ppm	  for	  the	  1H	  frequency.	  	  
2.7. Chemometric	  data	  analysis	  
In	   this	   study,	   the	   general	   workflow	   of	   data	   acquisition	   and	   analysis	   can	   be	   organized	   into	  
multiple	  steps.	  A	  first	  step	  relates	  to	  the	  extraction	  of	  urine	  samples.	  Due	  to	  the	  large	  number	  of	  
collected	   urine	   samples,	   sample	   preparation	   and	   analysis	   were	   performed	   in	   subsequent	  
batches	  of	  four	  animals.	  The	  first	  batch	  consisted	  of	  the	  urine	  samples	  of	  animals	  1,	  5,	  7	  and	  12.	  
The	   second	   batch	   contained	   the	   urine	   samples	   of	   animals	   2,	   4,	   6	   and	   11,	   and	   the	   last	   batch	  
included	  urine	  of	   animals	   3,	   8,	   9	   and	  10.	   Each	  batch	  was	   first	   analyzed	  on	   the	  ExactiveTM	   and	  
later	  on	   reanalyzed	  on	   the	  TripleTOF®	  4600.	   Samples	  were	  analysed	   in	  a	   random	  order	  during	  
each	  batch.	  As	  such,	  both	  full-­‐scan	  data	  for	  metabolic	  fingerprinting	  and	  MS/MS	  fragmentation	  
patterns	  for	  identification	  were	  acquired.	  Instrumental	  stability	  (quality	  control	  measure)	  during	  
mass	   spectrometric	   analyses	  was	   verified	   by	   considering	   standard	   injections.	   These	   injections	  
were	   run	   at	   the	   beginning	   and	   repeated	   every	   25	   samples.	   This	  mixture	   consisted	   of	   cortisol,	  
cortisone,	   dihydrocortisone,	   prednisolone,	   prednisone,	   methylprednisolone,	   20α-­‐
dihydroprednisolone	   and	   20β-­‐dihydroprednisolone.	   The	   following	   average	   coefficients	   of	  
variance	   (n	  =	  162)	  were	  obtained	   for	   the	  various	  glucocorticoids:	  6.39%	   for	  cortisol,	  5.51%	   for	  
cortisone,	  6.79%	  for	  dihydrocortisone,	  3.09%	  for	  prednisolone,	  4.35%	  for	  prednisone,	  8.39%	  for	  
methylprednisolone,	   7.61%	   for	   20α-­‐dihydroprednisolone	   and	   6.94%	   for	   20β-­‐
dihydroprednisolone.	   Based	   on	   the	   manuscript	   of	   Shah	   et	   al.	   (2000)	   [39],	   the	   acceptance	  
criterion	  to	  ensure	  system	  stability	  was	  set	  at	  15%.	  Since	  all	  absolute	  and	  average	  CVs	  were	  well	  
below	  15%,	  appropriate	   stability	  during	  analysis	  was	   concluded.	   In	   addition,	   relative	   retention	  
time	  changes	  during	  analysis	  were	  <	  1%	  (i.e.	  <	  0.04	  min). 
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The	  second	  step	  involved	  data	  pre-­‐processing	  (peak	  list	  generation),	  thereby	  using	  either	  SieveTM	  
2.1	   (Thermo	   Fisher	   Scientific,	   San	   José,	   USA)	   or	  MarkerViewTM	   1.2.1.1	   (SCIEX,	   California,	   USA)	  
software,	  to	  respectively	  process	  ExactiveTM	  (raw.files)	  and	  TripleTOF®	  4600	  (wiff.files)	  data	  files.	  
Taking	   into	   account	   that	   both	   full-­‐scan	   data	   sets	   enclosed	   information	   about	   both	   positively	  
and/or	   negatively	   charged	   ions,	   it	   was	   decided	   to	   handle	   both	   ionization	   modes	   separately	  
during	  peak	   list	  generation	   [23][40].	  Applied	  parameter	  values	   included	  an	  m/z-­‐range	  of	  150	   -­‐	  
650	   Da,	   a	  m/z	   width	   of	   5	   ppm,	   a	   retention	   time	   window	   ranging	   from	   1	   to	   9.5	   min,	   a	   peak	  
intensity	  threshold	  of	  100,000	  arbitrary	  units,	  a	  maximum	  peak	  width	  of	  0.5	  min	  and	  a	  maximum	  
number	   of	   10,000	   frames.	   Furthermore,	   corrections	   for	   inherent	   chromatographic	   variability	  
along	   samples	  were	  made	  during	   the	  peak	   alignment	  process.	   This	   strategy	   rendered	   a	   list	   of	  
features	   (detected	   ions)	   that	  were	   characterized	  by	   their	  m/z-­‐value,	   retention	   time	  and	   signal	  
abundance.	  The	  signal	  intensities	  of	  these	  ions	  were	  for	  each	  sample	  normalized	  by	  the	  average	  
signal	  intensity	  of	  the	  two	  deuterium	  labeled	  internal	  standards	  i.e.	  cortisol-­‐d4	  and	  prednisolone-­‐
d8,	  which	  were	  supplemented	  prior	  to	  extraction.	  Moreover,	  since	  urine	  is	  a	  matrix	  subjected	  to	  
potential	  dilution	  effects,	  a	  secondary	  normalization	  was	  implemented.	  As	  suggested	  by	  Jacob	  et	  
al.	   (2014)	   [42],	   normalization	   by	   means	   of	   specific	   gravity	   (Pocket	   RefractometerTM,	   Atago,	  
Tokyo)	  based	  on	  the	  Levine-­‐Fahy	  equation	  [42]	  (correction	  factor	  ranged	  from	  1.003	  to	  1.0044)	  
was	  implemented.	  
In	   the	   final	   step,	   multivariate	   statistical	   analysis	   was	   performed	   by	   means	   of	   SIMCATM	   13	  
software	   (Umetrics,	   Malmö,	   Sweden)	   in	   order	   to	   reveal	   significant	   differences	   between	   the	  
metabolic	   fingerprints,	   associated	   with	   the	   various	   treatments.	   For	   this	   particular	   purpose,	  
OPLS-­‐DA	  was	  implemented,	  for	  revealing	  metabolite	  ions	  with	  discriminating	  power	  towards	  the	  
samples’	   class	   membership.	   Prior	   to	   this	   OPLS-­‐DA	  modelling,	   data	   were	   log-­‐transformed	   and	  
Pareto	   scaled	   (1/√SD,	   where	   SD	   is	   the	   standard	   deviation)	   to	   induce	   normality	   and	   to	  
standardize	   the	   range	   of	   independent	   X-­‐variables,	   respectively	   [43].	   Within	   the	   applied	  
modelling	   strategy,	   a	  qualitative	   relationship	  between	   the	  X-­‐matrix	   (detected	  metabolite	   ions)	  
and	   the	   dependent	   Y-­‐variable	   (prednisolone	   treatment	   samples	   ‘Treatment’	   or	   control	   urine	  
samples	   ‘Control’)	   was	   established.	   In	   this	   regard,	   the	   Y-­‐variable	  was	   defined	   as	   a	   qualitative	  
variable,	   representing	  the	  class	  membership	   [44][45][46].	  The	  advantage	  of	  OPLS	  compared	  to	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conventional	  PLS	  relates	  to	  the	  applied	  model	  rotation	  whereby	  class	  separation	  is	  found	  in	  the	  
first	  predictive	  component	   (correlated	  variation)	  and	  variation	  that	   is	  not	  correlated	  with	  class	  
separation	   is	   found	   in	   the	   orthogonal	   components	   (orthogonal	   variation)	   [47].	  Model-­‐validity	  
was	  verified	  by	  performing	  a	  7-­‐fold	  internal	  cross	  validation-­‐analysis	  of	  variance	  (CV-­‐ANOVA,	  p-­‐
value	  <	  0.01)	  [48],	  permutation	  testing,	  and	  considering	  three	  model	  characteristics	  (R2(X),	  R2(Y)	  
and	  Q2(Y)).	  The	  first	  model	  characteristic	  corresponds	  to	  the	  predictive	  and	  orthogonal	  variation	  
in	  X	  that	  is	  explained	  by	  the	  model,	  the	  second	  characteristic	  defines	  the	  total	  sum	  of	  variation	  
in	  Y	  that	  is	  explained	  by	  the	  model	  and	  the	  third	  refers	  to	  the	  goodness	  of	  prediction,	  calculated	  
by	   full	   cross-­‐validation	   [48][49].	  Response	  permutation	   testing	  was	  performed	   to	  estimate	   the	  
significance	   of	   the	   generated	   models,	   whereby	   the	   order	   of	   elements	   in	   the	   Y-­‐vector	   was	  
randomly	  permutated	  100	  times	  [49].	  	  
2.8. Preliminary	  biomarker	  validation	  
After	  discovery	  of	  differentiating	  metabolites,	   it	   is	  necessary	   to	  evaluate	   the	  performance	  and	  
usefulness	   of	   the	   defined	   compounds	   [50]	   whereby	   a	   distinction	   should	   be	   made	   between	  
analytical	   method	   validation	   and	   clinical	   qualification.	   Validation	   is	   defined	   as	   the	   process	   of	  
assessing	  the	  biomarker	  and	  its	  measurement	  performance	  characteristics,	  and	  determining	  the	  
range	  of	  conditions	  under	  which	  the	  biomarker	  will	  give	  reproducible	  and	  accurate	  data	  [51][52].	  
While	   clinical	   qualification	   is	   the	   evidentiary	   process	   of	   linking	   a	   biomarker	   with	   biological	  
processes	  and	  clinical	  endpoints	  [52].	  Both	  processes	  are	  intertwined	  since	  the	  aim	  is	  to	  link	  the	  
biomarker	  with	   its	   intended	  use	   [53].	   In	   this	   study,	   the	   selectivity,	  bio-­‐analytical	  performance,	  
and	  urinary	  excretion	  kinetics	  of	   the	  proposed	  marker	  molecules	  were	   included	  as	  preliminary	  
validation.	  Statistical	  analysis	  was	  performed	  using	  SPSSTM	  statistics	  21.	  
2.9. Identification	  of	  biomarkers	  
After	   evaluation	   of	   the	   relevant	   biomarkers,	   various	   identification	   steps	   were	   undertaken,	  
thereby	  using	  the	  TripleTOF®	  4600	  full-­‐scan	  MS	  and	  MS/MS	  spectra.	  In	  first	  instance,	  an	  in	  silico	  
based	   strategy	  was	   applied.	   Elemental	   compositions	  were	   thereby	   determined	   using	   Formula	  
Finder,	  a	  tool	  within	  MasterViewTM	  (SCIEX),	  and	  based	  on	  precursor	  mass,	  fragment	  masses	  and	  
isotopic	  pattern.	  The	  elements	  that	  were	  allowed	  for	  formula	  prediction	  were	  restricted	  to	  the	  
basic	  elements	  of	  natural	  metabolites,	  i.e.	  hydrogen	  (H),	  carbon	  (C),	  oxygen	  (O),	  nitrogen	  (N)	  and	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sulphur	   (S).	   To	   this	   extent,	   a	   mass	   deviation	   window	   of	   5	   ppm	   was	   allowed.	   Subsequently,	  
chemical	  formulas	  were	  screened	  towards	  an	  in-­‐house	  database,	  which	  comprises	  the	  elemental	  
composition	  of	  1693	  steroidal	  compounds	  (based	  on	  the	  11th	  catalogue	  edition	  of	  steroids	  from	  
Steraloids	   inc.).	   Next,	   structural	   elucidation	   was	   pursued	   by	   applying	   a	   combinatorial-­‐based	  
prediction	   strategy,	   thereby	   using	   the	  MetFrag	   software	   tool	   [54].	   Within	   this	   approach,	   the	  
acquired	   fragmentation	   spectrum	   of	   an	   ion	   is	   matched	   towards	   theoretically	   predicted	  
fragments	  of	  candidate	  structures	  from	  public	  compound	  libraries	  (ChemSpider	  and	  PubChem),	  
which	  allows	  to	  rank	  candidate	  chemical	  structures.	  A	  second	  identification	  strategy	  was	  based	  
on	  compound	  purification	  (preparative	  chromatography)	  and	  subsequent	  1H-­‐NMR	  analysis.	  
3. Results	  and	  discussion	  
3.1. Peak	  list	  generation	  
Peak	  list	  generation	  using	  Orbitrap-­‐MS	  data	  resulted	  in	  a	  metabolic	  fingerprint,	  which	  enclosed	  
9952	   positively	   charged	   and	   9494	   negatively	   charged	   ions.	   However,	   by	   excluding	   the	   13C	  
containing	  ion	  species,	  the	  fingerprint	  was	  reduced	  to	  only	  6637	  positively	  and	  5626	  negatively	  
charged	  monoisotopic	  ions.	  The	  same	  strategy	  was	  applied	  to	  the	  QqTOF-­‐MS	  data	  and	  yielded	  a	  
metabolic	   fingerprint,	   which	   comprised	   5085	   positive	   and	   8036	   negative	   monoisotopic	   ion	  
species.	  	  
3.2. Predictive	  modeling	  	  
The	  acquired	  data	  matrices	  were	  normalized	  and	  reorganized	  into	  a	  control	  group	  (Control,	  n	  =	  
120)	  and	  a	  treatment	  group	  (Treatment,	  n	  =	  216),	  which	  comprised	  all	  urine	  samples	  that	  were	  
either	   collected	   prior	   to	   or	   during	   prednisolone	   treatment.	   It	   should	   hereby	   be	   noted	   that	   all	  
types	   of	   prednisolone	   administration	   (per	   os	   vs.	   intramuscular)	   and	   all	   different	   treatment	  
strategies	   (growth-­‐promoting	   vs.	   therapeutic,	   long-­‐	   vs.	   short-­‐term)	   were	   combined	   into	   the	  
same	   ‘Treatment’	   group.	   This	  was	   to	  guarantee	   that	  differentiating	  metabolites	  were	   relevant	  
for	  exogenous	  prednisolone	  treatment	  across	  administration	  routes.	  The	  multivariate	  statistical	  
analysis,	  which	   aimed	   to	   reveal	   such	  metabolites,	  will	   first	   be	   discussed	   for	   the	   data	   set	   that	  
originated	  from	  the	  Orbitrap	  mass	  spectrometric	  analysis.	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OPLS-­‐DA	   models	   were	   separately	   constructed	   for	   the	   negatively	   and	   positively	   charged	   ions	  
(Supplementary	  Figure	  6.1.)	  and	  were	  each	  time	  evaluated	  through	  various	  validation	  strategies,	  
i.e.	  CV-­‐ANOVA	  (p	  <	  0.01),	  permutation	  testing,	  and	  three	  model	  characteristics	  (R2(X),	  R2(Y),	  and	  
Q2(Y)).	  With	  respect	  to	  the	  latter	  strategy,	  the	  following	  parameter	  values	  were	  obtained	  for	  the	  
constructed	  OPLS-­‐DA	  models	  (based	  on	  either	  the	  positive	  or	  negative	  ions,	  respectively):	  0.408,	  
0.993	   and	   0.894,	   and	   0.598,	   0.977	   and	   0.782.	   In	   this	   context,	   good	  model	   predictability	   was	  
assumed	   if	   R2(Y)	   is	   ≥	   0.5	   [48][55].	   As	   such,	   based	   on	   the	   various	   validation	   strategies,	   overall	  
good	   model	   quality	   was	   concluded.	   Next,	   to	   reveal	   the	   significance	   of	   particular	   ions	   to	  
discriminate	  between	  the	  control	  and	  treatment	  class,	  an	  S-­‐plot	  was	  constructed	  (Figure	  6.2.A).	  	  
Figure	   6.2.	   Loading	   S-­‐plot	   representing	   the	   leading	   contribution	   of	   positive	   (A1,B1)	   and	   negative	   (A2,B2)	  
ionized	  metabolite	  ions,	  respectively	  determined	  with	  SieveTM	  (A)	  and	  MarkerViewTM	  (B).	  Ions	  with	  VIP	  ≥	  3	  
and	  |p1|	  ≥	  0.05	  and	  a	  |p(corr)|	  ≥	  0.05	  are	  in	  red.	  Depending	  on	  the	  position	  in	  the	  S-­‐plot	  and	  the	  associated	  
p-­‐	  and	  p(corr)-­‐values,	  an	  ion	  was	  significant	  important	  towards	  ‘Treatment’	  (upper,	  right	  part	  of	  the	  plot)	  
or	  towards	  ‘Control’	  (lower,	  left	  part	  of	  the	  plot)	  
Hereby,	   the	   x-­‐axis	   indicates	   the	   contribution	   (covariance	   p1)	   of	   a	   particular	   ion	   towards	   class	  
separation	   whereas	   the	   y-­‐axis	   refers	   to	   the	   correlation	   (p(corr))	   between	   samples	   and	   thus	  
Chapter	  VI	  
	  176	  
reliability	  of	  results	  [20][56].	  In	  this	  regard,	  ions	  with	  cut-­‐off	  values	  of	  |p1|	  ≥	  0.05	  and	  |p(corr)|	  ≥	  
0.05	  were	  considered	  as	  differentiating	  metabolites	  [56].	  The	  S-­‐plot	  results	  were	  integrated	  with	  
the	   VIP-­‐scores,	   which	   indicate	   the	   relative	   importance	   of	   the	   ions	   to	   discriminate	   between	  
classes	  [57].	  In	  this	  study,	  only	  ions	  with	  a	  VIP	  Score	  >	  3	  were	  considered	  as	  potentially	  relevant.	  
As	  such,	  19	  positively	  charged	  ions	  and	  11	  negatively	  charged	  ions	  were	  eventually	  retained	  and	  
considered	   as	   differentiating	   metabolites,	   allowing	   to	   discriminate	   between	   endogenous	   and	  
exogenous	   prednisolone.	   In	   order	   to	   determine	  which	   of	   these	   compounds	   could	   serve	   as	   an	  
actual	   biomarker	   for	   xenobiotic	   prednisolone	   treatment,	   additional	   criteria	   were	   taken	   into	  
consideration,	   i.e.	  the	  chromatographic	  performance	  (peak	  shape	  As	  ≤	  1.5)	  [58],	  signal-­‐to-­‐noise	  
ratio	  (≥	  3)	  [59]	  and	  points	  over	  the	  peak	  (≥	  15)	  [60].	  Based	  on	  these	  criteria,	  3	  positively	  ionized	  
metabolites	  were	   retained	   and	   all	   other	  metabolite	   ions	   excluded.	   These	   retained	  metabolite	  
ions	  were	  more	  strongly	  detected	  in	  the	  samples	  that	  were	  collected	  from	  prednisolone	  treated	  
animals	  (Table	  6.2.).	  	  
Table	  6.2.	  Differentiating	  metabolites	  with	  their	  respective	  identification	  number	  (ID),	  retention	  time	  (tR),	  
mass-­‐to-­‐charge	   ratio	   (m/z),	  molecular	  weight	   (MW),	  elemental	   composition	  of	   the	  associated	  molecule,	  
mass	  deviation	  (Δm),	  Variable	  Importance	  in	  Projection	  (VIP)	  score,	  S-­‐plot	  score	  (p1	  and	  p(corr)).	  




(ppm)	   VIP	  
S-­‐plot	  
p1	   p(corr)	  
Differential	  analysis	  with	  SieveTM	  
(1)*	   1.41	   283.1693	   282.1614	   C19H22O2	   0.1416	   6.04	   0.073	   0.839	  
2	   1.39	   265.1589	   264.1509	   C19H20O	   0.7919	   5.01	   0.061	   0.723	  
3	   2.00	   281.1539	   280.1458	   C19H20O2	   1.0670	   4.58	   0.056	   0.666	  
Differential	  analysis	  with	  MarkerViewTM	  
(1)*	   1.37	   283.1699	   282.1614	   C19H22O2	   2.2601	   4.10	   0.055	   0.683	  
4	   2.35	   319.1911	   318.1825	   C19H26O4	   2.2400	   3.69	   0.501	   0.689	  
*:	  This	  ion	  was,	  independently	  of	  the	  software	  used	  for	  generating	  the	  peak	  lists,	  by	  multivariate	  data	  
analysis	  assigned	  as	  ion	  with	  the	  highest	  correlation	  to	  the	  exogenous	  prednisolone	  treatment.	  	  
The	  same	  multivariate	  strategy	  was	  applied	  to	  the	  dataset	  obtained	  from	  QqTOF	  mass	  analysis.	  
Quality	   of	   the	   established	   OPLS-­‐DA	   models	   was	   evaluated	   as	   described	   before,	   considering	  
permutation	   testing,	  CV-­‐ANOVA,	  and	   three	  model	   characteristics.	   For	   the	  constructed	  models,	  
values	   for	  R2(X),	  R2(Y)	  and	  Q2(Y)	  were	  0.371,	  0.973	  and	  0.860	  (for	  the	  positive	   ions)	  and	  0.204,	  
0.877	  and	  0.665	  (for	  the	  negative	  ions).	  The	  latter	  R2(X)	  values	  are	  rather	  low,	  which	  is	  explained	  
by	  the	  fact	  that	  all	  prednisolone	  treatment	  data	  were	  combined,	  resulting	  in	  a	  higher	  variation.	  
As	  such,	  overall	  good	  model	  quality	  was	  concluded.	  Interpretation	  of	  the	  data	  by	  means	  of	  S-­‐plot	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and	   VIP-­‐scores,	   thereby	   using	   the	   previously	   proposed	   criteria,	   yielded	   16	   positively	   and	   10	  
negatively	  ion	  metabolites	  (Figure	  6.2.B).	  A	  further	  exclusion	  of	  ions	  was	  established	  by	  applying	  
the	  additional	  peak	  performance	  criteria,	  listed	  above,	  whereby	  only	  two	  positively	  charged	  ions	  
were	  retained	  (Table	  6.2.).	  	  
Independently	  of	  the	  dataset	  used	  for	  generation	  of	  the	  peak	  lists,	  the	  multivariate	  data	  analysis	  
assigned	  in	  both	  cases	  the	  same	  ion	  (i.e.	  metabolite	  biomarker)	  with	  the	  highest	  correlation	  to	  
the	  exogenous	  prednisolone	  treatment.	  This	  particular	  ion	  (further	  referred	  to	  as	  metabolite	  1)	  
was	  characterized	  by	  an	  m/z-­‐value	  of	  283.1693	  Da	  and	  a	  retention	  time	  ranging	  from	  1.37-­‐1.41	  
min.	  In	  total,	  four	  differentiating	  metabolites	  were	  retained.	  	  
3.3. Preliminary	  validation	  of	  suggested	  marker	  molecules	  
In	   literature,	   numerous	   metabolites	   have	   been	   claimed	   as	   biomarkers	   for	   discriminating	  
exogenous	   treatment	   with	   e.g.	   growth	   promoters	   as	   opposed	   to	   natural	   prevalence.	   For	  
example,	   19-­‐noretiochlanolone	   [61]	   and	   5α-­‐estrane-­‐3β,17α-­‐diol	   [62]	   have	   been	   revealed	   as	  
biomarkers	   of	   nortestosterone	   treatment	   in	   porcines	   and	   bovines,	   respectively.	   However,	   the	  
differentiating	   metabolites	   are	   in	   general	   rarely	   validated	   due	   to	   the	   absence	   of	   consistent	  
validation	  guidelines,	  in	  essence	  needed	  to	  assign	  a	  metabolite	  the	  biomarker	  label	  [50].	  Indeed,	  
although	  various	  statistical	  methods	  and	  their	  limitations	  are	  described,	  no	  rigorous	  procedures	  
or	   criteria	   are	   available	   to	   evaluate	   and	   validate	   biomarkers,	   required	   to	   endorse	   their	  
widespread	   acceptance	   [63][64][65][66][67].	   Upon	   further	   inclusion	   of	   data	   from	   multiple	  
independent	   validation	   experiments,	   the	   proposal	   of	   a	   threshold	   as	   was	   earlier	   described	   by	  
Pinel	  et	  al.	  (2015)	  [68]	  and	  Kaabia	  et	  al.	  (2013)	  [69]	  would	  be	  recommended.	  However,	  setting	  a	  
threshold	   based	   on	   our	   preliminary	   validation	   data	   was	   considered	   to	   early.	   It	   is	   generally	  
agreed	   that	   a	   cross-­‐validation	   experiment,	   which	   includes	   the	   independent	   validation	   of	   the	  
biomarker	  by	   replicating	   the	  experiment	  at	  different	   sites,	   gives	  high	   inter-­‐observer	  and	   intra-­‐
observer	   reproducibility	   [50][64][68].	   This	   was	   unfortunately	   not	   possible	   in	   light	   of	   the	  
experimental	  complexity	  of	  this	  work.	  Therefore,	  a	  preliminary	  validation	  strategy	  was	  followed	  
in	  this	  study	  comprising	  bio-­‐analytical	  assessment,	  selectivity	  evaluation	  and	  evaluating	  urinary	  
excretion	  kinetics	  [63][64][65][66][67].	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3.3.1. Bioanalytical	  assessment	  	  
Sensitivity	   and	   specificity	   of	   the	   four	   revealed	   differentiating	   metabolites	   are	   considered	   of	  
critical	  importance	  in	  gauging	  their	  validity	  as	  markers	  for	  exogenous	  (per	  os	  and	  intramuscular)	  
administration	  of	  prednisolone	  [34][70][71].	  Hereby,	  sensitivity	   indicates	  the	  true	  positive	  rate,	  
i.e.	  the	  biomarker’s	  presence	  during	  treatment,	  whereas	  specificity	  relates	  to	  the	  true	  negative	  
rate,	   i.e.	   the	   biomarker’s	   absence	   during	   control.	   In	   this	   study,	   sensitivity	  was	   determined	   by	  
assessing	   the	   presence	   of	   each	  marker	  metabolite	   in	   the	   urine	   samples,	   obtained	   during	   the	  
different	  prednisolone	   treatments	   (Treatment)	   (Table	  6.3.),	  whereby	  only	  metabolites	  1	  and	  4	  
were	  assigned	  a	  total	  sensitivity	  of	  >	  90%.	  Specificity	  was	  determined	  in	  the	  urine	  samples	  that	  
were	  collected	  during	  the	  acclimatization	  period	  (Control)	  and	  wash-­‐out	  periods	  (WO)	  between	  
the	   different	   prednisolone	   treatments.	   The	   first	   time	   point	   of	   the	   wash-­‐out	   periods	   was	  
excluded	   due	   to	   the	   unknown	   elimination	   kinetics	   of	   the	   differentiating	   metabolites.	  
Metabolites	  1,	  2,	  and	  3	  were	  effectively	  absent	  in	  more	  than	  90%	  of	  the	  urine	  samples,	  collected	  
outside	   the	   prednisolone	   treatment	   periods,	   which	   indicates	   a	   low	   chance	   of	   false	   positive	  
findings	  [72].	  	  
Table	  6.3.	  Metabolite	  ions	  with	  their	  respective	  sensitivity	  during	  the	  different	  prednisolone	  treatments,	  
specificity	  during	  the	  acclimatization	  and	  washout	  periods,	  area	  under	  the	  ROC	  curve	  (AUC)	  and	  odds	  
ratio.	  
	   ID	   1	   2	   3	   4	  
Sensitivity	   	   	   	   	   	  
	   PO1	   100%	   100%	   91.3%	   100%	  
	   IM1	   82.6%	   72.7%	   52.2%	   82.6%	  
	   PO2	   100%	   100%	   100%	   75.0%	  
	   IM2	   100%	   85.7%	   100%	   100%	  
	   Average	   93.4%	   88.3%	   78.7%	   90.2%	  
Specificity	   	   	   	   	   	  
	   Control	   100%	   100%	   100%	   86.4%	  
	   WO1	   100%	   80.0%	   87.5%	   80.0%	  
	   WO2	   96.4%	   93.3%	   100%	   84.8%	  
	   WO3	   85.7%	   88.9%	   88.9%	   80.0%	  
	   WO4	   92.3%	   93.1%	   89.6%	   82.7%	  
	   Average	   96.3%	   94.0%	   95.5%	   84.1%	  
AUC	   	   1.00	   0.94	   0.88	   0.97	  
Odds	  ratio	   	   366	   126	   79	   5	  
The	  sensitivity	  and	  specificity	  of	  each	  ion	  were	  subsequently	  visualized	  using	  receiver-­‐operating	  
characteristic	  (ROC)	  curves	  and	  its	  summary	  index,	  i.e.	  the	  area	  under	  curve	  (AUC)	  (Table	  6.3.).	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Normally,	  the	  AUC	  ranges	  from	  0.5	  (the	  area	  under	  the	  diagonal	  line,	  representing	  the	  extent	  of	  
class	  discrimination	  based	  on	   random	  chance)	   to	   1	   (perfect	   discrimination)	   [73].	   In	   this	   study,	  
the	   AUC	   obtained	   for	   metabolite	   1	   indicates	   perfect	   discrimination,	   whereas	   for	   the	   other	  
metabolites	  excellent	  discrimination	  could	  be	  achieved	  [32].	  	  
The	  odds	  ratio	  [74]	  was	  determined	  to	  quantify	  how	  strong	  the	  presence	  of	  each	  biomarker	  was	  
correlated	   with	   prednisolone	   treatment.	   In	   this	   context,	   a	   high	   odds	   ratio	   indicates	   a	   strong	  
correlation.	  The	  odds	  ratio	  of	  metabolite	  1	  was	  much	  higher	  than	  the	  odds	  ratios	  of	   the	  other	  
metabolites	   (Table	   6.3.),	   which	   evidenced	   the	   strong	   correlation	   between	   this	   biomarker	   and	  
prednisolone	  treatment	  [74].	  
In	  conclusion,	  based	  on	  the	  outlined	  parameters,	  metabolite	  1	  is	  attributed	  the	  highest	  potential	  
to	  serve	  as	  a	  reliable	  biomarker	  for	  exogenous	  prednisolone	  administration.	  
3.3.2. Selectivity	  	  
To	   verify	   that	   newly	   defined	   differentiating	  metabolites	   for	   prednisolone	   treatment	  were	   not	  
present	   in	   urine	   that	   contained	   endogenous	   prednisolone,	   12	   animals	   (cfr.	   Section	   2.1)	   were	  
intramuscularly	   injected	   with	   2	   mg	   tetracosactide	   hexaacetate	   (Utrecht	   University,	   Faculty	   of	  
Veterinary	   Medicine),	   a	   synthetic	   analogue	   of	   adrenocorticotropic	   hormone	   (ACTH),	  
corresponding	   to	   200	   I.U.	   of	   ACTH	   [9].	   After	   4	   hours,	   prednisolone	   was	   detected	   in	   all	   urine	  
samples,	   thereby	   reaching	   concentration	   levels	   that	   were	   similar	   to	   those	   obtained	   during	  
growth-­‐promoting	   treatments.	   However,	   none	   of	   the	   four	   defined	   differentiating	  metabolites	  
were	   present	   in	   these	   samples,	   endorsing	   the	   ability	   of	   these	   particular	   metabolites	   to	  
distinguish	   between	   exogenously	   administered	   (per	   os	   and	   intramuscular)	   and	   endogenously	  
synthesized	  prednisolone	  [75][76].	  
3.3.3. Urinary	  excretion	  kinetics	  
By	  achieving	  proper	   insights	   into	  the	  urinary	  kinetic	  profiles,	  the	  actionable	  sensitivity	   in	  terms	  
of	  detection	  window	  and	  screening	  capacities	  of	   the	  proposed	  biomarkers	  could	  be	  confirmed	  
[35][77][68].	  More	  specifically,	  an	  additional	  in	  vivo	  experiment	  was	  performed	  in	  which	  a	  single	  
cow	  (milking	  cow,	  3.5	  years,	  550	  kg	  body	  weight)	  received	  a	  single	  dose	  of	  0.5	  mg	  prednisolone	  
per	  kg-­‐1	  b.w.	  and	  per	  os.	  Urine	  was	  collected	  at	  different	  time	  points	  during	  the	  first	  32h	  (4h	  –	  
6h30	  –	  10h	  –	  21h	  –	  24h	  –	  26h30	  –	  29h30	  –	  31h15)	  after	  administration	  and	  alterations	   in	   the	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peak	   area	   of	   the	   marker	   metabolites	   and	   prednisolone	   were	   monitored.	   Additional	   urine	  
samples	  were	  collected	  4	  and	  7	  days	  after	  prednisolone	  administration	  (Figure	  6.3.).	  During	  this	  
experiment,	  all	  metabolites	  were	  detected,	  whereby	  metabolite	  1	  was	  five	  times	  more	  abundant	  
(in	  terms	  of	  peak	  area)	  in	  comparison	  with	  the	  other	  metabolites.	  Moreover,	  metabolite	  1	  was	  
still	  present	  at	  detectable	  concentration	   levels	  (S/N	  >	  3)	  at	  the	  moment	  that	  prednisolone	  was	  
no	   longer	   detected	   in	   the	   collected	   urine	   samples,	   i.e.	   until	   4	   days	   after	   treatment.	   This	  
specifically	   endorses	   the	   suitability	   of	  metabolite	   1	   as	   an	   actionable	   biomarker	   for	   exogenous	  
exogenous	   prednisolone	   administration.	   However,	   metabolites	   2,	   3,	   and	   4	   may	   fulfill	   a	  
supporting	   role	   in	   determining	   the	   origin	   of	   prednisolone	   in	   non-­‐compliant	   bovine	   urine	  
samples.	  	  
Figure	   6.3.	  Urinary	  metabolite	  excretion	  profile	  after	  administration	  of	  a	   single	  dose	  of	  0.5	  mg/kg	  body	  
weight	  prednisolone	  per	  os	  (indicated	  with	  arrow)	  to	  one	  milking	  cow,	  with	  Metabolite	  1	  (A);	  Metabolite	  2	  
(B);	  Metabolite	  3	  (C);	  Metabolite	  4	  (D)	  and	  Prednisolone	  (E).	  Results	  are	  expressed	  as	  peak	  area	  	  
3.4. Tentative	  identification	  of	  relevant	  biomarkers	  
The	   elemental	   composition	   of	   the	   four	   revealed	   biomarkers	   was	   determined	   by	   means	   of	  
FormulaFinder	   (MasterViewTM),	   thereby	   integrating	   the	   information	   about	   the	   precursor	  
accurate	  mass,	   fragment	  masses	   and	   isotopic	   patterns.	   Together	   with	   the	  maximally	   allowed	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mass	  deviation	  of	  5	  ppm,	  only	  one	   candidate	   chemical	   formula	   (Table	  6.4.)	  was	   suggested	   for	  
each	  biomarker	  and	  thus	  used	  for	  subsequent	  structural	  assessment.	  	  
For	   this	   particular	   purpose,	   the	   experimental	  MS/MS	   spectra	   from	   each	  metabolite	   ion	   were	  
matched	   towards	   the	   in	   silico	   predicted	   fragmentation	   pattern	   from	   candidate	   chemical	  
structures,	  corresponding	  to	  the	  determined	  chemical	  formula.	  These	  candidate	  structures	  were	  
retrieved	  from	  publically	  available	  databases	  (i.e.	  Metlin,	  PubChem	  and	  ChemSpider)	  and	  our	  in-­‐
house	  database.	  The	  respective	  use	  of	  MetFrag	  and	  MasterViewTM	  software	  allowed	  to	  retain	  a	  
‘best	  fitting’	  candidate	  structure	  (Table	  6.4.)	  to	  the	  degree	  of	  matching	  fragmentation	  profiles.	  	  
As	   metabolite	   1	   was	   proposed	   as	   the	   most	   potent	   biomarker	   for	   exogenous	   prednisolone	  
administration,	   additional	   efforts	   were	  made	   to	   reach	   the	   highest	   level	   of	   identification	   [30].	  
Since	   no	   authentic	   reference	   standard	   was	   available	   for	   the	   candidate	   structure,	   1H-­‐NMR	  
analysis	  was	  attempted	  to	  confirm	  the	  metabolite’s	   identity.	  For	   this	   reason,	  all	  urine	  samples	  
collected	  during	  prednisolone	  treatments	  were	  pooled	  and	  preparative	  HPLC	  was	  performed	  in	  
order	  to	  obtain	  a	  relatively	  pure	  fraction	  of	  the	  compound.	  Unfortunately,	  1H-­‐NMR	  analysis	  was	  
not	  able	  to	  reveal	  the	  compound’s	  structure,	  which	  was	  mainly	  due	  to	  the	  available	  low	  absolute	  





Table	  6.4.	  Metabolite	  ions	  with	  their	  identification	  number	  (ID),	  the	  possible	  identities	  defined	  by	  MetFrag	  (only	  the	  compound	  with	  Rank	  1	  are	  shown)	  and	  the	  in-­‐house	  
database.	  The	  number	  of	  matching	  fragments	  calculated	  by	  MasterViewTM.	  
ID	  
MetFrag	   	   In-­‐house	  database	  
#	  Candidate	  hits	  
Rank	  1	   Matching	  Fragments	  	   	   	  
Matching	  
Fragments	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For	  now,	  all	   revealed	  biomarkers	  were	  putatively	  annotated	   (Table	  6.4.),	   thereby	   reaching	   the	  
second	  highest	   level	  of	   identification,	  as	  defined	  by	  Sumner	  et	  al.	   (2007)	   [30]	  since	  a	  standard	  
for	  identification	  at	  the	  highest	  level	  of	  confidence	  is	   lacking.	  Besides,	  the	  physiological	  activity	  
and	  as	  a	   result	   the	   link	   to	  prednisolone	  administration	  of	   the	  newly	  defined	  compounds	  could	  
not	   be	  demonstrated	   yet,	   because	  no	   literature	   about	   these	   compounds	  was	   found.	   The	  only	  
retrieved	  background	  information	  comprised	  the	  identity	  of	  the	  compounds	  in	  online	  databases	  
Chemspider	  and/or	  PubChem.	  	  
4. Conclusion	  
The	  aim	  of	  this	  study	  was	  to	  identify	  biomarkers,	  which	  have	  the	  ability	  to	  discriminate	  between	  
endogenous	   formation	   and	   exogenous	   administration	   of	   the	   synthetic	   glucocorticoid	  
prednisolone.	   A	   strategy	   of	   metabolic	   fingerprinting	   was	   performed	   to	   assess	   potential	  
metabolite	  perturbations	  in	  the	  urine	  of	  cows,	  treated	  with	  prednisolone.	  Four	  metabolite	  ions	  
were	   found	   to	   emerge	   during	   prednisolone	   treatment.	   The	   selectivity	   of	   the	   markers	   was	  
proved,	   since	   none	   of	   these	   compounds	   were	   present	   in	   urine	   containing	   endogenous	  
prednisolone,	   of	   which	   the	   formation	   was	   induced	   by	   adrenocorticotropic	   hormone	  
administration.	   Besides,	   biological	   relevance	   of	   these	   ions	   was	   determined	   by	   means	   of	  
sensitivity	   and	   specificity.	   This	   showed	   that	   only	   one	   metabolite	   was	   highly	   suitable	   as	  
biomarker	   during	   growth-­‐promoting	   and	   therapeutic	   prednisolone	   treatment,	   reflected	   by	  
93.4%	   sensitivity	   and	   96.3%	   specificity.	   The	   urinary	   excretion	   profiles	   of	   the	   four	  metabolites	  
were	  considered	  as	  an	  additional	  criterion.	  The	  most	  potent	  compound	  could	  be	  detected	  up	  to	  
four	  days	  after	  a	  single	  per	  os	  prednisolone	  administration.	  The	  identity	  and	  qualification	  as	  fit-­‐
for-­‐purpose	   of	   the	   proposed	   biomarker	   ‘Metabolite	   1’	   needs	   to	   be	   further	   explored	   though	  
independent	  data	  sets	  that	  cover	  a	  larger	  population,	  different	  ages,	  sex,	  origin	  of	  feeding,	  etc.	  
Moreover,	   further	   validation	   of	   the	   proposed	   biomarker	   to	   confirm	   its	   specificity	   for	  
prednisolone	   treatment	   as	   opposed	   to	   treatment	   with	   other	   glucocorticoids	   or	   growth	  





Supplementary	   Figure	   6.1.	   Score	   plots	   for	   OPLS-­‐DA	   models	   representing	   the	   discrimination	   between	  
control	  (Blue)	  and	  treatment	  (Green),	  respectively	  determined	  with	  SieveTM	  (A)	  and	  MarkerViewTM	  (B)	  and	  
for	  positive	  (A1,B1)	  and	  negative	  (A2,	  B2)	  ionized	  metabolite	  ions.	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1. Research	  positioning	  and	  relevance	  
Natural	   glucocorticoids,	   with	   cortisol	   and	   cortisone	   as	   the	  main	   components,	   are	   involved	   in	  
metabolic	   and	   immunological	   responses.	   In	   the	   fifties,	   synthetic	   glucocorticoid	   analogues	  
entered	   the	  market	   because	   of	   their	   greater	   potency	   and	   longer	   pharmacological	   activity	   e.g.	  
dexamethasone,	   methylprednisolone	   and	   prednisolone	   [1].	   Besides	   their	   therapeutic	   use,	  
glucocorticoids	   are	   well	   known	   for	   their	   growth-­‐promoting	   effects	   in	   livestock	   [2][3].	   Illicit	  
treatment	  may	  however	   lead	   to	   the	  presence	  of	   potential	   harmful	   residues	  present	   in	   animal	  
derived	   food	  products	   [4].	   In	  order	   to	  protect	  consumers	  against	   these	  potential	   residues,	   the	  
therapeutic	   use	   and	   the	   detection	   thereof	   has	   been	   strictly	   regulated	   in	   the	   European	   Union	  
[5][6][7].	  	  
Recently,	  the	  European	  Commission	  reported	  an	  increasing	  prevalence	  of	  prednisolone	  residues	  
in	   bovine	   urine	   samples	   without	   any	   direct	   evidence	   for	   unauthorized	   administration.	   These	  
findings	   may	   be	   attributed	   to	   an	   increased	   sensitivity	   of	   the	   employed	   analytical	   detection	  
methods,	  nevertheless,	  many	  questions	  have	  been	  raised	  about	  the	  origin	  of	  this	  prednisolone.	  
One	  of	  the	  hypotheses	  put	  forward	  is	  that	  faecal	  contamination	  of	  urine	  may	  lead	  to	  enzymatic	  
activity	   such	   as	   steroid	   dehydrogenases,	   as	   has	   been	   observed	   for	   the	   testosterone	   to	  
boldenone	   conversion	   [8][9].	   Due	   to	   structural	   similarities	   of	   prednisolone	   and	   cortisol,	   the	  
formation	  of	  prednisolone	  could	  follow	  a	  similar	  process.	  Indeed,	  in	  vitro	  incubation	  of	  cortisol	  in	  
aqueous	   faecal	   solution,	   led	   to	   the	   formation	   of	   prednisolone	   [10].	   This	   transformation	   was	  
confirmed	   in	   cortisol	   enriched	   faecal	   contaminated	   urine	   [11][12].	   The	   influence	   of	   microbial	  
contamination	   on	   the	   occurrence	   of	   prednisolone	   required	   however	   more	   research,	   more	  
specifically	   regarding	   the	   long-­‐term	   stability	   of	   glucocorticoids	   in	   urine	   and	   faeces.	   Indeed,	   a	  
proper	  conservation	  protocol	  could	  allow	  detecting,	   in	  a	  reliable	  fashion,	  the	  possible	  abuse	  of	  
glucocorticoids	  excluding	  ex-­‐vivo	  prednisolone	  neoformation.	  	  
A	   second	  hypothesis	   concerns	   the	   relation	  between	  stress	  and	   the	   formation	  of	  prednisolone,	  
since	  elevated	  prednisolone	   levels	   in	  urine	  samples	  have	  been	  detected	  at	   the	  slaughterhouse	  
[13][14]	   and	   following	   pharmacologically-­‐induced	   increase	   of	   cortisol	   with	   tetracosactide	  
hexaacetate,	   a	   synthetic	   analogue	  of	   the	   adrenocorticotropic	   hormone	   [15].	   But	   prednisolone	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has	  occasionally	  been	  detected	  under	  normal	  housing	  conditions	  as	  well	   [16].	   In	   this	   regard,	  a	  
more	  in	  depth	  evaluation	  on	  the	  influence	  of	  stress	  on	  prednisolone	  prevalence	  in	  bovine	  urine	  
was	  urgently	  needed.	  	  
Besides	   an	   elucidation	   of	   the	   mechanisms	   responsible	   for	   prednisolone	   formation,	   a	   direct	  
discrimination	  between	  endogenous	  and	  exogenous	  prednisolone	  could	  offer	  potential	  as	  well.	  
Also	  in	  literature	  the	  need	  for	  a	  reliable	  biomarker	  has	  been	  suggested	  [3][17],	  and	  even	  more	  in	  
the	  light	  of	  the	  national	  control	  plans	  [18].	  Recently,	  the	  use	  of	  the	  urinary	  prednisolone/cortisol	  
concentration	  ratio	  and	  20β-­‐dihydroprednisolone	  were	  proposed	  as	  potential	  screening	  tools	  for	  
indicating	  exogenous	  administration	  of	  prednisolone	  [19],	  but	  these	  had	  not	  yet	  been	  confirmed	  
or	  validated.	  An	   in	  depth	  pharmacokinetic	  study	  of	  prednisolone	  and	   its	  metabolites	  and	  their	  
influence	   on	   endogenous	   glucocorticoids	   could	   give	   more	   insight	   in	   the	   relevance	   of	   the	  
suggested	  screening	  tools.	  As	  long	  as	  none	  of	  the	  suggested	  compounds	  can	  be	  confirmed,	  the	  
search	  for	  specific	  biomarkers	  still	  continues.	   In	  this	  context,	  untargeted	  metabolomics	  by	  full-­‐
scan	   high-­‐resolution	  mass	   spectrometry	   (e.g.	   TOF	   and	   Orbitrap)	   offers	   great	   opportunities	   to	  
discover	   potential	   biomarkers	   that	   may	   allow	   discrimination	   between	   exogenous	   and	  
endogenous	  prednisolone.	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2. Main	  research	  findings	  and	  main	  scientific	  contributions	  	  
A	  number	  of	  objectives	  have	  been	  defined	  within	  the	  conceptual	   framework	  of	   this	   thesis	  and	  
the	  accomplishments	  of	  each	  have	  been	  extensively	  described	  in	  the	  various	  research	  chapters.	  
An	  overview	  of	  the	  main	  realisations	  achieved	  in	  this	  work,	  is	  presented	  in	  Figure	  7.1.	  
	  
	  
Figure	  7.1.	  Schematic	  overview	  of	  the	  main	  accomplishments	  of	  this	  thesis.	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2.1. Glucocorticoid	  extraction	  and	  detection	  with	  high-­‐resolution	  Orbitrap-­‐MS	  
In	   the	   context	   of	   national	   residue	  monitoring	   plans,	   urine	   and	   faeces	   are	   frequently	   analysed	  
matrices	   to	  ensure	   the	  absence	  of	  glucocorticoid	   residues	   in	   food	  producing	  animals	   [7],	   since	  
both	   matrices	   are	   easily	   accessible	   through	   non-­‐invasive	   sampling.	   The	   analysis	   of	  
glucocorticoids	   in	   urine	   and	   faeces	   is	   however	   seen	   as	   a	   challenging	   task	   because	   they	   are	  
present	   at	   very	   low	   concentrations,	   commingled	   in	   a	   background	   of	   abundant	   primary	   and	  
secondary	  metabolites	  [20].	  This	  endorses	  the	  need	  for	  proper	  extraction	  procedures	  in	  order	  to	  
retain	   relevant	   analytes	   and	   remove	  matrix	   interferences	   at	   the	   same	   time.	   But	   since	   in	   this	  
work	  a	  metabolomic	  approach	  was	  intended,	  extraction	  should	  be	  kept	  as	  generic	  as	  possible.	  	  
By	   using	   a	   Plackett-­‐Burman	   experimental	   design,	   sample	   preparation	   procedures	   may	   be	  
developed	   in	   an	   efficient	   and	   time	   saving	   manner,	   enabling	   identification	   of	   the	   optimal	  
conditions	  with	  a	  minimum	  of	  experiments	   [21][22].	   In	  order	   to	  maintain	  a	   generic	   extraction	  
procedure,	  only	  a	  two-­‐step	  liquid-­‐liquid	  extraction	  was	  implemented	  for	  urine	  while	  for	  faeces	  a	  
defatting	   step	   and	   inclusion	   of	   SPE	   were	   necessary	   to	   reduce	  matrix	   interferences	   co-­‐eluting	  
with	  the	  compounds	  of	  interest.	  In	  order	  to	  maintain	  the	  generic	  character	  of	  the	  extraction	  and	  
to	   ensure	   the	   potential	   of	   a	   full-­‐scan	   untargeted	   screening	   including	   phase	   II	  metabolites,	   for	  
both	  urine	  and	  faeces,	  an	  extraction	  procedure	  without	  hydrolysis	  was	  selected.	  	  
The	   development	   of	   the	   analytical	   methods	   proved	   challenging	   due	   to	   the	   similar	   chemical	  
configuration	   and	   chromatographic	   behaviour	   of	   glucocorticoids.	   The	   selection	   of	  
chromatographic	   conditions	   and	   analytical	   column	   were	   based	   on	   literature	   [23],	   in-­‐house	  
findings	  [24]	  and	  different	  experimental	  setups.	  	  
The	  analytical	  method	  for	  the	  detection	  of	  glucocorticoids	  and	  related	  compounds	  was	  based	  on	  
full-­‐scan	   high-­‐resolution	   ExactiveTM	   Orbitrap	   mass	   spectrometry.	   The	   main	   relevance	   of	   this	  
novel	  method	  relates	   to	   its	  ability	  of	  post-­‐acquisition	  re-­‐interrogation	  of	  data	   requisite	   for	   the	  
intended	   metabolomic	   approach	   later	   in	   this	   work.	   After	   validation	   of	   our	   newly	   developed	  
UHPLC-­‐HRMS	  method	   according	   to	   the	   criteria	   specified	   in	   CD	   2002/657/EC	   [25],	   it	   appeared	  
that	   better	   or	   comparable	   LODs	   and	   LOQs	   were	   obtained	   for	   both	   urine	   and	   faeces	  
[10][11][15][26].	  In	  urine,	  an	  experimental	  determination	  of	  the	  LOQ	  and	  LOD	  was	  not	  possible	  
for	   cortisol,	   cortisone	   and	   dihydrocortisone	   since	   no	   actual	   blank	   sample	   (blank	   reference	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material)	   was	   available.	   Unless	   solvent	   would	   be	   used	   for	   calibration	   purposes;	   but	   this	   is	  
believed	  not	  to	  be	   indicative	   for	  determining	  the	  performance	  criteria	  of	  an	  analytical	  method	  
since	   no	   interfering	   matrix	   compounds	   are	   present	   [27].	   For	   the	   other	   glucocorticoids,	  
prednisolone,	   prednisone	   and	   methylprednisolone	   (not	   present/detected	   in	   the	   blank	   urine	  
matrix),	   blank	   urine	   reference	   material	   was	   available	   and	   therefore	   CCαs	   and	   CCβs	   could	   be	  
experimentally	  determined.	  In	  faeces,	  blank	  material	  was	  available	  and	  therefore	  LOD,	  LOQ,	  CCα	  
and	  CCβ	   could	   be	   experimentally	   determined	   for	   all	   analytes.	   Both	  methods	   demonstrated	   an	  
adequate	   performance	   in	   terms	   of	   linearity,	   repeatability,	   inter-­‐laboratory	   reproducibility	   and	  
precision	  as	  well.	  	  
These	   methods	   were	   used	   to	   determine	   the	   long-­‐term	   stability	   of	   glucocorticoids	   in	   urine	  
(Chapter	   II)	   and	   faeces	   (Chapter	   III).	   Besides,	   this	   full-­‐scan	   Orbitrap-­‐MS	  method	   also	   allowed	  
glucocorticoid	  urinary	  profiling	  (Chapter	  IV)	  and	  fingerprinting	  (Chapter	  III	  and	  VI).	  
2.2. Stability	  of	  glucocorticoids	  in	  urine	  and	  faeces	  
The	   collection,	   transportation	   and	   preservation	   of	   urine	   and	   faecal	   samples	   does	   not	   always	  
meet	   ideal	   conditions.	   One	   of	   the	   hypotheses	   for	   the	   increased	   frequency	   of	   prednisolone	  
detection	  in	  bovine	  urine	  samples	  is	  the	  potential	  transformation	  of	  the	  natural	  glucocorticoids	  
cortisol	   and	   cortisone	   into	   prednisolone	   and	   prednisone,	   respectively,	   due	   to	   inappropriate	  
storage	   and	   contamination	   with	   microorganisms	   [28][29][30].	   Contradictory	   results	   have	  
however	  been	  reported	   in	   literature	  on	  this	  matter	   [11][28][31].	  Therefore,	  the	  stability	  of	  the	  
potentially	   endogenous	   glucocorticoids	   prednisolone	   and	   prednisone	   and	   their	   main	  
metabolites	  in	  urine	  and	  faeces	  was	  considered	  in	  this	  study.	  	  
For	   the	   experimental	   setup	   of	   the	   long-­‐term	   stability	   study	   of	   glucocorticoids	   in	   urine	   and	  
faeces,	  it	  was	  important	  to	  pick	  up	  sufficient	  decrease	  in	  glucocorticoid	  levels.	  To	  anticipate	  on	  
this,	   both	  matrices	  were	   fortified	  with	   20	   μg	   L-­‐1.	   Based	   on	   the	   LOD/CCα,	   this	   implies	   that	  we	  
would	  be	  able	  to	  detect	  less	  then	  1.0-­‐2.5%	  of	  the	  initial	  concentration.	  	  
Hereby,	  multiple	  conditions	  were	  created	  to	  evaluate	  the	  influence	  of	  microbial	  activity	  on	  the	  
possible	  degradation	  of	  glucocorticoids	  in	  bovine	  urine	  (Chapter	  II).	  In	  case	  of	  (anaerobe)	  faecal	  
contamination,	   increased	   prednisolone	   was	   observed	   when	   preserved	   at	   4	   °C.	   This	   could	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indicate	   possible	   neoformation	   of	   prednisolone,	   however,	   large	   variability	   in	   the	   data	   was	  
noticed.	  After	  eliminating	   the	  bacterial	   contamination	  by	   filter-­‐sterilization,	  preservation	  up	   to	  
20	  weeks	  at	  room	  temperature	  was	  possible.	  But	  filter-­‐sterilization	  is	  a	  time	  consuming	  process	  
and	   should	   be	   performed	   immediately	   after	   sample	   collection,	   therefore	   the	   pH	   and	  
preservation	   temperature	   were	   evaluated	   as	   well.	   At	   extreme	   pH-­‐values,	   denaturation	   of	  
microbial	  enzymes	  may	  occur	  and	  prevent	  glucocorticoid	  degradation	   [32].	  On	  the	  other	  hand,	  
when	  stored	  at	   -­‐20	   °C,	  preferably	  at	   -­‐80	   °C,	  microbial	  activity	   is	  minimized	  and	  glucocorticoids	  
remained	  preserved	  [28].	  	  
Most	  of	   the	  stability	  studies	  available	   for	   faecal	  glucocorticoids	  were	  performed	  with	  antibody	  
assays	   [31].	   The	   major	   advantage	   of	   monitoring	   glucocorticoids	   in	   bovine	   faecal	   material	   by	  
UHPLC-­‐Orbitrap-­‐MS	   method	   (Chapter	   III)	   is	   to	   eliminate	   overestimation	   of	   the	   specified	  
glucocorticoids	   due	   to	   cross-­‐reactivity	   as	   seen	   with	   the	   more	   commonly	   employed	   antibody	  
assays	   [33].	   Removal	   of	   water,	   by	   lyophilisation,	   improved	   the	   long-­‐term	   stability	   of	  
glucocorticoids	   in	   faecal	   samples.	   However,	   lyophilisation	   is	   not	   always	   possible,	   therefore	  
alternatives	   such	  as	  addition	  of	  ethanol	  and	   freezing	  were	  considered	  as	  well.	   The	  addition	  of	  
ethanol	  influenced	  the	  extraction	  efficiency.	  This	  resulted	  in	  unreliable	  recoveries	  over	  time,	  and	  
is	   therefore	   not	   recommended.	   Also	   in	   literature,	   the	   addition	   of	   ethanol	   as	   conservator	   for	  
faecal	  material	  has	  given	  contradictory	  results	  [31][34].	  Although	  ethanol	  immediately	  stops	  all	  
bacterial	   activity	  within	   a	   sample	   [35],	   it	   possibly	   causes	   chemical	   alteration	  of	   hormones	  e.g.	  
oxidation	  that	  could	  influence	  the	  outcome	  of	  antibody	  assays	  [33].	  Under	  anaerobe	  conditions	  
at	  room	  temperature,	  possible	  neoformation	  due	  to	  (facultative)	  anaerobe	  bacteria	  (e.g.	  E.	  coli)	  
was	   observed.	   This	   could	   strengthen	   the	   hypothesis	   of	   prednisolone	   formation	   due	   to	   faecal	  
contamination,	   however,	   variation	   in	   the	  data	  was	   too	  big	   to	   confirm	   this.	   Freezing	  of	   bovine	  
faeces	  at	  -­‐80	  °C,	  minimized	  bacterial	  metabolism	  and	  improved	  stability.	  
2.3. The	  influence	  of	  stress	  on	  the	  prevalence	  of	  prednisolone	  in	  bovine	  urine	  
In	  literature	  it	  has	  been	  suggested	  that	  prednisolone	  can	  be	  formed	  under	  influence	  of	  stress.	  In	  
response	   to	   stress,	   the	   hypothalamic-­‐pituitary-­‐adrenal	   (HPA)	   axis	   is	   stimulated	   whereby	   the	  
adrenocorticotropic	  hormone	  (ACTH)	  promotes	  the	  synthesis	  and	  release	  of	  cortisol	  into	  plasma,	  
which	  finally	  results	  in	  increased	  urinary	  cortisol	  levels	  [36][37][38].	  This	  could	  be	  related	  to	  the	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presence	   of	   prednisolone	   in	   urine	   samples,	   since	   cortisol	   only	   differs	   from	   prednisolone	   by	   a	  
single	  ring	  double	  bond	  and	  this	  conversion	  has	  been	  demonstrated	  during	  in	  vitro	  experiments	  
[12][30].	   The	   plausibility	   of	   this	   is	   even	   strengthened	   more	   by	   the	   fact	   that	   most	   of	   the	  
prednisolone	  positive	  bovine	  urine	  samples	  were	  collected	  at	  slaughter	   [13][17].	  The	   influence	  
of	  stress	  due	  to	  transport	  to	  the	  slaughterhouse	  has	  also	  been	  demonstrated	  by	  Bertocchi	  et	  al.	  
(2013)	  [14].	  	  
In	  this	  study,	  urine	  samples	  collected	  under	  three	  different	  experimental	  conditions	  were	  tested:	  
supposedly	  non-­‐stressed	  animals	   (farm),	  animals	  exposed	   to	   ‘natural’	   stress	   (at	   slaughter)	  and	  
animals	   undergoing	   pharmacologically-­‐induced	   increase	   of	   cortisol	   upon	   administration	   of	  
tetracosactide	  hexaacetate,	  which	  is	  a	  synthetic	  analogue	  of	  ACTH	  (Chapter	  IV).	  	  
Housing	  conditions	  and	  management	  procedures	  at	   the	   farm	  may	   lead	   to	  a	  potential	   stressful	  
environment	   and	   possibly	   exert	   variable	   effects	   on	   the	   HPA-­‐function	   in	   livestock	   [39].	   No	  
significant	  differences	  between	  the	  urinary	  cortisol	  baseline	   levels	  at	  the	  concerned	  farms	  was	  
however	   noticed.	   This	   could	   indicate	   the	   absence	   of	   elevated	   stress	   levels	   of	   animals	   during	  
their	   normal	   housing	   conditions.	   None	   of	   the	   urine	   samples	   (n	   =	   42)	   collected	   under	   normal	  
housing	  conditions	  at	  four	  different	  farms	  contained	  prednisolone	  or	  prednisone.	  These	  results	  
are	  in	  line	  with	  the	  large-­‐scale	  field	  survey	  of	  Vincenti	  et	  al.	  (2012)[16].	  	  
In	  case	  of	  stress	  on	  the	  other	  hand,	  i.e.	  at	  slaughter	  and	  pharmacologically-­‐induced	  increase	  of	  
cortisol,	   a	   significant	   positive	   correlation	   between	   the	   concentration	   of	   cortisol	   and	  
prednisolone	   in	   urine	   could	   be	   observed	   in	   our	   study.	   Particularly	   after	   ACTH	   treatment,	   all	  
samples	   were	   prednisolone	   positive.	   These	   results	   are	   in	   line	   with	   Pompa	   et	   al.	   (2011)	   [15]	  
where	   similar	   prednisolone	   concentrations	   were	   consistently	   found	   in	   urine	   after	   ACTH	  
treatment.	  In	  our	  study,	  only	  one	  urine	  sample,	  collected	  during	  ACTH	  treatment,	  contained	  an	  
endogenous	  prednisolone	  level	  higher	  than	  the	  EURL	  threshold	  level	  of	  5	  μg	  L-­‐1	  [18]	  i.e.	  6.45	  μg	  
L-­‐1.	  Based	  on	  the	  findings	  of	  our	  study,	  a	  threshold	  level	  of	  3.5	  μg	  L-­‐1	  could	  be	  proposed.	  In	  this	  
case,	   two	  urine	   samples	  would	   be	  misidentified	   as	   non-­‐compliant.	  Hereby	   the	   alpha	   (α	   =	   5%)	  
error	  for	  a	  group	  B2f	  compound	  should	  be	  considered,	  since	  a	  false	  non-­‐compliant	  decision	  was	  
made.	  Besides,	   it	   is	  necessary	   to	   take	  a	  measurement	  uncertainty	   into	  account,	   since	  a	   recent	  
proficiency	  test	  (2012)	  estimated	  it	  at	  about	  50%.	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HRMS	  based	  metabolic	  fingerprinting	  was	  used	  to	  characterise	  the	  urinary	  metabolite	  patterns	  
under	   well-­‐defined	   conditions	   differing	   in	   degree	   of	   stress	   (Chapter	   IV).	   PCA-­‐modelling	   and	  
unsupervised	  HCA	  indicated	  that	  bovine	  urinary	  metabolic	  fingerprints	  could	  be	  clustered	  based	  
on	  their	  imposed	  stress	  situation.	  This	  could	  be	  a	  powerful	  tool	  to	  classify	  unknown	  bovine	  urine	  
samples	  and	  give	  information	  about	  the	  stress	  status	  of	  the	  animal.	  This	  could	  lead	  to	  a	  better	  
interpretation	  of	  urine	  samples	  tested	  positive	  for	  prednisolone	  or	  potentially	  other	  conditions	  
related	   to	   disturbed	   hormonal	   profiles	   (e.g.	   Cushing’s	   syndrome)	   [40][41].	   In	   this	   context,	  
metabolite	  ions	  with	  a	  leading	  role	  in	  stress	  discrimination	  were	  defined	  by	  means	  of	  supervised	  
OPLS-­‐DA	   (Chapter	   IV).	   These	   ions	   could	   be	   differentiated	   into	   three	   groups:	   the	   first	   group	  
comprised	   ions	  predictive	   for	   stress	  but	   independent	  of	   the	  origin	  of	   stress,	   the	   second	  group	  
were	  ions	  that	  were	  up-­‐	  or	  downregulated	  during	  ACTH	  treatment,	  and	  the	  last	  group	  were	  ions	  
that	  were	  only	   retrieved	   in	  urine	  samples	  collected	  at	  slaughter.	  Correlating	   the	  abundance	  of	  
these	   ions	   with	   cortisol	   levels	   was	   only	   possible	   for	   ions	   linked	   to	   pharmacologically-­‐induced	  
increase	  of	  cortisol,	  indicating	  that	  besides	  the	  HPA-­‐axis,	  also	  other	  processes	  are	  involved	  in	  the	  
stress	   response,	   e.g.	   sympathomedullary	   pathway.	   This	   results	   in	   the	   secretion	   of	  
catecholamines,	   norepinephrine	   and	   epinephrine	   into	   the	   circulation	   [42].	   After	   degradation	  
into	   homovanillic	   acid,	   normetanephrine,	   vanillylmandelic	   acid	   or	   metanephrine,	   these	  
compounds	  are	  excreted	  in	  urine	  [43].	  Nevertheless,	  none	  of	  these	  compounds	  could	  be	  directly	  
linked	  to	  the	  metabolite	  ions	  that	  were	  merely	  present	  in	  urine	  samples	  collected	  at	  slaughter.	  
During	  this	  study,	  only	  urine	  was	  considered,	  although	  the	  faecal	  metabolite	   fingerprint	  would	  
reflect	   the	   average	   level	   of	   metabolites	   over	   a	   larger	   time	   period	   [44].	   Therefore	   faecal	  
metabolite	   fingerprint	  might	   represent	   the	   stress	   status	   of	   an	   animal	  more	   accurately	   than	   a	  
single	  urine	   sample.	  But	  variations	   in	   faecal	  metabolites	   can	  only	  be	  measured	  after	   intestinal	  
passage,	   which	   takes	   12	   to	   48	   h	   [45].	   This	   makes	   faeces	   irrelevant	   at	   slaughter	   to	   correlate	  
prednisolone	  positive	  samples	  to	  transportation	  stress.	  	  
2.4. Pharmacokinetic	  and	  urinary	  profiling	  of	  glucocorticoids	  	  
Both	  urinary	  prednisolone	  concentrations	   following	  growth-­‐promoting	  administration	   (Chapter	  
V)	  and	  after	  natural	  stress	  and	  ACTH	  treatment	  (Chapter	  IV)	  were	  below	  the	  threshold	  suggested	  
by	   the	  EURL	   (5	  μg	  L-­‐1)	   [18].	  This	   indicates	   the	  need	   for	  a	  proper	   screening	   tool	   to	   confirm	   the	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origin	   of	   the	   detected	   prednisolone.	   In	   literature,	   the	   use	   of	   prednisolone/cortisol	   urinary	  
concentration	   ratios	   and	   the	  analysis	  of	   20β-­‐dihydroprednisolone	  were	   suggested	  as	  potential	  
screening	   tools	   [16][19][46][47].	   In	   order	   to	   evaluate	   these	   suggested	   screening	   tools,	   the	  
plasma	  pharmacokinetic	  properties	  and	  urinary	  excretion	  profiles	  of	  prednisolone,	  prednisone,	  
20α-­‐dihydroprednisolone	  and	  20β-­‐dihydroprednisolone	  were	  assessed	  by	  subjecting	  cattle	  to	  a	  
growth-­‐promoting	  and	  therapeutic	  prednisolone	  treatment	  (Chapter	  V).	  Based	  on	  these	  results,	  
it	   was	   concluded	   that	   20β-­‐dihydroprednisolone	  was	   the	  most	   abundant	   prednisolone-­‐derived	  
metabolite	  in	  plasma	  and	  urine.	  These	  results	  are	  in	  line	  with	  a	  recent	  in	  vivo	  study	  of	  Nebbia	  et	  
al.	  (2014)	  [4].	  However,	  no	  significant	  difference	  between	  the	  urinary	  20β-­‐dihydroprednisolone	  
concentrations	   upon	   growth-­‐promoting	   prednisolone	   administration	   and	   6	   h	   upon	  
pharmacologically-­‐induced	   increase	   of	   cortisol	   were	   noticed.	   Determining	   an	   appropriate	  
threshold	  value	  was	  hard	  due	   to	   the	   large	  variation	   in	  data	  and	  overlay	  between	  endogenous	  
and	  exogenous	  concentrations.	  	  
In	   addition,	   the	   metabolism	   of	   cortisol	   was	   investigated	   by	   profiling	   the	   natural	   urinary	  
glucocorticoid	  metabolites,	   i.e.	   cortisone,	   dihydrocortisone,	   allotetrahydrocortisol,	   urocortisol,	  
tetrahydrocortisone,	   corticosterone,	   deoxycorticosterone,	   α-­‐cortolone	   and	   6β-­‐hydroxycortisol.	  
During	   prednisolone	   treatment,	   a	   steady	   decrease	   in	   relative	   intensities	   of	   these	   urinary	  
metabolites	   was	   noticed.	   On	   the	   other	   hand,	   following	   ACTH	   treatment,	   cortisol	   secretion	  
increased.	   A	   significant	   difference	   (p	   ≤	   0.05)	   between	   prednisolone/cortisol	   ratios	   could	   be	  
detected.	  
Since	   the	   urinary	   prednisolone	   levels	   under	   ‘natural’	   stress	   (at	   slaughter)	   were	   evaluated	   in	  
Chapter	   IV,	   these	   prednisolone/cortisol	   ratios	  were	   considered	   as	  well	   in	   order	   to	   establish	   a	  
suspicious	   threshold.	  Hereby	   the	  mean	  value	   (μendogenous)	  of	  all	  urine	  samples	  with	  endogenous	  
prednisolone	   (n	  =	  79)	  was	  calculated	  and	  added	   to	  2	  or	  3	   times	   the	  standard	  deviation	  of	   the	  
same	   samples	   (μendogenous	   +	   2σ)	   or	   (μendogenous	   +	   3σ)	  which	   corresponds	   to	   a	   ratio	   of	   0.299	   and	  
0.426	  for	  the	  95th	  and	  99th	  percentile	  level	  of	  confidence,	  respectively	  (Figure	  7.2.)	  [48].	  Only	  six	  
of	   149	   considered	   urine	   samples	   were	   misclassified,	   which	   indicates	   that	   the	  
prednisolone/cortisol	  ratio	  has	  a	  sensitivity	  and	  specificity	  of	  94.2%	  and	  98.7%,	  respectively.	  As	  
compared	  to	  our	  newly	  discovered	  biomarker	  (Chapter	  VI),	  this	  is	  slightly	  more.	  Further	  studies	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are	   warranted	   to	   confirm	   the	   validity	   of	   both	   as	   potential	   biomarker	   for	   discriminating	  
endogenous	  from	  exogenous	  prednisolone.	  	  
	  
Figure	  7.2.	  Log	  prednisolone/cortisol	  urinary	  concentration	  ratios	  in	  bovine	  urine	  collected	  during	  oral	  and	  
intramuscular	  growth-­‐promoting	  prednisolone	  treatment,	  during	  ACTH	  administration	  and	  at	  slaughter.	  
	  
2.5. A	  biomarker	  for	  exogenous	  prednisolone	  treatment	  in	  cattle	  
In	   literature,	   the	   need	   for	   a	   specific	   biomarker	   that	   has	   the	   ability	   to	   discriminate	   between	  
endogenous	   formation	   and	   exogenous	   administration	   of	   prednisolone	   still	   exists	   [3][17].	  
Therefore,	   an	   in	   vivo	   study	   was	   conducted	   in	   which	   cattle	   subsequently	   were	   subjected	   to	   a	  
growth-­‐promoting	   and	   therapeutic	   treatment	   with	   prednisolone	   (Chapter	   VI).	   The	   specific	  
growth-­‐promoting	  and	  therapeutic	  dosages	  were	  based	  on	  literature	  [3][49].	  Lower	  doses	  were	  
not	   recommended,	   since	  prednisolone	   and	  prednisone	   concentrations	   retrieved	   in	  urine	  were	  
close	   to	   the	   CCαs	   (i.e.	   1	   μg	   L-­‐1	   and	   0.1	   μg	   L-­‐1,	   respectively).	   To	   ensure	   relevant	   levels	   of	  
prednisolone	   and	   potential	   metabolites	   in	   urine,	   a	   prednisolone	   dose	   of	   40	   mg	   day-­‐1	   was	  
administered	  during	  the	  growth-­‐promoting	  treatment.	  Several	  types	  of	  prednisolone	  treatments	  
(oral	   vs.	   intramuscular	   and	   growth-­‐promoting	   vs.	   therapeutic)	  were	   tested,	   to	   guarantee	   that	  
differentiating	   metabolites	   were	   relevant	   for	   exogenous	   prednisolone	   treatments	   across	  
administration	   routes	   and	   dosages.	   During	   this	   metabolomics	   study,	   different	   sources	   of	  
variation	  were	  included	  in	  the	  study	  subjects	  (breed,	  age).	  Unwanted	  sources	  of	  variation	  were	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minimized	   i.e.	   sample	   collection,	   preservation,	   pre-­‐treatment	   etc.	   To	   correct	   for	   inter-­‐animal	  
differences,	  each	  animal	  served	  as	  its	  own	  control.	  
A	  strategy	  of	  metabolic	  fingerprinting	  was	  followed	  to	  discover	  potential	  biomarkers	  in	  the	  urine	  
of	  cows,	  related	  to	  the	  type	  of	  prednisolone	  treatment.	  As	  such,	  four	  differentiating	  metabolite	  
ions	   emerged	   independently	   of	   the	   source	   of	   variation	   (oral	   vs.	   intramuscular,	   growth-­‐
promoting	   vs.	   therapeutic,	   age,	   breed).	   All	  markers	   proved	   selective,	   as	   these	  were	   absent	   in	  
urine	   containing	   endogenous	   prednisolone.	   The	   sensitivity	   and	   specificity	   calculations	   showed	  
that	   only	   one	   metabolite	   was	   highly	   suitable	   as	   biomarker	   during	   growth-­‐promoting	   and	  
therapeutic	   prednisolone	   treatment	   showing	   a	   sensitivity	   and	   specificity	   of	   93.4%	   and	   96.3%,	  
respectively.	  In	  addition,	  the	  most	  promising	  discriminating	  metabolite	  was	  longer	  detectable	  in	  
urine	   than	  prednisolone	   i.e.	  up	   to	   four	  days	  after	   a	   single	  per	  os	   prednisolone	  administration,	  
which	  emphasizes	  its	  potential	  as	  a	  screening	  tool.	  If	   in	  the	  light	  of	  the	  national	  control	  plan,	  a	  
suspect	  bovine	  urine	  sample	  is	  detected,	  confirmation	  with	  the	  newly	  defined	  biomarker	  could	  
allow	   discrimination	   between	   endogenous	   and	   exogenous	   prednisolone.	   To	   identify	  
discriminating	  metabolites,	  this	  work	  relied	  on	  the	  fragmentation	  profiles	  of	  Q-­‐ToF.	  But	  in	  order	  
to	  reach	  the	  highest	  level	  of	  identification,	  additional	  efforts	  were	  made	  in	  terms	  of	  preparative	  
HPLC	   and	   1H-­‐NMR	   analysis.	   Unfortunately,	   1H-­‐NMR	   analysis	   was	   not	   able	   to	   reveal	   the	  
compound’s	   structure,	   due	   to	   the	   available	   low	   absolute	   quantities	   (<	   10	  µg)	   in	   the	   collected	  
urine.	  For	  now,	  all	  revealed	  biomarkers	  were	  putatively	  annotated,	  thereby	  reaching	  the	  second	  
highest	   level	   of	   identification,	   as	   defined	   by	   Sumner	   et	   al.	   (2007)	   [50]	   since	   a	   standard	   for	  
identification	  at	  the	  highest	  level	  of	  confidence	  was	  lacking.	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3. Future	  perspectives	  
3.1. Further	  exploring	  the	  underlying	  mechanisms	  of	  prednisolone	  formation	  
Several	  hypotheses	  were	  put	  forward	  in	  chapters	  II,	  III	  and	  IV	  to	  explain	  the	  ‘natural’	  prevalence	  
of	  prednisolone	   in	  cattle	  urine,	   including	  stress	  and	  faecal	  contamination.	  Recently,	   it	  was	  also	  
hypothesized	  that	  the	  adrenal	  origin	  of	  prednisolone	  could	  not	  be	  ruled	  out	   [16].	  Therefore,	   it	  
would	  be	  interesting	  to	  investigate	  the	  possible	  involvement	  of	  the	  adrenal	  glands	  by	  means	  of	  
an	  adrenal	  cell	  line	  e.g.	  H295R.	  This	  cell	  line	  model	  facilitates	  investigations	  into	  adrenal	  steroid	  
hormone	   production	   as	   they	   can	   be	  manipulated	   to	   determine	   cellular	   responses	   to	   external	  
stimuli	  (e.g.	  ACTH)	  [51].	  	  
A	   first	   insight	   into	   the	   mechanism	   of	   cortisol	   degradation	   and	   prednisolone	   formation	   was	  
provided	  during	  in	  vitro	  incubation	  with	  bovine	  liver	  S9	  [12].	  Nevertheless,	  additional	  research	  to	  
understand	  the	  exact	  biological	  pathway	  of	  prednisolone	  formation	  is	  recommended.	  To	  achieve	  
this,	   several	   liver-­‐derived	   in	   vitro	   models	   could	   be	   used	   including	   simple	   enzyme-­‐containing	  
cellular	   fractions	   (i.e.	   S9	   fractions,	   microsomes)	   up	   to	   whole	   cell	   systems	   (i.e.	   primary	   cell	  
cultures,	  transformed	  cell	   lines,	  tissue	  slices).	  The	  latter	  are	  recognized	  as	  the	  closest	  model	  to	  
the	  whole	  liver	  in	  the	  in	  vivo	  situation	  [52].	  Combining	  several	  types	  of	  models	  will	  contribute	  to	  
the	  subcellular	  localization	  of	  the	  enzymes	  involved	  in	  the	  biotransformation	  [53][54].	  
3.2. Biomarker	  identification	  
During	   this	   study,	   four	   differentiating	   urinary	   metabolites	   were	   defined	   in	   chapter	   VI	   in	  
prednisolone	   treated	   cattle	   by	   multivariate	   statistical	   analysis.	   Despite	   the	   additional	   efforts	  
made,	   i.e.	   1H-­‐NMR	   and	   QqTOF-­‐MS,	   the	   compound’s	   structures	   could	   not	   be	   completely	  
elucidated.	  Moreover,	   the	   suggested	   structures	  were	  not	   related	   to	   the	  basic	   steroid	   skeleton	  
structure.	  This	  seems	  unexpected.	  However,	  the	  urinary	  fingerprints	  of	  the	  in	  vivo	  study	  showed	  
that	  prednisolone	  and	  ACTH	  treatment	  affected	  a	  wide	  variety	  of	  biological	  processes	  (Chapter	  
IV	   and	   VI).	   Therefore	   it	   could	   be	   anticipated	   that	   prednisolone	   indirectly	   stimulated	   the	  
formation	   of	   the	   differentiating	  metabolites.	   To	   investigate	   the	   exact	   biological	  mechanism(s)	  
that	   link(s)	   these	  markers	   to	   exogenous	   prednisolone,	   the	   chemical	   structure	   and	   identity	   of	  
these	   compounds	   and	   their	   localization	   in	   the	   organism	   should	   be	   revealed.	   Therefore,	  mass	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spectrometry	  imaging	  (MSI)	  of	  biological	  matrixes	  (e.g.	  liver,	  kidney)	  could	  be	  used.	  This	  2D	  and	  
3D	   surface-­‐based	   analysis	   provides	   deeper	   knowledge	   concerning	   the	   spatial	   organization	   of	  
compounds.	  During	  MSI,	  rigorous	  sample	  preparation	  is	  essential	  to	  achieve	  the	  most	  accurate,	  
reproducible	  and	  validated	  data	  possible	  [55][56][57].	  In	  plant	  sciences,	  the	  use	  of	  MSI	  has	  been	  
demonstrated	  by	  detecting	  a	  large	  array	  of	  metabolites	  [58].	  
3.3. Biomarker	  validation	  
Finding	  differentiating	  prednisolone/cortisol	  ratios	  and	  metabolites	  (Chapter	  VI)	  is	  not	  sufficient	  
to	   designate	   them	   as	   biomarkers,	   but	   more	   like	   a	   first	   step	   in	   the	   right	   direction.	   Before	  
implementation	   in	   routine	   applications,	   it	   is	   necessary	   to	   evaluate	   the	   performance	   and	  
usefulness	   of	   potential	   ratios	   and	   biomarkers.	   This	   process	   may	   encounter	   some	   difficulties,	  
since	  the	  absence	  of	  reference	  guidelines	  and/or	  a	  consensual	  list	  of	  criteria	  to	  be	  fulfilled	  [59].	  
This	   is	   in	   contrast	   with	   clinical	   biomarkers	   where	   the	   Food	   and	   Drug	   Agency	   provided	   a	  
definition	  of	  a	  valid	  biomarker	  [60]	  and	  several	  publications	  described	  the	  way	  to	  obtain	  clinical	  
useful	   biomarkers	   [61][62].	   Hereby	   a	   distinction	   between	   analytical	   method	   validation	   and	  
clinical	  qualification	  has	  been	  made.	  	  
During	   analytical	   validation,	   the	   potency	   of	   the	   analytical	   method	   to	   give	   reproducible	   and	  
accurate	   data	   of	   the	   specific	   biomarkers	   is	   ensured.	   This	   depends	   on	   the	   category	   of	   the	  
biomarker	   assay.	   In	   our	   study,	   the	   prednisolone/cortisol	   ratio	   (Chapter	   V)	   is	   a	   relative	  
quantitative	   assay	   and	   the	   stability,	   linearity,	   accuracy,	   precision,	   sensitivity	   and	   specificity	  
should	  be	   validated	   (Table	   7.1.).	   Besides,	   qualitative	  biomarkers	  were	  defined	   (present	   or	   not	  
present)	   (Chapter	  VI).	   Therefore	   it	   is	   sufficient	   to	   show	   that	   the	  analytical	  method	   is	   sensitive	  
and	  specific	  enough	  to	  detect	  the	  targeted	  analytes.	  Additionally,	  the	  stability	  of	  the	  analytes	  in	  
a	  sample	  should	  be	  considered	  after	  a	  freeze/thaw	  cycle	  and	  after	  leaving	  the	  urine	  samples	  at	  
the	  bench	  top	  for	  several	  hours	  (Table	  7.1.)	  [61][63][64].	  	  
During	  this	  study,	  the	  newly	  discovered	  differentiating	  metabolites	  could	  be	  determined	  in	  every	  
prednisolone	  treated	  animal	  with	  two	  kinds	  of	  MS	  techniques	  i.e.	  Orbitrap-­‐MS	  and	  QqTOF-­‐MS,	  
without	   noticing	   interfering	   compounds.	   This	   fulfils	   the	   sensitivity	   and	   specificity	   criteria.	   It	  
should	  be	  mentioned	  that	  the	  stability	  of	  the	  biomarkers	  was	  not	  directly	  evaluated.	  However,	  
the	  urine	  samples	  collected	  during	  the	  in	  vivo	  study	  were	  preserved	  at	  -­‐80	  °C	  as	  described	  by	  De	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Clercq	  et	  al.	  2013	  [65]	   (Chapter	   II)	  and	  analysed	  at	  different	  occasions.	  No	  significant	   intensity	  
changes	  of	  the	  defined	  biomarkers	  could	  be	  noticed.	  However,	  the	  stability	  of	  these	  compounds	  
should	  be	  further	  assessed,	  thereby	  focussing	  on	  both	  the	  effect	  of	  multiple	  freeze/thaw	  cycles	  
and	  the	  exposure	  to	  room	  temperature	  for	  several	  hours.	  	  
Table	  7.1.	  Summary	  of	  validation	  parameters	  applicable	  to	  each	  category	  of	  biomarker	  assay	  [63].	  





quantitative	   Qualitative	  
Sample	  stability	   X	   X	   X	   X	  
Reagent	  stability	   X	   X	   	   	  
Assay	  range	   X	   X	   X	   	  
Parallelism	   X	   X	   	   	  
Dilution	  linearity	   X	   X	   	   	  
Accuracy	   X	   X	   	   	  
Precision	   X	   X	   X	   	  
Sensitivity	   X	   X	   X	   X	  
Specificity	   X	   X	   X	   X	  
	  
The	  clinical	  qualification	  is	  the	  process	  used	  to	  confirm	  the	  ratios’	  and	  biomarkers’	  suitability	  and	  
robustness,	  in	  our	  case	  discriminating	  exogenous	  from	  endogenous	  prednisolone.	  In	  chapter	  VI,	  
a	  first	  preliminary	  validation	  was	  already	  performed	  based	  on	  the	  original	  dataset	  [64][65][68].	  
Of	   the	   four	  newly	  defined	   compounds,	  one	   revealed	  high	  potency	  as	  biomarker	   (m/z-­‐value	  of	  
283.1693	  Da	  and	  retention	  time	  1.40	  min)	  during	  all	  types	  of	  prednisolone	  treatment.	  However,	  
profound	  qualification	  of	  the	  marker	  is	  necessary	  and	  needs	  to	  be	  performed	  in	  an	  independent	  
dataset	   i.e.	   validation	   dataset.	   This	   experiment	   should	   cover	   a	   larger	   population	   in	   terms	   of	  
breed	  (milking	  cows,	  meat	  cows),	  age,	  sex,	  origin	  of	  feeding	  (different	  farms),	  animal	  physiology	  
(different	   moments	   of	   the	   estrous	   cycle)	   and	   more	   sampling	   points	   following	   prednisolone	  
treatment	   (1	   to	   6	   days)	   [61].	   In	   this	   way,	   the	   differential	   behaviour	   of	   the	   biomarker	   can	   be	  
confirmed	  and	  implemented	  in	  the	  frame	  of	  national	  control	  plans	  [68][69].	  	  
The	  classical	  approach	  (including	  screening	  and	  confirmation)	  to	  detect	  the	  unauthorized	  use	  of	  
prednisolone	   is	   not	   applicable	   since	  previous	   and	   this	  work	   showed	   that	  urinary	  prednisolone	  
could	  have	  both	  an	  endogenous	  and	  exogenous	  origin	  [18].	  	  
If	  a	  suspect	  bovine	  urine	  sample	  is	  detected,	  two	  approaches	  could	  be	  followed	  to	  discriminate	  
endogenous	  from	  exogenous	  prednisolone.	  The	  first	   is	  based	  on	  the	  EURL	  suggested	  threshold	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level	  of	  5	  μg	  L-­‐1	  [18].	  However,	  it	  must	  be	  considered	  that	  also	  lower	  (	  i.e.	  <	  5	  μg	  L-­‐1)	  exogenous	  
prednisolone	  levels	  were	  found	  during	  this	  study.	  To	  overcome	  this	  problem,	  screening	  for	  our	  
newly	  discovered	  biomarker	  or	  prednisolone/cortisol	  ratio	  could	  offer	  an	  alternative.	  However,	  
these	  are	  currently	  considered	  for	  screening	  purpose	  only.	  The	  EURL	  reflection	  paper	  states	  that	  
depending	   on	   the	   significance	   of	   the	   differences	   observed,	   biomarkers	   can	   be	   considered	   as	  
confirmatory	  methods	   [18].	   However,	   currently	   there	   are	   no	   criteria	   available	   for	   this	   type	   of	  
analysis.	   And	   until	   now,	   scientific	   and	   statistical	   considerations	   are	   not	   enough,	   but	   full	  
agreement	  with	  competent	  authorities	  will	  be	  needed.	  	  
3.4. Other	  mass	  spectrometric	  approaches	  
During	   this	   study,	   we	  mainly	   focussed	   on	   the	   full-­‐scan	   capacities	   of	   the	   Orbitrap-­‐MS	   and	   the	  
measured	  urinary	   fingerprints.	  Another	  approach	   to	  discriminate	  endogenous	   from	  exogenous	  
prednisolone	  is	  by	  considering	  its	  isotope	  ratio	  with	  the	  use	  of	  Isotope	  Ratio	  Mass	  Spectrometry	  
(IRMS).	  This	  is	  a	  versatile	  application,	  based	  on	  the	  fact	  that	  endogenous	  compounds	  reflect	  an	  
average	  of	  all	  carbon	  from	  different	  origins,	  while	  synthetic	  compounds	  are	  elaborated	  from	  a	  
single	  precursor	  with	  a	  defined	   13C/12C	   ratio	   [70][71][72].	  Due	   to	   the	   low	  concentration	  of	   the	  
analytes	  and	  the	  small	  contribution	  of	  13C	  to	  the	  analyte	  molecule	  (1%),	  the	  use	  of	  large	  volume	  
of	  samples	  and	  an	  effective	  clean-­‐up	  method	  are	   required	   to	  obtain	   the	  minimum	  of	  10	  ng	  of	  
carbon	   per	   compound	   [73].	   Numerous	   methods	   using	   GC-­‐combustion-­‐IRMS	   to	   distinguish	  
endogenous	   from	   synthetic	   steroids	   have	   been	   published,	   however,	   in	   residue	   analysis	   this	  
method	  is	  not	  (yet)	  routinely	  used	  for	  glucocorticoids.	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The	   anti-­‐inflammatory	   properties	   of	   the	   natural	   glucocorticoid	   cortisol	   have	   led	   to	   the	  
development	  of	   synthetic	   analogues,	  which	  exert	   even	  higher	   anti-­‐inflammatory	  activities.	  
Moreover,	   these	   drugs	   also	   induce	   body	   weight	   gain	   in	   production	   animals	   by	   improving	  
feed	  intake	  and	  lowering	  feed	  conversion.	  Due	  to	  their	  growth-­‐promoting	  effects,	  the	  use	  of	  
synthetic	   glucocorticoids	   is	   strictly	   regulated	   in	   the	   European	   Union	   (CD	   2003/74/EC).	  
Recently,	   the	   European	  Commission	   reported	   in	   the	  Commission	   Staff	  Working	  Document	  
about	  the	  implementation	  of	  national	  residue	  monitoring	  plans	  in	  the	  member	  states	  (2009	  -­‐	  
2012),	   an	   increasing	  occurrence	  of	  prednisolone	   residues	   in	  bovine	  urine	   samples	  without	  
any	   direct	   evidence	   for	   unauthorized	   administration.	   These	   findings	   have	   raised	   many	  
questions	  about	  the	  origin	  of	  this	  prednisolone.	  The	  research	  of	  this	  doctoral	  thesis	  intended	  
to	   further	   investigate	   the	   hypotheses	   suggested	   in	   literature	   and	   contribute	   to	   the	  
discrimination	   of	   endogenous	   from	   exogenous	   prednisolone	   by	   using	   a	   metabolomic	  
framework.	  	  
Chapter	  I	  –	  In	  this	  chapter,	  a	  comprehensive	  overview	  is	  provided	  on	  the	  origin	  and	  chemical	  
configuration	   of	   glucocorticoids.	   In	   the	   body,	   glucocorticoids	   exert	   a	   dual	   role,	   which	   is	  
translated	  into	  metabolic	  and	  immunological	  responses.	  Besides,	  glucocorticoids	  are	  known	  
to	   display	   growth-­‐promoting	   effects,	   which	   have	   led	   to	   their	   abuse	   in	   livestock.	   In	   this	  
regard,	   a	   brief	   outline	   of	   the	   legislative	   framework	   about	   glucocorticoids	   is	   provided.	  
Moreover,	   a	   summary	   is	   given	   on	   the	   predominant	   analytical	   strategies	   that	   are	   used	   for	  
extraction	   and	   detection	   of	   glucocorticoids.	   Herewith,	   the	   analytical	   platform	   and	   their	  
capacities	   that	   are	   employed	   in	   this	   doctoral	   thesis	   are	   discussed	   in	   detail.	   As	   these	  
analytical	   instruments	   are	   able	   to	   actualize	   various	   metabolomic	   experiments,	   the	   basic	  
principles	   of	   metabolomics	   are	   defined	   as	   well.	   Finally,	   the	   conceptual	   framework	   and	  
research	  objectives	  of	  this	  thesis	  are	  formulated.	  	  
Chapter	   II	   –	  This	  chapter	  describes	  the	  development	  and	  validation	  of	  a	  generic	  extraction	  
protocol	  and	  full-­‐scan	  high-­‐resolution	  mass	  spectrometry	  method	  that	  enables	  the	  analysis	  
of	  natural	  and	  synthetic	  glucocorticoids	  in	  urine.	  The	  extraction	  protocol	  was	  optimized	  by	  a	  
Plackett-­‐Burman	   experimental	   design.	   Detection	   of	   the	   selected	   glucocorticoids	   was	  
achieved	   by	   UHPLC-­‐ExactiveTM	   Orbitrap	  mass	   spectrometry.	   This	   analytical	   procedure	  was	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validated	   according	   to	   CD	   2002/657/EC	   and	   included	   linearity,	   precision,	   accuracy,	  
specificity/selectivity	   and	   sensitivity.	   This	   method	   was	   used	   to	   examine	   the	   stability	   of	  
glucocorticoids	  in	  bovine	  urine	  under	  various	  storage	  conditions	  (up	  to	  20	  weeks).	  This	  study	  
demonstrated	  that	  filter-­‐sterilization	  of	  urine,	  storage	  at	  -­‐80	  °C,	  and	  acidic	  conditions	  (pH	  3)	  
were	  optimal	  for	  preservation	  of	  glucocorticoids	  and	  significantly	  limit	  degradation	  up	  to	  20	  
weeks.	  	  
Chapter	   III	   –	   In	   this	  chapter	  an	  UHPLC	  hyphenated	  to	  ExactiveTM	  Orbitrap-­‐MS	  method	  was	  
developed	   to	   confirm	   the	  presence	  of	   glucocorticoids	   in	   bovine	   faeces	  during	   a	   long-­‐term	  
stability	   study.	   A	   Plackett-­‐Burman	   experimental	   design	   was	   successfully	   applied	   to	  
determine	   the	   key	   conditions	   for	   optimal	   extraction	   of	   glucocorticoids	   from	   faeces.	   The	  
targeted	   analysis	   was	   successfully	   validated	   according	   to	   CD	   2002/657/EC.	   The	   stability	  
study	   demonstrated	   that	   lyophilising	   faeces	   and	   storage	   at	   -­‐80	   °C	   were	   optimal	   for	  
preservation	   and	   significantly	   limited	   degradation	   of	   glucocorticoids	   in	   faeces	   up	   to	   10	  
weeks.	  	  
Chapter	  IV	  –	  The	  objective	  of	  this	  chapter	  relates	  to	  the	  hypothesis	  that	  prednisolone	  could	  
be	  generated	  under	  influence	  of	  stress.	  Therefore,	  the	  prevalence	  of	  prednisolone	  in	  bovine	  
urine	  under	  three	  conditions,	  differing	  in	  degree	  of	  stress,	  was	  verified:	  i.e.	  at	  the	  farm,	  upon	  
slaughter	   and	   following	   administration	   of	   a	   synthetic	   analogue	   of	   the	   adrenocorticotropic	  
hormone.	  Hereby,	  a	  significant	  positive	  correlation	  between	  cortisol	  and	  prednisolone	  could	  
be	  demonstrated.	  Only	  one	  urine	   sample	   showed	  prednisolone	   levels	  above	   the	   threshold	  
level	   suggested	   by	   the	   European	   Reference	   Laboratories	   (5	   μg/L),	   which	   endorsed	   the	  
relevance	   of	   this	   threshold	   level.	   Additionally,	   the	   urinary	   metabolic	   fingerprint	   was	  
evaluated	  and	  allowed	  a	  clear	  discrimination	  between	  the	  different	  stress	  conditions.	  A	  total	  
of	  169	  differentiating	  metabolites	  were	  assigned	  to	  have	  a	  key	  role	  in	  the	  urinary	  pattern	  in	  
response	  to	  stress.	  This	  could	  be	  a	  powerful	  tool	  to	  classify	  unknown	  urine	  samples	  and	  give	  
information	   about	   the	   stress	   status	   of	   the	   animals,	   and	   may	   eventually	   lead	   to	   a	   better	  
interpretation	   of	   analysis	   results	   of	   urine	   samples,	   which	   proved	   non-­‐compliant	   for	  
prednisolone.	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Chapter	   V	   –	   This	   chapter	   aimed	   to	   evaluate	   the	   applicability	   and	   validity	   of	   urinary	  
prednisolone/cortisol	   concentration	   ratios	   and	   the	   analysis	   of	   20β-­‐dihydroprednisolone	   as	  
potential	   screening	   tools	   to	   confirm	   the	   origin	   of	   prednisolone.	   This	   by	   deepening	   the	  
knowledge	   on	   the	   pharmacokinetic	   and	   urinary	   excretion	   profiles	   of	   prednisolone,	  
prednisone,	   20α-­‐dihydroprednisolone	   and	   20β-­‐dihydroprednisolone	   after	   oral	   and	  
intramuscular	   growth-­‐promoting	   and	   therapeutic	   prednisolone	   administration,	   and	  
pharmacologically-­‐induced	  increase	  of	  cortisol	  in	  an	  elaborate	  in	  vivo	  study.	  In	  addition,	  the	  
metabolism	   of	   cortisol	   was	   investigated	   by	   profiling	   the	   natural	   urinary	   glucocorticoid	  
metabolites	   during	   the	   different	   treatments.	   A	   significant	   negative	   feedback	   was	   noticed	  
during	   both	   growth-­‐promoting	   and	   therapeutic	   prednisolone	   treatments.	   The	   metabolite	  
20β-­‐dihydroprednisolone	  was	   not	   applicable	   as	   potential	   screening	   tools	   due	   to	   the	   large	  
variation	  in	  data	  and	  absence	  of	  significant	  differences	  during	  the	  different	  treatments.	  The	  
prednisolone/cortisol	   ratio	   was	   a	   more	   promising	   approach.	   However,	   the	   need	   for	   a	  
selective/specific	   biomarker	   enabling	   discrimination	   between	   endogenous	   and	   exogenous	  
prednisolone	  remains.	  
Chapter	   VI	   –	   In	   this	   chapter	   four	   potential	   biomarkers	  were	   identified	   that	  may	   have	   the	  
ability	   to	   discriminate	   between	   endogenously	   formed	   and	   exogenously	   administrated	  
prednisolone.	   To	   this	   extent,	   a	   strategy	   of	   metabolic	   fingerprinting	   was	   implemented	   to	  
assess	   potential	   metabolite	   differences	   in	   the	   urine	   of	   cows,	   subsequently	   exposed	   to	   a	  
growth-­‐promoting	  and	  therapeutic	  prednisolone	  treatment.	  After	  evaluating	  the	  sensitivity,	  
specificity,	   urinary	   excretion	   kinetics	   and	   selectivity,	   one	   compound	   was	   found	   highly	  
suitable	   as	  biomarker.	   Based	  on	  accurate	  mass,	   isotope	  patterns	   and	  MS/MS	   spectra,	   this	  
compound	  was	  putatively	  annotated	  and	  may	  be	  suggested	  as	  an	  actionable	  biomarker	  for	  
exogenous	  prednisolone	  administration.	  
Chapter	   VII	   –	   In	   this	   chapter,	   general	   conclusions	   and	   future	   research	   perspectives	   are	  
formulated.	  The	  use	  of	  adrenal	  cell	  models	  and	  liver-­‐derived	  in	  vitro	  models	  were	  suggested	  
to	   further	   explore	   the	   underlying	  mechanisms	   of	   endogenous	   prednisolone	   formation.	   In	  
addition,	   a	   more	   profound	   validation	   of	   the	   biomarker	   defined	   in	   chapter	   VI	   should	   be	  
performed	   in	   an	   independent	   dataset.	   After	   positive	   evaluation,	   the	   biomarker	   could	   be	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implemented	   as	   efficient	   screening	   tool	   to	   discriminate	   endogenous	   from	   exogenous	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Na	   de	   ontdekking	   van	   de	   anti-­‐inflammatoire	   eigenschappen	   van	   natuurlijke	   glucocorticoïden	  
(cortisol	   en	   cortisone)	   werden	   talrijke	   synthetische	   analogen	   ontwikkeld	   met	   sterkere	  
therapeutische	  effecten.	  Daarnaast	  vertonen	  deze	  ook	  een	  groeibevorderende	  werking.	  Door	  dit	  
laatste	  is	  het	  gebruik	  van	  glucocorticoïden	  sterk	  gereglementeerd	  binnen	  de	  Europese	  Unie	  (CD	  
2003/74/EC).	   De	   voorbije	   jaren	   werden	   echter	   in	   verschillende	   lidstaten	   niet-­‐conforme	  
prednisolone	   resultaten	   gerapporteerd	   in	   runderurine,	   zonder	   enige	   aanwijzing	   van	  
glucocorticoïdmisbruik.	  De	  oorsprong	  van	  dit	  prednisolone	  is	  nog	  niet	  gekend,	  hoewel	  meerdere	  
hypothesen	   in	   de	   literatuur	   beschreven	   worden.	   In	   deze	   doctoraatsthesis	   werd	   getracht	   om	  
deze	   hypothesen	   nader	   te	   bestuderen	   en	   een	   onderscheid	   tussen	   endogeen	   en	   exogeen	  
prednisolone	  mogelijk	  te	  maken	  met	  behulp	  van	  een	  ‘metabolomic’	  strategie.	  
Hoofdstuk	   I	   –	   In	   dit	   hoofdstuk	  wordt	   een	   overzicht	   gegeven	   van	   de	   oorsprong	   en	   chemische	  
configuratie	  van	  glucocorticoïden.	  In	  het	  lichaam	  vervullen	  glucocorticoïden	  meerdere	  functies,	  
wat	  zich	  vertaalt	   in	  metabole	  en	  immunologische	  reacties.	  Daarnaast	  bezitten	  glucocorticoïden	  
ook	   groeibevorderende	   effecten	  wat	   voor	   ongeautoriseerd	   gebruik	   zorgde	   in	   nutsdieren.	   Een	  
kort	   overzicht	   van	  de	  Europese	  wetgeving	  wordt	  hieromtrent	   gegeven.	  Vervolgens	  omsluit	   dit	  
hoofdstuk	   een	   overzicht	   van	   de	   verscheidene	   analytische	   technieken,	   die	   veelvuldig	   worden	  
toegepast	  voor	  de	  extractie	  en	  detectie	  van	  glucocorticoïden.	  Hierbij	  wordt	  vooral	   ingegaan	  op	  
het	   analytische	   instrumentarium	   dat	   gebruikt	   werd	   in	   deze	   doctoraatsthesis.	   Aangezien	   de	  
metabolome	   screeningsmogelijkheden	   van	   de	   apparatuur	   hier	   een	   belangrijke	   onderdeel	   van	  
uitmaken,	   worden	   de	   basisprincipes	   van	   metabolomics	   gedefinieerd.	   Tenslotte	   wordt	   het	  
conceptueel	  kader	  geschetst	  en	  de	  opbouw	  van	  de	  verschillende	  onderzoeksfasen	  aangegeven.	  
Hoofdstuk	   II	   –	   Dit	   hoofdstuk	   beschrijft	   de	   ontwikkeling	   en	   validatie	   van	   een	   holistisch	  
extractieprotocol	   en	   analytische	  methode	   voor	   natuurlijke	   en	   synthetische	   glucocorticoïden	   in	  
runderurine.	  Het	  extractieprotocol	  werd	  geoptimalizeerd	  met	  behulp	  van	  een	  Plackett-­‐Burman	  
experimenteel	   design.	   Scheiding	   en	   detectie	   van	   de	   geselecteerde	   glucocorticoïden	   werd	  
uitgevoerd	   met	   een	   UHPLC	   gekoppeld	   aan	   hoge-­‐resolutie	   ExactiveTM	   Orbitrap	  
massaspectrometrie.	  Bovendien	  werd	  via	  validatie	  vastgesteld	  dat	  de	  ontwikkelde	  methode	  een	  
correcte	  kwantificatie	  van	  glucocorticoïden	  toelaat.	  Deze	  validatie	  werd	  uitgevoerd	  volgens	  CD	  
2002/657/EC	   waarbij	   lineariteit,	   precisie,	   juistheid,	   gevoeligheid	   en	   specificiteit/selectiviteit	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werden	   geëvalueerd.	   Deze	   analytische	   methode	   werd	   toegepast	   om	   de	   stabiliteit	   van	  
glucocorticoïden	  in	  runderurine,	  onder	  verschillende	  omstandigheden	  gedurende	  20	  weken,	  na	  
te	   gaan.	   Hierbij	   werd	   vastgesteld	   dat	   glucocorticoïden	   in	   urine	   best	   stabiel	   blijven	   in	  
aangezuurde	  urine	  (pH	  3)	  bij	  een	  temperatuur	  van	  -­‐80	  °C	  en	  vrij	  van	  bacteriën	  door	  middel	  van	  
filtersterilisatie.	  
Hoofdstuk	   III	   –	   In	   dit	   hoofdstuk	   werd	   een	   UHPLC	   gekoppeld	   aan	   ExactiveTM	   Orbitrap-­‐MS	  
methode	  ontwikkeld	  om	  de	  aanwezigheid	  van	  glucocorticoïden	  in	  runderfeces	  tijdens	  een	  lange	  
termijn	  stabiliteitsstudie	  na	  te	  gaan.	  Met	  behulp	  van	  een	  Plackett-­‐Burman	  experimenteel	  design	  
werden	   de	   optimale	   extractie	   omstandigheden	   voor	   glucocorticoïden	   in	   feces	   bepaald.	   Deze	  
analytische	   methode	   werd	   succesvol	   gevalideerd	   volgens	   de	   richtlijnen	   beschreven	   in	   CD	  
2002/657/EC.	   In	   een	   lange	   termijn	   stabiliteitsstudie	   werd	   aangetoond	   dat	   vriesdrogen	   en	  
onmiddellijke	  bewaring	  bij	   -­‐80	  °C	  de	  beste	  manier	   is	  om	  de	  degradatie	  van	  glucocorticoïden	  te	  
minimaliseren	  gedurende	  10	  weken.	  
Hoofdstuk	   IV	   –	   Dit	   hoofdstuk	   onderzoekt	   de	   hypothese	   die	   de	   mogelijke	   vorming	   van	  
prednisolone	  beschrijft	  onder	  invloed	  van	  stress.	  Hiervoor	  werd	  de	  prevalentie	  van	  prednisolone	  
nagegaan	   onder	   drie	   verschillende	   omstandigheden,	   gekarakteriseerd	   door	   een	   verschillend	  
niveau	   aan	   stress:	   op	   de	   boerderij,	   aan	   de	   slachtlijn	   en	   na	   toediening	   van	   een	   synthetisch	  
analoog	  van	  het	  adrenocorticotroop	  hormoon	  dat	  stress	  induceert.	  Hierbij	  werd	  een	  significante	  
positieve	   correlatie	   tussen	   cortisol	   en	   prednisolone	  waargenomen.	  Uit	   de	   resultaten	  blijkt	   dat	  
slechts	   één	   urinestaal	   een	   hogere	   prednisoloneconcentratie	   bevat	   dan	   de	   grenswaarde	  
voorgesteld	  door	  de	  Europese	  Referentie	  Laboratoria	  (5	  μg/L).	  Dit	  toont	  de	  relevantie	  van	  deze	  
grenswaarde	  aan.	  Bijkomend	  kon	  aan	  de	  hand	  van	  het	  metabolietenprofiel	  in	  de	  urinestalen	  een	  
duidelijk	  onderscheid	  gemaakt	  worden	  tussen	  de	  verschillende	  stressomstandigheden.	  In	  totaal	  
werden	  169	  differentiërende	  metabolieten	  gekarakteriseerd	  afhankelijk	  van	  het	  soort	  stress.	  Dit	  
metabolietprofiel	  kan	  ingezet	  worden	  om	  onbekende	  urinestalen	  te	  classificeren	  naargelang	  de	  
stress	   status	   van	   het	   dier,	   wat	   leidt	   tot	   een	   betere	   interpretatie	   van	   analyseresultaten	   van	  
urinestalen	  met	  prednisoloneresiduen.	  
Hoofdstuk	   V	   –	   In	   dit	   hoofdstuk	  werden	   de	   toepasbaarheid	   en	   geschiktheid	   nagegaan	   van	   de	  
prednisolone/cortisol	   concentratieverhouding	   en	   de	   20β-­‐dihydroprednisolone	   concentratie	   als	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potentiële	   screeningsmerkers	   om	   zo	   de	   oorsprong	   van	   prednisolone	   te	   bevestigen.	   Hiervoor	  
werd	   de	   farmacokinetiek	   en	   urinaire	   excretie	   van	   prednisolone,	   prednisone,	  20α-­‐
dihydroprednisolone	   en	   20β-­‐dihydroprednisolone	   na	   orale	   en	   intramusculaire	  
groeibevorderende	   en	   therapeutische	   prednisolone	   behandeling	   en	   farmacologisch	  
geïnduceerde	  cortisol	   geëvalueerd	   in	  een	  uitvoerige	   in	   vivo	   studie.	  Daarnaast	  werd	  de	   invloed	  
onderzocht	  van	  de	  verschillende	  behandelingen	  op	  de	  urinaire	  concentraties	  van	  cortisol	  en	  zijn	  
metabolieten.	  Deze	  behandelingen	  leidden	  tot	  een	  significante	  negatieve	  feedback	  voor	  cortisol	  
en	  zijn	  metabolieten.	  Uit	  de	  resultaten	  bleek	  de	  metaboliet	  20β-­‐dihydroprednisolone	  ongeschikt	  
wegens	  de	  grote	  variatie	  in	  data	  en	  omwille	  van	  de	  afwezigheid	  van	  niet	  significante	  verschillen	  
tijdens	   de	   verschillende	   behandelingen.	   De	   prednisolone/cortisol	   ratio	   bleek	   daarentegen	  wel	  
een	  veelbelovende	  screeningsmerker.	  Daarnaast	  bestaat	  nog	  steeds	  de	  nood	  aan	  een	  voldoende	  
selectieve/specifieke	   biomerker	   die	   het	   onderscheid	   tussen	   endogene	   vorming	   en	   exogene	  
toediening	  toelaat.	  	  
Hoofdstuk	  VI	  –	   In	  dit	  hoofdstuk	  werden	  vier	  potentiële	  biomerkers	  in	  urine	  opgehelderd.	  Deze	  
zouden	   het	  mogelijk	  maken	   om	   de	   endogene	   of	   exogene	   oorsprong	   van	   prednisolone	   aan	   te	  
duiden.	   Hiervoor	   werd	   een	   metabole	   strategie	   toegepast	   in	   urine	   van	   runderen	   die	  
achtereenvolgens	   werden	   onderworpen	   aan	   een	   groeibevorderende	   en	   therapeutische	  
prednisolone	   behandeling.	   Na	   evaluatie	   van	   de	   sensitiviteit,	   specificiteit,	   urinaire	  
excretiekinetiek	  en	  selectiviteit	  kon	  één	  component	  weerhouden	  worden	  als	  de	  meest	  geschikte	  
biomerker.	  Gebaseerd	  op	  de	  accurate	  massa,	  het	   isotoopprofiel	  en	  het	  MS/MS	  spectrum	  werd	  
deze	  component	  potentieel	  geïdentificeerd	  en	  zou	  kunnen	  dienen	  als	  biomerker	  voor	  exogene	  
prednisolone	  toediening.	  
Hoofdstuk	  VII	  –	  In	  dit	  hoofdstuk	  werden	  de	  algemene	  conclusies	  en	  toekomstperspectieven	  van	  
dit	  onderzoek	  geformuleerd.	  Hierbij	  werd	  het	  nut	  van	  het	  bijnier	  cel-­‐model	  en	  in	  vitro	  modellen,	  
gebaseerd	   op	   de	   lever,	   voorgesteld	   om	   het	   onderliggende	   mechanisme	   van	  
prednisolonevorming	  nader	  te	  onderzoeken.	  Alvorens	  de	  voorgestelde	  biomerker	  (Hoofdstuk	  VI)	  
kan	  geïmplementeerd	  worden	  als	  efficiënte	  screeningstest	   in	  nationale	  controleplannen,	  dringt	  
zich	  een	  grondige	  validatie	  op	  van	  deze	  voorgestelde	  biomerker,	  in	  een	  onafhankelijke	  dataset.	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SCIENTIFIC	  TRAINING	  AND	  ACTIVITIES	  
International	  conference:	  
• 11th	   Annual	   International	   Conference	   of	   the	   Metabolomics	   Society,	   June	   2015,	   San	  
Francisco,	  USA.	  
Poster	  presentation:	  ‘Metabolic	  fingerprinting	  to	  reveal	  a	  novel	  biomarker	  for	  prednisolone	  
treatment	  in	  cattle’	  
• 7th	  International	  Symposium	  on	  Hormone	  and	  Veterinary	  Drug	  Residue	  Analysis,	  June	  2014,	  
Ghent,	  Belgium.	  
Oral	   presentation:	   ‘Metabolomic	   fingerprinting	   of	   glucocorticoids	   in	   urine	   by	   UHPLC-­‐
Orbitrap-­‐MS,	  Q-­‐Orbitrap-­‐MS	  and	  Qq-­‐ToF-­‐MS’	  
• 13th	   International	   Symposium	   on	   Hyphenated	   Techniques	   in	   Chromatography	   and	  
Separation	  Technology	  (HTC),	  January	  2014,	  Bruges,	  Belgium.	  
Poster	  presentation:	  ‘Metabolomic	  profiling	  of	  the	  glucocorticoid	  status	  of	  Holstein-­‐Friesian	  
cows	  by	  U-­‐HPLC-­‐HR-­‐Orbitrap	  MS	  upon	  administration	  of	  prednisolone’	  
• 6th	  International	  Symposium	  on	  Recent	  Advances	  in	  Food	  Analysis	  (RAFA),	  November	  2013,	  
Prague,	  Czech	  Republic.	  
Oral	   presentation:	   ‘High-­‐resolution	   mass	   spectrometry	   for	   metabolomic	   profiling	   of	   the	  
glucocorticoid	  status	  of	  Holstein-­‐Friesian	  cows	  after	  administration	  of	  prednisolone’	  
• Trends	  in	  Food	  Analysis	  VII	  Symposium	  (KVCV),	  September	  2013,	  Ghent,	  Belgium.	  
Poster	  presentation:	  ‘Metabolomic	  profiling	  of	  the	  glucocorticoid	  status	  of	  Holstein-­‐Friesian	  
cows	  by	  U-­‐HPLC-­‐HR-­‐Orbitrap	  MS	  upon	  administration	  of	  prednisolone’	  
• 14th	  International	  Symposium	  on	  Advances	  in	  Extraction	  Technologies	  (ExTech),	  September	  
2012,	  Messina,	  Italy.	  
Oral	   presentation:	   ‘Plackett-­‐Burman	  design:	   a	   tool	   to	   develop	   a	   generic	   extraction	   for	  U-­‐
HPLC-­‐Orbitrap-­‐MS	  analysis	  of	  glucocorticoids	  in	  livestock	  urine’	  
• Conference	  on	  Residues	  of	  Veterinary	  Drugs	  in	  Food	  (EuroResidue	  VII),	  May	  2012,	  Egmond	  
aan	  Zee,	  The	  Netherlands.	  
Poster	  presentation:	  ‘Endogenous	  formation	  of	  glucocorticoids	  in	  livestock	  urine:	  a	  stability	  
study’	  
National	  and	  International	  training	  
• Inter-­‐university	  pharmacokinetic	  and	  pharmacodynamic	  course.	  Fundamental	  Principles	  and	  
Application	  to	  Contemporary	  Drug	  Development,	  April	  2015,	  Louvain,	  Belgium.	  
• Q	   Exactive	   Operations	   Training	   Course,	   ThermoFisher	   Scientific,	   December	   2013,	   Ghent,	  
Belgium.	  
• AB	   Sciex	   Course:	   Basic	   Triple	   TOF®	   5600	   Small	  Molecule	   Training,	   June	   2013,	   Darmstadt,	  
Germany.	  
• Intensive	  Programme	  For	  Advanced	  Residue	  Analysis	  in	  Food	  (IPARAF	  Course),	  March	  -­‐	  April	  
2012,	  Nantes,	  France.	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Doctoral	  schools	  of	  Life	  Sciences	  and	  Medicine	  
• Project	  Management	  -­‐	  Cluster	  Career	  Management,	  January	  2014,	  Ghent	  University	  
• Communication	  Skills:	  	  
• Basic	  module,	  October	  2012,	  Ghent	  University.	  
• Communication	  skills:	  Conflict	  Handling,	  April	  2013,	  Ghent	  University.	  
• Basic	  statistics	  in	  research:	  
• Introduction	  SPSS,	  October	  2012,	  Instituut	  voor	  Permanente	  vorming	  (IVPV)	  
• Module	  1:	  Basic	  statistics,	  November	  -­‐	  December	  2012	  (IVPV)	  
• Module	  3:	  Experimental	  setup,	  April	  -­‐	  June	  2013	  (IVPV)	  
• Statistics	  -­‐	  Introduction	  to	  SPSS,	  October	  2012,	  Ghent	  University.	  
• Clinical	   studies:	   study	   design,	   implementation	   and	   reporting,	   August	   2012,	   Ghent	  
University.	  
Tutor	  of	  Master	  students	  
• 2011	  –	  2015:	  One	  thesis	  student	  from	  the	  Faculty	  of	  Pharmaceutical	  Science	  
	  	  Two	  thesis	  students	  from	  the	  Faculty	  of	  Veterinary	  Medicine	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n een land vol pillen en grillen zit ik aan de oever van de siroop tot plots een pratend wit 
konijn uit den Bussche langskomt en vraagt of ik wil helpen met een queeste. Gezien mijn drang 
naar avontuur moet ik niet lang nadenken en besluit ik haar te volgen. Na een sprong in het 
diepe kom ik in de wonderlijke wereld van LCA terecht, waar niets is wat het lijkt.  
Voor de poorten staat een Wannemacker en moet ik op mijn blote knieën beloven dat alles wat ik 
zie vertrouwelijk is en ik nooit iets aan iemand zal vertellen (oeps). Na dit plechtige moment en 
het afhandelen van de nodige papierwinkel, ontmoet ik de Energieke Koningin. Ze 
is zo snel als de wind, streeft naar een succesvol bestaan en gaat voor iedereen door 
een vuur. Ze helpt me waar nodig en geen moeite is haar te veel. Meteen heb ik een 
goed gevoel over de opdracht die voor mij ligt en begin ik met goeie moed aan de zoektocht naar 
de ware aard van prednisolone.  
Voor mijn queeste loop ik rond in een labyrinth van eilanden, vreemd geurende labo’s en vrolijke 
koffielokalen. Het wit konijn helpt me op weg en stelt mij voor aan Dupje. Ze lijkt op het eerste 
zicht normaal maar transformeert op vrijdagavond in Michael J. en kijkt elke dag fier naar 
haar verzameling lege cola-blikjes. Van het eiland naar het koffielokaal is een kleine stap. Ik ben 
nog niet goed binnen of de Kwislers springen tevoorschijn. Deze meisjes weten echt alles en zijn 
ook best grappig. Vooral omdat de ene wat trager praat (waardoor het lijkt alsof ze van ergens 
ver vandaan komt), terwijl de andere het altijd maar over beren heeft (hoewel ik hier nog geen 
enkele beer heb zien rondlopen). Bizar. Maar geestig! 
Van queestes oplossen krijgt een mens honger. Dus volg ik mijn neus en kom bij 
de Chef terecht. Hij is de kok van het eiland en is voornamelijk bekend om zijn 
‘experimental designs’ in de keuken. Vroeger waren ze blijkbaar niet altijd even 
geslaagd maar hij heeft duidelijk een lange weg afgelegd. Daarnaast blijkt hij ook thuis te zijn 
in de gokwereld, kan hij sierlijk 5 borden tegelijk dragen zoals een echte butler en is hij meester 
in het bouwen van hoge stapels. Al snel zijn we verloren in een eindeloze nerdytalk en de slappe 
lach. Maar het is tijd om verder te gaan en nog meer te ontdekken. Achter de volgende hoek 
DANK	  U!	  
242	  
staan talrijke magische machines die alles kunnen zien, nog scherper dan een glazen bol. Hier 
worden ze echter ‘massaspectrometers’ genoemd. Eén knipoog van hun groene lampjes en ik ben 
meteen verkocht. De elfjes Dirk, Mieke, Beata, Joke, Vicky en Lucie zorgen er dan ook voor dat 
alles draaiende blijft. Ook weten ze iedereen bij te staan met raad en daad. En ook mij wijzen ze 
de weg naar mijn volgende bestemming. Bedankt hiervoor.  
Om de volgende hypothese te onderzoeken kom ik via een 
lange gang in een labo terecht. Hier staan een paar sierlijke 
poezen te miauwen. Het gaat er vrolijk aan toe en ook hun 
namen klinken als echte magie in de oren: Hemeryck, 
Kiebooms, Rombouts, Decloedt en Wauters. Ze spinnen en grinnen erop los, met naast hen een 
sympathieke Chileense vogel. Dan zie ik plots de wijze uil, Johan. Hij neemt mij op zijn 
schouders en helpt me voorbij de statistische drempel. We vliegen zelfs naar Zele waar we knoeien 
met steriele potjes en spuiten. Alweer een missie geslaagd! 
Ik vervolg het pad zoals het komt, over bergen en dalen, met kronkels en obstakels. Mijn tocht is 
niet altijd even simpel maar mijn veiligheid is gegarandeerd want er is een blauwhelm waar ik 
altijd op kan rekenen. En ook al lijkt het heel donker, de vuurvliegjes Anliez, Jojo, Marjo en the 
boys zorgen voor licht en helpen mij vooruit!  
Daarenboven hoef ik mij niet alleen te voelen want ik ben omgeven door zeer goed gezelschap. 
Mijn kleinste metgezellen zijn Knabbel en Babbel! Ze zijn hun naam 
waardig want de een stopt maar niet met babbelen (met alle gevolgen van 
dien) en de andere proeft alles voor. Ook al zie ik ze niet, ik weet dat ze er 
altijd voor mij zijn. Ze zijn mijn beste vrienden en zou ze voor geen geld 
van de wereld kunnen missen! Ook de ‘grote zus’ en de GVR zorgen voor zeer aangenaam 




Uiteindelijk maakt het niet uit hoever ik vlieg en hoeveel avonturen ik ook meemaak, want naast 
mij loopt Peter Pan. In zijn vrije tijd is hij tegen wil en dank grafisch 
ontwerper. De ICT leraar die mij met Word leert werken. De 
geschiedenisleraar met nuttige maar vooral nutteloze weetjes. De huisman die 
zorgt voor eten op tafel, een proper huisje en voorziet in een hoog nussyness 
gehalte. Door vreemden wordt hij vaak mijn broer genoemd omdat we na een tijd op elkaar zijn 
gaan lijken. Maar voor mij is hij vooral mijn keppe.  
 
Na vier jaar lijkt de missie geslaagd en misschien vind je jezelf niet meteen terug in dit verhaal 
maar weet dat elk van jullie tot een stukje van de puzzel heeft bijgedragen. Dit cliché klopt nu 














* Elke gelijkenis met bestaande gebeurtenissen en/of personen berust louter op toeval. 
